
<html lang="en"     class="pb-page"  data-request-id="3b7646b6-f38e-4c4c-8507-38e431318042"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2020.63.issue-18;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.0c00961;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists" /></meta><meta name="dc.Creator" content="Katja  Silbermann" /></meta><meta name="dc.Creator" content="Jiyang  Li" /></meta><meta name="dc.Creator" content="Vigneshwaran  Namasivayam" /></meta><meta name="dc.Creator" content="Fabian  Baltes" /></meta><meta name="dc.Creator" content="Gerd  Bendas" /></meta><meta name="dc.Creator" content="Sven Marcel  Stefan" /></meta><meta name="dc.Creator" content="Michael  Wiese" /></meta><meta name="dc.Description" content="In the search for highly effective modulators addressing ABCG2-mediated MDR, 23 pyrimidines were synthesized and biologically assessed. Seven derivatives with (a) nitrogen- and/or halogen-containin..." /></meta><meta name="Description" content="In the search for highly effective modulators addressing ABCG2-mediated MDR, 23 pyrimidines were synthesized and biologically assessed. Seven derivatives with (a) nitrogen- and/or halogen-containin..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 31, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00961" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00961" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00961" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00961" /></link>
        
    
    

<title>Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00961" /></meta><meta property="og:title" content="Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0019.jpeg" /></meta><meta property="og:description" content="In the search for highly effective modulators addressing ABCG2-mediated MDR, 23 pyrimidines were synthesized and biologically assessed. Seven derivatives with (a) nitrogen- and/or halogen-containing residue(s) had extraordinary potencies against ABCG2 (IC50 &lt; 150 nM). The compounds competitively inhibited ABCG2-mediated Hoechst 33342 transport but were not substrates of ABCG2. The most potent MDR reverser, compound 19, concentration-dependently increased SN-38-mediated cancer cell death at 11 nM (EC50), time-dependently doubled SN-38 toxicity in a period of 7 days at 10 nM, and half-maximally accelerated cell death combined with SN-38 at 17 nM. No induction of ABCG2 was observed. Furthermore, 11 pyrimidines were revealed as triple ABCB1/ABCC1/ABCG2 inhibitors. Five possessed IC50 values below 10 μM against each transporter, classifying them as some of the 50 most potent multitarget ABC transporter inhibitors. The most promising representative, compound 37, reversed ABCB1-, ABCC1-, and ABCG2-mediated MDR, making it one of the three most potent ABC transporter inhibitors and reversers of ABC transporters-mediated MDR." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00961"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00961">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00961&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00961&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00961&amp;href=/doi/10.1021/acs.jmedchem.0c00961" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 18</span><span class="cit-fg-pageRange">, 10412-10432</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/18" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00939" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01086" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Katja Silbermann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katja Silbermann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical and Cellbiological Chemistry, Pharmaceutical Institute, Rheinische Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katja++Silbermann">Katja Silbermann</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiyang Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiyang Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical and Cellbiological Chemistry, Pharmaceutical Institute, Rheinische Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiyang++Li">Jiyang Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vigneshwaran Namasivayam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vigneshwaran Namasivayam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical and Cellbiological Chemistry, Pharmaceutical Institute, Rheinische Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vigneshwaran++Namasivayam">Vigneshwaran Namasivayam</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3031-3377" title="Orcid link">http://orcid.org/0000-0003-3031-3377</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fabian Baltes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fabian Baltes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical and Cellbiological Chemistry, Pharmaceutical Institute, Rheinische Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fabian++Baltes">Fabian Baltes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gerd Bendas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gerd Bendas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical and Cellbiological Chemistry, Pharmaceutical Institute, Rheinische Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gerd++Bendas">Gerd Bendas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sven Marcel Stefan</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sven Marcel Stefan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical and Cellbiological Chemistry, Pharmaceutical Institute, Rheinische Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>S.M.S.: email, <a href="/cdn-cgi/l/email-protection#5b28753675282f3e3d3a351b363e3f32283235752e3234753534"><span class="__cf_email__" data-cfemail="b2c19cdf9cc1c6d7d4d3dcf2dfd7d6dbc1dbdc9cc7dbdd9cdcdd">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sven+Marcel++Stefan">Sven Marcel Stefan</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Michael Wiese</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Wiese</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical and Cellbiological Chemistry, Pharmaceutical Institute, Rheinische Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>M.W.: email, <a href="/cdn-cgi/l/email-protection#8fe2f8e6eafceacffae1e6a2ede0e1e1a1ebea"><span class="__cf_email__" data-cfemail="e78a908e829482a792898eca85888989c98382">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Wiese">Michael Wiese</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5851-5336" title="Orcid link">http://orcid.org/0000-0002-5851-5336</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00961&amp;href=/doi/10.1021%2Facs.jmedchem.0c00961" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 18</span><span class="cit-pageRange">, 10412–10432</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 31, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 June 2020</li><li><span class="item_label"><b>Published</b> online</span>31 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 September 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00961" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00961</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10412%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DKatja%2BSilbermann%252C%2BJiyang%2BLi%252C%2BVigneshwaran%2BNamasivayam%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D18%26contentID%3Dacs.jmedchem.0c00961%26title%3DSuperior%2BPyrimidine%2BDerivatives%2Bas%2BSelective%2BABCG2%2BInhibitors%2Band%2BBroad-Spectrum%2BABCB1%252C%2BABCC1%252C%2Band%2BABCG2%2BAntagonists%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10432%26publicationDate%3DSeptember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00961"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">727</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00961" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Katja&quot;,&quot;last_name&quot;:&quot;Silbermann&quot;},{&quot;first_name&quot;:&quot;Jiyang&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Vigneshwaran&quot;,&quot;last_name&quot;:&quot;Namasivayam&quot;},{&quot;first_name&quot;:&quot;Fabian&quot;,&quot;last_name&quot;:&quot;Baltes&quot;},{&quot;first_name&quot;:&quot;Gerd&quot;,&quot;last_name&quot;:&quot;Bendas&quot;},{&quot;first_name&quot;:&quot;Sven&quot;,&quot;last_name&quot;:&quot;Marcel Stefan&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Wiese&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;31&quot;,&quot;issue&quot;:&quot;18&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;10412-10432&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00961&quot;},&quot;abstract&quot;:&quot;In the search for highly effective modulators addressing ABCG2-mediated MDR, 23 pyrimidines were synthesized and biologically assessed. Seven derivatives with (a) nitrogen- and/or halogen-containing residue(s) had extraordinary potencies against ABCG2 (IC50 &lt; 150 nM). The compounds competitively inhibited ABCG2-mediated Hoechst 33342 transport but were not substrates of ABCG2. The most potent MDR reverser, compound 19, concentration-dependently increased SN-38-mediated cancer cell death at 11 nM (EC50), time-dependently doubled SN-38 toxicity in a period of 7 days at 10 nM, and half-maximally accelerated cell death combined with SN-38 at 17 nM. No induction of ABCG2 was observed. Furthermore, 11 pyrimidines were revealed as triple ABCB1/ABCC1/ABCG2 inhibitors. Five possessed IC50 values below 10 μM against each transporter, classifying them as some of the 50 most potent multitarget ABC transporter inhibitors. The most promising representative, compound 37, reversed ABCB1-, ABCC1-, and ABCG2-mediated MDR, maki&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00961&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00961" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00961&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00961" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00961&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00961" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00961&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00961&amp;href=/doi/10.1021/acs.jmedchem.0c00961" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00961" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00961" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00961&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00961%26sid%3Dliteratum%253Aachs%26pmid%3D32787102%26genre%3Darticle%26aulast%3DSilbermann%26date%3D2020%26atitle%3DSuperior%2BPyrimidine%2BDerivatives%2Bas%2BSelective%2BABCG2%2BInhibitors%2Band%2BBroad-Spectrum%2BABCB1%252C%2BABCC1%252C%2Band%2BABCG2%2BAntagonists%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D18%26spage%3D10412%26epage%3D10432%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292227" title="Drug resistance">Drug resistance</a>,</li><li><a href="/action/doSearch?ConceptID=291917" title="Pyrimidine">Pyrimidine</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/18" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/jmcmar.2020.63.issue-18/20200924/jmcmar.2020.63.issue-18.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">In the search for highly effective modulators addressing ABCG2-mediated MDR, 23 pyrimidines were synthesized and biologically assessed. Seven derivatives with (a) nitrogen- and/or halogen-containing residue(s) had extraordinary potencies against ABCG2 (IC<sub>50</sub> < 150 nM). The compounds competitively inhibited ABCG2-mediated Hoechst 33342 transport but were not substrates of ABCG2. The most potent MDR reverser, compound <b>19</b>, concentration-dependently increased SN-38-mediated cancer cell death at 11 nM (EC<sub>50</sub>), time-dependently doubled SN-38 toxicity in a period of 7 days at 10 nM, and half-maximally accelerated cell death combined with SN-38 at 17 nM. No induction of ABCG2 was observed. Furthermore, 11 pyrimidines were revealed as triple ABCB1/ABCC1/ABCG2 inhibitors. Five possessed IC<sub>50</sub> values below 10 μM against each transporter, classifying them as some of the 50 most potent multitarget ABC transporter inhibitors. The most promising representative, compound <b>37</b>, reversed ABCB1-, ABCC1-, and ABCG2-mediated MDR, making it one of the three most potent ABC transporter inhibitors and reversers of ABC transporters-mediated MDR.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Multidrug resistance (MDR) in cancer chemotherapy remains until today a major obstacle in oncology.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In both chemonaive<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> as well as chemotreated patients,<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> the overexpression of ATP-binding cassette (ABC) transport proteins is associated with a negative prognosis and poor outcome of first-line chemotherapeutic intervention. Recurrence of certain cancers, such as leukemia,<a onclick="showRef(event, 'ref4 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref6 ref7">(4,6,7)</a> as well as lung,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> pancreatic,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> ovarian,<a onclick="showRef(event, 'ref3 ref9'); return false;" href="javascript:void(0);" class="ref ref3 ref9">(3,9)</a> or breast cancer,<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> was already connected to the overexpression of ABC transporters.<a onclick="showRef(event, 'ref3 ref6 ref7 ref8 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref3 ref6 ref7 ref8 ref10 ref11">(3,6−8,10,11)</a> These efflux pumps are not only negative prognostic markers for the development of metastasis<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> but collectively lead to decreased progression- and disease-free survival as well as increased mortality.<a onclick="showRef(event, 'ref3 ref6 ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref3 ref6 ref7 ref8 ref9 ref10 ref11">(3,6−11)</a> One of the most important representatives in this regard is ABCG2 (breast cancer resistance protein; BCRP).<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> ABCG2 confers resistance to a broad spectrum of chemically unrelated anticancer drugs, such as camptothecins, epipodophyllotoxins, mitoxantrone, and tyrosine kinase inhibitors (TKIs).<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Overexpression of this ABC transporter was found in several cancer cell lines derived from leukemia, as well as cancers from lung, ovary, colon, prostate gland, or breast.<a onclick="showRef(event, 'ref13 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref15">(13,15)</a> One strategy to treat certain advanced and/or relapsed cancers is the use of camptothecin (<b>1</b>; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) analogs [e.g., topotecan (<b>2</b>; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>)<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> or irinotecan (<b>3</b>; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a>] as second-line treatment. However, cell lines derived from certain malignancies acquired ABCG2 expression<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> after exposure to <b>1</b><a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and its analogs <b>2</b><a onclick="showRef(event, 'ref20 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref20 ref22 ref23">(20,22,23)</a> and <b>3</b><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> as well as its active metabolite SN-38 (<b>4</b>; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>),<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> leading to cross-resistance.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23 ref24 ref25">(20−25)</a> Other tumor cell lines even showed inherent ABCG2 expression and resistance toward camptothecins.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> One concept to overcome resistance against <b>1</b> in certain cancers was the design of compound <b>1</b> analogs that were less recognized by ABCG2, which led to promising candidates, such as diflomotecan,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> gimatecan,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> or lurtotecan.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Nonetheless, ABCG2-overexpressing cells always possessed a basic (cross-)resistance against these agents that could not be abolished by structural variations.<a onclick="showRef(event, 'ref24 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref24 ref29 ref30 ref31">(24,29−31)</a> In addition, certain representatives were shown to induce ABCG2 on mRNA and protein levels.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Compound <b>1</b> and its derivatives commonly used in second-line anticancer regimens.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another approach was the design of inhibitors of ABCG2 that blocked the efflux of compound <b>1</b> analogs and increased their persistence inside of cancer cells. Several tyrosine kinase inhibitors were proven to reverse ABCG2-mediated resistance against camptothecins.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> This was first described for canertinib (<b>5</b>; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>),<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> which reversed ABCG2-mediated resistance against <b>4</b>. Until today, only very few TKIs did likewise at low triple-digit to high double-digit nanomolar concentrations,<a onclick="showRef(event, 'ref33 ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35 ref36 ref37">(33−37)</a> such as ceritinib (<b>6</b>; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Most compounds exerted their reversing potential in the micromolar concentration range, and clinical evaluations of TKIs in combination with either <b>2</b><a onclick="showRef(event, 'ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41">(39−41)</a> or <b>3</b><a onclick="showRef(event, 'ref42 ref43 ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44 ref45 ref46">(42−46)</a> had only limited success. This was attributed to no benefit of the combination compared to single-drug treatment<a onclick="showRef(event, 'ref40 ref43 ref46'); return false;" href="javascript:void(0);" class="ref ref40 ref43 ref46">(40,43,46)</a> and/or severe adverse side effects.<a onclick="showRef(event, 'ref39 ref41 ref42 ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref39 ref41 ref42 ref44 ref45 ref46">(39,41,42,44−46)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Depiction of inhibitor- and MDR reverser-development regarding ABCG2-mediated drug transport: compound <b>5</b>, the very first TKI associated with inhibition of ABCG2 and reversal of ABCG2-mediated compound <b>1</b> analog resistance;<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> compound <b>6</b>, the most active TKI regarding MDR reversal against compound <b>2</b> in ABCG2-overexpressing cells (EC<sub>50</sub> ≈ 65 nM);<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> compound <b>7</b>, one of the first reported HTS-derived quinazolines as ABCG2 inhibitors;<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a> compound <b>8</b>, exceptional representative of a triple ABCB1/ABCC1/ABCG2 inhibitor;<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> compound <b>9</b>, one of the most potent ABCG2-mediated MDR reversers known until today (EC<sub>50</sub> = 12.7 nM);<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> compound <b>10</b>, one of only seven synthesized pyrimidine derivatives as ABCG2 inhibitors.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In need of the development of more potent and less adverse side effects-associated adjuvant modulators of ABCG2-related cancers, a bulk of compounds was generated on the basis of the main scaffolds of TKIs. These were mostly either quinazoline,<a onclick="showRef(event, 'ref32 ref33 ref36 ref47'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref36 ref47">(32,33,36,47)</a> quinoline,<a onclick="showRef(event, 'ref35 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref35 ref48 ref49">(35,48,49)</a> pyrimidine,<a onclick="showRef(event, 'ref38 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref38 ref50 ref51">(38,50,51)</a> or pyridine<a onclick="showRef(event, 'ref37 ref52'); return false;" href="javascript:void(0);" class="ref ref37 ref52">(37,52)</a> derivatives. Subsequent optimization of the backbone derived from compound <b>5</b><a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> resulted in either highly potent quinazoline-containing (e.g., <b>7</b>; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>),<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a> or broad-spectrum quinoline-containing ABCG2 inhibitors (e.g., <b>8</b>; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Further improvement resulted in one of the most potent ABCG2-mediated MDR reversers known until today (<b>9</b>; EC<sub>50</sub> = 12.7 nM; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The most recent and final improvement was the downsizing of the structures to a pyrimidine scaffold, yielding highly potent ABCG2 inhibitors and reversers of ABCG2-mediated MDR (e.g., <b>10</b>; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p">As only seven pyrimidine derivatives have been described as ABCG2 inhibitors in literature,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> the aim of the present study was further exploration of the pyrimidine class as ABCG2 inhibitors. The substitution pattern has carefully been selected according to our experience from previous studies<a onclick="showRef(event, 'ref53 ref54 ref55 ref56 ref57 ref58 ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55 ref56 ref57 ref58 ref59 ref60 ref61">(53−61)</a> as well as reports of TKIs targeting ABCG2.<a onclick="showRef(event, 'ref32 ref33 ref36 ref39 ref40 ref47 ref48 ref52'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref36 ref39 ref40 ref47 ref48 ref52">(32,33,36,39,40,47,48,52)</a> This included introduction of flexible nitrogen-(cyano or nitro)- and oxygen-(hydroxy or methoxy)-containing substituents with or without combination of halogens (fluorine, chlorine, bromine) but also bulky, rigid nitrogen- and oxygen-containing heterocycles. Compounds with high inhibitory power, low cytotoxicity, highly effective MDR reversal capability, and ABCG2 selectivity were in focus, neither being substrates of this transporter nor interfering with its expression.</div><div class="NLM_p">As our past investigations frequently led to the discovery of multitarget ABCB1, ABCC1, and ABCG2 inhibitors,<a onclick="showRef(event, 'ref54 ref55 ref61 ref62 ref63 ref64 ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref54 ref55 ref61 ref62 ref63 ref64 ref65 ref66">(54,55,61−66)</a> a second task of the present work was the screening of the 23 synthesized compounds against ABCB1 and ABCC1 as well as evaluating their capability to reverse ABCB1-, ABCC1-, and ABCG2-mediated MDR. As certain cancers simultaneously overexpress specific ABC transporters,<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a> and selective inhibition and/or downregulation of one transporter (e.g., ABCG2) might lead to compensatory up-regulation of another (e.g., ABCB1 and/or ABCC1),<a onclick="showRef(event, 'ref69 ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref69 ref70 ref71">(69−71)</a> broad-spectrum ABC transporter inhibitors are considered to be useful tools in a novel strategy to approach multidrug-resistant cancers.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a> However, until today only ∼1000 compounds have been evaluated regarding inhibition of ABCB1, ABCC1, and ABCG2. This group of compounds comprised less than 120 triple ABCB1/ABCC1/ABCG2 inhibitors, less than 50 of these exerting their effect at 10 μM or lower,<a onclick="showRef(event, 'ref38 ref49 ref54 ref55 ref61 ref62 ref63 ref64 ref65 ref66 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref38 ref49 ref54 ref55 ref61 ref62 ref63 ref64 ref65 ref66 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84">(38,49,54,55,61−66,74−84)</a> and less than 20 compounds at 5 μM or lower against all three transporters.<a onclick="showRef(event, 'ref55 ref63 ref74 ref77 ref78 ref79 ref80 ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref55 ref63 ref74 ref77 ref78 ref79 ref80 ref82 ref83">(55,63,74,77−80,82,83)</a> While ∼75 compounds were reported in the literature as reversers of ABCB1-, ABCC1-, and ABCG2-mediated MDR,<a onclick="showRef(event, 'ref47 ref48 ref50 ref51 ref52 ref65 ref66 ref85 ref86 ref87 ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref47 ref48 ref50 ref51 ref52 ref65 ref66 ref85 ref86 ref87 ref88 ref89">(47,48,50−52,65,66,85−89)</a> only two compounds have been proven to exert their MDR reversing effect due to inhibition of these ABC transporters, 9-deazapurine 55 (<b>11</b>; <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) and thienopyrimidine 14 (<b>12</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Reported triple reversers of ABCB1-, ABCC1-, and ABCG2-mediated MDR that proved to exert their effect due to inhibition of ABCB1, ABCC1, and ABCG2: 9-deazapurine 55 (<b>11</b>)<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> and thienopyrimidine 14 (<b>12</b>).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68467" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68467" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Synthesis of 4-anilino-6-methyl-2-phenylpyrimidine derivatives was achieved in three steps as depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. First, a Pinner pyrimidine synthesis was applied by condensing a benzamidine with ethyl acetoacetate in a freshly prepared sodium ethoxide solution to form the pyrimidine ring (<b>13</b>). Exposure to excess phosphoryl chloride yielded 4-chloro-6-methyl-2-phenylpyrimidine (<b>14</b>). Finally, the chlorinated pyrimidine was reacted with differently substituted anilines to obtain the desired products (<b>18</b>–<b>40</b>).</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0016.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of 4-Anilino-6-methyl-2-phenylpyrimidine Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaOEt/EtOH, reflux, overnight; (b) POCl<sub>3</sub> reflux, 8–9 h; (c) <i>i</i>-PrOH, microwave, 110 °C, 30 min.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Biological Investigation</h3><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7"> Inhibitory Activity against ABCG2</h4><div class="NLM_p">The synthesized compounds <b>18</b>–<b>40</b> were investigated for their inhibitory activity against ABCG2 using ABCG2-overexpressing MDCK II BCRP cells in Hoechst 33342 and pheophorbide A assays. In short, blockage of ABCG2-mediated transport results in both assays in enhanced intracellular accumulation of these fluorescent ABCG2 substrates. The degree of inhibition of the evaluated compounds correlates with the measured amount of fluorescence. Ko143 [(3<i>S</i>,6<i>S</i>,12a<i>S</i>)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1′,2′:1,6]pyrido[3,4-<i>b</i>]indole-3-propanoic acid 1,1-dimethylethyl ester; <b>41</b>] was chosen as reference compound. The results of the biological investigations are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The evaluated compounds were compared to certain pyrimidine analogs reported by Krapf et al. as these marked the starting scaffold of the present investigation.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Within this work, the designed and synthesized compounds can be divided into six subgroups: (i) nitrogen-containing derivatives (<b>18</b>–<b>22</b>); (ii) oxygen-containing analogs (<b>23</b>–<b>25</b>); (iii) halogen-containing pyrimidines (<b>26</b>–<b>28</b>); (iv) nitrogen- and halogen-containing derivatives (<b>29</b>–<b>33</b>); (v) oxygen- and halogen-containing analogs (<b>34</b>–<b>36</b>); (vi) pyrimidines with bulky and rigid heterocyclic residues (<b>37</b>–<b>40</b>). Compound <b>15</b> represents the unsubstituted pyrimidine derivative which had an IC<sub>50</sub> value of 0.648 μM in the Hoechst 33342 assay.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> In earlier studies, cyano or nitro substituents had a positive impact on ABCG2 inhibition<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> which could also be shown for the 3-cyano (<b>16</b>; IC<sub>50(Hoechst 33342)</sub> = 0.122 μM) and 4-cyano (<b>17</b>; IC<sub>50(Hoechst 33342)</sub> = 0.128 μM) analogs.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> In subgroup (i), the 3,4-dicyano analog <b>18</b> possessed slightly inferior inhibitory activity (IC<sub>50(Hoechst 33342)</sub> = 0.188 μM; IC<sub>50(Pheophorbide A)</sub> = 0.516 μM). The 3-methyl-4-cyano derivative <b>19</b> showed excellent inhibitory power in the Hoechst 33342 assay (IC<sub>50</sub> = 0.0935) with a maximal inhibition level (<i>I</i><sub>max</sub>) value similar to <b>41</b>. On the other hand, introduction of a carbon between the main scaffold and the 4-cyano (<b>20</b>) led to a major loss of inhibitory power.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory Potencies of Synthesized Pyrimidine Derivatives as Obtained in the Hoechst 33342 and Pheophorbide A Assays, Respectively, Using ABCG2-Overexpressing MDCK II BCRP Cells<a class="ref internalNav" href="#tbl1-fn1" aria-label="d">d</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0017.gif" alt="" id="gr6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0018.gif" alt="" id="gr7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn2"><div class="footnote" id="t1fn2"><sup><sup>a</sup></sup><p class="last">Constrained to <b>41</b>.</p></div><div class="footnote" id="t1fn3"><sup><sup>b</sup></sup><p class="last">Data taken from ref <a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a>.</p></div><div class="footnote" id="t1fn4"><sup><sup>c</sup></sup><p class="last">Data could not be analyzed due to autofluorescence of compound at wavelength 355 nm.</p></div><div class="footnote" id="tbl1-fn1"><sup><sup>d</sup></sup><p class="last">Data are expressed as the mean ± SEM (<i>n</i> ≥ 3). n.t. = not tested.</p></div></div><div></div></div><div class="NLM_p">The most potent pyrimidine-based ABCG2 inhibitor known until today with its 3-nitro-4-hydroxy substitution pattern had an IC<sub>50</sub> value of 0.0988 μM (<b>10</b>).<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Investigation of the 3-nitro (<b>21</b>) and 4-nitro (<b>22</b>) analogs resulted also in very potent inhibitors, the first being as potent as the cyano derivatives <b>16</b> and <b>17</b>; the latter exceeded the inhibitory potency of compound <b>10</b> by a factor of ∼2 in the Hoechst 33342 assay (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> A). Interestingly, in the pheophorbide A assay, both compounds <b>21</b> and <b>22</b> were equipotent (IC<sub>50</sub> ≈ 0.150 μM) but with a depressed <i>I</i><sub>max</sub> of <70%.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Concentration–effect curves of compound <b>22</b> (■, IC<sub>50</sub> = 0.0522 μM) in comparison to reference inhibitor <b>41</b> (●, IC<sub>50</sub> = 0.220 μM) in the Hoechst 33342 assay. (B) Concentration–effect curves of compound <b>30</b> (■, IC<sub>50</sub> = 0.0594 μM) in comparison to reference inhibitor <b>41</b> (●, IC<sub>50</sub> = 0.274 μM) in the pheophorbide A assay. Shown is the mean ± SEM of at least three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound set (ii) comprised pyrimidines with solely oxygen-containing substituents. Here, the 3-hydroxy analog <b>23</b> was 2-fold less potent than the cyano derivatives <b>16</b> and <b>17</b> in the Hoechst 33342. In the pheophorbide A assay, compound <b>23</b> was equipotent to the 3,4-dicyano derivative <b>18</b>. As already shown for compound <b>20</b>, the insertion of a methylene linker at position 3 resulted in a nearly 20-fold loss of inhibitory activity of compound <b>24</b> in the Hoechst 33342 assay. On the other hand, the 3-methoxy derivative <b>25</b> was equally potent as the 3-hydroxy compound <b>23</b> but with a higher <i>I</i><sub>max</sub> value similar to the standard inhibitor <b>41</b>.</div><div class="NLM_p">In group (iii), representatives with solely halogen-containing substituents were synthesized [(3-fluoro (<b>26</b>), 3-chloro (<b>27</b>), or 3-bromo (<b>28</b>)]. These variations resulted in compounds with equal inhibitory activity of around ∼1 μM in the Hoechst 33342 assay. Strikingly, compound <b>28</b> was ∼2-fold more potent compared to compounds <b>26</b> and <b>27</b> in the pheophorbide A assay (IC<sub>50</sub> = 0.386 μM).</div><div class="NLM_p">In the next step, combinations of the above stated substituents were evaluated. Within compound set (iv), compounds <b>29</b> and <b>30</b> (3-cyano-4-fluoro and 3-bromo-4-cyano, respectively) were found to be the most potent representatives as determined in the pheophorbide A assay, with IC<sub>50</sub> values in the high double-digit nanomolar concentration range. These data were confirmed in the Hoechst 33342 assay, although the determined IC<sub>50</sub> values were approximately 2- to 3.5-fold higher. However, it must be taken into account that both compounds had depressed <i>I</i><sub>max</sub> values in the pheophorbide A assay (59% and 40%, respectively) as shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> B (compound <b>30</b>), which artificially decreases the IC<sub>50</sub> value. This so-called “partial inhibition” frequently occurs in the literature.<a onclick="showRef(event, 'ref58 ref61 ref65 ref90 ref91 ref92 ref93 ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref58 ref61 ref65 ref90 ref91 ref92 ref93 ref94 ref95">(58,61,65,90−95)</a> Potential explanations could be reduced solubility or increased intrinsic toxicity of the compounds, but also an actual partial antagonisms against the transporter. The other way around, the 3-trifluoromethyl-4-cyano analog <b>31</b> had superior power against ABCG2 in the Hoechst 33342 assay, exceeding the most potent pyrimidine <b>10</b> up to now (IC<sub>50</sub> = 0.0693 μM) and being around 10-fold more potent than the unsubstituted representative <b>15</b>. Conversely, inhibition of ABCG2-mediated pheophorbide A transport was over 5-fold weaker. Discrepancies like these occur sometimes and depend on the manner of fluorescence dye and are influenced by, for example, its polarity, lipophilicity, membrane distribution, velocity of diffusion, and affinity to the transport protein.<a onclick="showRef(event, 'ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref96 ref97">(96,97)</a></div><div class="NLM_p">Unexpectedly, the 3-nitro-4-fluoro derivative <b>32</b> did not result in superior inhibitory power as described for its 3-cyano analog <b>29</b>. It was by factors of ∼3 and ∼9 less active in the Hoechst 33342 and pheophorbide A assays, respectively. The 3-chloro-4-nitro derivative <b>33</b> was the second most potent inhibitor in the Hoechst 33342 assay (IC<sub>50</sub> = 0.0589 μM), with a notable <i>I</i><sub>max</sub> value of above 75%. This could not be confirmed by the pheophorbide A data, as the determined IC<sub>50</sub> value was ∼4-fold higher.</div><div class="NLM_p">Given the positive impact of methoxy groups in some scaffolds on ABCG2 inhibition,<a onclick="showRef(event, 'ref58 ref90'); return false;" href="javascript:void(0);" class="ref ref58 ref90">(58,90)</a> certain representatives were synthesized containing either 3- or 4-methoxy and a neighbored halogen in group (v). The 3-methoxy-4-bromo derivative <b>34</b> had in both assays an inhibitory power against ABCG2 of ∼300 nM but a decreased <i>I</i><sub>max</sub> value in the pheophorbide A assay of about 50%. The 4-methoxy derivatives <b>35</b> and <b>36</b> were less preferred (IC<sub>50</sub> values of ∼1 μM and ∼0.5 μM, respectively). Collectively, the methoxy derivatives did not meet the expected results.</div><div class="NLM_p last">In group (vi), heteroaromatic and heterocyclic substituents at positions 3 and 4 of the pyrimidine scaffold were introduced to evaluate rigid nitrogen and oxygen substituents. The pyridine derivative <b>37</b> was by a factor of ∼2 superior compared to the quinoxaline analog <b>38</b> in the pheophorbide A assay. Unfortunately, these compounds could not be evaluated in the Hoechst 33342 assay due to autofluorescence. The nonaromatic oxygen analog to compound <b>38</b>, the 1,4-dioxane <b>39</b>, was inferior to its aromatic nitrogen counterpart, which might be due to loss of planarity and/or aromaticity. The phthalimide derivative <b>40</b> was inferior to its closed-ring pyrimidine analogs <b>37</b>–<b>39</b>. Collectively, the results concerning these compounds showed that a certain flexibility of the substituents is needed for good inhibitory activity.</div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> Screening against ABCB1 and ABCC1</h4><div class="NLM_p">All compounds were examined for their inhibitory power against ABCB1 and ABCC1 in order to investigate their selectivity over ABCG2 and to potentially discover multitarget ABCB1/ABCC1/ABCG2 inhibitors. The screening was performed at a concentration of 10 μM using a calcein AM assay with either ABCB1-overexpressing A2780/ADR or ABCC1-overexpressing MDCK II MRP1 cells. In short, inhibition of the transporter(s) results in enhanced persistence of calcein AM inside the cell, which becomes cleaved by unspecific esterases to fluorescent calcein. As already stated above for the Hoechst 33342 and pheophorbide A assays, the amount of measured fluorescence correlates to the degree of inhibition exerted by the compounds. Cyclosporine A (10 μM) was used as a positive control. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> A gives the results of the screening against ABCB1, while <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> B depicts the results regarding ABCC1.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibitory effect of screened compounds at 10 μM against ABCB1 using the ABCB1-overexpressing cell line A2780/ADR (A) and ABCC1 using the ABCC1-overexpressing cell line MDCK II MRP1 (B) applying a calcein AM assay. Data were normalized by defining the effect of 10 μM cyclosporine A as positive control (100%) and buffer medium as negative control (0%). Shown is the mean ± SEM of at least three independent experiments with duplicate measurements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several pyrimidines, especially representatives with methoxy substituents (<b>25</b>), halogen residues (<b>26</b>–<b>28</b>), or a combination of both substituents (<b>34</b>–<b>36</b>) had an inhibitory effect on ABCB1 and ABCC1. On the other hand, derivatives with cyano (<b>18</b>, <b>19</b>, <b>29</b>–<b>31</b>) and nitro (<b>21</b>, <b>22</b>, <b>32</b>, <b>33</b>) groups inhibited neither ABCB1 nor ABCC1 besides few exceptions (<b>21</b>, <b>22</b>). Compounds with an inhibition level of at least 25% were further evaluated for their IC<sub>50</sub> values, and the results are presented in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Generally, these compounds had similar inhibitory potencies against both transporters. The most potent ABCG2 inhibitors (<b>19</b>, <b>29</b>, <b>31</b>, <b>33</b>) were ABCG2-selective without noticeable affinity to the other two ABC transporters. Exceptions were compounds <b>21</b> and <b>22</b>. The former also slightly inhibited ABCC1, which made it a (rather ABCG2-seletive) dual ABCC1/ABCG2 inhibitor. The latter inhibited both ABCB1 and ABCC1, but also with great preference for ABCG2. Nevertheless, compound <b>22</b> can be considered as a rare finding of a triple ABCB1/ABCC1/ABCG2 inhibitor. In addition, compounds <b>25</b>, <b>27</b>, <b>28</b>, <b>34</b>–<b>38</b>, and <b>40</b> were also found to be multitarget ABCB1/ABCC1/ABCG2 inhibitors, which is extraordinary considering the amount of less than 120 compounds of this kind given in literature. Five of the herein presented compounds (<b>27</b>, <b>28</b>, <b>34</b>, <b>36</b>, <b>37</b>) had potencies ranging within the 50 most potent triple ABCB1/ABCC1/ABCG2 inhibitors known until today.<a onclick="showRef(event, 'ref38 ref49 ref54 ref55 ref61 ref62 ref63 ref64 ref65 ref66 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref38 ref49 ref54 ref55 ref61 ref62 ref63 ref64 ref65 ref66 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84">(38,49,54,55,61−66,74−84)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Inhibitory Potencies against ABCB1 and ABCC1 of Compounds That Had an Inhibition Level of at Least 25% in the Initial Screening<a class="ref internalNav" href="#tbl2-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> ± SEM [μM]</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">A2780/ADR (ABCB1)</th><th class="colsep0 rowsep0" align="center">MDCK II MRP1 (ABCC1)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>20</b></td><td class="colsep0 rowsep0" align="left">16.0 ± 1.6</td><td class="colsep0 rowsep0" align="left">nt</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>21</b></td><td class="colsep0 rowsep0" align="left">nt</td><td class="colsep0 rowsep0" align="left">11.2 ± 2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>22</b></td><td class="colsep0 rowsep0" align="left">11.2 ± 2.7</td><td class="colsep0 rowsep0" align="left">9.26 ± 0.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>25</b></td><td class="colsep0 rowsep0" align="left">13.4 ± 0.6</td><td class="colsep0 rowsep0" align="left">8.87 ± 1.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>26</b></td><td class="colsep0 rowsep0" align="left">nt</td><td class="colsep0 rowsep0" align="left">7.01 ± 1.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>27</b></td><td class="colsep0 rowsep0" align="left">5.92 ± 0.14</td><td class="colsep0 rowsep0" align="left">3.51 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>28</b></td><td class="colsep0 rowsep0" align="left">7.14 ± 0.33</td><td class="colsep0 rowsep0" align="left">3.53 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>34</b></td><td class="colsep0 rowsep0" align="left">5.03 ± 0.59</td><td class="colsep0 rowsep0" align="left">6.13 ± 0.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>35</b></td><td class="colsep0 rowsep0" align="left">8.99 ± 0.55</td><td class="colsep0 rowsep0" align="left">19.5 ± 4.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>36</b></td><td class="colsep0 rowsep0" align="left">7.30 ± 0.23</td><td class="colsep0 rowsep0" align="left">4.76 ± 0.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>37</b></td><td class="colsep0 rowsep0" align="left">5.13 ± 0.20</td><td class="colsep0 rowsep0" align="left">7.23 ± 0.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>38</b></td><td class="colsep0 rowsep0" align="left">13.4 ± 2.7</td><td class="colsep0 rowsep0" align="left">28.4 ± 5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>39</b></td><td class="colsep0 rowsep0" align="left">13.1 ± 1.5</td><td class="colsep0 rowsep0" align="left">30.4 ± 11.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>40</b></td><td class="colsep0 rowsep0" align="left">17.7 ± 3.6</td><td class="colsep0 rowsep0" align="left">18.3 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">cyclosporine A</td><td class="colsep0 rowsep0" align="left">1.20 ± 0.03</td><td class="colsep0 rowsep0" align="left">6.63 ± 0.67</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl2-fn1"><div class="footnote" id="tbl2-fn1"><sup><sup>a</sup></sup><p class="last">Data were obtained in a calcein AM assay using either A2780/ADR or MDCK II MRP1 cell lines. Maximum inhibition was defined by 10 μM cyclosporine A. Shown is the mean ± SEM of at least three independent experiments. nt = not tested due to lack of activity in initial screening assay.</p></div></div></div></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> Determination of the Concentration-Dependent Reversal of ABCG2-Mediated MDR</h4><div class="NLM_p">The ability of the most potent compounds to reverse ABCG2-mediated MDR was verified by a MTT-based approach, using a dilution series of the ABCG2 substrate <b>4</b>. In addition, certain concentrations of the tested compounds were added to evaluate whether the toxicity of compound <b>4</b> was enhanced by the presence of the tested compounds (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> A). This would be indicated by the shift of the concentration–effect curve to the left (closer to the curve of the parental cell line without ABCG2 expression), which means that less compound <b>4</b> is necessary for half-maximal growth inhibition due to the presence of the tested compound. This effect can be quantified by plotting the resistance factors of the different experiments as well as the parental cell line against the concentration of the tested compound. This half-maximal reversal concentration (EC<sub>50</sub>) is the compound concentration at which the cancer cells were half-maximally sensitized with respect to compound <b>4</b> and is comparable to IC<sub>50</sub> values in the inhibition assays (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> B).</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) MDR reversal assay obtained in a MTT-based cell viability assay for compound <b>19</b>. The curves show sensitization of ABCG2-overexpressing MDCK II BCRP cells with regard to compound <b>4</b>. Compound <b>19</b> was used at concentrations of 0 μM (●), 0.001 μM (■), 0.010 μM (▲), 0.100 μM (▼), and 1.000 μM (◆) and was compared to the wild type cell line without compound addition (○). Shown is the mean ± SEM of at least three independent experiments with duplicate measurements. (B) Calculated resistance factors derived from GI<sub>50</sub> values of graph (A) were plotted against the used concentrations of compound <b>19</b>. A nonlinear regression of the obtained curve yielded an EC<sub>50</sub> of 11 nM. Shown is the mean ± SEM of at least three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">All chosen compounds were able to achieve full MDR reversal. Their EC<sub>50</sub> values were in the low double-digit nanomolar concentration range (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), which gave proof that pyrimidines are very effective reversers of ABCG2-mediated MDR. The most efficient MDR reverser was compound <b>19</b>, which was able to sensitize MDCK II BCRP cells with an EC<sub>50</sub> value of 11.0 nM (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> A,B). This exceeds the efficacy of its parent compound <b>9</b><a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> and makes it one of the most potent MDR reversers reported until today.<a onclick="showRef(event, 'ref56 ref57 ref89'); return false;" href="javascript:void(0);" class="ref ref56 ref57 ref89">(56,57,89)</a> In addition, this EC<sub>50</sub> value is of a 6- and 12-fold higher potency compared to the results of the Hoechst 33342 or pheophorbide A assays, respectively. This phenomenon can be explained by different affinities of the ABCG2 substrates for the transporter and transport behavior of the different substrates.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> It might also be correlated to the different time frames of the assays (short term vs long term) and has already been observed in literature before.<a onclick="showRef(event, 'ref65 ref9800'); return false;" href="javascript:void(0);" class="ref ref65 ref9800">(65,98)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Results of the MDR Reversal Assay Obtained in a MTT-Based Cell Viability Assay<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> ± SEM [μM]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">0.0110 ± 0.0015</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">0.0159 ± 0.0009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">0.0209 ± 0.0005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">0.0150 ± 0.0020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">0.0152 ± 0.0016</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup><sup>a</sup></sup><p class="last">Resistance factors were plotted against the corresponding concentration of the investigated compound. The nonlinear regression of the obtained curve gave the EC<sub>50</sub>. Shown is the mean ± SEM (n ≥ 3).</p></div></div></div></div><div id="sec2_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Determination of the Time-Dependent Reversal of ABCG2-Mediated MDR</h4><div class="NLM_p">In order to investigate the MDR reversing property of the most potent representative (compound <b>19</b>) in more detail, a time-dependent MTT-based MDR reversal assay was conducted. In short, cells were exposed to a concentration of 0.5 μM compound <b>4</b> alone and in combination with 10 nM compound <b>19</b> over a time period of 7 days, determining the cell viability every day. These concentrations were chosen as 0.5 μM compound <b>4</b> showed in preliminary experiments no toxic effect on the resistant cells over 3 days, and 10 nM compound <b>19</b> nearly equals its EC<sub>50</sub> value. <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> A [normalized on control (pure cell culture medium)] and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> B (normalized on compound <b>4</b>) show the obtained results. As one can see, 10 nM compound <b>19</b> is sufficient to double the toxic effect of compound <b>4</b> over a period of 7 days. A statistically significant effect was seen after 5 days, which equals the timeline of a commonly used application in antineoplastic chemotherapy (so-called 5-day course; 5 days compound <b>2</b> iv application every 3 weeks).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(99)</a> To verify the concentration-dependency of this effect over time, this 7-day experiment was conducted using different concentrations of compound <b>19</b> (0, 10, 25, and 50 nM). <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> C presents the obtained results, showing that increased concentrations of compound <b>19</b> led to decreased cell viability over time. Plotting the inflection points of the curves of <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> C against the used concentrations of compound <b>19</b> results in a time–concentration graphic as indicated by <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> D. Several measures can be deduced from this plot: (i) <i>t</i><sub>max</sub>, which represents the time needed for the antineoplastic agent alone at a fixed concentration (in this case compound <b>4</b> at 0.5 μM) to half-maximally kill the cancer cells (∼7.25 days); (ii) <i>t</i><sub>min</sub>, which represents the minimum time needed to achieve half-maximal cell death by the antineoplastic agent at a fixed concentration in combination with a sensitizer (in this case compound <b>19</b>; ∼4.25 days); (iii) <i>c</i><sub>tmin</sub> (maximal cell death acceleration concentration), which is the concentration of the modulator needed to achieve <i>t</i><sub>min</sub> (in this case compound <b>19</b> at ∼50 nM); (iv) <i>c</i><sub><sup>1</sup>/<sub>2</sub>max</sub> (half-maximal cell death acceleration concentration), which gives the concentration of the modulator needed to achieve half-maximal cell death by the used antineoplastic agent at half of <i>t</i><sub>max</sub> (in this case compound <b>19</b> at ∼17.25 nM in ∼5.75 days in combination with compound <b>4</b> at 0.5 μM; <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> D). <i>c</i><sub><sup>1</sup>/<sub>2</sub>max</sub> is a compound-, cell-line-, antineoplastic-agent-, and assay-specific value, which is to our best knowledge described for the first time. It is a critical measure for judging the effectiveness of a modulator and its superiority to the treatment with an antineoplastic agent alone, especially regarding its relation over time. Besides IC<sub>50</sub> (relation to target) and EC<sub>50</sub> (capability to reverse MDR), <i>c</i><sub><sup>1</sup>/<sub>2</sub>max</sub> should be the third standard measure in future compound evaluations.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Time-dependent MDR reversal assay using a MTT-based approach. (A, B) Compound <b>19</b> was used at a concentration of 10 nM and was combined with 0.5 μM compound <b>4</b> over a period of 7 days. Shown is the mean ± SEM of at least three independent experiments with triplicate measurements. (A) Normalization was conducted on the effect-value of cells in pure cell culture medium without addition of compound <b>4</b> and/or compound <b>19</b>. (B) Normalization was conducted on the effect-value of compound <b>4</b> alone at the corresponding day. Significance was calculated applying multiple <i>t</i>-test and is given as the following: ∗, <i>p</i> ≤ 0.05; ∗∗, <i>p</i> ≤ 0.01; ∗∗∗, <i>p</i> ≤ 0.001; ∗∗∗∗, <i>p</i> ≤ 0.0001. (C) Cell viability versus time assay using 0.5 μM compound <b>4</b> and 0 nM (●), 10 nM (■), 25 nM (▲), 50 nM (▼) compound <b>19</b>. Shown is the mean ± SEM of at least three independent experiments with triplicate measurements. (D) The inflection points derived from the curves in graphic (C) have been plotted against the used concentration of compound <b>19</b>. Nonlinear regression revealed that when using 0.5 μM compound <b>4</b> in combination with compound <b>19</b>, the latter is able to accelerate half-maximal cell death by a factor of 1.7 (∼4.25 days vs ∼7.25 days). The half-maximal cell death acceleration concentration of compound <b>19</b> was ∼17.25 nM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Sensitization of ABCB1-overexpressing A2780/ADR cells against daunorubicin by compound <b>37</b> at concentrations of 0 μM (●), 0.5 μM (■), 1.0 μM (▲), 5.0 μM (▼), and 10 μM (◆) compared to the wild type cell line A2780 (○). (B) Resulting resistance factors derived from GI<sub>50</sub> values of graph (A) were plotted against the used concentrations of compound <b>37</b>. A nonlinear regression of the obtained curve yielded an EC<sub>50</sub> of 8.41 μM. (C) Sensitization of ABCC1-overexpressing MDCK II MRP1 cells against daunorubicin by compound <b>37</b> at concentrations of 0 μM (●), 0.5 μM (■), 1.0 μM (▲), 5.0 μM (▼), and 10 μM (◆) compared to the wild type cell line MDCK II (○). (D) Resulting resistance factors derived from GI<sub>50</sub> of graph (C) were plotted against the used concentrations of compound <b>37</b>. A nonlinear regression of the obtained curve yielded an EC<sub>50</sub> of 5.15 μM. (E) Sensitization of ABCG2-overexpressing MDCK II BCRP cells against compound <b>4</b> by compound <b>37</b> at concentrations of 0 μM (●), 0.001 μM (■), 0.010 μM (▲), 0.100 μM (▼), and 1.000 μM (◆) compared to the wild type cell line MDCK II (○). (F) Resulting resistance factors derived from GI<sub>50</sub> of graph (E) were plotted against the used concentrations of compound <b>37</b>. A nonlinear regression of the obtained curve yielded an EC<sub>50</sub> of 0.0164 μM. In all cases, the mean ± SEM of at least three independent experiments with duplicate measurements is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In summary, it can be stated that compound <b>19</b> (i) half-maximally sensitizes ABCG2-overexpressing cells at only 11 nM in combination with varying concentrations of compound <b>4</b>, (ii) sensitizes ABCG2-overexpressing cells in combination with 0.5 μM compound <b>4</b> two times as effective as compound <b>4</b> does alone, and (iii) accelerates cell death half-maximally at ∼17.25 nM considering treatment with compound <b>4</b> alone and (iv) the maximal possible acceleration of cell death was caused by by use of ∼50 nM compound <b>19</b>. In essence, this makes compound <b>19</b> the most potent sensitizer of ABCG2-mediated MDR in detail.</div></div><div id="sec2_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Evaluation of Multitarget ABCB1, ABCC1, and ABCG2 Inhibitors for Reversal of ABCB1-, ABCC1-, and ABCG2-Mediated MDR</h4><div class="NLM_p last">The five most potent triple ABCB1/ABCC1/ABCG2 inhibitors as indicated by <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> (compounds <b>27</b>, <b>28</b>, <b>34</b>, <b>36</b>, and <b>37</b>) were investigated for their ability to reverse ABCB1-, ABCC1-, and ABCG2-mediated MDR. While the first four compounds failed to sensitize ABCB1- and ABCC1-overexpressing cells regarding doxorubicin (data not shown), compound <b>37</b> was revealed to be a potent, broad-spectrum reverser of ABCB1-, ABCC1-, and ABCG2-mediated MDR. It half-maximally sensitized A2780/ADR (ABCB1), MDCK II MRP1 (ABCC1), and MCDK II BCRP (ABCG2) cells at 8.41 ± 0.48 μM, 5.15 ± 0.68 μM, and 0.0164 ± 0.0023 μM, respectively (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). These results make compound <b>37</b> a rare example of a triple ABCB1/ABCC1/ABCG2 inhibitor that reversed ABCB1-, ABCC1-, and ABCG2-mediated MDR, which has only been shown before for compounds <b>11</b> and <b>12</b> in the literature (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a></div></div><div id="sec2_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Determination of the Intrinsic Cytotoxicity Using ABCG2-Overexpressing and Wild Type Cells</h4><div class="NLM_p">To evaluate the cytotoxicity of the compounds, a screening was performed using ABCG2-overexpressing MDCK II BCRP cells and their parental cell line MDCK II in a MTT-based cell viability assay. For the screening, the highest concentration used in the inhibition assays (10 μM) was chosen and the cell viability was compared to pure culture medium as negative control (100%) and 10% DMSO as positive control (0%). The bar chart in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> shows that the compounds demonstrated no cytotoxicity at this concentration except for compounds <b>31</b> and <b>36</b>, which might be attributed to the trifluoromethyl substituent. These compounds as well as the most potent reversers of ABCG2-mediated MDR (<b>19</b>, <b>22</b>, <b>29</b>, <b>30</b>) were tested for their half-maximal growth inhibition concentrations (GI<sub>50</sub>), which are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. While compounds <b>31</b> and <b>36</b> had GI<sub>50</sub> values of 9.57 μM and 8.4 μM, respectively, the other evaluated compounds were less toxic (GI<sub>50</sub> > 15 μM). This was reflected in their therapeutic ratio [GI<sub>50(resistant cell line)</sub> divided by IC<sub>50(Hoechst 33342 or pheophorbide A)</sub>], which was in many cases greater than 100. Compounds <b>21</b> and <b>29</b> possessed the highest therapeutic ratios, but it must be considered that the concentration–effect curves of those representatives did not achieve full inhibition in the Hoechst 33342 and pheophorbide A assays, respectively. In this regard, their IC<sub>50</sub> values are overrated and artificially increased the therapeutic ratios. <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> gives the concentration–effect curves of compounds <b>29</b> (nontoxic) and <b>36</b> (toxic). All evaluated compounds exhibited no difference in intrinsic toxicity between transfected and wild type cells, which leads us to believe that they are not transported.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Bar chart showing the influence of the studied compounds (10 μM) on the cell viability of MDCK II BCRP (black) and MDCK II wild type (gray) cells. The data were obtained by a MTT-based assay defining culture medium as negative control (100%) and 10% DMSO as positive control (0%). Shown is the mean ± SEM of at least three independent experiments with duplicate measurements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Half-Maximal Growth Inhibition Values (GI<sub>50</sub>) of Selected Pyrimidines<a class="ref internalNav" href="#tbl4-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">GI<sub>50</sub> ± SEM [μM]</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">therapeutic ratio (tr)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">MDCK II BCRP</th><th class="colsep0 rowsep0" align="center">MDCK II wild-type</th><th class="colsep0 rowsep0" align="center" char=".">Hoechst 33342</th><th class="colsep0 rowsep0" align="center" char=".">pheophorbide A</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>19</b></td><td class="colsep0 rowsep0" align="left">15.7 ± 0.3</td><td class="colsep0 rowsep0" align="left">15.7 ± 0.6</td><td class="colsep0 rowsep0" align="char" char=".">167</td><td class="colsep0 rowsep0" align="char" char=".">90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>22</b></td><td class="colsep0 rowsep0" align="left">17.0 ± 0.2</td><td class="colsep0 rowsep0" align="left">16.7 ± 0.3</td><td class="colsep0 rowsep0" align="char" char=".">327</td><td class="colsep0 rowsep0" align="char" char=".">111</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>29</b></td><td class="colsep0 rowsep0" align="left">96.7 ± 3.5</td><td class="colsep0 rowsep0" align="left">102 ± 5</td><td class="colsep0 rowsep0" align="char" char=".">315</td><td class="colsep0 rowsep0" align="char" char=".">1122</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>30</b></td><td class="colsep0 rowsep0" align="left">145 ± 36</td><td class="colsep0 rowsep0" align="left">188 ± 58</td><td class="colsep0 rowsep0" align="char" char=".">1218</td><td class="colsep0 rowsep0" align="char" char=".">2441</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>31</b></td><td class="colsep0 rowsep0" align="left">9.57 ± 0.12</td><td class="colsep0 rowsep0" align="left">9.89 ± 0.04</td><td class="colsep0 rowsep0" align="char" char=".">139</td><td class="colsep0 rowsep0" align="char" char=".">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>36</b></td><td class="colsep0 rowsep0" align="left">8.40 ± 0.35</td><td class="colsep0 rowsep0" align="left">10.1 ± 2.1</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">DMSO</td><td class="colsep0 rowsep0" align="left">137 ± 4</td><td class="colsep0 rowsep0" align="left">123 ± 29</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl4-fn1"><div class="footnote" id="tbl4-fn1"><sup><sup>a</sup></sup><p class="last">Shown is the mean ± SEM of at least three independent experiments with duplicate measurements. The therapeutic ratio was calculated as the ratio of GI<sub>50</sub> values derived from the cell viability assay of the resistant cell line and IC<sub>50</sub> values of the resistant cell line derived from the Hoechst 33342 and pheophorbide A assays, respectively.</p></div></div></div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0010.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. MTT-based viability assays of compounds <b>29</b> (■) and <b>36</b> (●) using the MDCK II BCRP (closed) and wild type (open) cells. 10% DMSO and culture medium were used to define 0 and 100%, respectively. Shown is the mean ± SEM of at least three independent experiments with duplicate measurements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Determination of the Intrinsic Cytotoxicity of Compound <b>37</b> Using ABCB1-, ABCC1-, and ABCG2-Overexpressing and Corresponding Wild Type Cells</h4><div class="NLM_p last">The only representative of a potent triple ABCB1/ABCC1/ABCG2 inhibitor and effective reverser of ABCB1-, ABCC1-, and ABCG2-mediated MDR, compound <b>37</b>, was evaluated with respect to its intrinsic toxicity, applying the very same cell lines as used in the inhibition assays. Pyrimidine <b>37</b> showed almost no toxicity against A2780/ADR (ABCB1; GI<sub>50</sub> = 28.9 ± 2.9 μM; tr = 5.6) and A2780 (GI<sub>50</sub> = 22.6 ± 3.4 μM) cells, the MDCK II MRP1 (ABCC1; GI<sub>50</sub> = 35.4 ± 2.4; tr = 4.9) and MDCK II (GI<sub>50</sub> = 38.4 ± 2.2) cell line, as well as MDCK II BCRP (ABCG2; GI<sub>50</sub> = 42.1 ± 3.6; tr = 279) cells.</div></div><div id="sec2_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> Investigation of Compound Accumulation in MCF-7 Breast Cancer Cells</h4><div class="NLM_p">As indicated above, the data obtained in the cell viability assays hinted to the fact that the compounds are not transported by ABCG2. To underpin the hypothesis that the compounds are not substrates of ABCG2, the strong autofluorescent, nontoxic pyrimidine <b>38</b> was analyzed with confocal laser scanning microscopy. Because of the similarities in excitation and emission wavelengths to the green fluorescent protein (GFP) linked to ABCG2 in the MDCK II BCRP cell line, MCF-7/MX cells (ABCG2-overexpressing) and their parental counterpart MCF-7 were used to perform fluorescence studies. Pheophorbide A has been taken as a reference. From the fluorescence spectrum taken by a BD LS-55 fluorescence spectrometer, compound <b>38</b> shows an excitation maximum at 370 nm and emission maximum at 495 nm. For the measurement, an excitation wavelength of 405 nm and an emission filter of 500–530 nm (compound <b>38</b>) as well as 662–737 nm (pheophorbide A) were chosen. No difference in fluorescence intensity of compound <b>38</b> in ABCG2-overexpressing MCF-7/MX (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a> A) and parental MCF-7 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a> B) cells was observed. In contrast, there is a difference in pheophorbide A fluorescence between resistant (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a> C) and parental (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a> D) cell lines. The addition of compound <b>38</b> to MCF-7/MX cells with pheophorbide A (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a> E) increased accumulation of pheophorbide A inside the cells, although the intensity did not reach the level of the parental MCF-7 cell line. The slightly lower intensity can be explained by the concentration used in the assay (1 μM), which was only 2 times as high as the IC<sub>50</sub> value of compound <b>38</b>. These studies confirmed that compound <b>38</b> was able to inhibit active transport mediated by ABCG2 while not being an ABCG2 substrate. Taking these results and the formerly stated MTT-based cell viability assay results into account, the compound class of pyrimidines seems generally not to be transported by ABCG2.</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0011.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Confocal laser scanning microscopy analysis of accumulation of fluorescent compound <b>38</b> (A, B) or pheophorbide A (C, D, E) in ABCG2-overexpressing MCF-7/MX (A, C, E) or parental MCF-7 (B, D) cells: (A) compound <b>38</b> (1 μM) in ABCG2-overexpressing MCF-7/MX cells; (B) compound <b>38</b> (1 μM) in parental MCF-7 cells; (C) pheophorbide A (0.5 μM) in ABCG2-overexpressing MCF-7/MX cells; (D) pheophorbide A (0.5 μM) in parental MCF-7 cells; (E) pheophorbide A (0.5 μM) in the presence of compound <b>38</b> (1 μM) in ABCG2-overexpressing MCF-7/MX cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Determination of Mode of Inhibition</h4><div class="NLM_p">The most potent reverser of ABCG2-mediated MDR, compound <b>19</b>, was additionally analyzed regarding its mode of inhibition with respect to ABCG2-mediated Hoechst 33342 transport. Lineweaver–Burk analysis resulted in a competitive mode of action (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a> A), which is characterized by an increased <i>K</i><sub>m</sub> value and constant <i>v</i><sub>max</sub> value. This interrelationship is also depicted in the Cornish–Bowden plot in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a> B.</div><figure id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0012.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Determination of mode of inhibition by compound <b>19</b> using ABCG2-overexpressing MDCK II BCRP cells. (A) Lineweaver–Burk plot of ABCG2-mediated Hoechst 33342 transport at concentrations of 0.3, 0.4, 0.5, 0.6, 0.7, and 1.0 μM. Compound <b>19</b> was used at concentrations of 0 μM (○), 0.056 μM (●), 0.100 μM (■), 0.316 μM (▲), and 1.000 μM (▼). (B) Cornish–Bowden plot generated from direct plot of data, in which <i>K</i><sub>m</sub> (●) increases while <i>v</i><sub>max</sub> (■) remains constant. Depicted are representative experiments out of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Molecular Docking Studies of Compound <b>19</b></h4><div class="NLM_p">In order to understand the binding mode of compound <b>19</b> compared to the substrate Hoechst 33342 and their interaction with ABCG2, we performed molecular modeling studies. The cryoelectron microscopy (cryo-EM) structure of human ABCG2 in complex with the compound <b>41</b> analog MZ29 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FFC">6FFC</a>) and additional docking studies have recently been reported.<a onclick="showRef(event, 'ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref99 ref100">(100,101)</a> On this basis, we have reported putative binding modes of quinazoline-based ABCG2 inhibitors as well as the ABCG2 substrate Hoechst 33342 and further explained the mechanism of inhibition of the former.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a><a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a> A shows the two binding sites (S1 and S2) of ABCG2 as well as the binding poses of MZ29 (S1; <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a> B)<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(100)</a> and the proposed binding pose of Hoechst 33342 (S2; <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>C).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><figure id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0013.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Binding sites (A) and poses of MZ29 (B) as well as Hoechst 33342 (C) in human ABCG2, which is displayed in cartoon representation (chain A: light gray; chain B: dark gray). Both MZ29 (A) and Hoechst 33342 (B) are shown as stick models. (A) The putative binding sites obtained from the cryo-EM structure of human ABCG2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FFC">6FFC</a>) are schematically indicated as S1 and S2. (B) Binding pose of MZ29, an analog of compound <b>41</b> (carbon colored green) in the binding pocket of human ABCG2. (C) Docked pose of the ABCG2 substrate Hoechst 33342 (carbon colored magenta) in the binding pocket of human ABCG2. Oxygen atoms are colored in red and nitrogen atoms in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In this work, we have extended the molecular docking studies to predict the binding pose of compound <b>19</b> and explored the binding site as well as prevailing interactions. Among the top 100 binding poses identified from the molecular docking studies using LeadIT, 66% of poses were occupying the binding site S2 in comparison to 34% of poses in S1 (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a> A). The best scoring binding pose of compound <b>19</b> is shown in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a> B, and the 2D interaction diagram is highlighted in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a> C. The pyrimidine scaffold is positioned in the subpocket where the methylpiperazine partial structure of Hoechst 33342 binds. Due to the smaller ring size of the pyrimidine scaffold in comparison to quinazolines, the pyrimidine scaffold binds deeper into the S2 binding site. The phenyl ring substituted at position 2 of the pyrimidine is directed into the substrate binding pocket and forms strong hydrophobic interaction with Leu388. The two asparagine residues Asn387 and Asn391 form hydrogen bond interactions with the nitrogen atoms of the pyrimidine scaffold. The 3-methyl-4-cyanophenyl ring substituted at position 4 of the pyrimidine through an amine linker is positioned toward the nucleotide binding domain and located in the subpocket formed by a high number of hydrophobic residues Val130, Met131, Gly132, Thr180, and Val450. The 4-cyano group forms a strong electrostatic interaction with Arg191. The amine linker forms a hydrogen bond interaction with Glu451. The hydrogen bond interaction is in agreement with our previous docking and structure–activity relationship studies of quinazolines which specified that an amine linker is highly important for ABCG2 inhibition.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The binding mode and the interaction clearly highlight that compound <b>19</b> possibly established a competitive mode of inhibition against the substrate Hoechst 33342 in the S2 binding site of ABCG2 and substantiate the results obtained in the kinetic studies.</div><figure id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0014.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Putative binding poses of compound <b>19</b>: (A) top 100 docked poses of <b>19</b> (carbon colored cyan) observed in the cryo-EM structure of human ABCG2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FFC">6FFC</a>). (B) best scoring pose of <b>19</b> in the S2 binding site. (C) 2D interaction diagram. Oxygen atoms are colored in red and nitrogen atoms in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Determination of the Influence of Compound <b>19</b> on ABCG2 Expression</h4><div class="NLM_p">Compensatory induction of ABC transporters after chemotherapeutic intervention poses a potential risk for the success of anticancer regimens in general.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref30 ref31">(19−25,30,31)</a> Therefore, compound <b>19</b> was evaluated for its capability to interfere with ABCG2 expression to exclude an ABCG2 upregulation. Western blot analysis was performed after cultivation of resistant MDCK II BCRP cells with compound <b>19</b> alone and in combination with compound <b>4</b> for 4 and 7 days, respectively. These time intervals have been chosen as the MTT-based cell viability assay results given in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> A indicated a higher cell viability after 4 days when cells were treated either with compound <b>4</b> alone or in combination with compound <b>19</b>. The 7-day measurement has been chosen as it marked the end point of the time-dependent MDR reversal assay and equaled in parallel the longest period of exposure to the stated compounds with highest chance of a potential regulatory interference. As can be seen in <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>, exposure to compound <b>4</b> (0.5 μM) alone led to a 2-fold (day 4) and 5-fold (day 7) upregulation of ABCG2, respectively, which is in agreement with previous reports.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> There was no significant difference in total ABCG2 expression in MDCK II BCRP cells when exposed to compound <b>4</b> alone or in combination with compound <b>19</b>. The effect of compound <b>19</b> alone even showed a contradictory effect as it reduced ABCG2 amount by 36% (day 4; <i>p</i> = 0.0007) and 24% (day 7; not significant). Taken together, compound <b>19</b> is not an inducer of ABCG2 and has rather no noteworthy influence on ABCG2 expression.</div><figure id="fig15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0015.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Western blot analysis of ABCG2 protein expression in MDCK II BCRP cells exposed to compound <b>19</b> (10 nM) and/or compound <b>4</b> (0.5 μM) for 4 (left) and 7 days (right), respectively. Bands were normalized by stain-free total protein normalization and related to each untreated control sample. Shown is the mean ± SEM of at least three independent experiments. Significance was calculated by applying one-sample <i>t</i>-test and is given as the following: ∗, <i>p</i> ≤ 0.05; ∗∗, <i>p</i> ≤ 0.01; ∗∗∗, <i>p</i> ≤ 0.001; ∗∗∗∗, <i>p</i> ≤ 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45857" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45857" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The aim of this work was the exploration of the pyrimidine class as ABCG2-selective as well as broad-spectrum ABCB1/ABCC1/ABCG2 inhibitors based on our previous reports.<a onclick="showRef(event, 'ref55 ref57'); return false;" href="javascript:void(0);" class="ref ref55 ref57">(55,57)</a> Only seven of these derivatives have been reported previously, and only one was evaluated for its capability to reverse ABCG2-mediated MDR (compound <b>10</b>)<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> and none for its broad-spectrum like reversal of ABCB1-, ABCC1-, and ABCG2-mediated MDR. Within this work 23 further derivatives were generated. We found seven (<b>19</b>, <b>21</b>, <b>22</b>, <b>29</b>–<b>31</b>, <b>33</b>) highly potent ABCG2 inhibitors that possessed IC<sub>50</sub> values of ≤150 nM in either Hoechst 33342 and/or pheophorbide A assays, therefore significantly lower than the standard ABCG2 inhibitor <b>41</b>. Six of these compounds (<b>19</b>, <b>22</b>, <b>29</b>–<b>31</b>, <b>33</b>) exerted their inhibitory power in the high double-digit nanomolar concentration range, which makes them some of the most potent ABCG2 inhibitors known until today.<a onclick="showRef(event, 'ref54 ref55 ref56 ref57 ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref54 ref55 ref56 ref57 ref59 ref60 ref61">(54−57,59−61)</a> The most potent representatives (<b>19</b>, <b>22</b>, <b>29</b>–<b>31</b>) were proven to reverse ABCG2-mediated MDR in the low double-digit nanomolar concentration range, which is exceptional in the literature.<a onclick="showRef(event, 'ref55 ref56 ref57 ref59 ref60 ref61 ref89'); return false;" href="javascript:void(0);" class="ref ref55 ref56 ref57 ref59 ref60 ref61 ref89">(55−57,59−61,89)</a> Strikingly, the nontoxic and ABCG2-selective pyrimidine <b>19</b> had an EC<sub>50</sub> of only 11 nM, which makes it one of the 18 most potent reversers of ABCG2-mediated MDR known until today.<a onclick="showRef(event, 'ref56 ref89'); return false;" href="javascript:void(0);" class="ref ref56 ref89">(56,89)</a> Considering only data from the most commonly used 72 h MTT-based MDR reversal assay in the literature, it represents the most potent reverser of ABCG2-mediated MDR. Further analysis of this compound showed that it not only concentration-dependently enhanced the cytotoxic effect of compound <b>4</b> in ABCG2-overexpressing cells but also time-dependently increased compound <b>4</b> toxicity compared to compound <b>4</b> alone, doubling compound <b>4</b> toxicity in a time period of 7 days. A statistically significant difference was seen after 5 days, which correlates with a common compound <b>2</b> treatment used in antineoplastic therapy (5-day course).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(99)</a> While ∼50 nM compound <b>19</b> was sufficient to achieve half-maximal cell death (c<sub>tmin</sub>) at ∼60% of the time (<i>t</i><sub>min</sub>) in comparison to compound <b>4</b> treatment alone (<i>t</i><sub>max</sub>), only ∼17.25 nM compound <b>19</b> was necessary to half-maximally accelerate half-maximal cell death in ABCG2-overexpressing cells when exposed to compound <b>4</b> (<i>C</i><sub><sup>1</sup>/<sub>2</sub>tmax</sub>). There has never been a more detailed analysis of efficacy of a compound before, and these new measures could find implementation in future MDR reversal analysis.</div><div class="NLM_p">Further analysis of the binding behavior of compound <b>19</b> showed that it bound to the Hoechst 33342 binding site of ABCG2 leading to competitive inhibition. Molecular docking studies based on cryo-EM structures of human ABCG2<a onclick="showRef(event, 'ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref99 ref100">(100,101)</a> with compound <b>19</b> revealed its strong and deep interaction with the S2 binding site of ABCG2 and support our hypothesis regarding binding of quinazoline-based ABCG2 inhibitors as previously reported.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p">Western blot analysis revealed that compound <b>19</b> did not lead to ABCG2 upregulation within 4 and 7 days but rather led to a slight ABCG2 downregulation in these periods of time. This is important as induction of ABC transporters might lead to failure of chemotherapy in the first place.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22 ref23 ref24 ref25 ref30 ref31">(19−25,30,31)</a></div><div class="NLM_p">Taken together, its exceptional high inhibitory power against ABCG2, selectivity over ABCB1 and ABCC1, and extraordinary concentration- and time-dependent mediation of cell death in combination with a cytotoxic agent as well as its very low intrinsic toxicity and inability to induce ABCG2 make compound <b>21</b> a promising candidate for further in vivo investigations.</div><div class="NLM_p">As previous studies on selective ABC transporter inhibitors revealed frequently broad-spectrum ABC transporter modulators,<a onclick="showRef(event, 'ref54 ref55 ref61 ref62 ref63 ref64 ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref54 ref55 ref61 ref62 ref63 ref64 ref65 ref66">(54,55,61−66)</a> we further investigated the 23 pyrimidine derivatives for their mutlitarget inhibition ability. Ten multitarget ABCB1/ABCC1/ABCG2 inhibitors were discovered, which are up to now only presented by less  than 120 compounds in the literature. The potencies of five of the discovered compounds ranged within the 50 most potent broad-spectrum ABCB1 / ABCC1 / ABCG2 inhibitors as known in the literature.<a onclick="showRef(event, 'ref38 ref49 ref54 ref55 ref61 ref62 ref63 ref64 ref65 ref66 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref38 ref49 ref54 ref55 ref61 ref62 ref63 ref64 ref65 ref66 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84">(38,49,54,55,61−66,74−84)</a> Furthermore, compound <b>37</b> proved to reverse ABCB1-, ABCC1-, and ABCG2-mediated MDR in single-digit micromolar (ABCB1 and ABCC1) and double-digit nanomolar (ABCG2) concentration ranges. Only ∼75 compounds have been reported with this ability before,<a onclick="showRef(event, 'ref47 ref48 ref50 ref50 ref52 ref65 ref66 ref85 ref86 ref87 ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref47 ref48 ref50 ref50 ref52 ref65 ref66 ref85 ref86 ref87 ref88 ref89">(47,48,50,50,52,65,66,85−89)</a> and hit compound <b>37</b> belongs to only 3 known compounds in the literature which have been proven to inhibit ABCB1, ABCC1, and ABCG2 as well as reversing ABCB1-, ABCC1-, ABCG2-mediated MDR.<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a></div><div class="NLM_p">Cell viability assays indicated that the tested pyrimidines were rather nontoxic and furthermore not substrates of ABCG2. This hypothesis could be confirmed with confocal laser scanning microscopy using fluorescent pyrimidine <b>38</b>.</div><div class="NLM_p last">In essence, applying a highly interdisciplinary approach of chemical synthesis, living-cell-based fluorescence and absorbance accumulation assays, computational methods, and protein quantification experiments, we continued the long-lasting development of ABCG2 inhibitors based on TKIs containing a quinazoline scaffold, downsizing it until the basic pyrimidine scaffold was reached, which was superior in sensitizing ABCG2-overexpressing cells. These efforts revealed two exceptional and superior representatives, the ABCG2-selective compound <b>19</b> as well as the multitarget ABCB1/ABCC1/ABCG2 inhibitor and MDR reverser, compound <b>37.</b></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76783" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76783" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Materials</h4><div class="NLM_p last">Chemicals were purchased from Acros Organics (Geel, Belgium), Alfa Aesar (Karlsruhe, Germany), Sigma-Aldrich (Steinheim, Germany), and Merck (Darmstadt, Germany). Microwave reactions were performed in 10 or 30 mL vials with a CEM Discover SP (CEM GmbH, Kamp-Lintfort, Germany). The reaction progress was monitored by thin layer chromatography (TLC) using an aluminum plate coated with silica gel 60 F<sub>254</sub> (Merck Millipore, Billerica, MA, USA). Dichloromethane/methanol and ethyl acetate/petroleum ether (40–60 °C) were used as eluent. The identity of the compounds was confirmed by <sup>1</sup>H and <sup>13</sup>C NMR applying a Bruker Advance 500 MHz (500/126 MHz) or Bruker Advance 600 MHz (600/151 MHz). The chemical shifts (δ) were expressed in ppm. For the assignment of some <sup>13</sup>C signals, attached proton test (APT) was used. Multiplicity of the signals is indicated as singlet (s), doublet (d), doublet of doublets (dd), triplet of doublets (td), triplet (t), doublet of triplets (dt), quartet (q), and multiplet (m). The purity and molecular mass of compounds were confirmed by LC–MS analysis (Applied Biosystems API 2000 LC–MS/MS, HPLC Agilent 1100) using a photodiode array detector and a Nucleodur column 100-5 C18 (Macherey-Nagel, Düren, Germany) followed by ESI mass spectrometry using an API 2000 triple quadrupole mass spectrometer and Sciex Analyst software version 1.5.1. The purity of all compounds investigated in biological testing was determined as ≥95%.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Preparation of 6-Methyl-2-phenylpyrimidin-4-ol (<b>13</b>)</h4><div class="NLM_p last">Sodium (0.304 g, 13.2 mmol) was dissolved in 50 mL of ethanol to afford sodium ethoxide solution. Subsequently, benzamidine (1.31 g, 10.88 mmol), dissolved in 10 mL of ethanol, and ethyl acetoacetate (1.428 g, 10.97 mmol) were added to the sodium ethoxide solution, respectively. The resulting mixture was heated to reflux overnight and cooled down to room temperature. After the solvent had been removed under reduced pressure, 20 mL of water was added to the solid and the mixture was acidified with concentrated HCl to pH 5–6. The formed precipitate was vacuum filtered and washed with water three times. Finally, the obtained crude residue was recrystallized from DMF/H<sub>2</sub>O to give 6-methyl-2-phenylpyrimidin-4-ol as white solid (1.22 g; 60%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 12.49 (s, 1H), 8.13–8.09 (m, 2H), 7.58–7.55 (m, 1H), 7.53–7.49 (m, 2H), 6.20 (s, 1H), 2.28 (d, <i>J</i> = 0.9 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 164.56, 163.59, 156.92, 132.71, 131.42, 128.51, 127.68, 109.87, 23.45.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Preparation of 4-Chloro-6-methyl-2-phenylpyrimidine (<b>14</b>)</h4><div class="NLM_p last">The comound was synthesized from <b>13</b> (1.035 g, 5.07 mmol) and POCl<sub>3</sub> (20 mL). The solution was refluxed until the reaction was complete. Excess POCl<sub>3</sub> was removed under reduced pressure. The oily residue was transferred onto crushed ice portion by portion while keeping the temperature of solution below 10 °C. The product was extracted three times with ethyl acetate. The organic layer was washed with saturated NaHCO<sub>3</sub>, saturated NaCl solution and dried over magnesium sulfate. After filtration, ethyl acetate was removed under reduced pressure. Final purification was performed by column chromatography with ethyl acetate/petroleum ether (40–60 °C) = 1:8 as eluent to yield white crystals (0.782 g; 75%). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ: 8.47–8.44 (m, 2H), 7.52–7.47 (m, 3H), 7.11 (s, 1H), 2.60 (s, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 169.02, 165.05, 161.69, 136.27, 131.53, 128.75, 128.73, 118.59, 24.14.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> General Procedure for the Preparation of 4-Anilino-6-methyl-2-phenylpyrimidine Derivatives (<b>18</b>–<b>40</b>)</h4><div class="NLM_p last">A mixture of 1 equiv of <b>14</b> and 1 equiv of substituted aniline in 3 mL of isopropanol was heated to 110 °C in a microwave for 15–30 min. If reaction did not initiate, 0.1 equiv of conc HCl was added as catalyst. The precipitate was filtered off and washed with saturated sodium bicarbonate solution three times followed by distilled water three times. Further purification was performed by recrystallization or column chromatography.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 4-((6-Methyl-2-phenylpyrimidin-4-yl)amino)phthalonitrile (<b>18</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (145 mg, 0.71 mmol) and 3,4-dicyanoaniline (101 mg, 0.70 mmol) as described in the general procedure above. Further purification was performed by recrystallization from ethanol/H<sub>2</sub>O. White solid (13.6 mg, 6.2%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.35 (s, 1H), 8.54 (d, <i>J</i> = 2.2 Hz, 1H), 8.33–8.30 (m, 2H), 8.15 (dd, <i>J</i> = 2.2, 8.8 Hz, 1H), 8.05 (d, <i>J</i> = 8.7 Hz, 1H), 7.53–7.50 (m, 3H), 6.69 (s, 1H), 2.45 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 166.44, 162.47, 159.77, 144.84, 137.38, 134.88, 130.68, 128.51, 127.64, 122.81, 122.53, 116.41, 116.05, 115.29, 105.28, 105.11, 23.86. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>19</sub>H<sub>13</sub>N<sub>5</sub> [M + 1]<sup>+</sup>: 312.12. Found: 312.2. Purity: 92%.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-Methyl-4-((6-methyl-2-phenylpyrimidin-4-yl)amino)benzonitrile (<b>19</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (149 mg, 0.73 mmol) and 4-cyano-3-methylaniline (95 mg, 0.72 mmol) as described in the general procedure above. Further purification was performed by recrystallization from ethanol. White solid (103.9 mg, 48%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.94 (s, 1H), 8.38–8.33 (m, 2H), 7.92 (d, <i>J</i> = 1.7 Hz, 1H), 7.81 (dd, <i>J</i> = 2.2, 8.6 Hz, 1H), 7.73 (d, <i>J</i> = 8.5 Hz, 1H), 7.55–7.49 (m, 3H), 6.66 (s, 1H), 2.43 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 165.68, 162.46, 160.22, 144.37, 142.29, 137.65, 133.41, 130.46, 128.47, 127.64, 119.74, 118.50, 116.60, 104.60, 103.65, 23.83, 20.34. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>19</sub>H<sub>16</sub>N<sub>4</sub> [M + 1]<sup>+</sup>: 301.14. Found: 301.1. Purity: 99%</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-(4-((6-Methyl-2-phenylpyrimidin-4-yl)amino)phenyl)acetonitrile (<b>20</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (105 mg, 0.51 mmol) and 2-(4-aminophenyl)acetonitrile (65 mg, 0.49 mmol) as described in the general procedure above. Further purification was performed by column chromatography, dichloromethane/methanol = 200:1 to 20:1. White solid (113.4 mg, 77%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.58 (s, 1H), 8.37–8.33 (m, 2H), 7.81–7.76 (m, 2H), 7.53–7.48 (m, 3H), 7.36 (d, <i>J</i> = 8.6 Hz, 2H), 6.58 (d, <i>J</i> = 0.8 Hz, 1H), 3.99 (s, 2H), 2.39 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 164.87, 162.40, 160.59, 139.46, 137.89, 130.24, 128.51, 128.35, 127.61, 124.50, 120.02, 119.37, 103.46, 23.77, 21.77. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>19</sub>H<sub>16</sub>N<sub>4</sub> [M + 1]<sup>+</sup>: 301.14. Found: 301.0. Purity: 99%.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 6-Methyl-<i>N</i>-(3-nitrophenyl)-2-phenylpyrimidin-4-amine (<b>21</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (71 mg, 0.35 mmol) and 3-nitroaniline (49 mg, 0.35 mmol) as described in the general procedure above. Further purification was performed by recrystallization from isopropanol/H<sub>2</sub>O. Yellow solid (22.5 mg, 21%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.06 (s, 1H), 9.24 (t, <i>J</i> = 2.2 Hz, 1H), 8.46–8.42 (m, 2H), 7.95 (ddd, <i>J</i> = 0.9, 2.2, 8.2 Hz, 1H), 7.86 (ddd, <i>J</i> = 0.9, 2.3, 8.1 Hz, 1H), 7.64 (t, <i>J</i> = 8.1 Hz, 1H), 7.56–7.48 (m, 3H), 6.64 (d, <i>J</i> = 0.8 Hz, 1H), 4.30 (d, <i>J</i> = 4.3 Hz, 0H), 2.44 (d, <i>J</i> = 0.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 165.51, 162.35, 160.30, 148.09, 141.44, 137.60, 130.52, 129.97, 128.41, 127.69, 124.95, 116.05, 113.24, 104.30, 23.83. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub> [M + 1]<sup>+</sup>: 307.11. Found: 307.1. Purity: 99%.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 6-Methyl-<i>N</i>-(4-nitrophenyl)-2-phenylpyrimidin-4-amine (<b>22</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (100 mg, 0.49 mmol) and 4-nitroaniline (68 mg, 0.49 mmol) as described in the general procedure above. Further purification was performed by recrystallization from isopropanol/H<sub>2</sub>O. Yellow solid (18.7 mg, 13%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.25 (s, 1H), 8.41–8.37 (m, 2H), 8.32–8.28 (m, 2H), 8.09–8.05 (m, 2H), 7.57–7.51 (m, 3H), 6.72 (d, <i>J</i> = 0.7 Hz, 1H), 2.46 (d, <i>J</i> = 0.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 166.03, 162.55, 160.03, 146.72, 140.70, 137.47, 130.55, 128.52, 127.78, 125.15, 118.39, 105.00, 23.86. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub> [M + 1]<sup>+</sup>: 307.11. Found: 307.2. Purity: 99%.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-((6-Methyl-2-phenylpyrimidin-4-yl)amino)phenol (<b>23</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (210 mg, 1.03 mmol) and 3-bromoaniline (113 mg, 1.04 mmol) as described in the general procedure above. Further purification was performed by recrystallization from chloroform/<i>n</i>-hexane. White solid (122.9 mg, 43%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.36 (s, 2H), 8.39–8.34 (m, 2H), 7.52–7.46 (m, 3H), 7.26 (dd, <i>J</i> = 1.6, 2.7 Hz, 1H), 7.17–7.11 (m, 2H), 6.56 (d, <i>J</i> = 0.7 Hz, 1H), 6.45 (dt, <i>J</i> = 2.3, 6.6 Hz, 1H), 2.38 (d, <i>J</i> = 0.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 164.64, 162.45, 160.74, 157.74, 141.03, 137.99, 130.16, 129.36, 128.28, 127.68, 110.55, 109.47, 106.88, 103.32, 23.79. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>15</sub>N<sub>3</sub>O [M + 1]<sup>+</sup>: 278.12. Found: 278.1. Purity: 99%.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (3-((6-Methyl-2-phenylpyrimidin-4-yl)amino)phenyl)methanol (<b>24</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (103 mg, 0.50 mmol) and (4-aminophenyl)methanol (62 mg, 0.50 mmol) as described in the general procedure above. Further purification was performed by column chromatography, dichloromethane/methanol = 200:1 to 20:1. White solid (83.1 mg, 57%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.81 (s, 1H), 8.39–8.33 (m, 2H), 7.82 (s, 1H), 7.61 (dt, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.55–7.49 (m, 3H), 7.33 (t, <i>J</i> = 7.8 Hz, 1H), 7.01 (d, <i>J</i> = 7.5 Hz, 1H), 6.63 (s, 1H), 5.21 (s, 1H), 4.55 (s, 2H), 2.42 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 163.23, 161.78, 160.76, 143.34, 139.43, 136.70, 130.70, 128.42, 127.86, 120.65, 118.33, 118.18, 103.38, 62.84, 22.98. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>18</sub>H<sub>17</sub>N<sub>3</sub>O [M + 1]<sup>+</sup>: 292.14. Found: 292.1. Purity: 98%.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-(3-Methoxyphenyl)-6-methyl-2-phenylpyrimidin-4-amine (<b>25</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (182 mg, 0.89 mmol) and 3-methoxyaniline (186 mg, 1.51 mmol) as described in the general procedure above. Further purification was performed by recrystallization from isopropanol. White solid (23.6 mg, 9.1%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.51 (s, 1H), 8.38–8.34 (m, 2H), 7.59 (t, <i>J</i> = 2.1 Hz, 1H), 7.53–7.47 (m, 3H), 7.29–7.22 (m, 2H), 6.61 (ddd, <i>J</i> = 1.7, 2.5, 7.6 Hz, 1H), 6.58 (d, <i>J</i> = 0.8 Hz, 1H), 3.80 (s, 3H), 2.39 (d, <i>J</i> = 0.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 164.81, 162.41, 160.67, 159.62, 141.31, 138.00, 130.24, 129.46, 128.31, 127.55, 111.83, 107.86, 105.12, 103.59, 54.94, 23.79. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>18</sub>H<sub>17</sub>N<sub>3</sub>O [M + 1]<sup>+</sup>: 292.14. Found: 292.0. Purity: 99%</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(3-Fluorophenyl)-6-methyl-2-phenylpyrimidin-4-amine (<b>26</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (193 mg, 0.94 mmol) and 3-fluoroaniline (108 mg, 0.97 mmol) as described in the general procedure above. Further purification was performed by recrystallization from <i>n</i>-hexane. White solid (134.1 mg, 51%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.73 (s, 1H), 8.37–8.32 (m, 2H), 7.86 (dt, <i>J</i> = 2.3, 12.2 Hz, 1H), 7.55–7.48 (m, 3H), 7.46 (ddd, <i>J</i> = 1.0, 2.0, 8.3 Hz, 1H), 7.39 (td, <i>J</i> = 6.9, 8.2 Hz, 1H), 6.84 (tdd, <i>J</i> = 0.9, 2.6, 8.5 Hz, 1H), 6.61 (d, <i>J</i> = 0.8 Hz, 1H), 2.41 (d, <i>J</i> = 0.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 165.17, 162.44, 161.76, 160.47, 142.00, 137.86, 130.35, 130.26, 128.41, 127.54, 115.12, 108.19, 106.05, 103.91, 23.80. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>14</sub>FN<sub>3</sub> [M + 1]<sup>+</sup>: 280.12. Found: 280.1. Purity: 98%.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-(3-Chlorophenyl)-6-methyl-2-phenylpyrimidin-4-amine (<b>27</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (168 mg, 0.82 mmol) and 3-chloroaniline (102 mg, 0.80 mmol) as described in the general procedure above. Further purification was performed by recrystallization from <i>n</i>-hexane. White solid (148.7 mg, 63%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.72 (s, 1H), 8.39–8.31 (m, 2H), 8.11 (t, <i>J</i> = 2.1 Hz, 1H), 7.62 (ddd, <i>J</i> = 0.9, 2.1, 8.3 Hz, 1H), 7.56–7.46 (m, 3H), 7.39 (t, <i>J</i> = 8.1 Hz, 1H), 7.07 (ddd, <i>J</i> = 0.9, 2.2, 8.0 Hz, 1H), 6.60 (d, <i>J</i> = 0.8 Hz, 1H), 2.41 (d, <i>J</i> = 0.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 165.22, 162.37, 160.40, 141.64, 137.82, 133.03, 130.38, 130.34, 128.39, 127.54, 121.42, 118.90, 117.69, 103.93, 23.80. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>14</sub>ClN<sub>3</sub> [M + 1]<sup>+</sup>: 296.09. Found: 296.1. Purity: 99%.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(3-Bromophenyl)-6-methyl-2-phenylpyrimidin-4-amine (<b>28</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (123 mg, 0.60 mmol) and 3-bromoaniline (102 mg, 0.60 mmol) as described in the general procedure above. Further purification was performed by recrystallization from <i>n</i>-hexane. White solid (44.7 mg, 22%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.71 (s, 1H), 8.38–8.32 (m, 2H), 8.29 (t, <i>J</i> = 2.0 Hz, 1H), 7.65 (ddd, <i>J</i> = 0.9, 2.1, 8.2 Hz, 1H), 7.56–7.47 (m, 3H), 7.33 (t, <i>J</i> = 8.1 Hz, 1H), 7.20 (ddd, <i>J</i> = 0.9, 1.9, 7.9 Hz, 1H), 6.59 (d, <i>J</i> = 0.7 Hz, 1H), 2.41 (d, <i>J</i> = 0.7 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 165.22, 162.34, 160.36, 141.78, 137.80, 130.63, 130.39, 128.38, 127.55, 124.28, 121.83, 121.53, 118.04, 103.93, 23.81. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>14</sub>BrN<sub>3</sub> [M + 1]<sup>+</sup>: 340.04. Found: 340.1. Purity: 99%.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-Fluoro-5-((6-methyl-2-phenylpyrimidin-4-yl)amino)benzonitrile (<b>29</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (101 mg, 0.49 mmol) and 3-cyano-4-fluoroaniline (66 mg, 0.48 mmol) as described in the general procedure above. Further purification was performed by column chromatography, ethyl acetate/petroleum ether (40–60 °C) = 1:8 to 1:1. White solid (117.6 mg, 80%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.84 (s, 1H), 8.34–8.29 (m, 3H), 8.02 (ddd, <i>J</i> = 2.8, 4.8, 9.2 Hz, 1H), 7.56–7.47 (m, 4H), 6.59 (s, 1H), 2.41 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 165.45, 162.35, 160.21, 157.34, 137.71, 137.31, 130.42, 128.38, 127.56, 126.67, 123.15, 116.98, 114.13, 103.77, 99.77, 23.80. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>18</sub>H<sub>13</sub>FN<sub>4</sub> [M + 1]<sup>+</sup>: 305.11. Found: 305.1. Purity: 98%.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-Bromo-4-((6-methyl-2-phenylpyrimidin-4-yl)amino)benzonitrile (<b>30</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (102 mg, 0.50 mmol) and 3-bromo-4-cyanoaniline (97 mg, 0.49 mmol) as described in the general procedure above. Further purification was performed by column chromatography, ethyl acetate/petroleum ether (40–60 °C) = 1:8 to 1:1. White solid (93.4 mg, 52%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.94 (s, 1H), 8.57 (s, 1H), 8.32–8.29 (m, 2H), 7.93–7.87 (m, 2H), 7.63–7.55 (m, 3H), 6.85 (s, 1H), 2.51 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 163.28, 161.39, 160.27, 144.78, 135.29, 131.57, 128.71, 128.05, 124.86, 122.84, 118.61, 117.65, 106.71, 105.29, 22.41. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>18</sub>H<sub>13</sub>BrN<sub>4</sub> [M + 1]<sup>+</sup>: 365.03. Found: 365.0. Purity: 97%.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-((6-Methyl-2-phenylpyrimidin-4-yl)amino)-2-(trifluoromethyl)benzonitrile (<b>31</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (153 mg, 0.75 mmol) and 4-cyano-3-trifluoroaniline (139 mg, 0.74 mmol) as described in the general procedure above. Further purification was performed by recrystallization from ethanol. White solid (59.0 mg, 22%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.41 (s, 1H), 8.84 (s, 1H), 8.37–8.31 (m, 2H), 8.09 (d, <i>J</i> = 8.7 Hz, 1H), 8.02 (d, <i>J</i> = 8.8 Hz, 1H), 7.57–7.47 (m, 3H), 6.70 (s, 1H), 2.46 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 166.32, 162.41, 159.90, 144.95, 137.36, 136.19, 131.70, 130.69, 128.46, 127.57, 122.26, 121.41, 116.16, 116.10, 105.15, 99.16, 23.86. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>19</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub> [M + 1]<sup>+</sup>: 355.11. Found: 355.1. Purity: 99%.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-(4-Fluoro-3-nitrophenyl)-6-methyl-2-phenylpyrimidin-4-amine (<b>32</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (98 mg, 0.48 mmol) and 4-fluoro-3-nitroaniline (68 mg, 0.44 mmol) as described in the general procedure above. Further purification was performed by column chromatography, dichloromethane/methanol = 200:1 to 20:1. Yellow solid (96.5 mg, 68%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.99 (s, 1H), 9.11 (dd, <i>J</i> = 2.8, 6.9 Hz, 1H), 8.43–8.38 (m, 2H), 7.90 (ddd, <i>J</i> = 2.8, 3.8, 9.1 Hz, 1H), 7.58 (dd, <i>J</i> = 9.0, 11.2 Hz, 1H), 7.54–7.48 (m, 3H), 6.60 (d, <i>J</i> = 0.8 Hz, 1H), 2.43 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 165.48, 162.31, 160.12, 149.49, 137.56, 137.04, 136.22, 130.51, 128.38, 127.68, 126.38, 118.71, 115.45, 104.06, 23.81. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>13</sub>FN<sub>4</sub>O<sub>2</sub> [M + 1]<sup>+</sup>: 325.10. Found: 324.9. Purity: 99%.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-(3-Chloro-4-nitrophenyl)-6-methyl-2-phenylpyrimidin-4-amine (<b>33</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (114 mg, 0.56 mmol) and 3-chloro-4-nitroaniline (93 mg, 0.54 mmol) as described in the general procedure above. Further purification was performed by column chromatography, dichloromethane/methanol = 200:1 to 20:1. Pale yellow solid (75.0 mg, 41%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.14 (s, 1H), 8.39 (d, <i>J</i> = 2.3 Hz, 1H), 8.36–8.28 (m, 2H), 8.22 (d, <i>J</i> = 9.0 Hz, 1H), 7.94 (dd, <i>J</i> = 2.3, 9.0 Hz, 1H), 7.64–7.55 (m, 3H), 6.90 (s, 1H), 2.53 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 163.29, 161.33, 160.27, 144.61, 140.48, 135.06, 131.63, 128.73, 128.12, 127.72, 126.96, 121.13, 118.25, 105.35, 22.24. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>17</sub>H<sub>13</sub>ClN<sub>4</sub>O<sub>2</sub> [M + 1]<sup>+</sup>: 341.07. Found:341.2. Purity: 98%.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>-(4-Bromo-3-methoxyphenyl)-6-methyl-2-phenylpyrimidin-4-amine (<b>34</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (148 mg, 0.72 mmol) and 4-bromo-3-methoxyaniline (146 mg, 0.72 mmol) as described in the general procedure above. Further purification was performed by recrystallization from isopropanol/H<sub>2</sub>O. White solid (34.4 mg, 13%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.67 (s, 1H), 8.39–8.34 (m, 2H), 7.87 (d, <i>J</i> = 2.4 Hz, 1H), 7.53–7.48 (m, 4H), 7.18 (dd, <i>J</i> = 2.4, 8.6 Hz, 1H), 6.60 (d, <i>J</i> = 0.8 Hz, 1H), 2.41 (d, <i>J</i> = 0.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 165.21, 162.58, 160.62, 155.49, 141.23, 138.05, 132.73, 130.48, 128.50, 127.75, 112.90, 104.26, 104.08, 102.49, 56.06, 23.95. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>18</sub>H<sub>16</sub>BrN<sub>3</sub>O [M + 1]<sup>+</sup>: 370.05. Found: 370.0. Purity: 99%.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-(3-Fluoro-4-methoxyphenyl)-6-methyl-2-phenylpyrimidin-4-amine (<b>35</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (91 mg, 0.45 mmol) and 3-fluoro-4-methoxyaniline (60 mg, 0.42 mmol) as described in the general procedure above. Further purification was performed by column chromatography, ethyl acetate/petroleum ether (40–60 °C) = 1:8 to 1:1. White solid (84.0 mg, 64%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.49 (s, 1H), 8.35–8.30 (m, 2H), 7.76 (dd, <i>J</i> = 2.6, 13.9 Hz, 1H), 7.53–7.47 (m, 3H), 7.41 (ddd, <i>J</i> = 1.4, 2.6, 8.9 Hz, 1H), 7.19 (dd, <i>J</i> = 8.9, 9.8 Hz, 1H), 6.52 (d, <i>J</i> = 0.7 Hz, 1H), 3.84 (s, 3H), 2.38 (d, <i>J</i> = 0.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 164.77, 162.40, 160.56, 151.04, 142.23, 137.97, 133.56, 130.24, 128.34, 127.52, 115.69, 114.37, 108.33, 103.16, 56.28, 23.77. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>18</sub>H<sub>16</sub>FN<sub>3</sub>O [M + 1]<sup>+</sup>: 310.13. Found: 310.1. Purity: 100%.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i>-(4-Methoxy-3-(trifluoromethyl)phenyl)-6-methyl-2-phenylpyrimidin-4-amine (<b>36</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (53 mg, 0.26 mmol) and 3-trifluoro-4-methoxyaniline (49 mg, 0.26 mmol) as described in the general procedure above. Further purification was performed by column chromatography, ethyl acetate/petroleum ether (40–60 °C) = 1:8 to 1:1. Brown solid (73.8 mg, 81%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.13 (s, 1H), 8.29–8.22 (m, 3H), 7.91 (d, <i>J</i> = 8.8 Hz, 1H), 7.67 (t, <i>J</i> = 7.4 Hz, 1H), 7.61 (t, <i>J</i> = 7.6 Hz, 2H), 7.37 (d, <i>J</i> = 9.0 Hz, 1H), 6.81 (s, 1H), 3.91 (s, 3H), 2.53 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 160.64, 160.60, 159.88, 153.61, 132.52, 130.88, 128.80, 128.42, 126.71, 123.50, 119.89, 116.78, 113.69, 104.01, 56.39, 20.31. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>19</sub>H<sub>16</sub>F<sub>3</sub>N<sub>3</sub>O [M + 1]<sup>+</sup>: 360.12. Found: 360.0. Purity: 99%.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>N</i>-(6-Methyl-2-phenylpyrimidin-4-yl)quinolin-6-amine (<b>37</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (55 mg, 0.27 mmol) and quinolin-6-amine (46 mg, 0.32 mmol) as described in the general procedure above. Further purification was performed by recrystallization from ethyl acetate/<i>n</i>-hexane. Yellow solid (13.5 mg, 16%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.88 (s, 1H), 8.76 (dd, <i>J</i> = 1.7, 4.2 Hz, 1H), 8.56 (d, <i>J</i> = 2.4 Hz, 1H), 8.43–8.39 (m, 2H), 8.31–8.28 (m, 1H), 8.03–7.94 (m, 2H), 7.57–7.47 (m, 4H), 6.69 (d, <i>J</i> = 0.8 Hz, 1H), 2.43 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 165.15, 162.54, 160.62, 148.44, 144.24, 138.10, 137.89, 135.14, 130.32, 129.41, 128.52, 128.47, 127.68, 124.18, 121.74, 114.56, 103.89,23.85. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>20</sub>H<sub>16</sub>N<sub>4</sub> [M + 1]<sup>+</sup>: 313.14. Found: 313.2. Purity: 99%.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>N</i>-(6-Methyl-2-phenylpyrimidin-4-yl)quinoxalin-6-amine (<b>38</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (120 mg, 0.58 mmol) and quinoxalin-6-amine (85 mg, 0.58 mmol) as described in the general procedure above. Further purification was performed by recrystallization from ethanol/H<sub>2</sub>O, brown solid (38.2 mg, 21%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 10.11 (s, 1H), 8.88 (dd, <i>J</i> = 2.1, 14.2 Hz, 2H), 8.78 (d, <i>J</i> = 1.8 Hz, 1H), 8.45–8.42 (m, 2H), 8.08–8.02 (m, 2H), 7.57–7.53 (m, 3H), 6.74 (d, <i>J</i> = 0.8 Hz, 1H), 2.46 (d, <i>J</i> = 0.6 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 165.46, 162.59, 160.48, 145.84, 143.47, 143.20, 141.50, 138.63, 137.83, 130.51, 129.43, 128.50, 127.66, 124.48, 114.63, 104.60,23.88. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>19</sub>H<sub>15</sub>N<sub>5</sub> [M + 1]<sup>+</sup>: 314.13. Found: 314.0. Purity: 99%.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-6-methyl-2-phenylpyrimidin-4-amine (<b>39</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (102 mg, 0.50 mmol) and 2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-amine (71 mg, 0.47 mmol) as described in the general procedure above. Further purification was performed by column chromatography, ethyl acetate/petroleum ether (40–60 °C) = 1:8 to 1:1. Beige solid (123.8 mg, 84%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.65 (s, 1H), 8.34–8.26 (m, 2H), 7.56–7.48 (m, 3H), 7.38 (s, 1H), 7.09 (dd, <i>J</i> = 2.5, 8.7 Hz, 1H), 6.87 (d, <i>J</i> = 8.7 Hz, 1H), 6.55 (s, 1H), 4.30–4.20 (m, 4H), 2.39 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 161.96, 160.92, 143.26, 139.41, 133.19, 130.84, 128.57, 127.89, 117.09, 113.90, 109.62, 103.05, 64.38, 64.09, 23.02. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>19</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub> [M + 1]<sup>+</sup>: 320.13. Found: 319.8. Purity: 99%.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 5-((6-Methyl-2-phenylpyrimidin-4-yl)amino)isoindoline-1,3-dione (<b>40</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>14</b> (100 mg, 0.49 mmol) and 5-aminoisoindoline-1,3-dione (75 mg, 0.47 mmol) as described in the general procedure above. Further purification was performed by column chromatography, dichloromethane/methanol = 200:1 to 20:1. Yellow solid (31.7 mg, 21%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.17 (s, 1H), 10.58 (s, 1H), 8.46 (d, <i>J</i> = 1.9 Hz, 1H), 8.35 (dd, <i>J</i> = 1.9, 7.8 Hz, 2H), 8.06 (dd, <i>J</i> = 1.9, 8.3 Hz, 1H), 7.83 (d, <i>J</i> = 8.2 Hz, 1H), 7.61–7.51 (m, 3H), 6.78 (s, 1H), 2.48 (s, 3H). <sup>13</sup>C NMR (126 MHz, DMSO) δ: 169.20, 169.02, 161.98, 160.51, 145.45, 136.42, 134.42, 131.30, 128.76, 128.08, 125.47, 124.22, 123.86, 113.21, 104.98, 23.09. LC–MS (<i>m</i>/<i>z</i>) calcd for C<sub>19</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub> [M + 1]<sup>+</sup>: 331.11. Found: 331.1. Purity: 96%.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Biological Investigations</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Materials</h4><div class="NLM_p last">The reference compounds <b>41</b> ((3<i>S</i>,6<i>S</i>,12a<i>S</i>)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1′,2′:1,6]pyrido[3,4-<i>b</i>]indole-3-propanoic acid 1,1-dimethylethyl ester) and cyclosporine A were purchased from Tocris Bioscience (Bristol, U.K.). The fluorescence dyes pheophorbide A and calcein AM were provided by Calbiochem [EMD Chemicals (San Diego, CA, USA), supplied by Merck KgaA (Darmstadt, Germany)]. All other chemicals were purchased from Sigma-Aldrich (Taufkirchen, Germany), Carl Roth (Karlsruhe, Germany), or Merck KgaA (Darmstadt, Germany). The compounds and references were prepared as 10 mM stock solutions in DMSO and stored at −20 °C. Cell-based assays were carried out in Krebs-HEPES buffer (KHB) at pH of 7.4. KHB was prepared from 118.6 mM NaCl, 4.7 mM KCl, 1.2 mM KH<sub>2</sub>PO<sub>4</sub>, 4.2 mM NaHCO<sub>3</sub>, 1.3 mM CaCl<sub>2</sub>, 1.2 mM MgSO<sub>4</sub>, 11.7 mM <span class="smallcaps smallerCapital">d</span>-glucose monohydrate, and 10.0 mM HEPES (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid) in doubly distilled water. The pH of the solution was adjusted to 7.4 at 37 °C with sodium hydroxide solution, and then it was sterilized using a 0.2 μm membrane filter.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Cell Culture</h4><div class="NLM_p last">The cell lines MDCK II, MDCK II BCRP and MDCK II MRP1 were received as a generous gift from Dr. A. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands). MDCK II BCRP cells were generated by transfection of the canine kidney epithelial cell line MDCK II with the human wild-type cDNA C-terminally linked to the cDNA of the green fluorescent protein (GFP).<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(102)</a> These cells were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FCS), 50 μg/μL streptomycin, 50 U/mL penicillin G, and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine. Human ovarian carcinoma cell line A2780/ADR was purchased from European Collection of Animal Cell Culture (ECACC, no. 93112520) and cultured in RPMI-1640 medium supplemented with 10% FCS, 50 μg/μL streptomycin, 50 U/mL penicillin G, and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine. To preserve the doxorubicin resistance, every 10 passages the cells were grown with 1 μM doxorubicin for one passage. The breast cancer cell lines MCF-7 and MCF-7/MX were a generous gift from Dr. Erasmus Schneider (Wadsworth Center, Albany, NY, U.S.).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The cells were cultured in RPMI 1640 culture medium supplemented with 20% FCS, 50 U/mL penicillin G, and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine. All the cells were stored under liquid nitrogen in a mixture of 90% pure cell culture medium and 10% DMSO. Cell culturing was performed in 5% CO<sub>2</sub>-humidified atmosphere at 37 °C. Harvesting was conducted after a confluence of at least 90% was achieved for either subculturing or biological evaluation. The cells were detached with 0.05% trypsin and 0.02% EDTA, collected with medium, and centrifuged in a 50 mL Falcon (266<i>g</i>, 4 °C, 4 min). After removal of the supernatant, cells were resuspended in fresh culture medium. If cells were used for cell-based assays, they were afterward washed with KHB three times in order to remove excess culture medium. The cell count was determined by a CASY TT cell counter (Schärfe System GmbH, Reutlingen, Germany) equipped with a 150 μm capillary.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Hoechst 33342 Assay</h4><div class="NLM_p last">To investigate the inhibitory effect of the compounds on ABCG2, a Hoechst 33342 assay was performed as described earlier.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(103)</a> Dilutions of the compounds were prepared in KHB with addition of a certain amounts of methanol in case of solubility problems, which resulted in a final methanol concentration of less than 5%. An amount of 20 μL of the prepared dilutions was placed into black 96-well plates (Greiner, Frickenhausen, Germany). Cells were harvested as described before and then seeded into prepared plates at a density of approximately 30 000 cells per well in a volume of 160 μL. Following the preincubation of 30 min at 37 °C and 5% CO<sub>2</sub>, an amount of 20 μL of 10 μM Hoechst 33342 solution was added to each well, amounting to a final concentration of 1 μM Hoechst 33342. Fluorescence was measured in constant time intervals of 60 s for 120 min with an excitation wavelength of 355 nm and an emission wavelength of 460 nm using microplate readers (POLARstar and FLUOstar Optima by BMG Labtech, Offenburg, Germany). Average of fluorescence values in the steady state were calculated for each concentration and plotted against the logarithm of the compound concentration. Concentration–response curves were generated by nonlinear regression using the three- or four-parameter logistic equation. The statistically preferred model was chosen for calculating IC<sub>50</sub> value (GraphPad Prism, version 6.0, San Diego, CA, USA).</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Pheophorbide A Assay</h4><div class="NLM_p last">Additionally, the inhibitory potency against ABCG2 was examined using the pheophorbide A assay as described earlier.<a onclick="showRef(event, 'ref9800'); return false;" href="javascript:void(0);" class="ref ref9800">(98)</a> An amount of 20 μL of the compound dilutions was pipetted into 96-well U-shaped clear plates (Greiner, Frickenhausen, Germany), and the cell suspension was prepared. Approximately 45 000 cells were added to each well in a volume of 160 μL, and the plate was kept for 15 min at 37 °C and 5% CO<sub>2</sub>. Afterward, an amount of 20 μL of 5 μM pheophorbide A solution was added yielding a final concentration of 0.5 μM. The plate was incubated for 2 h and then measured at an excitation wavelength of 488 nm and emission of 695/50 nm using Guava easyCyte HT flow cytometry. Expression of ABCG2 was examined by the fluorescence of GFP detected at the wavelength of 525/30 nm. Data analysis was performed as described for the Hoechst 33342 assay.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Calcein AM Assay</h4><div class="NLM_p last">The calcein AM assay assay was performed to determine the selectivity of the compounds as already described earlier.<a onclick="showRef(event, 'ref66 ref9800'); return false;" href="javascript:void(0);" class="ref ref66 ref9800">(66,98)</a> The compounds were tested for their inhibitory activity toward ABCB1 and ABCC1 using A2780/ADR and MDCK II MRP1 cells, respectively. An amount of 20 μL of the compound dilutions was put into a 96-well flat-bottom clear plate (Greiner, Frickenhausen, Germany). After the cells were harvested and washed as described earlier, the cells were seeded into the plate at a density of 30 000 cells per well. The addition of the cell suspension to the dilutions of the compounds resulted in a total amount of 180 μL which were thereafter incubated for 30 min at 37 °C and 5% CO<sub>2</sub>. Afterward, an amount of 20 μL of a 3.125 μM calcein AM solution was added to each well and immediately measured every 60 s for a period of 60 min. The measurement was carried out at the excitation wavelength of 485 nm and emission of 520 nm using a microplate reader (POLARstar and FLUOstar Optima by BMG Labtech, Offenburg, Germany). The first linear increase of fluorescence was used for calculating slopes, which were then plotted against logarithmic concentrations of tested compounds. Data analysis was performed as described above.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> MTT Cell Viability Assay</h4><div class="NLM_p last">Intrinsic cytotoxicity of the compounds was determined by a MTT viability assay as described earlier.<a onclick="showRef(event, 'ref66 ref9800'); return false;" href="javascript:void(0);" class="ref ref66 ref9800">(66,98)</a> Solutions of test compounds in culture medium were prepared in concentrations ranging from 3.2 to 1000 μM. After these dilution series were pipetted into 96-well tissue culture plates (Starlab GmbH, Hamburg, Germany) cells were harvested as described before. MDCK II BCRP and the parental cells were seeded at a density of approximately 2000 cells per well in a volume of 180 μL of culture medium and stored under 5% CO<sub>2</sub> and 37 °C for 72 h. Culture medium and 10% (v/v) DMSO were used as negative and positive controls, respectively, and determined 100% and 0% viability, respectively. After the incubation period of 72 h, an amount of 40 μL (5 mg/mL) of MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added to each well and incubated for 1 h. Afterward, the supernatant was removed and the formed formazan was dissolved in 100 μL of DMSO. Absorbance was measured spectrophotometrically at 570 nm using an Ex Multiscan microplate photometer (Thermo Fischer Scientific, Waltham, MA, USA) with a background correction at 690 nm. The measured absorbance values were plotted against logarithmic concentrations, and the half-maximal growth inhibition (GI<sub>50</sub>) values were calculated with nonlinear regression using GraphPad Prism (version 6.0, San Diego, CA, USA).</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Time- and Concentration-Dependent MDR Reversal Assays</h4><div class="NLM_p last">The ability to reverse ABCG2-mediated multidrug resistance of MDCK II BCRP cells toward the cytotoxic substrate compound <b>4</b> was investigated for the most potent compounds. The MTT cell viability assay was extended by addition of 20 μL of a 0 μM, 0.01 μM, 0.1 μM, 1 μM, and 10 μM dilution of the tested compounds in combination with 20 μL of a dilution series of compound <b>4</b> ranging from 0.1 μM to 100 μM (concentration-dependent assay). For the time-dependent assay we added 20 μL of the compound dilution series using concentrations of 0 μM, 0.1 μM, 0.25 μM, and 0.5 μM and 20 μL of a fixed concentration of 5 μM compound <b>4</b> in a 96-well tissue culture plate (Starlab GmbH, Hamburg, Germany). A positive control was performed using MDCK parental cell line without the addition of the modulator. An amount of 160 μL of cell suspension was subsequently added to the wells resulting in a cell density of 2000 cells per well for the concentration-dependent assay and 10 000 (day 1), 5000 (day 2), 2000 (day 3), 1000 (day 4), 500 (day 5), 300 (day 6), 200 (day 7) for the time-dependent assay. In the concentration-dependent assay, the plates were incubated for 72 h at 37 °C and 5% CO<sub>2</sub> and were prepared and measured as described earlier for MTT assay. In the time-dependent assay, the cell viability was measured every day for a time period of 7 days.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Western Blotting of ABCG2</h4><div class="NLM_p last">As much as 86 000 MDCK II BCRP cells were seeded out into T25 flasks for 4-day analysis, and 17 200 cells for 7 days, respectively. After adhering, cells were incubated with compound <b>19</b> (10 nM) and/or cytostatic drug <b>4</b> (0.5 μM). After 4 and 7 days, cells were lysed using Invitrogen cell extraction buffer (Thermo Fisher Scientific Inc., Waltham, MA, USA), supplemented with Halt protease inhibition cocktail (Thermo Fisher Scientific Inc., Waltham, MA, USA) and PMSF (Thermo Fisher Scientific Inc., Waltham, MA, USA), according to the manufacturer’s instructions. Protein amount was measured by Pierce BCA protein assay kit (Thermo Fisher Scientific Inc., Waltham, MA, USA), and an amount of 15 μg of protein of each sample was analyzed by SDS–PAGE using 10% stain-free precast gels (BioRad Lab GmbH, Munich, Germany) followed by total protein normalization. Transfer to a PVDF membrane (Thermo Fisher Scientific Inc., Waltham, MA, USA) was conducted using 100 V and 350 mA for 1 h. After blocking, the membrane was incubated with primary anti-ABCG2 mouse antibody BXP-21 (Santa Cruz Biotechnology, Dallas, TX, USA) in a 1:200 dilution overnight at 4 °C. The next day, secondary anti-mouse antibody m-IgGk BP-HRP (Santa Cruz Biotechnology, Dallas, TX, USA) was added in a 1:10000 dilution for 1.5 h. Luminescence visualization was performed using Clarity Western ECL blotting substrates (BioRad Lab GmbH, Munich, Germany), ChemiDoc XRS+ imaging acquiring system, and Image Lab Software (BioRad Lab GmbH, Munich, Germany). The ABCG2 bands were related to total protein amount, measured by stain-free total protein normalization.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Confocal Laser Scanning Microscopy</h4><div class="NLM_p last">Confocal laser scanning microscopy was used to get an optical evidence of accumulation of fluorescent compound <b>38</b> and thereby investigate its transport by ABCG2 as already described before.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> For each probe 1 × 10<sup>5</sup> MCF-7 and MCF-7/MX were seeded into low μ-dish (ibidi GmbH, München, Germany) for 48 h. After reaching a confluence of 50–60%, the medium was changed to KHB. Afterward, compound <b>38</b> or/and pheophorbide A were added up to a concentration of 1 μM (compound <b>38</b>) and 0.5 μM (pheophorbide A) and a final volume of 900 μL. After the cells were incubated for 2 h at 37 °C and 5% CO<sub>2</sub>, the fluorescence was measured at an excitation wavelength of 405 nm and emission filter of 500–530 nm (compound <b>38</b>) and 662–737 nm (pheophorbide A). For the measurement Nikon A1 R microscope (Nikon, Düsseldorf, Germany) tempered at 37 °C and its visualization software Nikon NIS Elements (Nikon, Düsseldorf, Germany) were used.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Molecular Modeling Studies</h3><div class="NLM_p last">Human ABCG2 in complex with the fumitremorgin C-related inhibitor, MZ29 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FFC">6FFC</a>) was crystallized using cryoelectron microscopy (cryo-EM).<a onclick="showRef(event, 'ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref99 ref100">(100,101)</a> The structure was downloaded from RCSB Protein Data Bank (PDB) and prepared and protonated using the protein structure preparation and Protonate3D modules implemented in Molecular Operating Environment (MOE) 2018.01, respectively.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(104)</a> The prepared transporter structure of the human ABCG2 was applied for flexible ligand docking using LeadIT from BioSolveIT, GmbH, Germany.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(105)</a> During the docking simulations, the ligands were fully flexible while the residues of the receptor were treated as rigid. The binding site for the receptor was defined in 20 Å spacing of the amino acid residues centered based on the ligand MZ29. The selected compound was docked using FlexX module implemented in LeadIT and predicted the binding mode in the binding site of the transporter.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(106)</a> For docking and scoring, the default parameters were applied, and the top 100 highest scoring docked poses were stored for further analysis. Each receptor–ligand complex having the lowest binding free energy of interactions was visualized using MOE2018.01 and selected the putative binding mode of the docked compound.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(104)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00961" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43327" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43327" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00961?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00961</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings and the biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00961/suppl_file/jm0c00961_si_001.xlsx" class="ext-link">XLSX</a>)</p></li><li><p class="inline">LC–MS data of target compounds <b>18</b>–<b>40</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00961/suppl_file/jm0c00961_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00961/suppl_file/jm0c00961_si_003.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00961/suppl_file/jm0c00961_si_001.xlsx">jm0c00961_si_001.xlsx (11.07 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00961/suppl_file/jm0c00961_si_002.pdf">jm0c00961_si_002.pdf (3.83 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00961/suppl_file/jm0c00961_si_003.pdb">jm0c00961_si_003.pdb (1.4 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB accession code for <b>19</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FFC">6FFC</a>. Authors will release the atomic coordinates upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00961" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53801" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53801" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sven Marcel Stefan</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical and Cellbiological
Chemistry, Pharmaceutical Institute, Rheinische
Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</span>; 
    <span>Present Address:
                        S.M.S.: Translational Neurodegeneration Research and Neuropathology Lab, Department of Neuro-/Pathology, University of Oslo, Oslo, Norway</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ed9ec380c39e99888b8c83ad808889849e8483c3988482c38382"><span class="__cf_email__" data-cfemail="82f1acefacf1f6e7e4e3ecc2efe7e6ebf1ebecacf7ebedaceced">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Wiese</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical and Cellbiological
Chemistry, Pharmaceutical Institute, Rheinische
Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5851-5336" title="Orcid link">http://orcid.org/0000-0002-5851-5336</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e9849e808c9a8ca99c8780c48b868787c78d8c"><span class="__cf_email__" data-cfemail="8ee3f9e7ebfdebcefbe0e7a3ece1e0e0a0eaeb">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katja Silbermann</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical and Cellbiological
Chemistry, Pharmaceutical Institute, Rheinische
Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiyang Li</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical and Cellbiological
Chemistry, Pharmaceutical Institute, Rheinische
Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vigneshwaran Namasivayam</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical and Cellbiological
Chemistry, Pharmaceutical Institute, Rheinische
Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3031-3377" title="Orcid link">http://orcid.org/0000-0003-3031-3377</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabian Baltes</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical and Cellbiological
Chemistry, Pharmaceutical Institute, Rheinische
Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gerd Bendas</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical and Cellbiological
Chemistry, Pharmaceutical Institute, Rheinische
Friedrich-Wilhelms-University Bonn, An der Immenburg 4, 53121 Bonn, Germany</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>K.S. and J.L. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52760" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52760" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The financial support provided by China Scholarship Council (CSC) is acknowledged. We would like to thank BiosolveIT GmbH, Sankt Augustin (Germany), for providing the evaluation license for LeadIT.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">A2780/ADR</td><td class="NLM_def"><p class="first last">adriamycin-(doxorubicin)-selected A2780 cells</p></td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">ATP-binding cassette</p></td></tr><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term"><i>c</i><sub><sup>1</sup>/<sub>2</sub>tmax</sub></td><td class="NLM_def"><p class="first last">half-maximal cell death acceleration concentration</p></td></tr><tr><td class="NLM_term">calcein AM</td><td class="NLM_def"><p class="first last">calcein acetoxymethyl ester</p></td></tr><tr><td class="NLM_term">cryo-EM</td><td class="NLM_def"><p class="first last">cryogenic electron microscopy</p></td></tr><tr><td class="NLM_term"><i>c</i><sub>tmin</sub></td><td class="NLM_def"><p class="first last">maximal cell  death acceleration concentration</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal reversal concentration</p></td></tr><tr><td class="NLM_term">GFP</td><td class="NLM_def"><p class="first last">green fluorescent protein</p></td></tr><tr><td class="NLM_term">GI<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal growth inhibition concentration</p></td></tr><tr><td class="NLM_term"><i>I</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximal inhibition level</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">MCF-7/MX</td><td class="NLM_def"><p class="first last">mitoxantrone-selected Michigan Cancer Foundation-7 cells</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">MRP1</td><td class="NLM_def"><p class="first last">multidrug resistance-associated protein 1</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time needed for antineoplastic agent alone at fixed concentration to half-maximally kill cancer cells</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>min</sub></td><td class="NLM_def"><p class="first last">minimum time needed for antineoplastic agent in combination with sensitizer to half-maximally kill cancer cells</p></td></tr><tr><td class="NLM_term"><i>v</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximal transport velocity.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78610" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78610" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 106 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stavrovskaya, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybalkina, E. Y.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the studies of molecular mechanisms regulating multidrug resistance in cancer cells</span>. <i>Biochemistry (Moscow)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1134/S0006297918070015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1134%2FS0006297918070015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=30200862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlamtbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=779-786&author=A.+A.+Stavrovskayaauthor=E.+Y.+Rybalkina&title=Recent+advances+in+the+studies+of+molecular+mechanisms+regulating+multidrug+resistance+in+cancer+cells&doi=10.1134%2FS0006297918070015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Studies of Molecular Mechanisms Regulating Multidrug Resistance in Cancer Cells</span></div><div class="casAuthors">Stavrovskaya, A. A.; Rybalkina, E. Yu.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry (Moscow)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">BIORAK</span>;
        ISSN:<span class="NLM_cas:issn">0006-2979</span>.
    
            (<span class="NLM_cas:orgname">Pleiades Publishing, Ltd.</span>)
        </div><div class="casAbstract">Abstr.-Here we present new approaches to better understanding multidrug resistance (MDR) development in cancer cells, such as identification of components of a complex process of MDR evolution.  Recent advances in the studies of MDR are discussed: 1) chemotherapy agents might be involved in the selection of cancer stem cells resulting in the elevated drug resistance and enhanced tumorigenicity; 2) cell-cell interactions have a great effect on the MDR emergence and evolution; 3) mechanotransduction is an important signaling mechanism in cell-cell interactions; 4) proteins of the ABC transporter family which are often involved in MDR might be transferred between cells via microvesicles (epigenetic MDR regulation); 5) proteins providing cell-to-cell transfer of functional P-glycoprotein (MDR1 protein) via microvesicles have been investigated; 6) P-glycoprotein may serve to regulate apoptosis, as well as transcription and translation of target genes/proteins.  Although proving once again that MDR is a complex multi-faceted process, these data open new approaches to overcoming it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMeoL1idltcbVg90H21EOLACvtfcHk0ljZhgsIOX6Lvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlamtbnN&md5=1ba527d30126b6c7eb86093371f4bf34</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1134%2FS0006297918070015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS0006297918070015%26sid%3Dliteratum%253Aachs%26aulast%3DStavrovskaya%26aufirst%3DA.%2BA.%26aulast%3DRybalkina%26aufirst%3DE.%2BY.%26atitle%3DRecent%2520advances%2520in%2520the%2520studies%2520of%2520molecular%2520mechanisms%2520regulating%2520multidrug%2520resistance%2520in%2520cancer%2520cells%26jtitle%3DBiochemistry%2520%2528Moscow%2529%26date%3D2018%26volume%3D83%26spage%3D779%26epage%3D786%26doi%3D10.1134%2FS0006297918070015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Triller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korosec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debeljak, A.</span></span> <span> </span><span class="NLM_article-title">Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2006.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.lungcan.2006.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=16934363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BD28ros1Shsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2006&pages=235-240&author=N.+Trillerauthor=P.+Korosecauthor=I.+Kernauthor=M.+Kosnikauthor=A.+Debeljak&title=Multidrug+resistance+in+small+cell+lung+cancer%3A+expression+of+P-glycoprotein%2C+multidrug+resistance+protein+1+and+lung+resistance+protein+in+chemo-naive+patients+and+in+relapsed+disease&doi=10.1016%2Fj.lungcan.2006.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease</span></div><div class="casAuthors">Triller Nadja; Korosec Peter; Kern Izidor; Kosnik Mitja; Debeljak Andrej</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-40</span>
        ISSN:<span class="NLM_cas:issn">0169-5002</span>.
    </div><div class="casAbstract">The aim of this study was to investigate the expression of multidrug resistance-associated proteins in metastatic small cell lung cancer (SCLC) cells correlated to cisplatin/etoposide chemotherapy response and the level of those proteins in relapsed disease.  Samples were obtained by transbronchial fine needle aspiration biopsy (TBNA) of enlarged mediastinal lymph nodes in 17 patients.  After cytological confirmation of SCLC, cells were stained by a panel of mAbs against internal epitopes of P-gp (JSB-1), MRP1 (MRPr1), LRP (LRP-56) and cytokeratin (MNF116) and analyzed by flow cytometry.  We observed a significant negative correlation for better response rate to chemotherapy with individual expression of P-gp (r=-0.93, P<0.0001; Pearson correlation) and MRP1 (r=-0.78, P=0.0002; Pearson correlation) in chemo-naive SCLC cells and a non-significant correlation for LRP expression.  P-gp and MRP1 expression was markedly increased in metastatic cells in four out of five patients with relapsed disease (4-12 months after starting chemotherapy), in comparison to their chemo-naive values.  In conclusion, the results suggest that P-gp and MRP1 might be associated with SCLC cell survival during metastasis and chemotherapy, and that overexpression of those transporters in relapsed disease could assist short-term chemotherapy efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8V0qFoinzNzC850By6mxpfW6udTcc2earbPoY6Waf07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28ros1Shsw%253D%253D&md5=94ddf42d81411857b149e3def0578cb7</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2006.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2006.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DTriller%26aufirst%3DN.%26aulast%3DKorosec%26aufirst%3DP.%26aulast%3DKern%26aufirst%3DI.%26aulast%3DKosnik%26aufirst%3DM.%26aulast%3DDebeljak%26aufirst%3DA.%26atitle%3DMultidrug%2520resistance%2520in%2520small%2520cell%2520lung%2520cancer%253A%2520expression%2520of%2520P-glycoprotein%252C%2520multidrug%2520resistance%2520protein%25201%2520and%2520lung%2520resistance%2520protein%2520in%2520chemo-naive%2520patients%2520and%2520in%2520relapsed%2520disease%26jtitle%3DLung%2520Cancer%26date%3D2006%26volume%3D54%26spage%3D235%26epage%3D240%26doi%3D10.1016%2Fj.lungcan.2006.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sedlakova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caltova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervinka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezac, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spacek, J.</span></span> <span> </span><span class="NLM_article-title">Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer</span>. <i>Int. J. Gynecol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1097/IGC.0000000000000354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1097%2FIGC.0000000000000354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25594141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC2MvmvVansA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=236-243&author=I.+Sedlakovaauthor=J.+Lacoauthor=K.+Caltovaauthor=M.+Cervinkaauthor=J.+Tosnerauthor=A.+Rezacauthor=J.+Spacek&title=Clinical+significance+of+the+resistance+proteins+LRP%2C+Pgp%2C+MRP1%2C+MRP3%2C+and+MRP5+in+epithelial+ovarian+cancer&doi=10.1097%2FIGC.0000000000000354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer</span></div><div class="casAuthors">Sedlakova Iva; Laco Jan; Caltova Katerina; Cervinka Miroslav; Tosner Jindrich; Rezac Adam; Spacek Jiri</div><div class="citationInfo"><span class="NLM_cas:title">International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study aimed to evaluate the correlation between the expressions of lung resistance protein (LRP), P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP)-1, MRP3, and MRP5 and histopathological parameters and clinical outcome, and to determine the predictive and prognostic value of these transport proteins in patients with ovarian cancer.  METHODS:  Tumor samples from 111 chemonaive patients with epithelial ovarian cancer who underwent primary surgery from 2006 to 2010 were immunohistochemically stained for LRP, Pgp, MRP1, MRP3, and MRP5 expressions.  RESULTS:  MRP1 expression was greater among patients with late disease than among patients with early stage ovarian cancer [International Federation of Gynecology and Obstetrics (FIGO) I + II, 71.6% (confidence interval, 60-100); FIGO III + IV, 83.6% (confidence interval, 100-100); P = 0.03].  The histological subtype correlated with the expressions of LRP, Pgp, MRP1, and MRP3.  Relapse of disease during the next 24 months occurred more often among patients with higher Pgp and MRP1 than among patients with lower Pgp and MRP1 expressions.  FIGO stage, histological type, debulking efficiency, strong Pgp expression, and strong MRP1 expression correlated significantly with shorter progression-free survival (log-rank test, P = 0.001, P = 0.004, P = 0.001, P = 0.051, and P = 0.046, respectively).  FIGO stage, histological type, debulking efficiency, and strong MRP1 expression correlated with poor patient survival (log-rank test, P = 0.001, P = 0.042, P = 0.005, and P = 0.018, respectively).  CONCLUSIONS:  Pgp and MRP1 expressions were clinically significant in patients with ovarian cancer.  Pgp and MRP1 may be reliable, independent predictive and prognostic factors regarding the clinical outcome of ovarian cancer.  MRP3 is less important as a predictive and prognostic factor than MRP1 expression.  MRP5 and LRP expressions were not applicable prognostic parameters regarding ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRloUC4h7yBUUH3Rlp_k91zfW6udTcc2earbPoY6Waf07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvmvVansA%253D%253D&md5=e321a5e3d73ded729f1b07504a615f30</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1097%2FIGC.0000000000000354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FIGC.0000000000000354%26sid%3Dliteratum%253Aachs%26aulast%3DSedlakova%26aufirst%3DI.%26aulast%3DLaco%26aufirst%3DJ.%26aulast%3DCaltova%26aufirst%3DK.%26aulast%3DCervinka%26aufirst%3DM.%26aulast%3DTosner%26aufirst%3DJ.%26aulast%3DRezac%26aufirst%3DA.%26aulast%3DSpacek%26aufirst%3DJ.%26atitle%3DClinical%2520significance%2520of%2520the%2520resistance%2520proteins%2520LRP%252C%2520Pgp%252C%2520MRP1%252C%2520MRP3%252C%2520and%2520MRP5%2520in%2520epithelial%2520ovarian%2520cancer%26jtitle%3DInt.%2520J.%2520Gynecol.%2520Cancer%26date%3D2015%26volume%3D25%26spage%3D236%26epage%3D243%26doi%3D10.1097%2FIGC.0000000000000354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pen, X.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.-H.</span></span> <span> </span><span class="NLM_article-title">Analysis of drug resistance-associated proteins expressions of patients with the recurrent of acute leukemia via protein microarray technology</span>. <i>Eur. Rev. Med. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">543</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=24615181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC2crhsl2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=537-543&author=D.-F.+Zengauthor=J.+Zhangauthor=L.-D.+Zhuauthor=P.-Y.+Kongauthor=J.-P.+Liauthor=X.+Zhangauthor=W.+Xuauthor=J.-L.+Wangauthor=X.-G.+Penauthor=P.+Wangauthor=S.-H.+Liu&title=Analysis+of+drug+resistance-associated+proteins+expressions+of+patients+with+the+recurrent+of+acute+leukemia+via+protein+microarray+technology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of drug resistance-associated proteins expressions of patients with the recurrent of acute leukemia via protein microarray technology</span></div><div class="casAuthors">Zeng D-F; Zhang J; Zhu L-D; Kong P-Y; Li J-P; Zhang X; Xu W; Wang J-L; Pen X-G; Wang P; Liu S-H</div><div class="citationInfo"><span class="NLM_cas:title">European review for medical and pharmacological sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">537-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  To detect the expressions of drug-resistance related proteins in bone marrow mononuclear cells of acute leukemia (AL) patients using protein microarray and to analyze the clinical value of protein microarray in predicting prognosis of AL patients.  PATIENTS AND METHODS:  A total of 48 AL patients received chemotherapy were divided into four groups: recurrent acute myeloid leukemia group (R-AML; n=15); AML continue remission group (AML-CR; n = 13); recurrent acute lymphocytic leukemia group (R-ALL; n=13); and ALL-CR group (n=7).  Fifteen age-matched patients with non-hematologic disease were used as controls.  RESULTS:  Expression levels of P-gp, LRP/MVP, BCL-2, GST-π, PCNA, CXCR4 were increased significantly in both AML-R and ALL-R groups (p < 0.05).  Besides, LFA-1 and TRAIL-R were also up-expressed significantly in ALL-R group (p < 0.05).  In addition, the levels of P-gp, GST-π expressed in AML-R group were higher than those in AML-CR group (p < 0.05) and P-gp, LRP/MVP, GST-π, LFA-1 and CXCR4 in ALL-R were expressed higher than those in ALL-CR group (p < 0.05).  CONCLUSIONS:  The recurrent of AL were related closely to the over expression of drug resistance-related proteins.  Protein microarray can be used in the prediction of AL recurrence and would be beneficial in guiding individual therapy and patient prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSC-_lB5JAgGOqrn-c4Of3KfW6udTcc2eaxVW8Q0wQjIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crhsl2jsg%253D%253D&md5=1a92d313e7934696a5a3d4e9258d0d46</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DD.-F.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DL.-D.%26aulast%3DKong%26aufirst%3DP.-Y.%26aulast%3DLi%26aufirst%3DJ.-P.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DJ.-L.%26aulast%3DPen%26aufirst%3DX.-G.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DS.-H.%26atitle%3DAnalysis%2520of%2520drug%2520resistance-associated%2520proteins%2520expressions%2520of%2520patients%2520with%2520the%2520recurrent%2520of%2520acute%2520leukemia%2520via%2520protein%2520microarray%2520technology%26jtitle%3DEur.%2520Rev.%2520Med.%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D18%26spage%3D537%26epage%3D543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spier, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matzner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, W. S.</span></span> <span> </span><span class="NLM_article-title">P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">490</span>– <span class="NLM_lpage">495</span>, <span class="refDoi"> DOI: 10.1182/blood.V81.2.490.490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1182%2Fblood.V81.2.490.490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=8093668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADyaK3s7js1Cguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1993&pages=490-495&author=T.+M.+Groganauthor=C.+M.+Spierauthor=S.+E.+Salmonauthor=M.+Matznerauthor=J.+Rybskiauthor=R.+S.+Weinsteinauthor=R.+J.+Scheperauthor=W.+S.+Dalton&title=P-glycoprotein+expression+in+human+plasma+cell+myeloma%3A+correlation+with+prior+chemotherapy&doi=10.1182%2Fblood.V81.2.490.490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy</span></div><div class="casAuthors">Grogan T M; Spier C M; Salmon S E; Matzner M; Rybski J; Weinstein R S; Scheper R J; Dalton W S</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">490-5</span>
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    </div><div class="casAbstract">Multidrug-resistant (MDR) myeloma patients failing chemotherapy may express P-glycoprotein (PGP), which serves as an efflux pump protecting the neoplastic cells.  Unknown is whether PGP expression might relate to prior cytotoxic drug exposure.  To address this question, we studied 106 consecutive bone marrow samples from 104 myeloma patients with samples studied either before or after therapy and at the time of relapse.  We performed an established immunocytochemical assay of PGP using an MDR-1-specific monoclonal antibody and correlated PGP status with prior chemotherapy dosage.  Myeloma patients with no prior therapy had a low incidence of PGP expression (6%, 3/47), whereas those receiving chemotherapy had a significantly higher incidence (43%, 21/49) (P < .0001).  A substantially higher incidence of PGP expression (50%, 83%, respectively) occurred when the total vincristine dose exceeded 20 mg and when doxorubicin exceeded 340 mg.  In the 11 patients who received both high vincristine and doxorubicin dosages (> 20 mg, > 340 mg total dose) there was 100% incidence of PGP expression in the tumor cells.  These data provided the basis for a predictive mathematical model from which dose-related PGP expression normograms were generated.  Time with myeloma for PGP-negative patients (mean 33 months) had overlapping confidence limits with PGP-positive patients (mean 42 months), suggesting that disease duration was not a significant variable.  PGP expression did not correlate with other clinical factors or immunophenotypic factors.  Our findings indicate a strong correlation between PGP expression in myeloma and past chemotherapy in myeloma, in particular, related to prior exposure to the natural product agents vincristine and doxorubicin.  Additionally, the proportion of PGP-positive plasma cells was significantly higher in the doxorubicin-treated patients than the nondoxorubicin-treated patients (87.7% v 65.17%; P = .013).  Combined high vincristine and doxorubicin total dosage appear highly predictive of PGP expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJCAe_N__UvMSzjBFCN0BJfW6udTcc2eaxVW8Q0wQjIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s7js1Cguw%253D%253D&md5=5a29133423a74402e938706923c94f35</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1182%2Fblood.V81.2.490.490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V81.2.490.490%26sid%3Dliteratum%253Aachs%26aulast%3DGrogan%26aufirst%3DT.%2BM.%26aulast%3DSpier%26aufirst%3DC.%2BM.%26aulast%3DSalmon%26aufirst%3DS.%2BE.%26aulast%3DMatzner%26aufirst%3DM.%26aulast%3DRybski%26aufirst%3DJ.%26aulast%3DWeinstein%26aufirst%3DR.%2BS.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DDalton%26aufirst%3DW.%2BS.%26atitle%3DP-glycoprotein%2520expression%2520in%2520human%2520plasma%2520cell%2520myeloma%253A%2520correlation%2520with%2520prior%2520chemotherapy%26jtitle%3DBlood%26date%3D1993%26volume%3D81%26spage%3D490%26epage%3D495%26doi%3D10.1182%2Fblood.V81.2.490.490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sell, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zintl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerbrey, A.</span></span> <span> </span><span class="NLM_article-title">BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1443</span>– <span class="NLM_lpage">1447</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2402541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fsj.leu.2402541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=12145683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1Wqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=1443-1447&author=D.+Steinbachauthor=W.+Sellauthor=A.+Voigtauthor=J.+Hermannauthor=F.+Zintlauthor=A.+Sauerbrey&title=BCRP+gene+expression+is+associated+with+a+poor+response+to+remission+induction+therapy+in+childhood+acute+myeloid+leukemia&doi=10.1038%2Fsj.leu.2402541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia</span></div><div class="casAuthors">Steinbach, D.; Sell, W.; Voigt, A.; Hermann, J.; Zintl, F.; Sauerbrey, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1443-1447</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Breast cancer resistance protein (BCRP), also known as mitoxantrone resistance protein (MRX) or placenta ABC protein (ABC-P), is the second member of the ABCG subfamily of ABC transport proteins (gene symbol ABCG2).  Transfection and enforced expression of BCRP in drug-sensitive cells confers resistance to mitoxantrone, doxorubicin, daunorubicin and topotecan.  In this study the expression of BCRP gene was measured using TaqMan real-time PCR in 59 children with newly diagnosed AML.  Nine patients were also analyzed in relapse.  The median of BCRP gene expression was more than 10 times higher in patients who did not achieve remission after the first phase of chemotherapy (n = 24) as compared to patients who did achieve remission at this stage (n = 21; P = 0.012).  In first relapse the expression of the BCRP gene was higher than at diagnosis (P = 0.038).  Although high levels of BCRP gene expression were more frequent in subtypes of AML with a favorable prognosis, we found that within both risk groups (high and low risk), patients who expressed high levels of BCRP had a worse prognosis (P = 0.023).  Our results strongly suggest that the expression of the BCRP gene reduces the response to chemotherapy in AML and that BCRP expression is higher at the time of relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYUOHDoO_UbLVg90H21EOLACvtfcHk0lhtTCnUphfnBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1Wqs7c%253D&md5=019751e7474b806321731eaea698786f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2402541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2402541%26sid%3Dliteratum%253Aachs%26aulast%3DSteinbach%26aufirst%3DD.%26aulast%3DSell%26aufirst%3DW.%26aulast%3DVoigt%26aufirst%3DA.%26aulast%3DHermann%26aufirst%3DJ.%26aulast%3DZintl%26aufirst%3DF.%26aulast%3DSauerbrey%26aufirst%3DA.%26atitle%3DBCRP%2520gene%2520expression%2520is%2520associated%2520with%2520a%2520poor%2520response%2520to%2520remission%2520induction%2520therapy%2520in%2520childhood%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2002%26volume%3D16%26spage%3D1443%26epage%3D1447%26doi%3D10.1038%2Fsj.leu.2402541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damiani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tribelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calistri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geromin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarvesio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelutti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanin, R.</span></span> <span> </span><span class="NLM_article-title">The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">825</span>– <span class="NLM_lpage">828</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=16704962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD28XntF2jtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2006&pages=825-828&author=D.+Damianiauthor=M.+Tribelliauthor=E.+Calistriauthor=A.+Gerominauthor=A.+Chiarvesioauthor=A.+Micheluttiauthor=M.+Cavallinauthor=R.+Fanin&title=The+prognostic+value+of+P-glycoprotein+%28ABCB%29+and+breast+cancer+resistance+protein+%28ABCG2%29+in+adults+with+de+novo+acute+myeloid+leukemia+with+normal+karyotype"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype</span></div><div class="casAuthors">Damiani, Daniela; Tiribelli, Mario; Calistri, Elisabetta; Geromin, Antonella; Chiarvesio, Alexsia; Michelutti, Angela; Cavallin, Margherita; Fanin, Renato</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">825-828</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Multidrug resistance is a major cause of treatment failure in acute myeloid leukemia (AML).  P-glycoprotein (PGP) over-expression has an unfavorable prognostic significance, while the role of breast cancer resistance protein (BCRP) is less clear, esp. in AML patients with a normal karyotype.  We studied 73 consecutive AML patients with a normal karyotype.  BCRP was over-expressed in 24 patients (33%) and was significantly co-expressed with PGP (13/24 vs 11/49, p=0.006) and with CD56.  Only PGP, along with age and CD34, affected the achievement of complete remission (p=0.02), while BCRP-pos. cases showed an increased risk of relapse (p=0.005) and a shorter disease-free survival (p=0.027).  BCRP over-expression did not influence the achievement of remission, but significantly affected the duration of complete remissions.  BCRP may, therefore, be regarded as a prognostic factor in patients with normal karyotype AML, for the design of risk-adapted post-remission therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWiSxJTSBaMbVg90H21EOLACvtfcHk0liotgdR-mnNxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntF2jtb4%253D&md5=4b2f18005b2632f631525de2981b8578</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDamiani%26aufirst%3DD.%26aulast%3DTribelli%26aufirst%3DM.%26aulast%3DCalistri%26aufirst%3DE.%26aulast%3DGeromin%26aufirst%3DA.%26aulast%3DChiarvesio%26aufirst%3DA.%26aulast%3DMichelutti%26aufirst%3DA.%26aulast%3DCavallin%26aufirst%3DM.%26aulast%3DFanin%26aufirst%3DR.%26atitle%3DThe%2520prognostic%2520value%2520of%2520P-glycoprotein%2520%2528ABCB%2529%2520and%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%2520in%2520adults%2520with%2520de%2520novo%2520acute%2520myeloid%2520leukemia%2520with%2520normal%2520karyotype%26jtitle%3DHaematologica%26date%3D2006%26volume%3D91%26spage%3D825%26epage%3D828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.-S.</span></span> <span> </span><span class="NLM_article-title">Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients</span>. <i>Pathol. Int.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1111/j.1440-1827.2011.02772.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1111%2Fj.1440-1827.2011.02772.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=22360504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC383lvFCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=167-175&author=S.+H.+Leeauthor=H.+Kimauthor=J.-H.+Hwangauthor=H.+S.+Leeauthor=J.+Y.+Choauthor=Y.-S.+Yoonauthor=H.-S.+Han&title=Breast+cancer+resistance+protein+expression+is+associated+with+early+recurrence+and+decreased+survival+in+resectable+pancreatic+cancer+patients&doi=10.1111%2Fj.1440-1827.2011.02772.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients</span></div><div class="casAuthors">Lee Sang Hyub; Kim Haeryoung; Hwang Jin-Hyeok; Lee Hye Seung; Cho Jai Young; Yoon Yoo-Seok; Han Ho-Seong</div><div class="citationInfo"><span class="NLM_cas:title">Pathology international</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The prognosis of pancreatic ductal adenocarcinoma (PDAC) remains dismal even after complete resection, with most recurrences occurring within 1-2 years postoperatively.  Adenosine triphosphate (ATP)-binding cassette (ABC) transporters have been demonstrated to play major roles in multidrug resistance (MDR) of cancers.  In this study, we evaluated the expression statuses and the clinical significance of MDR1 (ABCB1), MDR-associated proteins (MRPs/ABCC) 1, 2 and 3, and breast cancer resistance protein (BCRP/ABCG2) in 67 surgically resected PDACs by immunohistochemistry.  MDR1, MRP1, MRP2, MRP3 and BCRP were expressed in 35 (52.2%), 56 (83.6%), 61 (91.0%), 49 (73.1%) and 49 (73.1%) out of 67 cases, respectively.  The expression statuses of the MDR-related proteins were positively correlated with each other (P < 0.05).  Tumors expressing MRP1 (P= 0.015), MRP2 (P= 0.022) and MRP3 (P < 0.001) demonstrated more frequent perineural invasion.  MDR1 expression was significantly correlated with lymphatic invasion (P= 0.047).  High BCRP expression in PDAC was a significant prognostic factor for early tumor recurrence (HR = 2.43, P= 0.003) and poor survival (HR = 2.63, P= 0.001).  MDR-related proteins are frequently expressed in PDAC, and high BCRP expression is a significant independent predictor for early recurrence and poor survival.  Immunohistochemical analysis for BCRP expression in PDAC may be a useful test in identifying a subgroup of patients with a poor prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTweVYj99EDj4NpW7w2tapOfW6udTcc2eYVnV0rK7X4Wbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383lvFCrug%253D%253D&md5=4c10b59d6b30b8664e12e62edeacc920</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1827.2011.02772.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1827.2011.02772.x%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DHwang%26aufirst%3DJ.-H.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DCho%26aufirst%3DJ.%2BY.%26aulast%3DYoon%26aufirst%3DY.-S.%26aulast%3DHan%26aufirst%3DH.-S.%26atitle%3DBreast%2520cancer%2520resistance%2520protein%2520expression%2520is%2520associated%2520with%2520early%2520recurrence%2520and%2520decreased%2520survival%2520in%2520resectable%2520pancreatic%2520cancer%2520patients%26jtitle%3DPathol.%2520Int.%26date%3D2012%26volume%3D62%26spage%3D167%26epage%3D175%26doi%3D10.1111%2Fj.1440-1827.2011.02772.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Prognostic value and implication for chemotherapy treatment of ABCB1 in epithelial ovarian cancer: a meta-analysis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0166058</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0166058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1371%2Fjournal.pone.0166058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=27812204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFKls77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0166058&author=S.+Sunauthor=J.+Caiauthor=Q.+Yangauthor=Y.+Zhuauthor=S.+Zhaoauthor=Z.+Wang&title=Prognostic+value+and+implication+for+chemotherapy+treatment+of+ABCB1+in+epithelial+ovarian+cancer%3A+a+meta-analysis&doi=10.1371%2Fjournal.pone.0166058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic value and implication for chemotherapy treatment of ABCB1 in epithelial ovarian cancer: a meta-analysis</span></div><div class="casAuthors">Sun, Si; Cai, Jing; Yang, Qiang; Zhu, Yapei; Zhao, Simei; Wang, Zehua</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e0166058/1-e0166058/24</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background Chemotherapy resistance is reported to correlate with up-regulation of anti-tumor agent transporter ABCB1 (p-gp) in epithelial ovarian cancer (EOC), but the results remain controversial.  To reconcile the results, a systematic review followed by meta-anal. was performed to assess the assocn. between high ABCB1 status or ABCB1 gene variants and overall survival (OS), progression free survival (PFS), and total response rate (TR) in patients with EOC.  Materials and Methods Electronic searches were performed using Pubmed, EMBASE, Web of Science and Chinese Wanfang databases from Jan. 1990 to Feb. 2016.  Summary hazard ratio (HR), risk ratio (RR) and 95% confidence intervals (CIs) were combined using fixed or random- effects models as appropriate.  Results Thirty-eight retrospective studies of 8607 cases qualified for meta-anal. were identified.  Our results suggested that ABCB1 over-expression was significantly assocd. with unfavorable OS (HR = 1.54; 95% CI, 1.25-1.90), PFS (HR = 1.49; 95% CI, 1.22-1.82) and TR (RR = 0.63; 95% CI, 0.54-0.75).  After adjustment for age, clin. stage, residual disease, histol. type and tumor grade, high ABCB1 status remained to be a significant risk factor for adverse OS and PFS.  Patients with recurrent ABCB1 positivity suffered from poorer OS than those with primary ABCB1 positivity.  However, stratified by chemotherapy regimen, inverse correlation between high ABCB1 status and poor OS, PFS and TR were only found in patients underwent platinum-based chemotherapy but not in patients received std. platinum/paclitaxel-based chemotherapy.  No evidence was found for any assocn. between ABCB1 gene polymorphisms and OS, PFS or TR.  Conclusion High ABCB1 status is significantly assocd. with chemo-resistance and poor prognosis in patients with EOC.  Large-scale, prospective studies are needed to assess the clin. value of ABCB1 expression in EOC more accurately.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ90v9n7RX1rVg90H21EOLACvtfcHk0liotgdR-mnNxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFKls77O&md5=32f1162b3048950590031c384629cd68</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0166058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0166058%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DPrognostic%2520value%2520and%2520implication%2520for%2520chemotherapy%2520treatment%2520of%2520ABCB1%2520in%2520epithelial%2520ovarian%2520cancer%253A%2520a%2520meta-analysis%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0166058%26doi%3D10.1371%2Fjournal.pone.0166058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregorcyk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolm, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, R. R.</span></span> <span> </span><span class="NLM_article-title">P-glycoprotein expression as a predictor of breast cancer recurrence</span>. <i>Ann. Surg. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1007/BF02409045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1007%2FBF02409045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=8770296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADyaK28zms1Wiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1996&pages=8-14&author=S.+Gregorcykauthor=Y.+Kangauthor=D.+Brandtauthor=P.+Kolmauthor=G.+Singerauthor=R.+R.+Perry&title=P-glycoprotein+expression+as+a+predictor+of+breast+cancer+recurrence&doi=10.1007%2FBF02409045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">p-Glycoprotein expression as a predictor of breast cancer recurrence</span></div><div class="casAuthors">Gregorcyk S; Kang Y; Brandt D; Kolm P; Singer G; Perry R R</div><div class="citationInfo"><span class="NLM_cas:title">Annals of surgical oncology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-14</span>
        ISSN:<span class="NLM_cas:issn">1068-9265</span>.
    </div><div class="casAbstract">BACKGROUND:  Many new prognostic factors for breast cancer have been described, and yet the ability to predict patient outcomes remains poor.  Overexpression of p-glycoprotein (p-gp), the multidrug resistance efflux pump, confers a worse prognosis to patients with certain leukemias and other tumors.  The purpose of this study was to analyze the potential usefulness of p-gp expression as a prognostic factor in patients with breast cancer.  METHODS:  Paraffin blocks were obtained from 55 previously untreated patients who underwent surgery between 1987 and 1988.  To determine p-gp expression, tumor cell suspensions were incubated with the p-gp-specific C219 monoclonal antibody and analyzed using an indirect immunofluorescent flow cytometric assay.  RESULTS:  Twenty-four (44%) of the tumors were p-gp positive and 31 (56%) were p-gp negative.  Among the p-gp positive patients, 65% had recurrence of their disease, whereas only 13% of the p-gp negative patients experienced recurrence (p = 0.0001).  The 5-year disease-free rate for p-gp positive patients was 39% compared with 83% for p-gp negative patients (p = 0.0001).  In univariate analysis examining 10 different variables, significant predictors of recurrence were p-gp, stage, and tumor size.  Multivariate analysis using Cox Proportional Hazards regression showed that only p-gp and stage were significant independent predictors of recurrence (p = 0.0002).  CONCLUSIONS:  p-gp is frequently expressed in patients with untreated breast cancer, with p-gp-positive patients being at significantly greater risk for disease recurrence. p-gp appears to be a useful prognostic factor in breast cancer and could potentially help guide management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_ypUREnYfDIxhnOQkIHOxfW6udTcc2eZ_qbEQdZuqhrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28zms1Wiuw%253D%253D&md5=9f054d023b41325bd45ebccad3624528</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2FBF02409045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02409045%26sid%3Dliteratum%253Aachs%26aulast%3DGregorcyk%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DBrandt%26aufirst%3DD.%26aulast%3DKolm%26aufirst%3DP.%26aulast%3DSinger%26aufirst%3DG.%26aulast%3DPerry%26aufirst%3DR.%2BR.%26atitle%3DP-glycoprotein%2520expression%2520as%2520a%2520predictor%2520of%2520breast%2520cancer%2520recurrence%26jtitle%3DAnn.%2520Surg.%2520Oncol.%26date%3D1996%26volume%3D3%26spage%3D8%26epage%3D14%26doi%3D10.1007%2FBF02409045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filipits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietze, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lax, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielinski, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hausmaninger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubista, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samonigg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span> <span> </span><span class="NLM_article-title">Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian breast and colorectal cancer study group</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1161</span>– <span class="NLM_lpage">1168</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.03.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1200%2FJCO.2005.03.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=15718312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitl2gurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1161-1168&author=M.+Filipitsauthor=G.+Pohlauthor=M.+Rudasauthor=O.+Dietzeauthor=S.+Laxauthor=R.+Grillauthor=R.+Pirkerauthor=C.+C.+Zielinskiauthor=H.+Hausmaningerauthor=E.+Kubistaauthor=H.+Samoniggauthor=R.+Jakesz&title=Clinical+role+of+multidrug+resistance+protein+1+expression+in+chemotherapy+resistance+in+early-stage+breast+cancer%3A+the+Austrian+breast+and+colorectal+cancer+study+group&doi=10.1200%2FJCO.2005.03.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: The Austrian Breast and Colorectal Cancer Study Group</span></div><div class="casAuthors">Filipits, Martin; Pohl, Gudrun; Rudas, Margaretha; Dietze, Otto; Lax, Sigurd; Grill, Renate; Pirker, Robert; Zielinski, Christoph C.; Hausmaninger, Hubert; Kubista, Ernst; Samonigg, Hellmut; Jakesz, Raimund</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1161-1168</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: The multidrug resistance protein 1 (MRP1) is expressed in human breast cancer cells and may contribute to the clin. drug resistance of breast cancer patients.  Therefore, we detd. the impact of MRP1 expression on the clin. outcome of adjuvant therapy in patients with early-stage breast cancer.  Patients and Methods: Immunostaining for MRP1 was performed on tissue sections from 516 premenopausal, hormone receptor-pos. breast cancer patients with stage I and II disease.  Statistical analyses were performed to assess the effect of MRP1 expression on survival and to test for interaction between MRP1 expression and treatment.  Results: MRP1 expression independently predicted shorter relapse-free survival (RFS) and overall survival (OS) in patients treated with cyclophosphamide, methotrexate, and fluorouracil (CMF; RFS: hazard ratio [HR] = 1.48; 95% CI, 1.16 to 1.88; P = .002; OS: HR = 1.82; 95% CI, 1.10 to 3.01; P = .02), but it did not predict shorter RFS and OS in patients who received tamoxifen plus goserelin (RFS: HR = 0.99; 95% CI, 0.74 to 1.31; P = .9; OS: HR = 0.68; 95% CI, 0.40 to 1.15; P = .1).  Tests for interaction between MRP1 expression and treatment were statistically significant for both RFS (P = .04) and OS (P = .006).  Conclusion: Our data suggest that MRP1 expression plays an important role in the clin. resistance to adjuvant CMF chemotherapy but does not seem to affect response to adjuvant endocrine treatment with tamoxifen plus goserelin.  Thus, MRP1 may be a useful marker for the selection of patients with early-stage breast cancer for the appropriate adjuvant therapy after prospective confirmatory evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlUpaouxrMy7Vg90H21EOLACvtfcHk0ljYsyCt48Cfzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitl2gurw%253D&md5=a2ed9f4db2046dc66f99306eeb6d98e4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.03.033%26sid%3Dliteratum%253Aachs%26aulast%3DFilipits%26aufirst%3DM.%26aulast%3DPohl%26aufirst%3DG.%26aulast%3DRudas%26aufirst%3DM.%26aulast%3DDietze%26aufirst%3DO.%26aulast%3DLax%26aufirst%3DS.%26aulast%3DGrill%26aufirst%3DR.%26aulast%3DPirker%26aufirst%3DR.%26aulast%3DZielinski%26aufirst%3DC.%2BC.%26aulast%3DHausmaninger%26aufirst%3DH.%26aulast%3DKubista%26aufirst%3DE.%26aulast%3DSamonigg%26aufirst%3DH.%26aulast%3DJakesz%26aufirst%3DR.%26atitle%3DClinical%2520role%2520of%2520multidrug%2520resistance%2520protein%25201%2520expression%2520in%2520chemotherapy%2520resistance%2520in%2520early-stage%2520breast%2520cancer%253A%2520the%2520Austrian%2520breast%2520and%2520colorectal%2520cancer%2520study%2520group%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D1161%26epage%3D1168%26doi%3D10.1200%2FJCO.2005.03.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eno, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahzad, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenshein, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer</span>. <i>Am. J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1097/COC.0b013e3181ec5f4b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1097%2FCOC.0b013e3181ec5f4b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=20921883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WkurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=488-493&author=K.+Matsuoauthor=M.+L.+Enoauthor=E.+H.+Ahnauthor=M.+M.+Shahzadauthor=D.+D.+Imauthor=N.+B.+Rosensheinauthor=A.+K.+Sood&title=Multidrug+resistance+gene+%28MDR-1%29+and+risk+of+brain+metastasis+in+epithelial+ovarian%2C+fallopian+tube%2C+and+peritoneal+cancer&doi=10.1097%2FCOC.0b013e3181ec5f4b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug Resistance Gene (MDR-1) and Risk of Brain Metastasis in Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer</span></div><div class="casAuthors">Matsuo, Koji; Eno, Michele L.; Ahn, Edward H.; Shahzad, Mian M. K.; Im, Dwight D.; Rosenshein, Neil B.; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">488-493</span>CODEN:
                <span class="NLM_cas:coden">AJCODI</span>;
        ISSN:<span class="NLM_cas:issn">0277-3732</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: To evaluate risk factors that predict brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.  Methods: All patients with FIGO stage I to IV who underwent initial cytoreductive surgery between Jan. 1995 and Jan. 2009 were evaluated.  The tumor samples were evaluated for 7 markers including multidrug resistance gene (MDR-1), DNA aneuploidity and S-phase fraction, human epidermal growth factor receptor 2, estrogen receptor, progesterone receptor, p53 mutation, epidermal growth factor receptor, and CD31.  Biomarker expression was evaluated as a predictor of hematogenous metastasis to the following locations: (i) liver and spleen, (ii) lung, and (iii) brain.  Results: There were 309 cases identified during the period.  Of those, 5 (1.6%, 95% CI: 0.2%-3.0%) women developed brain metastasis.  Time to onset of brain metastasis was significantly longer than that for other recurrent sites (median time to recurrence after initial cytoredn., brain vs. lung vs. liver, 21.4 vs. 12.6 vs. 11.0 mo, P< 0.05).  Significantly increased expression of MDR-1 was seen in tumors from women who developed brain metastasis (brain vs. nonbrain sites, 80% vs. 4.2%-24.3%, P= 0.004).  In multivariate anal., MDR-1 was the only significant variable assocd. with the risk of brain metastasis.  MDR-1 expression predicted brain metastasis (receiver-operator-characteristic curve anal., AUC 0.808, P= 0.018), and with a 10% pos. expression of MDR-1 as the cutoff value, sensitivity, specificity, pos. predictive value, neg. predictive value, accuracy of prediction of brain metastasis were 80%, 86.1%, 15.4%, 99.3%, and 85.9%, resp. (odds ratio: 24.7, 95% CI: 2.64-232, P= 0.002).  Conclusions: Increased expression of MDR-1 in the tumor tissue obtained at initial cytoredn. is assocd. with increased risk of developing brain metastases in women with epithelial ovarian, fallopian tube, or peritoneal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_xRbjF-3nabVg90H21EOLACvtfcHk0ljYsyCt48Cfzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WkurbL&md5=905a59d23e27d5124dcdfe2cbff2da1a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1097%2FCOC.0b013e3181ec5f4b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOC.0b013e3181ec5f4b%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuo%26aufirst%3DK.%26aulast%3DEno%26aufirst%3DM.%2BL.%26aulast%3DAhn%26aufirst%3DE.%2BH.%26aulast%3DShahzad%26aufirst%3DM.%2BM.%26aulast%3DIm%26aufirst%3DD.%2BD.%26aulast%3DRosenshein%26aufirst%3DN.%2BB.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DMultidrug%2520resistance%2520gene%2520%2528MDR-1%2529%2520and%2520risk%2520of%2520brain%2520metastasis%2520in%2520epithelial%2520ovarian%252C%2520fallopian%2520tube%252C%2520and%2520peritoneal%2520cancer%26jtitle%3DAm.%2520J.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D34%26spage%3D488%26epage%3D493%26doi%3D10.1097%2FCOC.0b013e3181ec5f4b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">ABCG2: determining its relevance in clinical drug resistance</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1007/s10555-007-9042-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1007%2Fs10555-007-9042-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=17323127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1KqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=39-57&author=R.+W.+Robeyauthor=O.+Polgarauthor=J.+Deekenauthor=K.+W.+Toauthor=S.+E.+Bates&title=ABCG2%3A+determining+its+relevance+in+clinical+drug+resistance&doi=10.1007%2Fs10555-007-9042-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">ABCG2: determining its relevance in clinical drug resistance</span></div><div class="casAuthors">Robey, Robert W.; Polgar, Orsolya; Deeken, John; To, Kin Wah; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-57</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Multidrug resistance is a major obstacle to successful cancer treatment.  One mechanism by which cells can become resistant to chemotherapy is the expression of ABC transporters that use the energy of ATP hydrolysis to transport a wide variety of substrates across the cell membrane.  There are three human ABC transporters primarily assocd. with the multidrug resistance phenomenon, namely Pgp, MRP1, and ABCG2.  All three have broad and, to a certain extent, overlapping substrate specificities, transporting the major drugs currently used in cancer chemotherapy.  ABCG2 is the most recently described of the three major multidrug-resistance pumps, and its substrates include mitoxantrone, topotecan, irinotecan, flavopiridol, and methotrexate.  Despite several studies reporting ABCG2 expression in normal and malignant tissues, no trials have thus far addressed the role of ABCG2 in clin. drug resistance.  This gives us an opportunity to critically review the disappointing results of past clin. trials targeting Pgp and to propose strategies for ABCG2.  We need to know in which tumor types ABCG2 contributes to the resistance phenotype.  We also need to develop standardized assays to detect ABCG2 expression in vivo and to carefully select the chemotherapeutic agents and clin. trial designs.  This review focuses on our current knowledge about normal tissue distribution, tumor expression profiles, and substrates and inhibitors of ABCG2, together with lessons learned from clin. trials with Pgp inhibitors.  Implications of SNPs in the ABCG2 gene affecting the pharmacokinetics of substrate drugs, including many non-chemotherapy agents and ABCG2 expression in the SP population of stem cells are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohVW7mqrWFVLVg90H21EOLACvtfcHk0lhoOAqTXDP9fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1KqtL0%253D&md5=fd6e32da8ddccc75c8f1c6d92bb0bd56</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10555-007-9042-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-007-9042-6%26sid%3Dliteratum%253Aachs%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DPolgar%26aufirst%3DO.%26aulast%3DDeeken%26aufirst%3DJ.%26aulast%3DTo%26aufirst%3DK.%2BW.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DABCG2%253A%2520determining%2520its%2520relevance%2520in%2520clinical%2520drug%2520resistance%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2007%26volume%3D26%26spage%3D39%26epage%3D57%26doi%3D10.1007%2Fs10555-007-9042-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unadkat, J. D.</span></span> <span> </span><span class="NLM_article-title">Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport – an update</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1208/s12248-014-9668-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1208%2Fs12248-014-9668-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25236865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFygu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=65-82&author=Q.+Maoauthor=J.+D.+Unadkat&title=Role+of+the+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29+in+drug+transport+%E2%80%93+an+update&doi=10.1208%2Fs12248-014-9668-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport-an update</span></div><div class="casAuthors">Mao, Qingcheng; Unadkat, Jashvant D.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-82</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The human breast cancer resistance protein (BCRP, gene symbol ABCG2) is an ATP-binding cassette (ABC) efflux transporter.  It was so named because it was initially cloned from a multidrug-resistant breast cancer cell line where it was found to confer resistance to chemotherapeutic agents such as mitoxantrone and topotecan.  Since its discovery in 1998, the substrates of BCRP have been rapidly expanding to include not only therapeutic agents but also physiol. substances such as estrone-3-sulfate, 17β-estradiol 17-(β-D-glucuronide) and uric acid.  Likewise, at least hundreds of BCRP inhibitors have been identified.  Among normal human tissues, BCRP is highly expressed on the apical membranes of the placental syncytiotrophoblasts, the intestinal epithelium, the liver hepatocytes, the endothelial cells of brain microvessels, and the renal proximal tubular cells, contributing to the absorption, distribution, and elimination of drugs and endogenous compds. as well as tissue protection against xenobiotic exposure.  As a result, BCRP has now been recognized by the FDA to be one of the key drug transporters involved in clin. relevant drug disposition.  We published a highly-accessed review article on BCRP in 2005, and much progress has been made since then.  In this review, we provide an update of current knowledge on basic biochem. and pharmacol. functions of BCRP as well as its relevance to drug resistance and drug disposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojBFIoPBT7CbVg90H21EOLACvtfcHk0lhoOAqTXDP9fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFygu7fM&md5=c4b8d6e1286fc6340cf4a8159f525c22</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1208%2Fs12248-014-9668-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-014-9668-6%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DUnadkat%26aufirst%3DJ.%2BD.%26atitle%3DRole%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%2520in%2520drug%2520transport%2520%25E2%2580%2593%2520an%2520update%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26spage%3D65%26epage%3D82%26doi%3D10.1208%2Fs12248-014-9668-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardwick, L. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velamakanni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veen, H. W.</span></span> <span> </span><span class="NLM_article-title">The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2)</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fsj.bjp.0707218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=17375082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Wku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2007&pages=163-174&author=L.+J.+A.+Hardwickauthor=S.+Velamakanniauthor=H.+W.+van+Veen&title=The+emerging+pharmacotherapeutic+significance+of+the+breast+cancer+resistance+protein+%28ABCG2%29&doi=10.1038%2Fsj.bjp.0707218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2)</span></div><div class="casAuthors">Hardwick, L. J. A.; Velamakanni, S.; van Veen, H. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-174</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The breast cancer resistance protein (also termed ABCG2) is an ATP-binding cassette transporter, which mediates the extrusion of toxic compds. from the cell, and which was originally identified in relation to the development of multidrug resistance of cancer cells.  ABCG2 interacts with a range of substrates including clin. drugs but also substances such as sterols, porphyrins and a variety of dietary compds.  Physiol. functions of ABCG2 at both cellular and systemic levels are reviewed.  For example, ABCG2 expression in erythrocytes may function in porphyrin homeostasis.  In addn., ABCG2 expression at apical membranes of cells such as hepatocytes, enterocytes, endothelial and syncytiotrophoblast cells may correlate to protective barrier or secretory functions against environmental or clin. administered substances.  ABCG2 also appears influential in the inter-patient variation and generally poor oral bioavailability of certain chemotherapeutic drugs such as topotecan.  As this often precludes an oral drug administration strategy, genotypic and environmental factors altering ABCG2 expression and activity are considered.  Finally, clin. modulation of ABCG2 activity is discussed.  Some of the more recent strategies include co-administered modulating agents, hammerhead ribozymes or antisense oligonucleotides, and with specificity in cell targeting, these may be used to reduce drug resistance and increase drug bioavailability to improve the profile of chemotherapeutic efficacy vs. toxicity.  While many such strategies remain in relative infancy at present, increased knowledge of modulators of ABCG2 could hold the key to novel approaches in medical treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom3w5nPxaNRLVg90H21EOLACvtfcHk0lhoOAqTXDP9fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Wku74%253D&md5=fdd17189ef8fdb4a95c21d96fd0fd7a5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707218%26sid%3Dliteratum%253Aachs%26aulast%3DHardwick%26aufirst%3DL.%2BJ.%2BA.%26aulast%3DVelamakanni%26aufirst%3DS.%26aulast%3Dvan%2BVeen%26aufirst%3DH.%2BW.%26atitle%3DThe%2520emerging%2520pharmacotherapeutic%2520significance%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D151%26spage%3D163%26epage%3D174%26doi%3D10.1038%2Fsj.bjp.0707218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Möbus, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfaff, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreienberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaubitzsch, S.</span></span> <span> </span><span class="NLM_article-title">Long time therapy with topotecan in patients with recurrence of ovarian carcinoma</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3551</span>– <span class="NLM_lpage">3556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11848522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvFGmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=3551-3556&author=V.+M%C3%B6busauthor=P.+N.+Pfaffauthor=T.+Volmauthor=R.+Kreienbergauthor=S.+Kaubitzsch&title=Long+time+therapy+with+topotecan+in+patients+with+recurrence+of+ovarian+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Long time therapy with topotecan in patients with recurrence of ovarian carcinoma</span></div><div class="casAuthors">Mobus, Volker; Pfaff, Peter N.; Volm, Tanja; Kreienberg, Rolf; Kaubitzsch, Sabine</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3551-3556</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">In several phase II and III topotecan studies the large no. of patients with stable disease is striking.  Since no severe organ toxicity has been described for topotecan, long-term therapy with topotecan seems to be reasonable.  In this summary we present evidence, that long-term topotecan therapy can be managed without cumulative hematol. and non-hematol. toxicity.  Thirty-three patients with recurrent ovarian cancer, who were treated with at least 7 courses of topotecan, were evaluated in this retrospective study (patient database from SmithKline Beecham, Germany).  Most of the patients had more than 2 previous courses of chemotherapy.  The starting dose was between 1.0 and 1.5 mg/m2 topotecan administered for 5 days every 3 wk as an i.v. infusion.  All patients were evaluated for toxicity, 32 patients for response.  The 33 patients received 343 courses of topotecan, an av. of more than 10 courses per patient.  The highest no. of courses given to a single patient was 33.  The hematotoxicity was in the expected range, but toxicity was not cumulative.  The no. of interventions for growth factors and blood cell transfusions were const. over the whole therapy.  Dose redns. were conducted in more than 75% of the patients as early as in course two.  There was no grade 3 or 4 non-hematol. toxicity.  Alopecia was the only toxicity to be cumulative.  Remissions were obsd. in 12 out of 32 eligible patients.  The remissions were achieved after an av. of 4.3 courses (range 2-7).  The median time to progression was 33 wk.  Long-term therapy with topotecan is reasonable and can be conducted without cumulative hematol. toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3zVaZdTuIQbVg90H21EOLACvtfcHk0ljOcrO6r1apOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvFGmsb0%253D&md5=4ef623f52cfcdfcc6d5229b9ad5d6870</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B6bus%26aufirst%3DV.%26aulast%3DPfaff%26aufirst%3DP.%2BN.%26aulast%3DVolm%26aufirst%3DT.%26aulast%3DKreienberg%26aufirst%3DR.%26aulast%3DKaubitzsch%26aufirst%3DS.%26atitle%3DLong%2520time%2520therapy%2520with%2520topotecan%2520in%2520patients%2520with%2520recurrence%2520of%2520ovarian%2520carcinoma%26jtitle%3DAnticancer%2520Res.%26date%3D2001%26volume%3D21%26spage%3D3551%26epage%3D3556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckardt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramlau, R.</span></span> <span> </span><span class="NLM_article-title">Recent advances with topotecan in the treatment of lung cancer</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1194</span>– <span class="NLM_lpage">1204</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-10-1194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1634%2Ftheoncologist.12-10-1194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=17962613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1194-1204&author=M.+O%E2%80%99Brienauthor=J.+Eckardtauthor=R.+Ramlau&title=Recent+advances+with+topotecan+in+the+treatment+of+lung+cancer&doi=10.1634%2Ftheoncologist.12-10-1194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances with topotecan in the treatment of lung cancer</span></div><div class="casAuthors">O'Brien, Mary; Eckardt, John; Ramlau, Rodryg</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1194-1204</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Topotecan is a semisynthetic deriv. of camptothecin that specifically targets topoisomerase I.  It has well-established antineoplastic properties and has been successfully combined with other antineoplastic agents with activity dependent on DNA disruption, such as cisplatin and etoposide.  Topotecan is indicated for the treatment of small cell lung cancer (SCLC) sensitive disease after failure of first-line chemotherapy and metastatic ovarian carcinoma after failure of initial or subsequent chemotherapy.  Since the approval of topotecan for the second-line treatment of SCLC, studies have been conducted in the first-line setting.  Recent studies demonstrate the utility of i.v. topotecan in combination with cisplatin for untreated SCLC.  Further, an oral formulation of topotecan is currently under investigation and may provide added convenience for patients.  Oral topotecan has been studied in the first- and second-line settings for both SCLC and non-small cell lung cancer (NSCLC).  Three recent phase III trials have demonstrated the activity of oral topotecan.  In the first study of chemotherapy-naive patients with extensive-disease SCLC, oral topotecan plus cisplatin provided efficacy and safety similar to those of etoposide plus cisplatin.  In a second study of patients with relapsed SCLC, treatment with oral topotecan showed a statistically significant and clin. meaningful longer overall survival time and improvement in dyspnea and quality of life compared with best supportive care alone in all prognostic groups.  Finally, in previously treated patients with NSCLC, single-agent oral topotecan was shown to be noninferior in 1-yr survival rate relative to the current std. of i.v. docetaxel.  In future studies, oral topotecan will represent a good candidate for combination therapy with other i.v. or oral chemotherapy agents, monoclonal antibodies, and small mol. tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM0akGR-WUlrVg90H21EOLACvtfcHk0ljOcrO6r1apOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrP&md5=ca58348a79672414db1fd9fcbf55e5e1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-10-1194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-10-1194%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%26aulast%3DEckardt%26aufirst%3DJ.%26aulast%3DRamlau%26aufirst%3DR.%26atitle%3DRecent%2520advances%2520with%2520topotecan%2520in%2520the%2520treatment%2520of%2520lung%2520cancer%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1194%26epage%3D1204%26doi%3D10.1634%2Ftheoncologist.12-10-1194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galdy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cella, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spada, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murgioni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravenda, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampino, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazio, N.</span></span> <span> </span><span class="NLM_article-title">Systematic therapy beyond first-line in advanced gastric cancer: an overview of the main randomized clinical trials</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2015.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.critrevonc.2015.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=26697987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC28rkt1KjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2016&pages=1-12&author=S.+Galdyauthor=C.+A.+Cellaauthor=F.+Spadaauthor=S.+Murgioniauthor=A.+M.+Frezzaauthor=S.+P.+Ravendaauthor=M.+G.+Zampinoauthor=N.+Fazio&title=Systematic+therapy+beyond+first-line+in+advanced+gastric+cancer%3A+an+overview+of+the+main+randomized+clinical+trials&doi=10.1016%2Fj.critrevonc.2015.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials</span></div><div class="casAuthors">Galdy Salvatore; Cella Chiara Alessandra; Spada Francesca; Murgioni Sabina; Frezza Anna Maria; Ravenda Simona Paola; Zampino Maria Giulia; Fazio Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Following progression on first-line platinum and fluoropyrimidine-based chemotherapy, prognosis for advanced gastric cancer patients is extremely poor.  Thus, new and effective treatments are required.  Based on positive results of recent randomized controlled trials, second-line monochemotherapies with either irinotecan or taxanes confer a median overall survival of approximately 5 months in gastro-esophageal and gastric adenocarcinoma.  Combination of weekly paclitaxel and ramucirumab, a novel anti-angiogenic VEGFR2 antibody, pushes the overall survival up to over 9.5 months, whereas apatinib, a novel oral VEGFR2 tyrosine kinase inhibitor, seems to be promising in heavily pretreated patients.  In contrast, the role of EGFR/HER2 and mTOR inhibitors is controversial.  Studies are heterogeneous for tumor population, geographical areas, quality of life assessment, type of first-line therapy and response to that, making clinical practice application of the trial results difficult.  Furthermore, sustainability is challenging due to high cost of novel biotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTD8kRPQnDjf7t7lRqEFUJVfW6udTcc2eaYB_a9Zva4srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rkt1KjsQ%253D%253D&md5=c1bb5df45446bf3fd0745769f60e74f8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2015.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2015.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DGaldy%26aufirst%3DS.%26aulast%3DCella%26aufirst%3DC.%2BA.%26aulast%3DSpada%26aufirst%3DF.%26aulast%3DMurgioni%26aufirst%3DS.%26aulast%3DFrezza%26aufirst%3DA.%2BM.%26aulast%3DRavenda%26aufirst%3DS.%2BP.%26aulast%3DZampino%26aufirst%3DM.%2BG.%26aulast%3DFazio%26aufirst%3DN.%26atitle%3DSystematic%2520therapy%2520beyond%2520first-line%2520in%2520advanced%2520gastric%2520cancer%253A%2520an%2520overview%2520of%2520the%2520main%2520randomized%2520clinical%2520trials%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2016%26volume%3D99%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.critrevonc.2015.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiozawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatomi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikegami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamihira, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, S.</span></span> <span> </span><span class="NLM_article-title">Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1223</span>, <span class="refDoi"> DOI: 10.1006/bbrc.2001.4267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1006%2Fbbrc.2001.4267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11162657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptlCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2001&pages=1216-1223&author=S.+Kawabataauthor=M.+Okaauthor=K.+Shiozawaauthor=K.+Tsukamotoauthor=K.+Nakatomiauthor=H.+Sodaauthor=M.+Fukudaauthor=Y.+Ikegamiauthor=K.+Sugaharaauthor=Y.+Yamadaauthor=S.+Kamihiraauthor=L.+A.+Doyleauthor=D.+D.+Rossauthor=S.+Kohno&title=Breast+cancer+resistance+protein+directly+confers+SN-38+resistance+of+lung+cancer+cells&doi=10.1006%2Fbbrc.2001.4267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells</span></div><div class="casAuthors">Kawabata, Shigeru; Oka, Mikio; Shiozawa, Ken; Tsukamoto, Kazuhiro; Nakatomi, Katsumi; Soda, Hiroshi; Fukuda, Minoru; Ikegami, Yoji; Sugahara, Kazuyuki; Yamada, Yasuaki; Kamihira, Shimeru; Doyle, L. Austin; Ross, Douglas D.; Kohno, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1216-1223</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Breast cancer resistance protein (BCRP), an ABC half-transporter, is overexpressed in cancer cell lines selected with doxorubicin/verapamil, topotecan, or mitoxantrone.  BCRP-overexpressing cells show cross-resistance to camptothecin derivs. such as irinotecan, SN-38 (the active metabolite of irinotecan), and topotecan.  To test whether BCRP confers SN-38 resistance, we selected two SN-38 resistant sublines from PC-6 human small-cell lung cancer cells by SN-38, and then characterized these cells.  Compared to PC-6 cells, the resistant sublines PC-6/SN2-5 and PC-6/SN2-5H were approx. 18- and 34-fold resistant, resp.  The intracellular SN-38 accumulation was reduced in the sublines, and BCRP mRNA was overexpressed in proportion to the degree of SN-38 resistance.  These findings suggest that BCRP confers SN-38 resistance in the sublines.  To confirm this hypothesis, PC-6/SN2-5 cells were transfected with antisense oligonucleotides complementary to portions of BCRP mRNA.  The antisense oligonucleotides significantly suppressed BCRP mRNA expression, and enhanced SN-38 sensitivity in the subline.  These data indicate that BCRP is directly involved with SN-38 resistance, by efflux transport of SN-38.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp94jSgfFuPnrVg90H21EOLACvtfcHk0lhRIGvftU75aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptlCrsg%253D%253D&md5=d3e2199a04430e59605416d693b567fd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.2001.4267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.2001.4267%26sid%3Dliteratum%253Aachs%26aulast%3DKawabata%26aufirst%3DS.%26aulast%3DOka%26aufirst%3DM.%26aulast%3DShiozawa%26aufirst%3DK.%26aulast%3DTsukamoto%26aufirst%3DK.%26aulast%3DNakatomi%26aufirst%3DK.%26aulast%3DSoda%26aufirst%3DH.%26aulast%3DFukuda%26aufirst%3DM.%26aulast%3DIkegami%26aufirst%3DY.%26aulast%3DSugahara%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DKamihira%26aufirst%3DS.%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DRoss%26aufirst%3DD.%2BD.%26aulast%3DKohno%26aufirst%3DS.%26atitle%3DBreast%2520cancer%2520resistance%2520protein%2520directly%2520confers%2520SN-38%2520resistance%2520of%2520lung%2520cancer%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2001%26volume%3D280%26spage%3D1216%26epage%3D1223%26doi%3D10.1006%2Fbbrc.2001.4267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maliepaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gastelen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Waardenburg, R. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruevekamp-Helmers, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floot, B. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span> <span> </span><span class="NLM_article-title">Overexpression of the <i>BCRP/MXR/ABCP</i> gene in a topotecan-selected ovarian tumor cell line</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4559</span>– <span class="NLM_lpage">4563</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10493507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVKksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=4559-4563&author=M.+Maliepaardauthor=M.+A.+van+Gastelenauthor=L.+A.+de+Jongauthor=D.+Pluimauthor=R.+A.+M.+van+Waardenburgauthor=M.+C.+Ruevekamp-Helmersauthor=B.+G.+J.+Flootauthor=J.+H.+M.+Schellens&title=Overexpression+of+the+BCRP%2FMXR%2FABCP+gene+in+a+topotecan-selected+ovarian+tumor+cell+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line</span></div><div class="casAuthors">Maliepaard, Marc; Van Gastelen, Margot A.; De Jong, Laurina A.; Pluim, Dick; Van Waardenburg, Robert C. A. M.; Ruevekamp-Helmers, Marjan C.; Floot, Ben G. J.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4559-4563</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Topotecan- or mitoxantrone-selected cell lines (T8 and MX3, resp.), derived from the human IGROV1 ovarian cancer cell line, were resistant to the topoisomerase I inhibitors topotecan, SN-38 (the active metabolite of irinotecan), and 9-aminocamptothecin, as well as to the topoisomerase II drug mitoxantrone.  In both resistant cell lines, decreased accumulation of topotecan and mitoxantrone was obsd., caused by enhanced energy-dependent efflux of the drugs involved.  In both cell lines, we found that the breast cancer resistance protein/mitoxantrone resistance/placenta-specific ATP binding cassette (BCRP/MXR/ABCP) gene was overexpressed.  Furthermore, BCRP/MXR/ABCP expression levels in various partially revertant T8 cells correlated with the levels of resistance to topotecan, SN-38, and mitoxantrone, strongly suggesting BCRP/MXR/ABCP to be the transporter responsible for the enhanced efflux.  Pharmacodynamic anal. demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s.  In conclusion, we report for the first time that BCRP/MXR/ABCP can also be upregulated upon exposure of tumor cells to the clin. important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient.  This highly efficient efflux of topotecan by BCRP/MXR/ABCP may have clin. relevance for patients being treated with topotecan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkkbyzfYDaxrVg90H21EOLACvtfcHk0lhRIGvftU75aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVKksbo%253D&md5=626719a6e276cde3b86e5a83427a51b8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaliepaard%26aufirst%3DM.%26aulast%3Dvan%2BGastelen%26aufirst%3DM.%2BA.%26aulast%3Dde%2BJong%26aufirst%3DL.%2BA.%26aulast%3DPluim%26aufirst%3DD.%26aulast%3Dvan%2BWaardenburg%26aufirst%3DR.%2BA.%2BM.%26aulast%3DRuevekamp-Helmers%26aufirst%3DM.%2BC.%26aulast%3DFloot%26aufirst%3DB.%2BG.%2BJ.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DOverexpression%2520of%2520the%2520BCRP%252FMXR%252FABCP%2520gene%2520in%2520a%2520topotecan-selected%2520ovarian%2520tumor%2520cell%2520line%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D4559%26epage%3D4563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dexheimer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sordet, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavielle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Novel-E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3229</span>– <span class="NLM_lpage">3238</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1158%2F1535-7163.MCT-07-0441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=18089716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3229-3238&author=K.+Takagiauthor=T.+S.+Dexheimerauthor=C.+Redonauthor=O.+Sordetauthor=K.+Agamaauthor=G.+Lavielleauthor=A.+Pierreauthor=S.+E.+Batesauthor=Y.+Pommier&title=Novel-E-ring+camptothecin+keto+analogues+%28S38809+and+S39625%29+are+stable%2C+potent%2C+and+selective+topoisomerase+I+inhibitors+without+being+substrates+of+drug+efflux+transporters&doi=10.1158%2F1535-7163.MCT-07-0441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters</span></div><div class="casAuthors">Takagi, Kazutaka; Dexheimer, Thomas S.; Redon, Christophe; Sordet, Olivier; Agama, Keli; Lavielle, Gilbert; Pierre, Alain; Bates, Susan E.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3229-3238</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Camptothecin (CPT) analogs are powerful anticancer agents but are chem. unstable due to their α-hydroxylactone six-membered E-ring structure, which is essential for trapping topoisomerase I (Top1)-DNA cleavage complexes.  To stabilize the E-ring, CPT keto analogs with a five-membered E-ring lacking the oxygen of the lactone ring (S38809 and S39625) have been synthesized.  S39625 has been selected for advanced preclin. development based on its promising activity in tumor models.  Here, we show that both keto analogs are active against purified Top1 and selective against Top1 in yeast and human cancer cells.  The keto analogs show improved cytotoxicity toward colon, breast, and prostate cancer cells and leukemia cells compared with CPT.  The drug-induced Top1-DNA cleavage complexes induced by the keto analogs show remarkable persistence both with purified Top1 and in cells following 1-h drug treatments.  Moreover, we find that S39625 is not a substrate for either the ABCB1 (multidrug resistance-1/P-glycoprotein) or ABCG2 (mitoxantrone resistance/breast cancer resistance protein) drug efflux transporters, which sets S39625 apart from the clin. used CPT analogs topotecan or SN-38 (active metabolite of irinotecan).  Finally, we show that nanomolar concns. of S38809 or S39625 induce intense and persistent histone γ-H2AX.  The chem. stability of the keto analogs and the ability of S39625 to produce high levels of persistent Top1-DNA cleavage complex and its potent antiproliferative activity against human cancer cell lines make S39625 a promising new anticancer drug candidate.  Histone γ-H2AX could be used as a biomarker for the upcoming clin. trials of S39625.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsAvXCcUmkvLVg90H21EOLACvtfcHk0lhRIGvftU75aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsr3L&md5=3a428d2a4871232a86096569c4550fb2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0441%26sid%3Dliteratum%253Aachs%26aulast%3DTakagi%26aufirst%3DK.%26aulast%3DDexheimer%26aufirst%3DT.%2BS.%26aulast%3DRedon%26aufirst%3DC.%26aulast%3DSordet%26aufirst%3DO.%26aulast%3DAgama%26aufirst%3DK.%26aulast%3DLavielle%26aufirst%3DG.%26aulast%3DPierre%26aufirst%3DA.%26aulast%3DBates%26aufirst%3DS.%2BE.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DNovel-E-ring%2520camptothecin%2520keto%2520analogues%2520%2528S38809%2520and%2520S39625%2529%2520are%2520stable%252C%2520potent%252C%2520and%2520selective%2520topoisomerase%2520I%2520inhibitors%2520without%2520being%2520substrates%2520of%2520drug%2520efflux%2520transporters%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3229%26epage%3D3238%26doi%3D10.1158%2F1535-7163.MCT-07-0441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volk, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocchi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-C.</span></span> <span> </span><span class="NLM_article-title">BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">837</span>, <span class="refDoi"> DOI: 10.1016/S0006-2952(00)00396-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2FS0006-2952%2800%2900396-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10930538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltlWgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=831-837&author=C.-H.+Yangauthor=E.+Schneiderauthor=M.-L.+Kuoauthor=E.+L.+Volkauthor=E.+Rocchiauthor=Y.-C.+Chen&title=BCRP%2FMXR%2FABCP+expression+in+topotecan-resistant+human+breast+carcinoma+cells&doi=10.1016%2FS0006-2952%2800%2900396-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells</span></div><div class="casAuthors">Yang, C.-H.; Schneider, E.; Kuo, M.-L.; Volk, E. L.; Rocchi, E.; Chen, Y.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">831-837</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">We have previously described a mitoxantrone-resistant MCF7 cell line that is cross-resistant to topotecan, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11), and 9-aminocamptothecin, but not to camptothecin.  A novel mechanism that resulted in decreased topotecan accumulation in MCF7/MX cells was proposed (Yang, C.J.; et al., 1995).  We now have developed a topotecan-resistant cancer cell line from wild-type MCF7 cells.  MCF7/TPT300 cells were 68.9-fold resistant to topotecan, 68.3-fold to 10-hydroxy-7-ethylcamptothecin (SN-38), and 116-fold to mitoxantrone, but only 4.1-fold to camptothecin.  Topotecan efflux was increased in MCF7/TPT300 cells compared with MCF7/WT cells, and this increase was reversed upon ATP depletion by sodium azide, suggesting an energy-dependent drug efflux mechanism.  However, MCF7/TPT300 cells did not overexpress P-glycoprotein or the multidrug resistance-assocd. protein (MRP1).  In contrast, overexpression of the breast cancer resistance protein (BCRP/MXR/ABCP) was obsd. in MCF7/TPT300 cells as well as DNA topoisomerase I down-regulation.  Our data suggest that enhanced topotecan efflux contributes partly to topotecan resistance in MCF7/TPT300 cells, possibly mediated by BCRP/MXR/ABCP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoItOCSF823urVg90H21EOLACvtfcHk0li0ZTjLe6kVBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltlWgtL4%253D&md5=2debb1cb7ab8782a7928341d556c1d1a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2800%2900396-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252800%252900396-8%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.-H.%26aulast%3DSchneider%26aufirst%3DE.%26aulast%3DKuo%26aufirst%3DM.-L.%26aulast%3DVolk%26aufirst%3DE.%2BL.%26aulast%3DRocchi%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DY.-C.%26atitle%3DBCRP%252FMXR%252FABCP%2520expression%2520in%2520topotecan-resistant%2520human%2520breast%2520carcinoma%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2000%26volume%3D60%26spage%3D831%26epage%3D837%26doi%3D10.1016%2FS0006-2952%2800%2900396-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maliepaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span> <span> </span><span class="NLM_article-title">Transport of topoisomerase I inhibitors by the breast cancer resistance protein</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>922</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2000.tb07037.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1111%2Fj.1749-6632.2000.tb07037.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11193894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntVCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=922&publication_year=2000&pages=188-194&author=J.+H.+M.+Schellensauthor=M.+Maliepaardauthor=R.+J.+Scheperauthor=G.+L.+Schefferauthor=J.+W.+Jonkerauthor=J.+W.+Smitauthor=J.+H.+Beijnenauthor=A.+H.+Schinkel&title=Transport+of+topoisomerase+I+inhibitors+by+the+breast+cancer+resistance+protein&doi=10.1111%2Fj.1749-6632.2000.tb07037.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of topoisomerase I inhibitors by the breast cancer resistance protein: Potential clinical implications</span></div><div class="casAuthors">Schellens, Jan H. M.; Maliepaard, Marc; Scheper, Rik J.; Scheffer, George L.; Jonker, Johan W.; Smit, Johan W.; Beijnen, Jos H.; Schinkel, Alfred H.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">922</span>
        (<span class="NLM_cas:issue">Camptothecins</span>),
    <span class="NLM_cas:pages">188-194</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">The multidrug resistance protein BCRP (breast cancer resistance protein) is a member of the ATP-binding cassette family of drug transporters.  Overexpression of BCRP caused by exposure of cells to mitoxantrone (MX) or doxorubicin/verapamil resulted in a resistance pattern that is different from what is generally seen in the case of P-glycoprotein and MRP1 overexpression.  Recently, the BCRP gene has been described in ovarian, breast, colon, and gastric cancer and fibrosarcoma cell lines.  Our human tumor cells T8 and MX3, derived from the ovarian cancer cell line IGROV1 by stepwise increased exposure to topotecan and MX, are resistant to topotecan, CPT11, SN38, and 9-aminocamptothecin as well as MX.  Increased energy-dependent efflux of affected drugs was noted.  BCRP is a very efficient transporter of topotecan.  Our recent studies, using the monoclonal antibody (mAb) BXP34, revealed that BCRP is located in the plasma membrane of the T8 and MX3 cell lines.  Preliminary results of staining of human tumor cells showed low or absent levels of BCRP in a panel of solid tumors and acute myeloid leukemia cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPn0QwPct2nLVg90H21EOLACvtfcHk0li0ZTjLe6kVBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntVCrsA%253D%253D&md5=868dbe4d966603c1e7f523a4539b2fe7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2000.tb07037.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2000.tb07037.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DMaliepaard%26aufirst%3DM.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DJonker%26aufirst%3DJ.%2BW.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26atitle%3DTransport%2520of%2520topoisomerase%2520I%2520inhibitors%2520by%2520the%2520breast%2520cancer%2520resistance%2520protein%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2000%26volume%3D922%26spage%3D188%26epage%3D194%26doi%3D10.1111%2Fj.1749-6632.2000.tb07037.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwahana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsui, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imagawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohgo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejima, A.</span></span> <span> </span><span class="NLM_article-title">Growth inhibitory effect if a new campthotecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell Line PC6</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1097/00001813-200006000-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1097%2F00001813-200006000-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10912951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVegtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2000&pages=353-362&author=M.+Ishiiauthor=M.+Iwahanaauthor=I.+Mitsuiauthor=M.+Minamiauthor=S.+Imagawaauthor=A.+Tohgoauthor=A.+Ejima&title=Growth+inhibitory+effect+if+a+new+campthotecin+analog%2C+DX-8951f%2C+on+various+drug-resistant+sublines+including+BCRP-mediated+camptothecin+derivative-resistant+variants+derived+from+the+human+lung+cancer+cell+Line+PC6&doi=10.1097%2F00001813-200006000-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6</span></div><div class="casAuthors">Ishii, Mineko; Iwahana, Michio; Mitsui, Ikuo; Minami, Megumi; Imagawa, Setsuko; Tohgo, Akiko; Ejima, Akio</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-362</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">DX-8951f, a new water-sol. camptothecin (CPT) deriv., has been reported to show potent antitumor effects against various tumors in vitro and in vivo.  We further evaluated the cytotoxic effect of DX-8951f against eight drug-resistant sublines derived by stepwise exposure of human oat cell carcinoma PC-6 to various drugs.  In paclitaxel-, adriamycin-, vincristine- and etoposide-resistant cells, over-expression of P-glycoprotein (P-gp) and a correlative redn. in drug accumulation and typical drug-sensitivity pattern were confirmed.  The etoposide-resistant line with the highest P-gp level was cross-resistant also to SN-38, CPT-11 and topotecan (TPT), but not to 9-aminocamptothecin (9-AC), CPT and DX-8951f.  SN-38- and CPT-11-resistant cells, of which topoisomerase I activities and levels were similar to those of the parent cells, showed cross-resistance clearly to TPT, 9-AC and mitoxantrone, but hardly to DX-8951f.  In these two resistant sublines, the intracellular topotecan level was significantly lower than that in parental PC-6 and the reduced accumulation was mediated by breast cancer resistant protein (BCRP).  The cisplatin-resistant variant, which had a 2-fold increase in glutathione content, showed no cross-resistance and the 5-fluorouracil-resistant variant, which had a 50% decrease in glutathione content, exhibited collateral sensitivity to most of the other anticancer agents including DX-8951f.  We concluded that DX-8951f showed a potent cytotoxic effect on various types of drug-resistant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHN95P5NWZALVg90H21EOLACvtfcHk0li0ZTjLe6kVBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVegtLc%253D&md5=2734e7e280f96a907f6ba8c448653985</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2F00001813-200006000-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-200006000-00005%26sid%3Dliteratum%253Aachs%26aulast%3DIshii%26aufirst%3DM.%26aulast%3DIwahana%26aufirst%3DM.%26aulast%3DMitsui%26aufirst%3DI.%26aulast%3DMinami%26aufirst%3DM.%26aulast%3DImagawa%26aufirst%3DS.%26aulast%3DTohgo%26aufirst%3DA.%26aulast%3DEjima%26aufirst%3DA.%26atitle%3DGrowth%2520inhibitory%2520effect%2520if%2520a%2520new%2520campthotecin%2520analog%252C%2520DX-8951f%252C%2520on%2520various%2520drug-resistant%2520sublines%2520including%2520BCRP-mediated%2520camptothecin%2520derivative-resistant%2520variants%2520derived%2520from%2520the%2520human%2520lung%2520cancer%2520cell%2520Line%2520PC6%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2000%26volume%3D11%26spage%3D353%26epage%3D362%26doi%3D10.1097%2F00001813-200006000-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bessho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achiwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niimi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span> <span> </span><span class="NLM_article-title">Role of ABCG2 as biomarker for predicting resistance to CPT11/SN-38 in lung cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2006.00164.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1111%2Fj.1349-7006.2006.00164.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=16542215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs1Omurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=192-198&author=Y.+Besshoauthor=T.+Oguriauthor=H.+Achiwaauthor=H.+Muramatsuauthor=H.+Maedaauthor=T.+Niimiauthor=S.+Satoauthor=R.+Ueda&title=Role+of+ABCG2+as+biomarker+for+predicting+resistance+to+CPT11%2FSN-38+in+lung+cancer&doi=10.1111%2Fj.1349-7006.2006.00164.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer</span></div><div class="casAuthors">Bessho, Yuji; Oguri, Tetsuya; Achiwa, Hiroyuki; Muramatsu, Hideki; Maeda, Hiroyoshi; Niimi, Takashi; Sato, Shigeki; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">192-198</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">To examine the mechanism of resistance to 7-ethyl-10-hydroxycamptothecin (SN-38) in lung cancer, we continuously exposed the non-small-cell lung cancer (NSCLC) cell line NCI-H23 to SN-38 and selected the SN-38-resistant clone H23/SN-38.  After 2 mo of culturing in SN-38-free conditions, H23/SN-38 cells recovered their sensitivity to SN-38 and were subsequently established as the revertant H23/SN-38REV cell line.  Because H23/SN-38 cells show cross resistance to certain anticancer drugs, such as topotecan, etoposide, doxorubicin and mitoxantrone, we examd. the gene and protein expression levels of drug efflux transporters of the ATP-binding cassette (ABC) family.  We found that both gene and protein expression of ABCG2/BCRP (ABCG2) in H23/SN-38 cells was increased compared with that in NCI-H23 cells and H23/SN-38REV cells.  The cellular accumulation of topotecan in H23/SN-38 cells was decreased compared with that in NCI-H23 and H23/SN-38REV cells, and treatment with reserpine (an inhibitor of ABCG2) increased the cellular accumulation of topotecan in H23/SN-38 cells.  Furthermore, treatment with reserpine also altered the sensitivity of H23/SN-38 cells to SN-38.  These results indicate that the upregulation of ABCG2 was functional, and related to the resistance of H23/SN-38 cells to SN-38.  Moreover, we found that gene expression levels of ABCG2 were significantly correlated with the concn. of SN-38 for 50% cell survival in 13 NSCLC cells (r = 0.592, P < 0.05).  The present results indicate that the induction of ABCG2 by SN-38 does confer acquired resistance to CPT-11/SN-38, but the induction of ABCG2 and subsequent drug resistance are reversible.  However, the expression level of ABCG2 may be a useful indicator of CPT-11/SN-38 activity in lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLxN5ZFT5Rw7Vg90H21EOLACvtfcHk0ljWTJyG-8g0nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs1Omurk%253D&md5=55a3c2b03ac4efa18d0268a4fdb60c07</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2006.00164.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2006.00164.x%26sid%3Dliteratum%253Aachs%26aulast%3DBessho%26aufirst%3DY.%26aulast%3DOguri%26aufirst%3DT.%26aulast%3DAchiwa%26aufirst%3DH.%26aulast%3DMuramatsu%26aufirst%3DH.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DNiimi%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DRole%2520of%2520ABCG2%2520as%2520biomarker%2520for%2520predicting%2520resistance%2520to%2520CPT11%252FSN-38%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2006%26volume%3D97%26spage%3D192%26epage%3D198%26doi%3D10.1111%2Fj.1349-7006.2006.00164.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagashima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiozawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuuchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, S.</span></span> <span> </span><span class="NLM_article-title">BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1007/s00280-006-0212-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1007%2Fs00280-006-0212-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=16520985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1SmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=594-600&author=S.+Nagashimaauthor=H.+Sodaauthor=M.+Okaauthor=T.+Kitazakiauthor=K.+Shiozawaauthor=Y.+Nakamuraauthor=M.+Takemuraauthor=H.+Yabuuchiauthor=M.+Fukudaauthor=K.+Tsukamotoauthor=S.+Kohno&title=BCRP%2FABCG2+levels+account+for+the+resistance+to+topoisomerase+I+inhibitors+and+reversal+effects+by+gefitinib+in+non-small+cell+lung+cancer&doi=10.1007%2Fs00280-006-0212-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer</span></div><div class="casAuthors">Nagashima, Seiji; Soda, Hiroshi; Oka, Mikio; Kitazaki, Takeshi; Shiozawa, Ken; Nakamura, Yoichi; Takemura, Masaaki; Yabuuchi, Hikaru; Fukuda, Minoru; Tsukamoto, Kazuhiro; Kohno, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">594-600</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Breast cancer resistance protein (BCRP) confers resistance against topoisomerase I inhibitors in cancer cells.  Very recently, the authors reported that gefitinib reverses BCRP-mediated drug resistance by direct inhibition.  However, it remains undetd. how much BCRP contributes to the resistance to topoisomerase I inhibitors in non-small cell lung cancer (NSCLC).  The present study was designed to examine whether BCRP levels in NSCLC cells are correlated with the resistance to topoisomerase I inhibitors and the reversal effect by gefitinib.  Methods: BCRP levels and its function were evaluated by Western blotting and flow-cytometry, resp.  Gefitinib-insensitive NSCLC cells expressed various levels of BCRP, which were closely correlated not only with the IC50 values of SN-38 (r=0.874, P<0.05) and those of topotecan (r=0.968, P<0.001), but also with the reversal effects of 1 μM gefitinib on SN-38 resistance (r=0.956, P<0.001) and topotecan resistance (r=0.977, P=0.0001).  Results: BCRP levels accounted for between 80 and 90% of the variation in the resistance to topoisomerase I inhibitors and the reversal effects by gefitinib.  Also, gefitinib increased intracellular topotecan accumulation in proportion to the BCRP levels.  Conclusions: These findings suggest that BCRP is the most important mol. responsible for topoisomerase I inhibitor resistance, and that the development of BCRP inhibitors is an effective approach for overcoming this resistance.  In addn., the examn. of BCRP levels in NSCLC tissues may identify an optimal patient population for treatment with topoisomerase I inhibitors alone or in combination with BCRP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13sMpfTcgPLVg90H21EOLACvtfcHk0ljWTJyG-8g0nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1SmsLs%253D&md5=2eeab9a906ca519fcfcc5d7ba4140b77</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs00280-006-0212-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-006-0212-y%26sid%3Dliteratum%253Aachs%26aulast%3DNagashima%26aufirst%3DS.%26aulast%3DSoda%26aufirst%3DH.%26aulast%3DOka%26aufirst%3DM.%26aulast%3DKitazaki%26aufirst%3DT.%26aulast%3DShiozawa%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DTakemura%26aufirst%3DM.%26aulast%3DYabuuchi%26aufirst%3DH.%26aulast%3DFukuda%26aufirst%3DM.%26aulast%3DTsukamoto%26aufirst%3DK.%26aulast%3DKohno%26aufirst%3DS.%26atitle%3DBCRP%252FABCG2%2520levels%2520account%2520for%2520the%2520resistance%2520to%2520topoisomerase%2520I%2520inhibitors%2520and%2520reversal%2520effects%2520by%2520gefitinib%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2006%26volume%3D58%26spage%3D594%26epage%3D600%26doi%3D10.1007%2Fs00280-006-0212-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Perez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhagen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antony, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadjem, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin and homocamptothecins</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">836</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.063149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1124%2Fjpet.103.063149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=15075385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVykt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2004&pages=836-842&author=S.+E.+Batesauthor=M.+Medina-Perezauthor=G.+Kohlhagenauthor=S.+Antonyauthor=T.+Nadjemauthor=R.+W.+Robeyauthor=Y.+Pommier&title=ABCG2+mediates+differential+resistance+to+SN-38+%287-ethyl-10-hydroxycamptothecin+and+homocamptothecins&doi=10.1124%2Fjpet.103.063149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins</span></div><div class="casAuthors">Bates, Susan E.; Medina-Perez, Wilma Y.; Kohlhagen, Glenda; Antony, Smitha; Nadjem, Tim; Robey, Robert W.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">836-842</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">One activity potentially limiting the efficacy of camptothecin anticancer agents is their cellular efflux by the ATP-binding cassette half-transporter, ABCG2.  Homocamptothecins are novel anticancer drugs that inhibit topoisomerase 1 with a greater potency than camptothecins.  Homocamptothecins differ from camptothecins by their E-ring, which is seven-membered instead of the six-membered ring of camptothecins.  We report herein that, like camptothecins, homocamptothecin and its difluoro deriv. BN80915 are substrates for ABCG2.  However, the resistance of three selected cell lines overexpressing wild-type or mutant ABCG2 to homocamptothecin or BN80915 was less than resistance to SN-38 (7-ethyl-10-hydroxycamptothecin), indicating that both the seven-membered E-ring present in homocamptothecin and the A- and B-ring modifications present in SN-38 are involved in substrate recognition by ABCG2.  HEK-293 cells transfected with vectors encoding wild-type or mutant ABCG2 were less resistant to both homocamptothecins than to SN-38.  However, transfectants overexpressing mutant ABCG2 had relative resistance values for homocamptothecin and BN80915 4- to 14-fold higher than cells expressing wild-type ABCG2, suggesting that the gain of function resulting from mutation at amino acid 482, although not affecting SN-38, extends to the homocamptothecins.  Resistance was reversed by the ABCG2 inhibitor fumitremorgin C.  BN80915 was 17-fold more potent than SN-38 in wild-type ABCG2-transfected cells, suggesting that BN80915 has the potential to overcome ABCG2-related resistance to SN-38, the active metabolite of CPT-11 (irinotecan).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZClD9Z5kQgLVg90H21EOLACvtfcHk0ljWTJyG-8g0nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVykt7g%253D&md5=274f9c9ba24d1d4cc1843e614725004e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.063149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.063149%26sid%3Dliteratum%253Aachs%26aulast%3DBates%26aufirst%3DS.%2BE.%26aulast%3DMedina-Perez%26aufirst%3DM.%26aulast%3DKohlhagen%26aufirst%3DG.%26aulast%3DAntony%26aufirst%3DS.%26aulast%3DNadjem%26aufirst%3DT.%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DABCG2%2520mediates%2520differential%2520resistance%2520to%2520SN-38%2520%25287-ethyl-10-hydroxycamptothecin%2520and%2520homocamptothecins%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D310%26spage%3D836%26epage%3D842%26doi%3D10.1124%2Fjpet.103.063149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perego, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Cesare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Isabella, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carenini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beggiolin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plumbo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tartiglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratesi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carminati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunino, F.</span></span> <span> </span><span class="NLM_article-title">A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6034</span>– <span class="NLM_lpage">6037</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2011&pages=6034-6037&author=P.+Peregoauthor=M.+De+Cesareauthor=P.+De+Isabellaauthor=N.+Careniniauthor=G.+Beggiolinauthor=G.+Pezzoniauthor=M.+Plumboauthor=L.+Tartigliaauthor=G.+Pratesiauthor=C.+Pisanoauthor=P.+Carminatiauthor=G.+L.+Schefferauthor=F.+Zunino&title=A+novel+7-modified+camptothecin+analog+overcomes+breast+cancer+resistance+protein-associated+resistance+in+a+mitoxantrone-selected+colon+carcinoma+cell+line"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerego%26aufirst%3DP.%26aulast%3DDe%2BCesare%26aufirst%3DM.%26aulast%3DDe%2BIsabella%26aufirst%3DP.%26aulast%3DCarenini%26aufirst%3DN.%26aulast%3DBeggiolin%26aufirst%3DG.%26aulast%3DPezzoni%26aufirst%3DG.%26aulast%3DPlumbo%26aufirst%3DM.%26aulast%3DTartiglia%26aufirst%3DL.%26aulast%3DPratesi%26aufirst%3DG.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DCarminati%26aufirst%3DP.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DZunino%26aufirst%3DF.%26atitle%3DA%2520novel%25207-modified%2520camptothecin%2520analog%2520overcomes%2520breast%2520cancer%2520resistance%2520protein-associated%2520resistance%2520in%2520a%2520mitoxantrone-selected%2520colon%2520carcinoma%2520cell%2520line%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D61%26spage%3D6034%26epage%3D6037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maliepaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gastelen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohgo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hausheer, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Waardenburg, R. C. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span> <span> </span><span class="NLM_article-title">Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins <i>in vitro</i> using non-substrate drugs or the BCRP inhibitor GF120918</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">941</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11309344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1elsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=935-941&author=M.+Maliepaardauthor=M.+A.+van+Gastelenauthor=A.+Tohgoauthor=F.+H.+Hausheerauthor=R.+C.+A.+M.+van+Waardenburgauthor=L.+A.+de+Jongauthor=D.+Pluimauthor=J.+H.+Beijnenauthor=J.+H.+M.+Schellens&title=Circumvention+of+breast+cancer+resistance+protein+%28BCRP%29-mediated+resistance+to+camptothecins+in+vitro+using+non-substrate+drugs+or+the+BCRP+inhibitor+GF120918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using nonsubstrate drugs or the BCRP inhibitor GF 120918</span></div><div class="casAuthors">Maliepaard, Mare; van Gastelen, Margot A.; Tohgo, Akiko; Hausheer, Frederick H.; van Waardenburg, Robert C. A. M.; de Jong, Laurina A.; Pluim, Dick; Beijnen, Jos H.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">935-941</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8 and MX3 to camptothecins more extensively and investigating whether resistance can be reversed by inhibiting BCRP by GF120918.  Camptothecins studied were topotecan, CPT-11, and its active metabolite SN-38, 9-aminocamptothecin, and the novel exptl. camptothecins NX211, DX8951f, and BNP1350.  Notably, DX8951f and BNP1350 appeared to be very poor substrates for BCRP, with much lower resistance factors obsd. both in T8 and MX3 cells than obsd. for the other camptothecins tested.  In the presence of a nontoxic dose level of GF120918, the intracellular accumulation of topotecan in the T8 and MX3 cells was completely restored to the intracellular levels obsd. in the sensitive IGROV1 parental cell line.  This resulted in almost complete reversal of drug resistance to topotecan and to most of the other topoisomerase I drugs tested in the T8 cell line and to complete reversal in the MX3 cells.  However, coincubation of DX8951f or BNP1350 with GF120918 did not affect the cytotoxicity of either of these drugs significantly.  From the combined data, we conclude that the affinities of topoisomerase I drugs for BCRP are, in decreasing order: SN-38 > topotecan > 9-aminocamptothecin ∼ CPT-11 > NX211 > DX8951f > BNP1350.  Furthermore, GF120918 appears to be a potent reversal agent of BCRP-mediated resistance to camptothecins, with almost complete reversal noted at 100 nM.  Potential BCRP-mediated resistance to topoisomerase I inhibitors can also be avoided by using the BCRP-insensitive drugs DX8951f or BNP1350.  This observation may have important clin. implications for future development of novel camptothecins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn1KA-rPrFobVg90H21EOLACvtfcHk0ljlCaDWfWfBOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1elsbo%253D&md5=b381852cab5ffd4959526f22b64290e8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaliepaard%26aufirst%3DM.%26aulast%3Dvan%2BGastelen%26aufirst%3DM.%2BA.%26aulast%3DTohgo%26aufirst%3DA.%26aulast%3DHausheer%26aufirst%3DF.%2BH.%26aulast%3Dvan%2BWaardenburg%26aufirst%3DR.%2BC.%2BA.%2BM.%26aulast%3Dde%2BJong%26aufirst%3DL.%2BA.%26aulast%3DPluim%26aufirst%3DD.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DCircumvention%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%2529-mediated%2520resistance%2520to%2520camptothecins%2520in%2520vitro%2520using%2520non-substrate%2520drugs%2520or%2520the%2520BCRP%2520inhibitor%2520GF120918%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D935%26epage%3D941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Hattum, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogsteen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlüper, H. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maliepaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhagen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinedo, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boven, E.</span></span> <span> </span><span class="NLM_article-title">Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumor activity</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6600508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fsj.bjc.6600508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=12237778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVGqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2002&pages=665-672&author=A.+H.+van%0AHattumauthor=J.+J.+Hoogsteenauthor=H.+M.+M.+Schl%C3%BCperauthor=M.+Maliepaardauthor=G.+L.+Schefferauthor=R.+J.+Scheperauthor=G.+Kohlhagenauthor=Y.+Pommierauthor=H.+M.+Pinedoauthor=E.+Boven&title=Induction+of+breast+cancer+resistance+protein+by+the+camptothecin+derivative+DX-8951f+is+associated+with+minor+reduction+of+antitumor+activity&doi=10.1038%2Fsj.bjc.6600508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity</span></div><div class="casAuthors">van Hattum, A. H.; Hoogsteen, I. J.; Schlueper, H. M. M.; Maliepaard, M.; Scheffer, G. L.; Scheper, R. J.; Kohlhagen, G.; Pommier, Y.; Pinedo, H. M.; Boven, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">665-672</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">DX-8951f (exatecan mesylate), a new water-sol. deriv. of camptothecin, is currently being evaluated in phase II clin. trials.  Resistance may be acquired when treating cancer patients with DX-8951f.  Therefore, the authors selected a subline of the human ovarian cancer cell line A2780 for resistance against DX-8951f to investigate possible mechanisms of resistance.  This DX-8951f-resistant subline, designated 2780DX8 (resistance factor = 9.3), displayed a typical cross-resistance pattern including compds., such as topotecan (resistance factor = 34), SN-38 (resistance factor = 47), mitoxantrone (resistance factor = 59) and doxorubicin (resistance factor = 2.9), which have previously been assocd. with the expression of breast cancer resistance protein.  2780DX8 cells did not show changes in the topoisomerase I gene, in topoisomerase I protein levels or catalytic activity.  Overexpression of breast cancer resistance protein could be detected, both at the mRNA and protein level, while staining for Pgp, MRP1, or LRP was neg.  GF120918, an inhibitor of breast cancer resistance protein, was able to reverse the DX-8951f-induced resistance in 2780DX8 cells.  In vivo expts. in well-established 2780DX8 human tumor xenografts demonstrated that the growth inhibition induced by CPT-11 was more affected by breast cancer resistance protein expression than that of DX-8951f.  These data indicate for the first time that DX-8951f is able to induce breast cancer resistance protein as a mechanism of resistance.  Breast cancer resistance protein, however, results in only minor redn. of antitumor activity of DX-8951f which is an advantage over topotecan and CPT-11/SN-38.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSpTsPOcp8QbVg90H21EOLACvtfcHk0lga7Xc8IKqSVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVGqu7g%253D&md5=5eb7b6b36d3f89d830d69ff095e8f57f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600508%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BHattum%26aufirst%3DA.%2BH.%26aulast%3DHoogsteen%26aufirst%3DJ.%2BJ.%26aulast%3DSchl%25C3%25BCper%26aufirst%3DH.%2BM.%2BM.%26aulast%3DMaliepaard%26aufirst%3DM.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DKohlhagen%26aufirst%3DG.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26aulast%3DBoven%26aufirst%3DE.%26atitle%3DInduction%2520of%2520breast%2520cancer%2520resistance%2520protein%2520by%2520the%2520camptothecin%2520derivative%2520DX-8951f%2520is%2520associated%2520with%2520minor%2520reduction%2520of%2520antitumor%2520activity%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2002%26volume%3D87%26spage%3D665%26epage%3D672%26doi%3D10.1038%2Fsj.bjc.6600508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Hattum, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlüper, H. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hausheer, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinedo, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boven, E.</span></span> <span> </span><span class="NLM_article-title">Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1002/ijc.10434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1002%2Fijc.10434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=12115582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVGntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=22-29&author=A.+H.+van%0AHattumauthor=H.+M.+M.+Schl%C3%BCperauthor=F.+H.+Hausheerauthor=H.+M.+Pinedoauthor=E.+Boven&title=Novel+camptothecin+derivative+BNP1350+in+experimental+human+ovarian+cancer%3A+determination+of+efficacy+and+possible+mechanisms+of+resistance&doi=10.1002%2Fijc.10434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance</span></div><div class="casAuthors">Van Hattum, Annemarie H.; Schluper, Hennie M. M.; Hausheer, Frederick H.; Pinedo, Herbert M.; Boven, Epie</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-29</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The novel camptothecin deriv. BNP1350 ((7-[2-trimethylsilyl)ethyl]-20(S)-camptothecin), also known as Karenitecin, has been developed for superior oral bioavailability and increased lactone stability.  In our study, we describe the antiproliferative effects of BNP1350, SN-38 and topotecan in 4 human ovarian cancer cell lines.  BNP1350 was slightly more potent than SN-38 (p<0.01) and was considerably more potent than topotecan (p<0.01).  We extended these studies to well-established human ovarian cancer xenografts in which we compared the growth inhibition induced by BNP1350 with that of topotecan given in equitoxic schedules.  The growth inhibition in all 3 xenografts induced by BNP1350 was ≥75%, which was significantly better than that resulting from topotecan (p<0.05).  We then selected BNP1350-resistant variants of the A2780 human ovarian cancer cell line, 2780K4 (resistance factor: 41) and 2780K32 (resistance factor: 90), to analyze possible resistance mechanisms.  These variants exhibited cross-resistance against all camptothecins tested.  In comparison with 2780K4 cells, 2780K32 cells were relatively more resistant against SN-38, topotecan, DX-8951f and BNP1350.  In addn., 2780K32 cells were highly cross-resistant against mitoxantrone.  In both 2780K4 and 2780K32, the amt. of topoisomerase I was not changed but the catalytic activity was reduced.  Furthermore, 2780K32 cells clearly overexpressed the breast cancer resistance protein (BCRP), as demonstrated for both the gene and the protein.  In contrast to topotecan, BNP1350 proved not to be a good substrate for BCRP.  Overall, we conclude that BNP1350 offers advantages over topotecan expressed by high efficacy in exptl. human ovarian cancer and poor affinity for BCRP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopTHWO4MpXH7Vg90H21EOLACvtfcHk0lga7Xc8IKqSVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVGntLg%253D&md5=19bc250d6b7cfe4dbbbffe47f3a73ed5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fijc.10434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10434%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BHattum%26aufirst%3DA.%2BH.%26aulast%3DSchl%25C3%25BCper%26aufirst%3DH.%2BM.%2BM.%26aulast%3DHausheer%26aufirst%3DF.%2BH.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26aulast%3DBoven%26aufirst%3DE.%26atitle%3DNovel%2520camptothecin%2520derivative%2520BNP1350%2520in%2520experimental%2520human%2520ovarian%2520cancer%253A%2520determination%2520of%2520efficacy%2520and%2520possible%2520mechanisms%2520of%2520resistance%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D100%26spage%3D22%26epage%3D29%26doi%3D10.1002%2Fijc.10434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erlichman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerner, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallgren, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spieker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maliepaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bible, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span> <span> </span><span class="NLM_article-title">The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 6-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance-mediated drug efflux</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11212277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3MXht1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=739-748&author=C.+Erlichmanauthor=S.+A.+Boernerauthor=C.+G.+Hallgrenauthor=R.+Spiekerauthor=X.-Y.+Wangauthor=C.+D.+Jamesauthor=G.+L.+Schefferauthor=M.+Maliepaardauthor=D.+D.+Rossauthor=K.+C.+Bibleauthor=S.+H.+Kaufmann&title=The+HER+tyrosine+kinase+inhibitor+CI1033+enhances+cytotoxicity+of+6-ethyl-10-hydroxycamptothecin+and+topotecan+by+inhibiting+breast+cancer+resistance-mediated+drug+efflux"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux</span></div><div class="casAuthors">Erlichman, Charles; Boerner, Scott A.; Hallgren, Christopher G.; Spieker, Rebecca; Wang, Xiao-Yang; James, C. David; Scheffer, George L.; Maliepaard, Marc; Ross, Douglas D.; Bible, Keith C.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">739-748</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Because the activities of HER family members are elevated and/or aberrant in a variety of human neoplasms, these cell surface receptors are receiving increasing attention as potential therapeutic targets.  In the present study, we examd. the effect of combining the HER family tyrosine kinase inhibitor CI1033 (PD 183805) with the topoisomerase (topo) I poison 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan, in a no. of different cell lines.  Colony-forming assays revealed that the antiproliferative effects of simultaneous treatment with CI1033 and SN-38 were synergistic in T98G glioblastoma cells and HCT8 colorectal carcinoma cells, whereas sequential treatments were additive at best.  In addnl. studies examg. the mechanistic basis for these findings in T98G cells, immunoblotting revealed that the inhibitory effects of CI1033 on epidermal growth factor receptor autophosphorylation were unaffected by SN-38.  Likewise, CI1033 had no effect on topo I polypeptide levels, localization, or activity.  Nonetheless, CI1033 markedly enhanced the no. of covalent topo I-DNA complexes stabilized by SN-38 or the related agent topotecan (TPT).  Anal. of intracellular SN-38 levels by high-performance liq. chromatog. and intracellular TPT levels by flow microfluorometry revealed that CI1033 increased the steady-state accumulation of SN-38 and TPT by 9.4 ± 1.9- and 1.8 ± 0.2-fold, resp.  Further evaluation revealed that the initial rate of TPT uptake was unaffected by CI1033, whereas the rate of efflux was markedly diminished.  Addnl. studies demonstrated that T98G and HCT8 cells express the breast cancer resistance protein (BCRP), a recently cloned ATP binding cassette transporter.  Moreover, CI1033 enhanced the uptake and cytotoxicity of SN-38 and TPT in cells transfected with BCRP but not empty vector.  Conversely, CI1033 accumulation was diminished in cells expressing BCRP, suggesting that CI1033 is a substrate for this efflux pump.  These results indicate that CI1033 can modulate the accumulation and subsequent cytotoxicity of two widely used topo I poisons in cells that have no history of previous exposure to these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgpLth6O-Z0LVg90H21EOLACvtfcHk0lgbO-7G0rQPRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXht1Gmt74%253D&md5=93b4e887dde792b70d881bc94b6793ca</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DHallgren%26aufirst%3DC.%2BG.%26aulast%3DSpieker%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.-Y.%26aulast%3DJames%26aufirst%3DC.%2BD.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DMaliepaard%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DD.%2BD.%26aulast%3DBible%26aufirst%3DK.%2BC.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DThe%2520HER%2520tyrosine%2520kinase%2520inhibitor%2520CI1033%2520enhances%2520cytotoxicity%2520of%25206-ethyl-10-hydroxycamptothecin%2520and%2520topotecan%2520by%2520inhibiting%2520breast%2520cancer%2520resistance-mediated%2520drug%2520efflux%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D739%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.-W.</span></span> <span> </span><span class="NLM_article-title">Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">11971</span>– <span class="NLM_lpage">11985</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.18632%2Foncotarget.2647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25436978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC2MzhslWhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=11971-11985&author=X.-K.+Wangauthor=K.+K.+W.+Toauthor=L.-Y.+Huangauthor=J.-H.+Xuauthor=K.+Yangauthor=F.+Wangauthor=Z.-C.+Huangauthor=S.+Yeauthor=L.-W.+Fu&title=Afatinib+circumvents+multidrug+resistance+via+dually+inhibiting+ATP+binding+cassette+subfamily+G+member+2+in+vitro+and+in+vivo&doi=10.18632%2Foncotarget.2647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo</span></div><div class="casAuthors">Wang Xiao-Kun; Huang Li-Yan; Yang Ke; Wang Fang; Huang Zhen-Cong; Fu Li-Wu; To Kenneth Kin Wah; Xu Jing-Hong; Ye Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11971-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multidrug resistance (MDR) to chemotherapeutic drugs is a formidable barrier to the success of cancer chemotherapy.  Expressions of ATP-binding cassette (ABC) transporters contribute to clinical MDR phenotype.  In this study, we found that afatinib, a small molecule tyrosine kinase inhibitor (TKI) targeting EGFR, HER-2 and HER-4, reversed the chemoresistance mediated by ABCG2 in vitro, but had no effect on that mediated by multidrug resistance protein ABCB1 and ABCC1.  In addition, afatinib, in combination with topotecan, significantly inhibited the growth of ABCG2- overexpressing cell xenograft tumors in vivo.  Mechanistic investigations exhibited that afatinib significantly inhibited ATPase activity of ABCG2 and downregulated expression level of ABCG2, which resulted in the suppression of efflux activity of ABCG2 in parallel to the increase of intracellular accumulation of ABCG2 substrate anticancer agents.  Taken together, our findings may provide a new and useful combinational therapeutic strategy of afatinib with chemotherapeutical drug for the patients with ABCG2 overexpressing cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrZfMDjQbKJmhHGZei4OW9fW6udTcc2eY1TeXNf7Xt_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzhslWhtA%253D%253D&md5=8f91286a39ee9f15f2a87287e794ec96</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2647%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.-K.%26aulast%3DTo%26aufirst%3DK.%2BK.%2BW.%26aulast%3DHuang%26aufirst%3DL.-Y.%26aulast%3DXu%26aufirst%3DJ.-H.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DZ.-C.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DFu%26aufirst%3DL.-W.%26atitle%3DAfatinib%2520circumvents%2520multidrug%2520resistance%2520via%2520dually%2520inhibiting%2520ATP%2520binding%2520cassette%2520subfamily%2520G%2520member%25202%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D11971%26epage%3D11985%26doi%3D10.18632%2Foncotarget.2647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance <i>in vitro</i>, <i>in vivo</i> and <i>ex vivo</i></span>. <i>Exp. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">e303</span>, <span class="refDoi"> DOI: 10.1038/emm.2016.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Femm.2016.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=28303028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVWms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=e303&author=K.+Yangauthor=Y.+Chenauthor=K.+K.+W.+Toauthor=F.+Wangauthor=D.+Liauthor=L.+Chenauthor=L.+Fu&title=Alectinib+%28CH5424802%29+antagonizes+ABCB1-+and+ABCG2-mediated+multidrug+resistance+in+vitro%2C+in+vivo+and+ex+vivo&doi=10.1038%2Femm.2016.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo</span></div><div class="casAuthors">Yang, Ke; Chen, Yifan; To, Kenneth Kin Wah; Wang, Fang; Li, Delan; Chen, Likun; Fu, Liwu</div><div class="citationInfo"><span class="NLM_cas:title">Experimental & Molecular Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e303</span>CODEN:
                <span class="NLM_cas:coden">EMMEF3</span>;
        ISSN:<span class="NLM_cas:issn">2092-6413</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Alectinib, an inhibitor of anaplastic lymphoma kinase (ALK), was approved by the Food and Drug Administration (FDA) for the treatment of patients with ALK-pos. non-small cell lung cancer (NSCLC).  Here we investigated the reversal effect of alectinib on multidrug resistance (MDR) induced by ATP-binding cassette (ABC) transporters, which is the primary cause of chemotherapy failure.  We provide the first evidence that alectinib increases the sensitivity of ABCB1- and ABCG2-overexpressing cells to chemotherapeutic agents in vitro and in vivo.  Mechanistically, alectinib increased the intracellular accumulation of ABCB1/ABCG2 substrates such as doxorubicin (DOX) and Rhodamine 123 (Rho 123) by inhibiting the efflux function of the transporters in ABCB1- or ABCG2-overexpressing cells but not in their parental sensitive cells.  Furthermore, alectinib stimulated ATPase activity and competed with substrates of ABCB1 or ABCG2 and competed with [125I] iodoarylazidoprazosin (IAAP) photolabeling bound to ABCB1 or ABCG2 but neither altered the expression and localization of ABCB1 or ABCG2 nor the phosphorylation levels of AKT and ERK.  Alectinib also enhanced the cytotoxicity of DOX and the intracellular accumulation of Rho 123 in ABCB1-overexpressing primary leukemia cells.  These findings suggest that alectinib combined with traditional chemotherapy may be beneficial to patients with ABCB1- or ABCG2-mediated MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovC2uTLcj2vLVg90H21EOLACvtfcHk0lijawh_5C-T2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVWms7o%253D&md5=3307b29638f0965d215784981011e9eb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Femm.2016.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femm.2016.168%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTo%26aufirst%3DK.%2BK.%2BW.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DAlectinib%2520%2528CH5424802%2529%2520antagonizes%2520ABCB1-%2520and%2520ABCG2-mediated%2520multidrug%2520resistance%2520in%2520vitro%252C%2520in%2520vivo%2520and%2520ex%2520vivo%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2017%26volume%3D49%26spage%3De303%26doi%3D10.1038%2Femm.2016.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbuti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, A.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurpel, J. N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) inhibitor cabozantinib</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.phrs.2017.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=28131876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisFSmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2017&pages=89-98&author=G.-N.+Zhangauthor=Y.-K.+Zhangauthor=Y.-J.+Wangauthor=A.+M.+Barbutiauthor=X.-J.+Zhuauthor=X.-Y.+Yuauthor=A.-W.+Wenauthor=J.+N.+D.+Wurpelauthor=Z.-S.+Chen&title=Modulating+the+function+of+ATP-binding+cassette+subfamily+G+member+2+%28ABCG2%29+inhibitor+cabozantinib&doi=10.1016%2Fj.phrs.2017.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib</span></div><div class="casAuthors">Zhang, Guan-Nan; Zhang, Yun-Kai; Wang, Yi-Jun; Barbuti, Anna Maria; Zhu, Xi-Jun; Yu, Xin-Yue; Wen, Ai-Wen; Wurpel, John N. D.; Chen, Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cabozantinib (XL184) is a small mol. tyrosine kinase receptor inhibitor, which targets c-Met and VEGFR2.  Cabozantinib has been approved by the Food and Drug Administration to treat advanced medullary thyroid cancer and renal cell carcinoma.  In the present study, we evaluated the ability of cabozantinib to modulate the function of the ATP-binding cassette subfamily G member 2 (ABCG2) by sensitizing cells that are resistant to ABCG2 substrate antineoplastic drugs.  We used a drug-selected resistant cell line H460/MX20 and three ABCG2 stable transfected cell lines ABCG2-482-R2, ABCG2-482-G2, and ABCG2-482-T7, which overexpress ABCG2.  Cabozantinib, at non-toxic concns. (3 or 5 μM), sensitized the ABCG2-overexpressing cells to mitoxantrone, SN-38, and topotecan.  Our results indicate that cabozantinib reverses ABCG2-mediated multidrug resistance by antagonizing the drug efflux function of the ABCG2 transporter instead of downregulating its expression.  The mol. docking anal. indicates that cabozantinib binds to the drug-binding site of the ABCG2 transporter.  Overall, our findings demonstrate that cabozantinib inhibits the ABCG2 transporter function and consequently enhances the effect of the antineoplastic agents that are substrates of ABCG2.  Cabozantinib may be a useful agent in anticancer treatment regimens for patients who are resistant to ABCG2 substrate drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdkxleAdX6tbVg90H21EOLACvtfcHk0lijawh_5C-T2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisFSmur8%253D&md5=81e2b494db185b4e91c2d31fccbea3dc</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DG.-N.%26aulast%3DZhang%26aufirst%3DY.-K.%26aulast%3DWang%26aufirst%3DY.-J.%26aulast%3DBarbuti%26aufirst%3DA.%2BM.%26aulast%3DZhu%26aufirst%3DX.-J.%26aulast%3DYu%26aufirst%3DX.-Y.%26aulast%3DWen%26aufirst%3DA.-W.%26aulast%3DWurpel%26aufirst%3DJ.%2BN.%2BD.%26aulast%3DChen%26aufirst%3DZ.-S.%26atitle%3DModulating%2520the%2520function%2520of%2520ATP-binding%2520cassette%2520subfamily%2520G%2520member%25202%2520%2528ABCG2%2529%2520inhibitor%2520cabozantinib%26jtitle%3DPharmacol.%2520Res.%26date%3D2017%26volume%3D119%26spage%3D89%26epage%3D98%26doi%3D10.1016%2Fj.phrs.2017.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, Q.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldblatt, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">793</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2008.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bcp.2008.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=19059384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitVOmurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2009&pages=781-793&author=Z.+Shiauthor=A.+K.+Tiwariauthor=S.+Shuklaauthor=R.+W.+Robeyauthor=I.-W.+Kimauthor=S.+Parmarauthor=S.+E.+Batesauthor=Q.-S.+Siauthor=C.+S.+Goldblattauthor=I.+Abrahamauthor=L.-W.+Fuauthor=S.+V.+Ambudkarauthor=Z.-S.+Chen&title=Inhibiting+the+function+of+ABCB1+and+ABCG2+by+the+EGFR+tyrosine+kinase+inhibitor+AG1478&doi=10.1016%2Fj.bcp.2008.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478</span></div><div class="casAuthors">Shi, Zhi; Tiwari, Amit K.; Shukla, Suneet; Robey, Robert W.; Kim, In-Wha; Parmar, Smitaben; Bates, Susan E.; Si, Qiu-Sheng; Goldblatt, Curtis S.; Abraham, Ioana; Fu, Li-Wu; Ambudkar, Suresh V.; Chen, Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">781-793</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The tyrphostin 4-(3-chloroanilino)-6,7-dimethoxyquinazoline (AG1478) is a potent and specific EGFR tyrosine kinase inhibitor (TKI); its promising pre-clin. results have led to clin. trials.  Overexpression of ATP-binding cassette (ABC) transporters such as ABCB1, ABCC1 and ABCG2 is one of the main causes of multidrug resistance (MDR) and usually results in the failure of cancer chemotherapy.  However, the interaction of AG1478 with these ABC transporters is still unclear.  In the present study, we have investigated this interaction and found that AG1478 has differential effects on these transporters.  In ABCB1-overexpressing cells, non-toxic doses of AG1478 were found to partially inhibit resistance to ABCB1 substrate anticancer drugs as well as increase intracellular accumulation of [3H]-paclitaxel.  Similarly, in ABCG2-overexpressing cells, AG1478 significantly reversed resistance to ABCG2 substrate anticancer drugs and increased intracellular accumulation of [3H]-mitoxantrone as well as fluorescent compd. BODIPY-prazosin.  AG1478 also profoundly inhibited the transport of [3H]-E217βG and [3H]-methotrexate by ABCG2.  We also found that AG1478 slightly stimulated ABCB1 ATPase activity and significantly stimulated ABCG2 ATPase activity.  Interestingly, AG1478 did not inhibit the photolabeling of ABCB1 or ABCG2 with [125I]-iodoarylazidoprazosin.  Addnl., AG1478 did not alter the sensitivity of parental, ABCB1- or ABCG2-overexpressing cells to non-ABCB1 and non-ABCG2 substrate drug and had no effect on the function of ABCC1.  Overall, we conclude that AG1478 is able to inhibit the function of ABCB1 and ABCG2, with a more pronounced effect on ABCG2.  Our findings provide valuable contributions to the development of safer and more effective EGFR TKIs for use as anticancer agents in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYeG-aGqdzKbVg90H21EOLACvtfcHk0lifZci9L0x2QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitVOmurs%253D&md5=51f7053a870d2e67f300b892947eb89d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2008.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2008.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DTiwari%26aufirst%3DA.%2BK.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DKim%26aufirst%3DI.-W.%26aulast%3DParmar%26aufirst%3DS.%26aulast%3DBates%26aufirst%3DS.%2BE.%26aulast%3DSi%26aufirst%3DQ.-S.%26aulast%3DGoldblatt%26aufirst%3DC.%2BS.%26aulast%3DAbraham%26aufirst%3DI.%26aulast%3DFu%26aufirst%3DL.-W.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DChen%26aufirst%3DZ.-S.%26atitle%3DInhibiting%2520the%2520function%2520of%2520ABCB1%2520and%2520ABCG2%2520by%2520the%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520AG1478%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2009%26volume%3D77%26spage%3D781%26epage%3D793%26doi%3D10.1016%2Fj.bcp.2008.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span>; <span class="NLM_string-name">Yang, N.</span>; <span class="NLM_string-name">Cai, C.-Y.</span>; <span class="NLM_string-name">Lei, Z.-Y.</span>; <span class="NLM_string-name">Wang, J.-Q.</span>; <span class="NLM_string-name">Gupta, P.</span>; <span class="NLM_string-name">Teng, Q.-X.</span>; <span class="NLM_string-name">Chen, Z.-S.</span>; <span class="NLM_string-name">Kong, D.</span>; <span class="NLM_string-name">Yang, D.-H.</span></span> <span> </span><span class="NLM_article-title">VS-4718 antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells by inhibiting the efflux function of ABC transporters</span>.  <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.3389%2Ffphar.2018.01236" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Ji&author=N.+Yang&author=C.-Y.+Cai&author=Z.-Y.+Lei&author=J.-Q.+Wang&author=P.+Gupta&author=Q.-X.+Teng&author=Z.-S.+Chen&author=D.+Kong&author=D.-H.+Yang&title=VS-4718+antagonizes+multidrug+resistance+in+ABCB1-+and+ABCG2-overexpressing+cancer+cells+by+inhibiting+the+efflux+function+of+ABC+transporters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01236%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DY.%26atitle%3DVS-4718%2520antagonizes%2520multidrug%2520resistance%2520in%2520ABCB1-%2520and%2520ABCG2-overexpressing%2520cancer%2520cells%2520by%2520inhibiting%2520the%2520efflux%2520function%2520of%2520ABC%2520transporters%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">44643</span>– <span class="NLM_lpage">44659</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.5989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.18632%2Foncotarget.5989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=26556876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC28vgvFaisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=44643-44659&author=J.+Huauthor=X.+Zhangauthor=F.+Wangauthor=X.+Wangauthor=K.+Yangauthor=M.+Xuauthor=K.+K.+W.+Toauthor=Q.+Liauthor=L.+Fu&title=Effect+of+ceritinib+%28LDK378%29+on+enhancement+of+chemotherapeutic+agents+in+ABCB1+and+ABCG2+overexpressing+cells+in+vitro+and+in+vivo&doi=10.18632%2Foncotarget.5989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo</span></div><div class="casAuthors">Hu Jing; Li Qingshan; Hu Jing; Zhang Xu; Wang Fang; Wang Xiaokun; Yang Ke; Xu Meng; Fu Liwu; To Kenneth K W</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">44643-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multidrug resistance (MDR) is the leading cause of treatment failure in cancer chemotherapy.  The overexpression of ATP-binding cassette (ABC) transporters, particularly ABCB1, ABCC1 and ABCG2, play a key role in mediating MDR by pumping anticancer drugs out from cancer cells.  Ceritinib (LDK378) is a second-generation tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) currently in phase III clinical trial for the treatment of non-small cell lung cancer.  Here, we found that ceritinib remarkably enhanced the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 over-expressing cancer cells in vitro and in vivo.  Ceritinib significantly increased the intracellular accumulation of chemotherapeutic agents such as doxorubicin (DOX) by inhibiting ABCB1 or ABCG2-mediated drug efflux in the transporters-overexpressing cells.  Mechanistically, ceritinib is likely a competitive inhibitor of ABCB1 and ABCG2 because it competed with [(125)I]-iodoarylazidoprazosin for photo affinity labeling of the transporters.  On the other hand, at the transporters-inhibiting concentrations, ceritinib did not alter the expression level of ABCB1 and ABCG2, and phosphorylation status of AKT and ERK1/2.  Thus the findings advocate further clinical investigation of combination chemotherapy of ceritinib and other conventional chemotherapeutic drugs in chemo-refractory cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_pzeWjl0LuWgRQsDqrjW_fW6udTcc2eb4BTwI_uO5KLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vgvFaisQ%253D%253D&md5=90f4dd647cca64bf7b847959e59ef980</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5989%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DTo%26aufirst%3DK.%2BK.%2BW.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DEffect%2520of%2520ceritinib%2520%2528LDK378%2529%2520on%2520enhancement%2520of%2520chemotherapeutic%2520agents%2520in%2520ABCB1%2520and%2520ABCG2%2520overexpressing%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D44643%26epage%3D44659%26doi%3D10.18632%2Foncotarget.5989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donfrancesco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ioris, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pasquale, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilari, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cialfi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Laurentis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominici, C.</span></span> <span> </span><span class="NLM_article-title">Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response</span>. <i>Pediatr. Blood. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/pbc.22219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1002%2Fpbc.22219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=19821523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BD1Mjmt1GmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=55-61&author=A.+Donfrancescoauthor=M.+A.+De+Iorisauthor=H.+P.+McDowellauthor=M.+D.+De+Pasqualeauthor=I.+Ilariauthor=A.+Jenknerauthor=A.+Castellanoauthor=S.+Cialfiauthor=C.+De+Laurentisauthor=C.+Dominici&title=Gefitinib+in+combination+with+oral+topotecan+and+cyclophosphamide+in+relapsed+neuroblastoma%3A+pharmacological+rationale+and+clinical+response&doi=10.1002%2Fpbc.22219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response</span></div><div class="casAuthors">Donfrancesco Alberto; De Ioris Maria Antonietta; McDowell Heather Prudence; De Pasquale Maria Debora; Ilari Ilaria; Jenkner Alessandro; Castellano Aurora; Cialfi Samantha; De Laurentis Clementina; Dominici Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric blood & cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  Activity and toxiciy of gefitinib in combination with topotecan and cyclophosphamide (CPA) were evaluated in a case-series of relapsed neuroblastoma (NB) patients.  The in vitro activity of the combination was also assessed.  PROCEDURE:  Gefitinib (250 mg/day), topotecan (0.8 mg/m(2)/day), and CPA (50 mg/m(2)/day) (GTC) were administered orally for 14 consecutive days out of 28 days.  Antitumor activity of gefitinib as single agent and in combination with either topotecan or CPA was assessed in a panel of NB cell lines.  RESULTS:  Ninety-two courses were given in 10 patients.  Grade 4 neutropenia was observed in 7/92 courses (8%) and grade 4 thrombocytopenia in 8/92 (9%).  Two patients had a grade 2 liver toxicity, four a grade 1/2 skin toxicity, and two a grade 1/2 diarrhea.  Dose reduction of topotecan and/or CPA was required in eight patients.  After four courses, three patients were in partial response (PR) and four with a stable disease (SD), while three experienced a progressive disease (PD).  Time to progression (TTP) was 9 months (range, 1-27).  After a median follow-up of 16 months (range 5-54), seven patients are died of disease (DOD) and three alive with disease (AWD).  All but one patient discontinued oral chemotherapy because of a PD, whilst one patient stopped chemotherapy after 27 months with a SD.  In vitro, gefitinib was synergistic with topotecan and additive with CPA.  CONCLUSION:  The GTC combination was well tolerated and the TTP was encouraging.  These promising results, also supported by in vitro evidence, should be further confirmed in a phase II study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTr-dJ9m_ZXzz0SWnHPWbmmfW6udTcc2eb4BTwI_uO5KLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mjmt1GmtQ%253D%253D&md5=22d2f0551cbdc2af97d971d1e0aa1719</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fpbc.22219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.22219%26sid%3Dliteratum%253Aachs%26aulast%3DDonfrancesco%26aufirst%3DA.%26aulast%3DDe%2BIoris%26aufirst%3DM.%2BA.%26aulast%3DMcDowell%26aufirst%3DH.%2BP.%26aulast%3DDe%2BPasquale%26aufirst%3DM.%2BD.%26aulast%3DIlari%26aufirst%3DI.%26aulast%3DJenkner%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DA.%26aulast%3DCialfi%26aufirst%3DS.%26aulast%3DDe%2BLaurentis%26aufirst%3DC.%26aulast%3DDominici%26aufirst%3DC.%26atitle%3DGefitinib%2520in%2520combination%2520with%2520oral%2520topotecan%2520and%2520cyclophosphamide%2520in%2520relapsed%2520neuroblastoma%253A%2520pharmacological%2520rationale%2520and%2520clinical%2520response%26jtitle%3DPediatr.%2520Blood.%2520Cancer%26date%3D2010%26volume%3D54%26spage%3D55%26epage%3D61%26doi%3D10.1002%2Fpbc.22219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lheureux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pautier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgeois, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lortholary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plantade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilquin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarisse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc-Fournier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, F.</span></span> <span> </span><span class="NLM_article-title">Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial</span>. <i>Int. J. Gynecol. Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1488</span>, <span class="refDoi"> DOI: 10.1097/IGC.0b013e31826d1438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1097%2FIGC.0b013e31826d1438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=23027040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252Fhs1Whtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1483-1488&author=S.+Lheureuxauthor=S.+Kriegerauthor=B.+Weberauthor=P.+Pautierauthor=M.+Fabbroauthor=F.+Selleauthor=H.+Bourgeoisauthor=T.+Petitauthor=A.+Lortholaryauthor=A.+Plantadeauthor=M.+Briandauthor=A.+Leconteauthor=N.+Richardauthor=O.+Vilquinauthor=B.+Clarisseauthor=C.+Blanc-Fournierauthor=F.+Joly&title=Expected+benefits+of+topotecan+combined+with+lapatinib+in+recurrent+ovarian+cancer+according+to+biological+profile%3A+a+phase+2+trial&doi=10.1097%2FIGC.0b013e31826d1438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial</span></div><div class="casAuthors">Lheureux Stephanie; Krieger Sophie; Weber Beatrice; Pautier Patricia; Fabbro Michel; Selle Frederic; Bourgeois Hugues; Petit Thierry; Lortholary Alain; Plantade Anne; Briand Melanie; Leconte Alexandra; Richard Nicolas; Vilquin Paul; Clarisse Benedicte; Blanc-Fournier Cecile; Joly Florence</div><div class="citationInfo"><span class="NLM_cas:title">International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1483-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Lapatinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), also inhibits breast cancer resistance protein (BCRP) involved in resistance to topotecan.  The aim of this multicenter study was to assess the efficacy of the combination topotecan-lapatinib in epithelial ovarian cancer relapsing after a first line of chemotherapy.  METHODS:  Patients having relapsed within 6 months (n = 20) or between 6 and 12 months (n = 19) received weekly topotecan (3.2 mg/m given intravenously on days 1, 8, and 15) and daily oral lapatinib (1250 mg).  Translational studies were performed on tumor and serum.  RESULTS:  An objective (partial) response was observed for 5 patients (14%), all with late relapse.  The rates of overall benefits, including responses and stabilizations, were 37% and 62% in patients having relapsed within or after 6 months, respectively.  Corresponding median time to progression were 58 and 94 days.  The most frequent toxicity was hematological, including grade 4 neutropenia (18%) and thrombocytopenia (3%).  None of the tumors overexpressed HER2 or EGFR, and no mutation was found.  Two Kras mutations were identified.  Positive expressions of BCRP and cyclin A (median, 70% and 40%) were not correlated to the response to treatment.  CONCLUSIONS:  This study failed to demonstrate a clinical benefit of lapatinib-topotecan compared to previously described activity with topotecan alone in a context of low levels of EGFR and HER2 expressions, and no biomarkers could be identified.  The absence of correlation between BCRP expression and clinical outcomes suggests that other mechanisms of resistance to topotecan could predominate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT36k4GOwlqSUBuFdjgVNKSfW6udTcc2ebcFJJKCizZsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252Fhs1Whtg%253D%253D&md5=30fb57fca073a2de9d6ee67d3853038a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1097%2FIGC.0b013e31826d1438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FIGC.0b013e31826d1438%26sid%3Dliteratum%253Aachs%26aulast%3DLheureux%26aufirst%3DS.%26aulast%3DKrieger%26aufirst%3DS.%26aulast%3DWeber%26aufirst%3DB.%26aulast%3DPautier%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DM.%26aulast%3DSelle%26aufirst%3DF.%26aulast%3DBourgeois%26aufirst%3DH.%26aulast%3DPetit%26aufirst%3DT.%26aulast%3DLortholary%26aufirst%3DA.%26aulast%3DPlantade%26aufirst%3DA.%26aulast%3DBriand%26aufirst%3DM.%26aulast%3DLeconte%26aufirst%3DA.%26aulast%3DRichard%26aufirst%3DN.%26aulast%3DVilquin%26aufirst%3DO.%26aulast%3DClarisse%26aufirst%3DB.%26aulast%3DBlanc-Fournier%26aufirst%3DC.%26aulast%3DJoly%26aufirst%3DF.%26atitle%3DExpected%2520benefits%2520of%2520topotecan%2520combined%2520with%2520lapatinib%2520in%2520recurrent%2520ovarian%2520cancer%2520according%2520to%2520biological%2520profile%253A%2520a%2520phase%25202%2520trial%26jtitle%3DInt.%2520J.%2520Gynecol.%2520Cancer.%26date%3D2012%26volume%3D22%26spage%3D1483%26epage%3D1488%26doi%3D10.1097%2FIGC.0b013e31826d1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weroha, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberg, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, K. L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakhilm, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. F.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeney, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peethambaram, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, P.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2011.03.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ygyno.2011.03.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=21514634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslOns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2011&pages=116-120&author=S.+J.+Werohaauthor=A.+L.+Obergauthor=K.+L.+A.+Zieglerauthor=S.+R.+Dakhilmauthor=K.+M.+Rowlandauthor=L.+C.+Hartmannauthor=D.+F.+Mooreauthor=G.+L.+Keeneyauthor=P.+P.+Peethambaramauthor=P.+Haluska&title=Phase+II+trial+of+lapatinib+and+topotecan+%28LapTop%29+in+patients+with+platinum-refractory%2Fresistant+ovarian+and+primary+peritoneal+carcinoma&doi=10.1016%2Fj.ygyno.2011.03.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma</span></div><div class="casAuthors">Weroha, S. John; Oberg, Ann L.; Ziegler, Katie L. Allen; Dakhilm, Shaker R.; Rowland, Kendrith M.; Hartmann, Lynn C.; Moore, Dennis F., Jr.; Keeney, Gary L.; Peethambaram, Prema P.; Haluska, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-120</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Resistance to chemotherapy is a major challenge in the treatment of ovarian/peritoneal cancer.  One purported mechanism of topotecan resistance is the breast cancer resistance protein (BCRP) and P-glycoprotein (Pgp).  We designed a phase II clin. trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small mol. pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan.  Patients with platinum-refractory or resistant epithelial ovarian/peritoneal cancer were treated with topotecan 3.2 mg/m2 IV on Day 1, 8 and 15 and lapatinib 1250 mg PO daily, continuously in 28 day cycles.  The primary endpoint was response rate.  For correlative studies, archived tissue was assessed for expression of EGFR, HER2, HIF-1α, CD31, and BCRP.  18 Patients were enrolled and treated.  Four experienced evidence of clin. benefit: one partial response and three with stable disease.  Using a two-stage Simon design, the trial was stopped after the first stage due to insufficient activity.  Grades 3+ and 4+ adverse events (AE) were experienced in 14 and 4 patients, resp.  The most common grade 3/4 AE were neutropenia (56%), thrombocytopenia (28%), and diarrhea (22%).  The combination of lapatinib plus topotecan for the treatment of platinum refractory/resistant epithelial ovarian cancer lacks sufficient activity to warrant further investigation.  In particular, hematol. adverse events were substantial.  Expression of correlative study markers did not reveal patterns of predicted benefit or toxicity.  Disruption of erbB signaling and BCRP/Pgp efflux with lapatinib was insufficient for overcoming topotecan resistance, suggesting alternative mechanisms of resistance are involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQxhyz5fb5xbVg90H21EOLACvtfcHk0ljDK7tPmSnicw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslOns7c%253D&md5=3acf75d974638693616fca43ea28091c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2011.03.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2011.03.030%26sid%3Dliteratum%253Aachs%26aulast%3DWeroha%26aufirst%3DS.%2BJ.%26aulast%3DOberg%26aufirst%3DA.%2BL.%26aulast%3DZiegler%26aufirst%3DK.%2BL.%2BA.%26aulast%3DDakhilm%26aufirst%3DS.%2BR.%26aulast%3DRowland%26aufirst%3DK.%2BM.%26aulast%3DHartmann%26aufirst%3DL.%2BC.%26aulast%3DMoore%26aufirst%3DD.%2BF.%26aulast%3DKeeney%26aufirst%3DG.%2BL.%26aulast%3DPeethambaram%26aufirst%3DP.%2BP.%26aulast%3DHaluska%26aufirst%3DP.%26atitle%3DPhase%2520II%2520trial%2520of%2520lapatinib%2520and%2520topotecan%2520%2528LapTop%2529%2520in%2520patients%2520with%2520platinum-refractory%252Fresistant%2520ovarian%2520and%2520primary%2520peritoneal%2520carcinoma%26jtitle%3DGynecol.%2520Oncol.%26date%3D2011%26volume%3D122%26spage%3D116%26epage%3D120%26doi%3D10.1016%2Fj.ygyno.2011.03.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span> <span> </span><span class="NLM_article-title">A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma</span>. <i>Medicine (Philadelphia, PA, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">e9053</span>, <span class="refDoi"> DOI: 10.1097/MD.0000000000009053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1097%2FMD.0000000000009053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2luro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=e9053&author=L.+Wangauthor=L.+Liangauthor=T.+Yangauthor=Y.+Qiaoauthor=Y.+Xiaauthor=L.+Liuauthor=C.+Liauthor=P.+Luauthor=X.+Jiang&title=A+pilot+clinical+study+of+apatinib+plus+irinotecan+in+patients+with+recurrent+high-grade+glioma&doi=10.1097%2FMD.0000000000009053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study</span></div><div class="casAuthors">Wang, Lei; Liang, Lijun; Yang, Tao; Qiao, Yun; Xia, Youyou; Liu, Liang; Li, Chao; Lu, Peizhi; Jiang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Medicine (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">e9053</span>CODEN:
                <span class="NLM_cas:coden">MEDIAV</span>;
        ISSN:<span class="NLM_cas:issn">0025-7974</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Malignant glioma is the most common primary malignant brain tumor that displays high vascularity, making vascular endothelial growth factor receptors become promising targets.  This study was conducted to evaluate the efficacy and safety of apatinib, a new potent oral small-mol. tyrosine kinase inhibitor targeted vascular endothelial growth factor receptor 2, combined with irinotecan, in patients with recurrent malignant glioma.  Methods: Ten patients with recurrent malignant glioma who were experiencing relapse after treatment of temozolomide were enrolled in this study.  They received oral apatinib (500mg qd) in conjunction with irinotecan (340 mg/m2 or 125 mg/m2 depending on use of enzyme-inducing antiepileptic drugs) for 6 cycles.  After that the patients continued to take apatinib as maintenance.  Dosage adjustment occurred in only 3 (30.0%) patients.  Results: Among the 10 patients, 9 were available for the efficacy evaluation.  There were 5 with partial response, 2 with stable disease and 2 with progressive disease.  The objective response rate and the disease control rate (DCR) were 55% (5/9) and 78% (7/9), resp.  The median progress free survival time was 8.3 mo.  As for safety anal., the most 3 common adverse events were gastrointestinal reaction (31.8%), hypertension (22.7%), and myelosuppression (18.0%).  Conclusion: Apatinib combined with irinotecan seems to be a promising therapeutic option for recurrent malignant glioma patients.  Perspective clin. studies with adequate sample size are required to validate our results.  Trial registration: NCT02848794/Ahead-BG306.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV8bypxFNfW7Vg90H21EOLACvtfcHk0ljDK7tPmSnicw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2luro%253D&md5=502fad5077f271b1312373b915bbce37</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1097%2FMD.0000000000009053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMD.0000000000009053%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DQiao%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DX.%26atitle%3DA%2520pilot%2520clinical%2520study%2520of%2520apatinib%2520plus%2520irinotecan%2520in%2520patients%2520with%2520recurrent%2520high-grade%2520glioma%26jtitle%3DMedicine%2520%2528Philadelphia%252C%2520PA%252C%2520U.%2520S.%2529%26date%3D2017%26volume%3D96%26spage%3De9053%26doi%3D10.1097%2FMD.0000000000009053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furman, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navid, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daw, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarville, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spunt, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Galindo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panetta, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajjar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santana, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, C. F.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4599</span>– <span class="NLM_lpage">4604</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.19.6642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1200%2FJCO.2008.19.6642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=19687340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCns7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4599-4604&author=W.+L.+Furmanauthor=F.+Navidauthor=N.+C.+Dawauthor=M.+B.+McCarvilleauthor=L.+M.+McGregorauthor=S.+L.+Spuntauthor=C.+Rodriguez-Galindoauthor=J.+C.+Panettaauthor=K.+R.+Crewsauthor=J.+Wuauthor=A.+J.+Gajjarauthor=P.+J.+Houghtonauthor=V.+M.+Santanaauthor=C.+F.+Stewart&title=Tyrosine+kinase+inhibitor+enhances+the+bioavailability+of+oral+irinotecan+in+pediatric+patients+with+refractory+solid+tumors&doi=10.1200%2FJCO.2008.19.6642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors</span></div><div class="casAuthors">Furman, Wayne L.; Navid, Fariba; Daw, Najat C.; McCarville, M. Beth; McGregor, Lisa M.; Spunt, Sheri L.; Rodriguez-Galindo, Carlos; Panetta, John C.; Crews, Kristine R.; Wu, Jianrong; Gajjar, Amar J.; Houghton, Peter J.; Santana, Victor M.; Stewart, Clinton F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4599-4604</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">To assess the max.-tolerated dosages (MTDs), and dose-limiting toxicities (DLTs) of the epidermal growth factor receptor inhibitor gefitinib and of i.v. irinotecan when administered together in children with refractory solid tumors.  To assess the effect of gefitinib on the pharmacokinetics of i.v. irinotecan and on the bioavailability of a single oral dose of irinotecan.  I.v. irinotecan (15 or 20 mg/m2) was given daily for 5 days of 2 consecutive weeks.  Oral gefitinib (150 or 112.5 mg/m2) was concomitantly given daily for 12 or 21 days.  A single oral dose of irinotecan was given on day 9 of course 2 to allow pharmacokinetic anal.  The study enrolled 29 patients with recurrent solid tumors.  The 21-day regimen of oral gefitinib with irinotecan was not tolerated.  Diarrhea was the most common DLT.  The MTD of the combination regimen was 15 mg/m2/d of i.v. irinotecan for 5 days of 2 consecutive weeks and 112.5 mg/m2/d of gefitinib given for 12 days.  Gefitinib increased the bioavailability of oral irinotecan by four-fold over that obsd. in historical controls (median, 0.09 v 0.42; P < .000001), reducing the apparent clearance (an inverse measure of exposure) of irinotecan and SN-38 by 37% and 38%, resp. (P < .0001).  A partial response was obsd. in a patient with refractory Ewing sarcoma.  I.v. irinotecan given with 12 days of oral gefitinib is well tolerated in children.  We obsd. one partial response.  Gefitinib significantly enhances the bioavailability of oral irinotecan.  This combination warrants further investigation, particularly with orally administered irinotecan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp7zdd78C72bVg90H21EOLACvtfcHk0ljNoKJyJfAeug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCns7%252FJ&md5=6c3fae6c49642dbf2cd410b321baa1f7</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.19.6642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.19.6642%26sid%3Dliteratum%253Aachs%26aulast%3DFurman%26aufirst%3DW.%2BL.%26aulast%3DNavid%26aufirst%3DF.%26aulast%3DDaw%26aufirst%3DN.%2BC.%26aulast%3DMcCarville%26aufirst%3DM.%2BB.%26aulast%3DMcGregor%26aufirst%3DL.%2BM.%26aulast%3DSpunt%26aufirst%3DS.%2BL.%26aulast%3DRodriguez-Galindo%26aufirst%3DC.%26aulast%3DPanetta%26aufirst%3DJ.%2BC.%26aulast%3DCrews%26aufirst%3DK.%2BR.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGajjar%26aufirst%3DA.%2BJ.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DSantana%26aufirst%3DV.%2BM.%26aulast%3DStewart%26aufirst%3DC.%2BF.%26atitle%3DTyrosine%2520kinase%2520inhibitor%2520enhances%2520the%2520bioavailability%2520of%2520oral%2520irinotecan%2520in%2520pediatric%2520patients%2520with%2520refractory%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4599%26epage%3D4604%26doi%3D10.1200%2FJCO.2008.19.6642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoff, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogaard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldrum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbruzzese, J. L.</span></span> <span> </span><span class="NLM_article-title">A phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma</span>. <i>Jpn. J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1093/jjco/hyi229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1093%2Fjjco%2Fhyi229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=16449240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BD287jtVertQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2006&pages=100-103&author=P.+M.+Hoffauthor=R.+A.+Wolffauthor=K.+Bogaardauthor=S.+Waldrumauthor=J.+L.+Abbruzzese&title=A+phase+I+study+of+escalating+doses+of+the+tyrosine+kinase+inhibitor+semaxanib+%28SU5416%29+in+combination+with+irinotecan+in+patients+with+advanced+colorectal+carcinoma&doi=10.1093%2Fjjco%2Fhyi229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma</span></div><div class="casAuthors">Hoff Paulo M; Wolff Robert A; Bogaard Karla; Waldrum Sherry; Abbruzzese James L</div><div class="citationInfo"><span class="NLM_cas:title">Japanese journal of clinical oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-3</span>
        ISSN:<span class="NLM_cas:issn">0368-2811</span>.
    </div><div class="casAbstract">BACKGROUND:  One of the most studied pro-angiogenic factors involved in the development of colorectal cancer is the vascular endothelial growth factor (VEGF).  The small molecule tyrosine kinase inhibitor semaxanib (SU5416) is one of the several agents targeting the VEGF signaling pathway, and its development centered mostly in the treatment of colorectal cancer.  METHODS:  We designed and conducted an NCI-sponsored trial to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of semaxanib given twice weekly in combination with weekly irinotecan in patients with advanced colorectal cancer who had failed at least one prior treatment.  The irinotecan dose was fixed at 125 mg/m(2) given weekly for 4 weeks followed by 2 weeks of rest.  Patients with prior pelvic irradiation received a reduced dose of 100 mg/m(2).  The semaxanib dose was escalated, going from 85 to 110 mg/m(2) and finally to 145 mg/m(2).  RESULTS:  Ten patients were treated in our study and all were evaluable for toxicity.  There were no drug-related Grade 4 toxicities.  There was one episode of Grade 3 headache and one episode of Grade 3 vomiting.  The most common Grades 1 and 2 toxicities included diarrhea, abdominal cramping, anemia and nausea.  Nine patients completed at least one 6 week cycle of treatment and were considered evaluable for response.  Among those nine, two had a partial response, three had stable disease and four had progressive disease after the first cycle.  CONCLUSIONS:  Both irinotecan and semaxanib could be given at their full single-agent recommended doses without significant toxicity, and the combination showed signs of clinical activity.  However, owing to discouraging results from Phase III trials, it is unlikely that this combination will be further explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQI6NH5C7JgwmHOrQ6qeX-mfW6udTcc2ebLD_vhaVBAVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287jtVertQ%253D%253D&md5=0c60fd64a89368f4ac5adc7c5b6ef760</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1093%2Fjjco%2Fhyi229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjjco%252Fhyi229%26sid%3Dliteratum%253Aachs%26aulast%3DHoff%26aufirst%3DP.%2BM.%26aulast%3DWolff%26aufirst%3DR.%2BA.%26aulast%3DBogaard%26aufirst%3DK.%26aulast%3DWaldrum%26aufirst%3DS.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520escalating%2520doses%2520of%2520the%2520tyrosine%2520kinase%2520inhibitor%2520semaxanib%2520%2528SU5416%2529%2520in%2520combination%2520with%2520irinotecan%2520in%2520patients%2520with%2520advanced%2520colorectal%2520carcinoma%26jtitle%3DJpn.%2520J.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D36%26spage%3D100%26epage%3D103%26doi%3D10.1093%2Fjjco%2Fhyi229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boven, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartog, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brega, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Countouriotis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumors</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">1000</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6605852</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fsj.bjc.6605852" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=20717111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1WlsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=993-1000&author=E.+Bovenauthor=C.+Massardauthor=J.+P.+Armandauthor=C.+Tillierauthor=V.+Hartogauthor=N.+M.+Bregaauthor=A.+M.+Countouriotisauthor=A.+Ruiz-Garciaauthor=J.+C.+Soria&title=A+phase+I%2C+dose-finding+study+of+sunitinib+in+combination+with+irinotecan+in+patients+with+advanced+solid+tumors&doi=10.1038%2Fsj.bjc.6605852"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours</span></div><div class="casAuthors">Boven, E.; Massard, C.; Armand, J. P.; Tillier, C.; Hartog, V.; Brega, N. M.; Countouriotis, A. M.; Ruiz-Garcia, A.; Soria, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">993-1000</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Sunitinib is a multitargeted, oral tyrosine kinase inhibitor with antitumor and antiangiogenic activity.  We investigated the safety and pharmacokinetics of sunitinib in combination with irinotecan in patients with advanced, refractory solid tumors.  Methods: Sunitinib was initially administered once daily at 37.5 mg per day on days 1-14 of a 21-day cycle, in which irinotecan 250 mg m-2 was given on day 1.  In a second cohort, the sunitinib dose was reduced to 25 mg per day.  Blood samples were collected for pharmacokinetic studies.  Results: In the sunitinib 37.5 mg per day cohort, 3 out of 10 evaluable patients had objective responses, but dose-limiting toxicities (DLTs) of neutropenia, pneumococcal sepsis, and fatigue were obsd.  There were no DLTs in the sunitinib 25 mg per day cohort.  Paired observations of pharmacokinetic parameter values of sunitinib and irinotecan alone vs the combination did not reveal significant drug-drug interactions.  The max. tolerated dose was defined as sunitinib 25 mg per day (days 1-14) with irinotecan 250 mg m-2 (day 1), but no activity was obsd. at this dose.  Conclusion: Although a higher sunitinib dose of 37.5 mg per day (days 1-14) with irinotecan showed preliminary evidence of antitumor activity, this dose was poorly tolerated.  Therefore, this particular combination will not be pursued for further studies.  British Journal of Cancer (2010) 103, 993-1000; doi:10.1038/sj.bjc.6605852 www.bjcancer.com Published online 17 August 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSLdbu3rXbFrVg90H21EOLACvtfcHk0lhA4iDMqxrcLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1WlsrfN&md5=0a8ce1112c4faef025cbf4ed7a7d241b</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605852%26sid%3Dliteratum%253Aachs%26aulast%3DBoven%26aufirst%3DE.%26aulast%3DMassard%26aufirst%3DC.%26aulast%3DArmand%26aufirst%3DJ.%2BP.%26aulast%3DTillier%26aufirst%3DC.%26aulast%3DHartog%26aufirst%3DV.%26aulast%3DBrega%26aufirst%3DN.%2BM.%26aulast%3DCountouriotis%26aufirst%3DA.%2BM.%26aulast%3DRuiz-Garcia%26aufirst%3DA.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DA%2520phase%2520I%252C%2520dose-finding%2520study%2520of%2520sunitinib%2520in%2520combination%2520with%2520irinotecan%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D103%26spage%3D993%26epage%3D1000%26doi%3D10.1038%2Fsj.bjc.6605852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reardon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vredenburgh, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desjardins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gururangan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathornsumetee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herndon, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, H. S.</span></span> <span> </span><span class="NLM_article-title">Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma</span>. <i>J. Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1007/s11060-011-0631-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1007%2Fs11060-011-0631-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=21744079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyrtLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=621-627&author=D.+A.+Reardonauthor=J.+J.+Vredenburghauthor=A.+Coanauthor=A.+Desjardinsauthor=K.+B.+Petersauthor=S.+Gururanganauthor=S.+Sathornsumeteeauthor=J.+N.+Richauthor=J.+E.+Herndonauthor=H.+S.+Friedman&title=Phase+I+study+of+sunitinib+and+irinotecan+for+patients+with+recurrent+malignant+glioma&doi=10.1007%2Fs11060-011-0631-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma</span></div><div class="casAuthors">Reardon, David A.; Vredenburgh, James J.; Coan, April; Desjardins, Annick; Peters, Katherine B.; Gururangan, Sridharan; Sathornsumetee, Sith; Rich, Jeremy N.; Herndon, James E.; Friedman, Henry S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">621-627</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We detd. the max. tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, sunitinib, when administered with irinotecan among recurrent malignant glioma (MG) patients.  For each 42-day cycle, sunitinib was administered once a day for four consecutive weeks followed by a 2 wk rest.  Irinotecan was administered i.v. every other week.  Each agent was alternatively escalated among cohorts of 3-6 patients enrolled at each dose level.  Patients on CYP3A-inducing anti-epileptic drugs were not eligible.  Twenty-five patients with recurrent MG were enrolled, including 15 (60%) with glioblastoma (GBM) and 10 (40%) with grade 3 MG.  Five patients progressed previously on bevacizumab and two had received prior VEGFR tyrosine kinase inhibitor therapy.  The MTD was 50 mg of sunitinib combined with 75 mg/m2 of irinotecan.  DLT were primarily hematol. and included grade 4 neutropenia in 3 patients and one patient with grade 4 thrombocytopenia.  Non-hematol. DLT included grade 3 mucositis (n = 1) and grade 3 dehydration (n = 1).  Progression-free survival (PFS)-6 was 24% and only one patient achieved a radiog. response.  The combination of sunitinib and irinotecan was assocd. with moderate toxicity and limited anti-tumor activity.  Further studies with this regimen using the dosing schedules evaluated in this study are not warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8tDSqIYAxZ7Vg90H21EOLACvtfcHk0lhA4iDMqxrcLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyrtLfK&md5=a0f07732c407a80b4f742b5b1da09622</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs11060-011-0631-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-011-0631-4%26sid%3Dliteratum%253Aachs%26aulast%3DReardon%26aufirst%3DD.%2BA.%26aulast%3DVredenburgh%26aufirst%3DJ.%2BJ.%26aulast%3DCoan%26aufirst%3DA.%26aulast%3DDesjardins%26aufirst%3DA.%26aulast%3DPeters%26aufirst%3DK.%2BB.%26aulast%3DGururangan%26aufirst%3DS.%26aulast%3DSathornsumetee%26aufirst%3DS.%26aulast%3DRich%26aufirst%3DJ.%2BN.%26aulast%3DHerndon%26aufirst%3DJ.%2BE.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26atitle%3DPhase%2520I%2520study%2520of%2520sunitinib%2520and%2520irinotecan%2520for%2520patients%2520with%2520recurrent%2520malignant%2520glioma%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2011%26volume%3D105%26spage%3D621%26epage%3D627%26doi%3D10.1007%2Fs11060-011-0631-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trombetta, L. D.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>421</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.01.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.canlet.2018.01.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=29331420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslOgtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=421&publication_year=2018&pages=186-198&author=Y.+F.+Fanauthor=W.+Zhangauthor=L.+Zengauthor=Z.+N.+Leiauthor=C.+Y.+Caiauthor=P.+Guptaauthor=D.+H.+Yangauthor=Q.+Cuiauthor=Z.+D.+Qinauthor=Z.+S.+Chenauthor=L.+D.+Trombetta&title=Dacomitinib+antagonizes+multidrug+resistance+%28MDR%29+in+cancer+cells+by+inhibiting+the+efflux+activity+of+ABCB1+and+ABCG2+transporters&doi=10.1016%2Fj.canlet.2018.01.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters</span></div><div class="casAuthors">Fan, Ying-Fang; Zhang, Wei; Zeng, Leli; Lei, Zi-Ning; Cai, Chao-Yun; Gupta, Pranav; Yang, Dong-Hua; Cui, Qingbin; Qin, Zuo-Dong; Chen, Zhe-Sheng; Trombetta, Louis D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">421</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">186-198</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The development of multidrug resistance (MDR) to chemotherapy remains a major challenge in the treatment of cancer.  Numerous mechanisms have been recognized that cause MDR, but one of the most important mechanisms is overexpression of ATP-binding cassette transporters, through which the efflux of various anticancer drugs against their concn. gradients is powered by ATP.  At the same time, some TKIs have been shown to be capable of inhibiting ABC transporter-mediated MDR.  As many TKIs are substrates or inhibitors of ABC transporters, this study investigates whether dacomitinib could interact with ABC subfamily members that mediate MDR, including ABCB1, ABCG2 (BCRP) and ABCC1.  The results showed that dacomitinib at 1.0μM significantly reversed drug resistance mediated by ABCB1 and ABCG2, but not ABCC1, doing so by antagonizing the drug efflux function in ABCB1- and ABCG2-overexpressing cell lines.  Therefore, the mechanisms of this modulating effect are likely to be the following: first, as an inhibitor of ABCB1 or ABCG2 transporters, dacomitinib binds to drug-substrate site in transmembrane domains (TMD) stably in a noncompetitive manner; or second, dacomitinib inhibits ATPase activity and maintains the stability of TMD conformation in a concn.-dependent manner thereby inhibiting the drug efflux function of ABCB1 or ABCG2 transporter.  This study provides a useful combinational therapeutic strategy with dacomitinib and substrates of ABCB1 and/or ABCG2 transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNoQc-zmcdSrVg90H21EOLACvtfcHk0lhA4iDMqxrcLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslOgtLs%253D&md5=ff4b80d0070530e60588ac50cd4b2cf0</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.01.021%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DY.%2BF.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DZ.%2BN.%26aulast%3DCai%26aufirst%3DC.%2BY.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DD.%2BH.%26aulast%3DCui%26aufirst%3DQ.%26aulast%3DQin%26aufirst%3DZ.%2BD.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26aulast%3DTrombetta%26aufirst%3DL.%2BD.%26atitle%3DDacomitinib%2520antagonizes%2520multidrug%2520resistance%2520%2528MDR%2529%2520in%2520cancer%2520cells%2520by%2520inhibiting%2520the%2520efflux%2520activity%2520of%2520ABCB1%2520and%2520ABCG2%2520transporters%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D421%26spage%3D186%26epage%3D198%26doi%3D10.1016%2Fj.canlet.2018.01.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">4089</span>– <span class="NLM_lpage">4106</span>, <span class="refDoi"> DOI: 10.1111/bph.13189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1111%2Fbph.13189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25988710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOhurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=4089-4106&author=K.+K.+Toauthor=D.+C.+Poonauthor=Y.+Weiauthor=F.+Wangauthor=G.+Linauthor=L.+Fu&title=Pelitinib+%28EKB-569%29+targets+the+up-regulation+of+ABCB1+and+ABCG2+induced+by+hyperthermia+to+eradicate+lung+cancer&doi=10.1111%2Fbph.13189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer</span></div><div class="casAuthors">To, Kenneth K. W.; Poon, Daniel C.; Wei, Yuming; Wang, Fang; Lin, Ge; Fu, Liwu</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4089-4106</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Pelitinib is a potent irreversible EGFR TK inhibitor currently in clin. trials for the treatment of lung cancer.  Hyperthermia has been applied concomitantly with chemotherapy and radiotherapy to enhance treatment outcome.  In this study, we investigated the ability of the combination of pelitinib with other conventional anticancer drugs to specifically target cancer cells with up-regulated efflux transporters ABCB1/ABCG2 after hyperthermia as a novel way to eradicate the cancer stem-like cells responsible for cancer recurrence.  Exptl. Approach : Alterations in intracellular topotecan accumulation, the efflux of fluorescent probe substrates, expression and ATPase activity of ABCB1/ABCG2 and tumorsphere formation capacity of side population (SP) cells sorted after hyperthermia were examd. to elucidate the mechanism of pelitinib-induced chemosensitization.  Key Results : While pelitinib did not modulate ABCB1/ABCG2 expressions, the combination of pelitinib with transporter substrate anticancer drugs induced more marked apoptosis, specifically in cells exposed to hyperthermia.  The flow cytometric assay showed that both ABCB1- and ABCG2-mediated drug effluxes were significantly inhibited by pelitinib in a concn.-dependent manner.  The inhibition kinetics suggested that pelitinib is a competitive inhibitor of ABCB1/ABCG2, which is consistent with its ability to stimulate their ATPase activity.  SP cells sorted after hyperthermia were found to be more resistant to anticancer drugs, presumably due to the up-regulation of ABCB1 and ABCG2.  Importantly, pelitinib specifically enhanced the chemosensitivity but reduced the tumorsphere formation capacity of these SP cells.  Conclusions and Implications : This study demonstrated a novel approach, exploiting drug resistance, to selectively kill cancer stem-like cells after hyperthermia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbh7vkVQ2dtbVg90H21EOLACvtfcHk0ljPM0DfDuaCNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOhurnN&md5=d84e534bd828820f4e05cd9afa940a0d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fbph.13189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13189%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DK.%2BK.%26aulast%3DPoon%26aufirst%3DD.%2BC.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DPelitinib%2520%2528EKB-569%2529%2520targets%2520the%2520up-regulation%2520of%2520ABCB1%2520and%2520ABCG2%2520induced%2520by%2520hyperthermia%2520to%2520eradicate%2520lung%2520cancer%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D4089%26epage%3D4106%26doi%3D10.1111%2Fbph.13189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span> <span> </span><span class="NLM_article-title">The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1007/s10637-015-0205-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1007%2Fs10637-015-0205-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25597754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWnsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=300-309&author=T.+J.+Mathiasauthor=K.+Natarajanauthor=S.+Shuklaauthor=K.+A.+Doshiauthor=Z.+N.+Singhauthor=S.+V.+Ambudkarauthor=M.+R.+Baer&title=The+FLT3+and+PDGFR+inhibitor+crenolanib+is+a+substrate+of+the+multidrug+resistance+protein+ABCB1+but+does+not+inhibit+transport+function+at+pharmacologically+relevant+concentrations&doi=10.1007%2Fs10637-015-0205-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations</span></div><div class="casAuthors">Mathias, Trevor J.; Natarajan, Karthika; Shukla, Suneet; Doshi, Kshama A.; Singh, Zeba N.; Ambudkar, Suresh V.; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">300-309</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Crenolanib (crenolanib besylate, 4-piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]-, monobenzenesulfonate) is a potent and specific type I inhibitor of fms-like tyrosine kinase 3 (FLT3) that targets the active kinase conformation and is effective against FLT3 with internal tandem duplication (ITD) with point mutations induced by, and conferring resistance to, type II FLT3 inhibitors in acute myeloid leukemia (AML) cells.  Crenolanib is also an inhibitor of platelet-derived growth factor receptor alpha and beta and is in clin. trials in both gastrointestinal stromal tumors and gliomas.  We tested crenolanib interactions with the multidrug resistance-assocd. ATP-binding cassette proteins ABCB1 (P-glycoprotein), ABCG2 (breast cancer resistance protein) and ABCC1 (multidrug resistance-assocd. protein 1), which are expressed on AML cells and other cancer cells and are important components of the blood-brain barrier.  We found that crenolanib is a substrate of ABCB1, as evidenced by approx. five-fold resistance of ABCB1-overexpressing cells to crenolanib, reversal of this resistance by the ABCB1-specific inhibitor PSC-833 and stimulation of ABCB1 ATPase activity by crenolanib.  In contrast, crenolanib was not a substrate of ABCG2 or ABCC1.  Addnl., it did not inhibit substrate transport by ABCB1, ABCG2 or ABCC1, at pharmacol. relevant concns.  Finally, incubation of the FLT3-ITD AML cell lines MV4-11 and MOLM-14 with crenolanib at a pharmacol. relevant concn. of 500 nM did not induce upregulation of ABCB1 cell surface expression.  Thus ABCB1 expression confers resistance to crenolanib and likely limits crenolanib penetration of the central nervous system, but crenolanib at therapeutic concns. should not alter cellular exposure to ABC protein substrate chemotherapy drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE_ac0g0ThIbVg90H21EOLACvtfcHk0ljPM0DfDuaCNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWnsrk%253D&md5=6de25ffa46c1a3cdac6cdb1154baa28c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0205-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0205-y%26sid%3Dliteratum%253Aachs%26aulast%3DMathias%26aufirst%3DT.%2BJ.%26aulast%3DNatarajan%26aufirst%3DK.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DDoshi%26aufirst%3DK.%2BA.%26aulast%3DSingh%26aufirst%3DZ.%2BN.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DThe%2520FLT3%2520and%2520PDGFR%2520inhibitor%2520crenolanib%2520is%2520a%2520substrate%2520of%2520the%2520multidrug%2520resistance%2520protein%2520ABCB1%2520but%2520does%2520not%2520inhibit%2520transport%2520function%2520at%2520pharmacologically%2520relevant%2520concentrations%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D300%26epage%3D309%26doi%3D10.1007%2Fs10637-015-0205-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, Q. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span> <span> </span><span class="NLM_article-title">Olmutinib (BI1482694/HM61713), a novel epidermal growth factor receptor tyrosine kinase inhibitor, reverses ABCG2-mediated multidrug resistance in cancer cells</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1097</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.3389%2Ffphar.2018.01097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=30356705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpt1Wqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1097&author=W.+Zhangauthor=Y.+F.+Fanauthor=C.+Y.+Caiauthor=J.+Q.+Wangauthor=Q.+X.+Tengauthor=Z.+N.+Leiauthor=L.+Zengauthor=P.+Guptaauthor=Z.+S.+Chen&title=Olmutinib+%28BI1482694%2FHM61713%29%2C+a+novel+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+reverses+ABCG2-mediated+multidrug+resistance+in+cancer+cells&doi=10.3389%2Ffphar.2018.01097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Olmutinib (BI1482694/HM61713), a novel epidermal growth factor receptor tyrosine kinase inhibitor, reverses ABCG2-mediated multidrug resistance in cancer cells</span></div><div class="casAuthors">Zhang, Wei; Fan, Ying-Fang; Cai, Chao-Yun; Wang, Jing-Quan; Teng, Qiu-Xu; Lei, Zi-Ning; Zeng, Leli; Gupta, Pranav; Chen, Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1097</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The main characteristic of tumor cell resistance is multidrug resistance (MDR).  MDR is the principle cause of the decline in clin. efficacy of chemotherapeutic drugs.  There are several mechanisms that could cause MDR.  Among these, one of the most important mechanisms underlying MDR is the overexpression of ATP (ATP)-binding cassette (ABC) super-family of transporters, which effectively pump out cytotoxic agents and targeted anticancer drugs across the cell membrane.  In recent years, studies found that ABC transporters and tyrosine kinase inhibitors (TKIs) interact with each other.  TKIs may behave as substrates or inhibitors depending on the expression of specific pumps, drug concn., their affinity for the transporters and types of co-administered agents.  Therefore, we performed in vitro expts. to observe whether olmutinib could reverse MDR in cancer cells overexpressing ABCB1, ABCG2, or ABCC1 transporters.  The results showed that olmutinib at 3 μM significantly reversed drug resistance mediated by ABCG2, but not by ABCB1 and ABCC1, by antagonizing the drug efflux function in ABCG2-overexpressing cells.  In addn., olmutinib at reversal concn. affected neither the protein expression level nor the localization of ABCG2.  The results obsd. from the accumulation/efflux study of olmutinib showed that olmutinib reversed ABCG2-mediated MDR with an increasing intracellular drug accumulation due to inhibited drug efflux.  We also had consistent results with the ATPase assay that olmutinib stimulated ATPase activity of ABCG2 up to 3.5-fold.  Addnl., the mol. interaction between olmutinib and ABCG2 was identified by docking simulation.  Olmutinib not only interacts directly with ABCG2 but also works as a competitive inhibitor of the transport protein.  In conclusion, olmutinib could reverse ABCG2-mediated MDR.  The reversal effect of olmutinib on ABCG2-mediated MDR cells is not due to ABCG2 expression or intracellular localization, but rather related to its interaction with ABCG2 protein resulting in drug efflux inhibition and ATPase stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW7PCUH2QHK7Vg90H21EOLACvtfcHk0lhnW3hoqPtpgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpt1Wqtrs%253D&md5=1dc98b10f7f196fcc2fe29ed32cc7e47</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01097%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DFan%26aufirst%3DY.%2BF.%26aulast%3DCai%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BQ.%26aulast%3DTeng%26aufirst%3DQ.%2BX.%26aulast%3DLei%26aufirst%3DZ.%2BN.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26atitle%3DOlmutinib%2520%2528BI1482694%252FHM61713%2529%252C%2520a%2520novel%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520reverses%2520ABCG2-mediated%2520multidrug%2520resistance%2520in%2520cancer%2520cells%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1097%26doi%3D10.3389%2Ffphar.2018.01097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, Q. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span> <span> </span><span class="NLM_article-title">Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2019.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bcp.2019.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=31078601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFyjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2019&pages=120-127&author=Z.+X.+Wuauthor=Q.+X.+Tengauthor=C.+Y.+Caiauthor=J.+Q.+Wangauthor=Z.+N.+Leiauthor=Y.+Yangauthor=Y.+F.+Fanauthor=J.+Y.+Zhangauthor=J.+Liauthor=Z.+S.+Chen&title=Tepotinib+reverses+ABCB1-mediated+multidrug+resistance+in+cancer+cells&doi=10.1016%2Fj.bcp.2019.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells</span></div><div class="casAuthors">Wu, Zhuo-Xun; Teng, Qiu-Xu; Cai, Chao-Yun; Wang, Jing-Quan; Lei, Zi-Ning; Yang, Yuqi; Fan, Ying-Fang; Zhang, Jian-Ye; Li, Jun; Chen, Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">120-127</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Overexpression of ABCB1 transporters plays a crucial role in mediating multidrug resistance (MDR).  Therefore, it is important to inhibit ABCB1 activity in order to maintain an effective intracellular level of chemotherapeutic drugs.  Tepotinib is a MET tyrosine kinase inhibitor with potential anticancer effect and it is currently in clin. trials.  In this study, we investigated whether tepotinib could antagonize ABC transporters-mediated MDR.  Our results suggest that tepotinib significantly reversed ABCB1-mediated MDR but not ABCG2- or ABCC1-mediated MDR.  Mechanistic studies show that tepotinib significantly reversed ABCB1-mediated MDR by attenuating the efflux activity of ABCB1 transporter.  The ATPase assay showed that tepotinib inhibited the ATPase activity of ABCB1 in a concn.-dependent manner.  Furthermore, treatment with tepotinib did not change protein expression or subcellular localization of ABCB1.  Docking anal. indicated that tepotinib interacted with the drug-binding site of the ABCB1 transporter.  Our study provides a potential chemotherapeutic strategy of co-administrating tepotinib with other conventional chemotherapeutic agents to overcome MDR and improve therapeutic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplnqcY4M5vZrVg90H21EOLACvtfcHk0lhnW3hoqPtpgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFyjsb0%253D&md5=3bdd1fc5ab757748269d5468710bf06a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%2BX.%26aulast%3DTeng%26aufirst%3DQ.%2BX.%26aulast%3DCai%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BQ.%26aulast%3DLei%26aufirst%3DZ.%2BN.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DY.%2BF.%26aulast%3DZhang%26aufirst%3DJ.%2BY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26atitle%3DTepotinib%2520reverses%2520ABCB1-mediated%2520multidrug%2520resistance%2520in%2520cancer%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2019%26volume%3D166%26spage%3D120%26epage%3D127%26doi%3D10.1016%2Fj.bcp.2019.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L. W.</span></span> <span> </span><span class="NLM_article-title">Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cells to chemotherapy under hypoxia</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2015.06.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bcp.2015.06.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=26206183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1SqtrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=27-37&author=K.+K.+Toauthor=D.+C.+Poonauthor=Y.+Weiauthor=F.+Wangauthor=G.+Linauthor=L.+W.+Fu&title=Vatalanib+sensitizes+ABCB1+and+ABCG2-overexpressing+multidrug+resistant+colon+cells+to+chemotherapy+under+hypoxia&doi=10.1016%2Fj.bcp.2015.06.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia</span></div><div class="casAuthors">To, Kenneth K. W.; Poon, Daniel C.; Wei, Yuming; Wang, Fang; Lin, Ge; Fu, Li-wu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cancer microenvironment is characterized by significantly lower oxygen concn.  This hypoxic condition is known to reduce drug responsiveness to cancer chemotherapy via multiple mechanisms, among which the upregulation of the ATP-binding cassette (ABC) efflux transporters confers resistance to a wide variety of structurally unrelated anticancer drugs.  Vatalanib (PTK787/ZK22584) is a multitargeted tyrosine kinase inhibitor for all isoforms of VEGFR, PDGFR and c-Kit, which exhibit potent anticancer activity in vitro and in vivo.  The authors investigated the potentiation effect of vatalanib on the anticancer activity of conventional cytotoxic drugs in colon cancer cell lines under both normoxic and hypoxic conditions.  Mechanistically, vatalanib was found to inhibit ABCG2 and ABCB1 efflux activity, presumably by acting as a competitive inhibitor and interfering with their ATPase activity.  Under hypoxic growth condition, ABCG2 and ABCB1-overexpressing cells sorted out by FACS technique as side population (SP) were found to be significantly more responsive to SN-38 (ABCG2 and ABCB1 substrate anticancer drug) in the presence of vatalanib.  The anchorage independent soft agar colony formation capacity of the SP cells was remarkably reduced upon treatment with a combination of SN-38 and vatalanib, compared to SN-38 alone.  However, vatalanib, at concns. that produced the circumvention of the transporters-mediated resistance, did not appreciably alter ABCG2/ABCB1 mRNA or protein expression levels or the phosphorylation of Akt and extracellular signal-regulated kinase (ERK1/2).  The authors' study thus advocates the further investigation of vatalanib for use in combination chemotherapy to eradicate drug-resistant cancer cells under hypoxia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq6tmHFlXBbbVg90H21EOLACvtfcHk0lgl91LBy4WqnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1SqtrzO&md5=331ffaccd4a3e14d8e139b8150f4ad70</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.06.034%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DK.%2BK.%26aulast%3DPoon%26aufirst%3DD.%2BC.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DFu%26aufirst%3DL.%2BW.%26atitle%3DVatalanib%2520sensitizes%2520ABCB1%2520and%2520ABCG2-overexpressing%2520multidrug%2520resistant%2520colon%2520cells%2520to%2520chemotherapy%2520under%2520hypoxia%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2015%26volume%3D97%26spage%3D27%26epage%3D37%26doi%3D10.1016%2Fj.bcp.2015.06.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juvale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">4-Substituted-2-phenylquinazolines as inhibitors of BCRP</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6766</span>– <span class="NLM_lpage">6769</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bmcl.2012.08.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=23017888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVSjsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6766-6769&author=K.+Juvaleauthor=M.+Wiese&title=4-Substituted-2-phenylquinazolines+as+inhibitors+of+BCRP&doi=10.1016%2Fj.bmcl.2012.08.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">4-Substituted-2-phenylquinazolines as inhibitors of BCRP</span></div><div class="casAuthors">Juvale, Kapil; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6766-6769</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We investigated several 2-phenylquinazolines with different substitutions at position 4 for their BCRP inhibition.  Compds. with Ph ring attached via an amine-contg. linker at position 4 were found to be potent inhibitors of BCRP.  In general compds. with meta substitution of Ph ring at position 4 were found to have higher inhibitory effect, compd. 12 being the most potent and selective towards BCRP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf-v9OH4Nxr7Vg90H21EOLACvtfcHk0lgl91LBy4WqnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVSjsrbJ&md5=e96d4566ff6ae54c8e454bda7b50c873</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.024%26sid%3Dliteratum%253Aachs%26aulast%3DJuvale%26aufirst%3DK.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3D4-Substituted-2-phenylquinazolines%2520as%2520inhibitors%2520of%2520BCRP%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6766%26epage%3D6769%26doi%3D10.1016%2Fj.bmcl.2012.08.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juvale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Investigation of quinazolines as inhibitors of breast cancer resistance protein</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7858</span>– <span class="NLM_lpage">7873</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bmc.2013.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=24184213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWmsb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=7858-7873&author=K.+Juvaleauthor=J.+Gallusauthor=M.+Wiese&title=Investigation+of+quinazolines+as+inhibitors+of+breast+cancer+resistance+protein&doi=10.1016%2Fj.bmc.2013.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2)</span></div><div class="casAuthors">Juvale, Kapil; Gallus, Jennifer; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7858-7873</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chemotherapy is one of the major forms of cancer treatment.  Unfortunately, tumors are prone to multidrug resistance leading to failure of treatment.  Breast cancer resistance protein (BCRP), the second member of ABC transporter subfamily G, has been found to play a major role in drug efflux and hence multidrug resistance.  Until now, very few potent and selective BCRP inhibitors like Ko143 have been identified.  In the search for more potent and selective BCRP inhibitors, we synthesized and investigated a series of differently substituted quinazoline compds.  Several variations at positions 2, 4, 6 and 7 of the quinazoline scaffold were carried out to develop a structure-activity-relationship anal. for these compds.  It was found that compds. bearing a Ph substituent at position 2 of the 4-anilinoquinazoline scaffold were most potent.  On the aniline ring at position 4 of the quinazoline moiety substituents like NO2, CN, CF3 led to very high BCRP inhibition potencies.  The most potent compds. were further investigated for their intrinsic cytotoxicity and their ability to reverse the multidrug resistance.  Compd. 20, an anilinoquinazoline bearing a Ph ring at position 2 and meta-nitro substitution on the 4-anilino ring, was found to have the highest therapeutic ratio.  The most active compds. from each variation were also investigated for their effect on BCRP expression.  It was found that compd. 20 has no significant effect on BCRP expression, while compd. 31 decreased the surface BCRP expression.  The only difference in the two compds. was the presence of a 3,4-dimethoxyphenyl ring in compd. 31 instead of Ph substitution at position 2 of the quinazoline moiety.  From the study of all target compds., compd. 20 was the most prominent compd. having inhibitory potency even higher than Ko143, the most potent BCRP inhibitor known.  Compd. 20 was also found to be selective towards BCRP with a very high therapeutic ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwQG7UwDr2PrVg90H21EOLACvtfcHk0lgl91LBy4WqnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWmsb3P&md5=45a1d684ff3849c478498ede66d0cda8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DJuvale%26aufirst%3DK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DInvestigation%2520of%2520quinazolines%2520as%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D7858%26epage%3D7873%26doi%3D10.1016%2Fj.bmc.2013.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 4-anilino-quinazolines and -quinolines as inhibitors of breast cancer resistance protein (ABCG2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5449</span>– <span class="NLM_lpage">5461</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00330</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00330" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5449-5461&author=M.+K.+Krapfauthor=M.+Wiese&title=Synthesis+and+biological+evaluation+of+4-anilino-quinazolines+and+-quinolines+as+inhibitors+of+breast+cancer+resistance+protein+%28ABCG2%29&doi=10.1021%2Facs.jmedchem.6b00330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2)</span></div><div class="casAuthors">Krapf, Michael K.; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5449-5461</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chemotherapeutic treatment of cancer often fails due to overexpression of the ATP-binding cassette (ABC) transport proteins, like ABCG2, triggering active efflux of various structurally unrelated drugs.  This so-called multidrug resistance (MDR) may be reversed by selective, potent, and nontoxic inhibitors of ABCG2.  As only a few potent inhibitors are known, new compds. based on a 4-substituted-2-phenylquinazoline scaffold were investigated.  Substitution with hydroxy, cyano, nitro, acetamido, and fluoro, e.g., I, led to high inhibitory activities toward ABCG2.  The ability to reverse MDR of the most active compds. was confirmed in a MTT efficacy assay.  Moreover, a negligibly low intrinsic cytotoxicity was found resulting in a high therapeutic ratio.  Investigations of the inhibitory activity toward ABCB1 and ABCC1 yielded a high selectivity toward ABCG2 for the quinazoline compds.  Quinoline-based analogs showed lower inhibitory activity and selectivity.  The study yielded a variety of promising compds., some with superior properties compared to those of the std. inhibitor Ko143.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdz9Uvqz3i6rVg90H21EOLACvtfcHk0lilfbtz1Q_pHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCnurY%253D&md5=a127c60fe7ecf9d5fc76a13903e794db</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00330%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25204-anilino-quinazolines%2520and%2520-quinolines%2520as%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5449%26epage%3D5461%26doi%3D10.1021%2Facs.jmedchem.6b00330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.08.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2017.08.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=28841513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOrs7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=587-611&author=M.+K.+Krapfauthor=J.+Gallusauthor=M.+Wiese&title=Synthesis+and+biological+investigation+of+2%2C4-substituted+quinazolines+as+highly+potent+inhibitors+of+breast+cancer+resistance+protein&doi=10.1016%2Fj.ejmech.2017.08.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2)</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">587-611</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Expression of ABCG2, a member of the ABC transporter superfamily, was correlated to the clin. outcome of multiple cancers and is often assocd. with the occurrence of multidrug resistance (MDR) in chemotherapy.  Inhibition of the transport protein by potent and selective inhibitors might be a way to treat cancer more efficiently and improve the therapy of cancer patients.  Recently the authors reported the synthesis of new inhibitors based on a quinazoline scaffold.  In the present study more structural variations were explored.  Compds. with 3,4-dimethoxy groups and meta or para nitro substituents are highly potent inhibitors of ABCG2.  The most potent compd. was more than five-fold more potent than Ko143, one of the best inhibitors of ABCG2.  To det. the new compds. selectivity toward ABCG2 their inhibitory effects on ABCB1 and ABCC1 were also studied identifying selective as well as broadspectrum inhibitors.  Furthermore, intrinsic cytotoxicity and efficacy regarding the reversal of multidrug resistance toward SN-38 and mitoxantrone were explored.  The most potent compds. were able to reverse the resistance toward the cytostatic agents with EC50 values <20 nM.  Addnl., the type of interaction between inhibitors and the ABCG2 substrate Hoechst 33342 was studied yielding competitive and non-competitive interactions suggesting different modes of binding.  Finally the effect of the derivs. on vanadate-sensitive ATPase activity of ABCG2 was detd.  According to the different effects on ATPase activity the authors conclude the existence of different binding sites.  This study provides the structural requirements for high potency inhibition and elucidates the interaction with ABCG2 setting the basis for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE5dQXb6qJ5bVg90H21EOLACvtfcHk0lilfbtz1Q_pHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOrs7jM&md5=d0fb787cddc361a521b402ea76d2bb51</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.08.020%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520investigation%2520of%25202%252C4-substituted%2520quinazolines%2520as%2520highly%2520potent%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D587%26epage%3D611%26doi%3D10.1016%2Fj.ejmech.2017.08.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">4-Anilino-2-pyridylquinazolines and -pyrimidines as highly potent and nontoxic inhibitors of breast cancer resistance protein (ABCG2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4474</span>– <span class="NLM_lpage">4495</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00441</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00441" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFSks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4474-4495&author=M.+K.+Krapfauthor=J.+Gallusauthor=M.+Wiese&title=4-Anilino-2-pyridylquinazolines+and+-pyrimidines+as+highly+potent+and+nontoxic+inhibitors+of+breast+cancer+resistance+protein+%28ABCG2%29&doi=10.1021%2Facs.jmedchem.7b00441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2)</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4474-4495</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transport proteins remains a major problem in the chemotherapeutic treatment of cancer and might be overcome by inhibition of the transporter.  Because of the lack of understanding, the complex mechanisms involved in the transport process, in particular for breast cancer resistance protein (BCRP/ABCG2), there is a persistent need for studies of inhibitors of ABCG2.  In this study, the authors investigated a systematic series of 4-substituted-2-pyridylquinazolines in terms of their inhibitory potency as well as selectivity toward ABCG2.  For comparison, the quinazoline scaffold was reduced to the significantly smaller 4-methylpyrimidine basic structure.  Furthermore, the cytotoxicity and the ability to reverse MDR was tested with the chemotherapeutic agents SN-38 and mitoxantrone (MX).  Interaction of the compds. with ABCG2 was investigated by a colorimetric ATPase assay.  Enzyme kinetic studies were carried out with Hoechst 33342 as fluorescent dye and substrate of ABCG2 to elucidate the compds. binding modes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBVIj0DPElPrVg90H21EOLACvtfcHk0lilfbtz1Q_pHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFSks7k%253D&md5=cd9380f0b33fb110c3cde721345f6fe5</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00441%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3D4-Anilino-2-pyridylquinazolines%2520and%2520-pyrimidines%2520as%2520highly%2520potent%2520and%2520nontoxic%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4474%26epage%3D4495%26doi%3D10.1021%2Facs.jmedchem.7b00441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraege, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juvale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.03.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2016.03.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=27100033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsFyms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2016&pages=212-229&author=S.+Kraegeauthor=K.+Stefanauthor=K.+Juvaleauthor=T.+Rossauthor=T.+Willmesauthor=M.+Wiese&title=The+combination+of+quinazoline+and+chalcone+moieties+leads+to+novel+potent+heterodimeric+modulators+of+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29&doi=10.1016%2Fj.ejmech.2016.03.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2)</span></div><div class="casAuthors">Kraege, Stefanie; Stefan, Katja; Juvale, Kapil; Ross, Thomas; Willmes, Thomas; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">212-229</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">During the last decade it has been found that chalcones and quinazolines are promising inhibitors of ABCG2.  The combination of these two scaffolds offers a new class of heterocyclic compds. with potentially high inhibitory activity against ABCG2.  For this purpose we investigated 22 different heterodimeric derivs.  In this series only methoxy groups were used as substituents as these had been proven superior for inhibitory activity of chalcones.  All compds. were tested for their inhibitory activity, specificity and cytotoxicity.  The most potent ABCG2 inhibitor in this series showed an IC50 value of 0.19 μM.  It possesses low cytotoxicity (GI50 = 93 μM), the ability to reverse MDR and is nearly selective toward ABCG2.  Most compds. contg. dimethoxy groups showed slight activity against ABCB1 too.  Among these three compds. (17, 19 and 24) showed even higher activity toward ABCB1 than ABCG2.  All inhibitors were further screened for their effect on basal ATPase activity.  Although the basal ATPase activity was partially stimulated, the compds. were not transported by ABCG2.  Thus, quinazoline-chalcones are a new class of effective ABCG2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAiBrpQVZkPrVg90H21EOLACvtfcHk0lje-6CHe6Omag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsFyms7Y%253D&md5=91877b15d0301ec2bbcd468f63ea1a2b</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.03.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.03.067%26sid%3Dliteratum%253Aachs%26aulast%3DKraege%26aufirst%3DS.%26aulast%3DStefan%26aufirst%3DK.%26aulast%3DJuvale%26aufirst%3DK.%26aulast%3DRoss%26aufirst%3DT.%26aulast%3DWillmes%26aufirst%3DT.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DThe%2520combination%2520of%2520quinazoline%2520and%2520chalcone%2520moieties%2520leads%2520to%2520novel%2520potent%2520heterodimeric%2520modulators%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D117%26spage%3D212%26epage%3D229%26doi%3D10.1016%2Fj.ejmech.2016.03.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">2,4,6-Substituted quinazolines with extraordinary inhibitory potency toward ABCG2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7952</span>– <span class="NLM_lpage">7976</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVChtbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7952-7976&author=M.+K.+Krapfauthor=J.+Gallusauthor=V.+Namasivayamauthor=M.+Wiese&title=2%2C4%2C6-Substituted+quinazolines+with+extraordinary+inhibitory+potency+toward+ABCG2&doi=10.1021%2Facs.jmedchem.8b01011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Namasivayam, Vigneshwaran; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7952-7976</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several members of the ABC transporter superfamily play a decisive role in the development of multidrug resistance (MDR) in cancer.  One of these MDR assocd. efflux transporters is ABCG2.  One way to overcome this MDR is the coadministration of potent inhibitors of ABCG2.  In this study, we identified novel inhibitors contg. a 2,4,6-substituted quinazoline scaffold.  Introduction of a 6-nitro function led to extraordinarily potent compds. that were highly selective for ABCG2 and also able to reverse the MDR toward the chemotherapeutic drugs SN-38 and mitoxantrone.  The binding of substrate Hoechst 33342 and the two potent inhibitors 31 and 41 which differ in their mechanism of inhibition was rationalized using the recently published cryo-EM structures of ABCG2.  For a better understanding of the interaction between the inhibitors and ABCG2, addnl. investigations regarding the ATPase activity, the interaction with Hoechst 33342, and with the conformational sensitive 5D3 antibody were carried out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHoikCuvyt-bVg90H21EOLACvtfcHk0lje-6CHe6Omag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVChtbjO&md5=376bdc61d3a65d7ea6877e7b69ca0d74</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01011%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3D2%252C4%252C6-Substituted%2520quinazolines%2520with%2520extraordinary%2520inhibitory%2520potency%2520toward%2520ABCG2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7952%26epage%3D7976%26doi%3D10.1021%2Facs.jmedchem.8b01011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahdati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">New inhibitors of breast cancer resistance protein (ABCG2) containing a 2,4-disubstituted pyridopyrimidine scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3389</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltVGlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3389-3408&author=M.+K.+Krapfauthor=J.+Gallusauthor=S.+Vahdatiauthor=M.+Wiese&title=New+inhibitors+of+breast+cancer+resistance+protein+%28ABCG2%29+containing+a+2%2C4-disubstituted+pyridopyrimidine+scaffold&doi=10.1021%2Facs.jmedchem.7b01012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Vahdati, Sahel; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3389-3408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) occurring during cancer chemotherapy is a major obstacle for effectiveness and response to therapy and is often caused by ATP-binding cassette (ABC) efflux transporters.  Belonging to the family of ABC transporters, breast cancer resistance protein is getting more and more in the spotlight of research.  As a strategy to overcome MDR, inhibitors of ABC transporters were synthesized, which could be applied in combination with cytostatic drugs.  For this purpose, 2,4-disubstituted pyridopyrimidine derivs. were synthesized.  The investigations confirmed three key characteristics of good inhibitors: a low intrinsic cytotoxicity and a high potency and selectivity toward ABCG2.  For selected compds. the interaction with ABCG2 was elucidated and their effect on ATPase activity and conformation sensitive 5D3 antibody binding was investigated.  Their ability to reverse MDR in coadministration with the active metabolite of irinotecan and mitoxantron was confirmed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1PrWr1uAkvLVg90H21EOLACvtfcHk0lhelA9h8buqIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltVGlsro%253D&md5=aa27ba46b274bcb0501e596b92973efa</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01012%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DVahdati%26aufirst%3DS.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DNew%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%2520containing%2520a%25202%252C4-disubstituted%2520pyridopyrimidine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3389%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.7b01012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spindler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of quinazoline derivatives - a SAR study of novel inhibitors of ABCG2</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">525</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2018.10.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=30390439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2019&pages=506-525&author=M.+K.+Krapfauthor=J.+Gallusauthor=A.+Spindlerauthor=M.+Wiese&title=Synthesis+and+biological+evaluation+of+quinazoline+derivatives+-+a+SAR+study+of+novel+inhibitors+of+ABCG2&doi=10.1016%2Fj.ejmech.2018.10.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Spindler, Anna; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">506-525</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) is a major obstacle for effective chemotherapeutic treatment of cancer frequently leading to failure of the therapy.  MDR is often assocd. with the overexpression of ABC transport proteins like ABCB1 or ABCG2 which efflux harmful substances out of cells at the cost of ATP hydrolysis.  One way to overcome MDR is to apply potent inhibitors of ABC transporters to restore the sensitivity of the cells toward cytostatic agents.  This study focusses on the synthesis and evaluation of novel 2,4-disubstituted quinazoline derivs. regarding the structure-activity-relationship (SAR), their ability to reverse MDR and their mode of interaction with ABCG2.  Hence, the inhibitory potency and selectivity toward ABCG2 was detd.  Moreover, the intrinsic cytotoxicity and the reversal of MDR were investigated.  Interaction type studies with the substrate Hoechst 33342 and conformational analyses of ABCG2 with 5D3 monoclonal antibody were performed for a better understanding of the underlying mechanisms.  In our study we could further enhance the inhibitory effect against ABCG2 (compd. I, IC50: 55 nM) and identify the structural features that are crucial for inhibitory potency, the impact on transport activity and binding to the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpRCSRKm5X7bVg90H21EOLACvtfcHk0lhLzlvNkFOx6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qsLvJ&md5=0199c580e5f555ebfac47322c1adf7a2</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DSpindler%26aufirst%3DA.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520quinazoline%2520derivatives%2520-%2520a%2520SAR%2520study%2520of%2520novel%2520inhibitors%2520of%2520ABCG2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D161%26spage%3D506%26epage%3D525%26doi%3D10.1016%2Fj.ejmech.2018.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinkhammer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Specific inhibitors of the breast cancer resistance protein (BCRP)</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1498</span>– <span class="NLM_lpage">1505</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201000216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1002%2Fcmdc.201000216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=20632361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFWgsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1498-1505&author=A.+Pickauthor=W.+Klinkhammerauthor=M.+Wiese&title=Specific+inhibitors+of+the+breast+cancer+resistance+protein+%28BCRP%29&doi=10.1002%2Fcmdc.201000216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Inhibitors of the Breast Cancer Resistance Protein (BCRP)</span></div><div class="casAuthors">Pick, Anne; Klinkhammer, Werner; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1498-1505</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A new class of specific breast cancer resistance protein (BCRP) inhibitors was identified, showing no inhibition of the ATP binding cassette (ABC) transporters P-gp and MRP1.  Some of these modulators inhibit BCRP with high potency; they are only slightly less potent than Ko143 and could serve as promising lead structures for the design of novel effective BCRP inhibitors.  These inhibitors are structurally related to tariquidar (XR9576) and belong to a library of multidrug-resistance modulators synthesized by our research group.  The absence of the tetrahydroisoquinoline substructure appears to play a crucial role for specificity; we found that the presence of this substructure is not essential for interaction with BCRP.  To det. the type of interaction between pheophorbide A and compds. with and without the tetrahydroisoquinoline substructure, various substrate pheophorbide A concns. were used in enzyme kinetics assays.  The resulting data show that these compds. share a noncompetitive-type interaction with pheophorbide A.  Expts. with imatinib and pheophorbide A revealed a mixed-type interaction.  The combination of imatinib and compds. with and without the tetrahydroisoquinoline substructure resulted in a pos. cooperative effect, indicating that imatinib engages a binding site distinct from that of the new compds. on one side and distinct from that of pheophorbide A on the other side as well.  The results of this study suggest that the category of BCRP-specific inhibitors, which includes only fumitremorgin C, Ko143 and analogs, and novobiocin needs to be extended by this new class of inhibitors, which possess three key characteristics: specificity, potency, and low toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdbFkR4oCa3bVg90H21EOLACvtfcHk0lhLzlvNkFOx6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFWgsbnK&md5=751e5cb7fb4a5db8645196ff3b3ae28a</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000216%26sid%3Dliteratum%253Aachs%26aulast%3DPick%26aufirst%3DA.%26aulast%3DKlinkhammer%26aufirst%3DW.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DSpecific%2520inhibitors%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%2529%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D1498%26epage%3D1505%26doi%3D10.1002%2Fcmdc.201000216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Pyrrolopyrimidine derivatives as novel inhibitors of multidrug resistance-associated Protein 1 (MRP1, ABCC1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3018</span>– <span class="NLM_lpage">3033</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01644</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01644" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1SqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3018-3033&author=S.+M.+Schmittauthor=K.+Stefanauthor=M.+Wiese&title=Pyrrolopyrimidine+derivatives+as+novel+inhibitors+of+multidrug+resistance-associated+Protein+1+%28MRP1%2C+ABCC1%29&doi=10.1021%2Facs.jmedchem.5b01644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1)</span></div><div class="casAuthors">Schmitt, Sven Marcel; Stefan, Katja; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3018-3033</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Five series of pyrrolo[3,2-d]pyrimidines were synthesized and evaluated with respect to potency and selectivity toward multidrug resistance-assocd. protein 1 (MRP1, ABCC1).  This transport protein is a major target to overcome multidrug resistance in cancer patients.  We investigated differently substituted pyrrolopyrimidines using the doxorubicin selected and MRP1 overexpressing small cell lung cancer cell line H69 AR in a calcein AM and daunorubicin cell accumulation assay.  New compds. with high potency and selectivity were identified.  Piperazine residues at position 4 bearing large phenylalkyl side chains proved to be beneficial for MRP1 inhibition.  Its replacement by an amino group led to decreased activity.  Aliph. and aliph.-arom. variations at position 5 and 6 revealed compds. with IC50 values in high nanomolar range.  All investigated compds. had low affinity toward P-glycoprotein (P-gp, ABCB1).  Pyrrolopyrimidines with small substituents showed moderate inhibition against breast cancer resistance protein (BCRP, ABCG2).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc-LdtLQMGi7Vg90H21EOLACvtfcHk0lhLzlvNkFOx6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1SqsrY%253D&md5=a7ef32c9b2c134621d9d56f296397a9c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01644%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DS.%2BM.%26aulast%3DStefan%26aufirst%3DK.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DPyrrolopyrimidine%2520derivatives%2520as%2520novel%2520inhibitors%2520of%2520multidrug%2520resistance-associated%2520Protein%25201%2520%2528MRP1%252C%2520ABCC1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3018%26epage%3D3033%26doi%3D10.1021%2Facs.jmedchem.5b01644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juvale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.06.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2013.06.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=23851114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVeis73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=115-126&author=K.+Juvaleauthor=K.+Stefanauthor=M.+Wiese&title=Synthesis+and+biological+evaluation+of+flavones+and+benzoflavones+as+inhibitors+of+BCRP%2FABCG2&doi=10.1016%2Fj.ejmech.2013.06.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2</span></div><div class="casAuthors">Juvale, Kapil; Stefan, Katja; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">115-126</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) often leads to a failure of cancer chemotherapy.  Breast Cancer Resistance Protein (BCRP/ABCG2), a member of the superfamily of ATP binding cassette proteins has been found to confer MDR in cancer cells by transporting mols. with amphiphilic character out of the cells using energy from ATP hydrolysis.  Inhibiting BCRP can be a soln. to overcome MDR.  The authors synthesized a series of flavones, 7,8-benzoflavones and 5,6-benzoflavones with varying substituents at positions 3, 3' and 4' of the (benzo)flavone structure.  All synthesized compds. were tested for BCRP inhibition in Hoechst 33342 and pheophorbide A accumulation assays using MDCK cells expressing BCRP.  All the compds. were further screened for their P-glycoprotein (P-gp) and Multidrug resistance-assocd. protein 1 (MRP1) inhibitory activity by calcein AM accumulation assay to check the selectivity towards BCRP.  In addn. most active compds. were investigated for their cytotoxicity.  It was obsd. that in most cases 7,8-benzoflavones are more potent in comparison to the 5,6-benzoflavones.  In general it was found that presence of a 3-OCH3 substituent leads to increase in activity in comparison to presence of OH or no substitution at position 3.  Also, it was found that presence of 3',4'-OCH3 on Ph ring lead to increase in activity as compared to other substituents.  Compd. 24, a 7,8-benzoflavone deriv. was found to be most potent being 50 times selective for BCRP and showing very low cytotoxicity at higher concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoep2o4_wG7XrVg90H21EOLACvtfcHk0lj7bcBpUicdZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVeis73E&md5=961e1899a816717d108c5c8e71944f70</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.06.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.06.035%26sid%3Dliteratum%253Aachs%26aulast%3DJuvale%26aufirst%3DK.%26aulast%3DStefan%26aufirst%3DK.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520flavones%2520and%2520benzoflavones%2520as%2520inhibitors%2520of%2520BCRP%252FABCG2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D67%26spage%3D115%26epage%3D126%26doi%3D10.1016%2Fj.ejmech.2013.06.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">9-Deazapurines as broad-spectrum inhibitors of the ABC transport proteins P-glycoprotein, multidrug resistance-associated protein 1, and breast cancer resistance protein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8758</span>– <span class="NLM_lpage">8780</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Cit7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8758-8780&author=K.+Stefanauthor=S.+M.+Schmittauthor=M.+Wiese&title=9-Deazapurines+as+broad-spectrum+inhibitors+of+the+ABC+transport+proteins+P-glycoprotein%2C+multidrug+resistance-associated+protein+1%2C+and+breast+cancer+resistance+protein&doi=10.1021%2Facs.jmedchem.7b00788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein</span></div><div class="casAuthors">Stefan, Katja; Schmitt, Sven Marcel; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8758-8780</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P-Glycoprotein (P-gp, ABCB1), multidrug resistance-assocd. protein 1 (MRP1, ABCC1), and breast cancer resistance protein (BCRP, ABCG2) are the three major ABC transport proteins conferring resistance to many structurally diverse anticancer agents, leading to the phenomenon called multidrug resistance (MDR).  Much effort has been put into the development of clin. useful compds. to reverse MDR.  Broad-spectrum inhibitors of ABC transport proteins can be of great use in cancers that simultaneously coexpress two or three transporters.  In this work, the authors continued the effort to generate new, potent, nontoxic, and multiply effective inhibitors of the three major ABC transporters.  The best compd. (I) was active in a very low micromolar concn. range against all three transporters and restored sensitivity toward daunorubicin (P-gp and MRP1) and SN-38 (BCRP) in A2780/ADR (P-gp), H69AR (MRP1), and MDCK II BCRP cells.  Addnl., the compd. is a noncompetitive inhibitor of daunorubicin (MRP1), calcein AM (P-gp), and pheophorbide A (BCRP) transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq07xlNCwYzL7Vg90H21EOLACvtfcHk0lj7bcBpUicdZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Cit7%252FL&md5=a4c6a3553f7c885f1ae24d3f974ce448</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00788%26sid%3Dliteratum%253Aachs%26aulast%3DStefan%26aufirst%3DK.%26aulast%3DSchmitt%26aufirst%3DS.%2BM.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3D9-Deazapurines%2520as%2520broad-spectrum%2520inhibitors%2520of%2520the%2520ABC%2520transport%2520proteins%2520P-glycoprotein%252C%2520multidrug%2520resistance-associated%2520protein%25201%252C%2520and%2520breast%2520cancer%2520resistance%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8758%26epage%3D8780%26doi%3D10.1021%2Facs.jmedchem.7b00788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silbermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elshawadfy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Identification of thienopyrimidine scaffold as inhibitor of the ABC transport protein ABCC1 (MRP1) and related transporters using a combined virtual screening approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4383</span>– <span class="NLM_lpage">4400</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01821</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01821" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlWisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4383-4400&author=K.+Silbermannauthor=S.+M.+Stefanauthor=R.+Elshawadfyauthor=V.+Namasivayamauthor=M.+Wiese&title=Identification+of+thienopyrimidine+scaffold+as+inhibitor+of+the+ABC+transport+protein+ABCC1+%28MRP1%29+and+related+transporters+using+a+combined+virtual+screening+approach&doi=10.1021%2Facs.jmedchem.8b01821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening Approach</span></div><div class="casAuthors">Silbermann, Katja; Stefan, Sven Marcel; Elshawadfy, Randa; Namasivayam, Vigneshwaran; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4383-4400</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A virtual screening protocol with combination of similarity search and pharmacophore modeling was applied to virtually screen a large compd. library to gain new scaffolds regarding ABCC1 inhibition.  Biol. investigation of promising candidates revealed four compds. as ABCC1 inhibitors, three of them with scaffolds not assocd. with ABCC1 inhibition until now.  The best hit mol.-a thienopyrimidine-was a moderately potent, competitive inhibitor of the ABCC1-mediated transport of calcein AM which also sensitized ABCC1-overexpressing cells toward daunorubicin.  Further evaluation showed that it was a moderately potent, competitive inhibitor of the ABCB1-mediated transport of calcein AM, and noncompetitive inhibitor of the ABCG2-mediated pheophorbide A transport.  In addn., the thienopyrimidine could also sensitize ABCB1- as well as ABCG2-overexpressing cells toward daunorubicin and SN-38, resp., in concn. ranges that qualified it as one of the ten best triple ABCC1/ABCB1/ABCG2 inhibitors in the literature.  Besides, three more new multitarget inhibitors were identified by this virtual screening approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriD8it8lIcF7Vg90H21EOLACvtfcHk0lj7bcBpUicdZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlWisbs%253D&md5=f02035affb6b17b0b4962758565b63cb</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01821%26sid%3Dliteratum%253Aachs%26aulast%3DSilbermann%26aufirst%3DK.%26aulast%3DStefan%26aufirst%3DS.%2BM.%26aulast%3DElshawadfy%26aufirst%3DR.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520thienopyrimidine%2520scaffold%2520as%2520inhibitor%2520of%2520the%2520ABC%2520transport%2520protein%2520ABCC1%2520%2528MRP1%2529%2520and%2520related%2520transporters%2520using%2520a%2520combined%2520virtual%2520screening%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4383%26epage%3D4400%26doi%3D10.1021%2Facs.jmedchem.8b01821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluchino, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span> <span> </span><span class="NLM_article-title">Revisiting the role of ABC transporters in multidrug-resistance cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1038/s41568-018-0005-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fs41568-018-0005-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=29643473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=452-464&author=R.+W.+Robeyauthor=K.+M.+Pluchinoauthor=M.+D.+Hallauthor=A.+T.+Fojoauthor=S.+E.+Batesauthor=M.+M.+Gottesman&title=Revisiting+the+role+of+ABC+transporters+in+multidrug-resistance+cancer&doi=10.1038%2Fs41568-018-0005-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting the role of ABC transporters in multidrug-resistant cancer</span></div><div class="casAuthors">Robey, Robert W.; Pluchino, Kristen M.; Hall, Matthew D.; Fojo, Antonio T.; Bates, Susan E.; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">452-464</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Most patients who die of cancer have disseminated disease that has become resistant to multiple therapeutic modalities.  Ample evidence suggests that the expression of ATP-binding cassette (ABC) transporters, esp. the multidrug resistance protein 1 (MDR1, also known as P-glycoprotein or P-gp), which is encoded by ABC subfamily B member 1 (ABCB1), can confer resistance to cytotoxic and targeted chemotherapy.  However, the development of MDR1 as a therapeutic target has been unsuccessful.  At the time of its discovery, appropriate tools for the characterization and clin. development of MDR1 as a therapeutic target were lacking.  Thirty years after the initial cloning and characterization of MDR1 and the implication of two addnl. ABC transporters, the multidrug resistance-assocd. protein 1 (MRP1; encoded by ABCC1)), and ABCG2, in multidrug resistance, interest in investigating these transporters as therapeutic targets has waned.  However, with the emergence of new data and advanced techniques, we propose to re-evaluate whether these transporters play a clin. role in multidrug resistance.  With this Opinion article, we present recent evidence indicating that it is time to revisit the investigation into the role of ABC transporters in efficient drug delivery in various cancer types and at the blood-brain barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTrmO71Nb38rVg90H21EOLACvtfcHk0lh2V0Zi2UotUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgt7Y%253D&md5=9c4b00f17a7ae98158862504bf1a8292</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fs41568-018-0005-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-018-0005-8%26sid%3Dliteratum%253Aachs%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DPluchino%26aufirst%3DK.%2BM.%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DFojo%26aufirst%3DA.%2BT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DRevisiting%2520the%2520role%2520of%2520ABC%2520transporters%2520in%2520multidrug-resistance%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2018%26volume%3D18%26spage%3D452%26epage%3D464%26doi%3D10.1038%2Fs41568-018-0005-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span> <span> </span><span class="NLM_article-title">Co-expression of ATP binding cassette transporters is associated with poor prognosis in acute myleoid leukemia</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.3892/ol.2018.8095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.3892%2Fol.2018.8095" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=452-464&author=B.+Liuauthor=L.-J.+Liauthor=X.+Gongauthor=W.+Zhangauthor=H.+Zhangauthor=L.+Zhao&title=Co-expression+of+ATP+binding+cassette+transporters+is+associated+with+poor+prognosis+in+acute+myleoid+leukemia&doi=10.3892%2Fol.2018.8095"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.3892%2Fol.2018.8095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2018.8095%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.-J.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DL.%26atitle%3DCo-expression%2520of%2520ATP%2520binding%2520cassette%2520transporters%2520is%2520associated%2520with%2520poor%2520prognosis%2520in%2520acute%2520myleoid%2520leukemia%26jtitle%3DOncol.%2520Lett.%26date%3D2018%26volume%3D15%26spage%3D452%26epage%3D464%26doi%3D10.3892%2Fol.2018.8095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofrichter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenzel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunkelmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paarmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhlich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plath, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brüning, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinze, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahnke, J.</span></span> <span> </span><span class="NLM_article-title">ABC Transporters B1, C1 and G2 differentially regulate neuroregeneration in mice</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e35613</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0035613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1371%2Fjournal.pone.0035613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=22545122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslantLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=T.+Schumacherauthor=M.+Krohnauthor=J.+Hofrichterauthor=C.+Langeauthor=J.+Stenzelauthor=J.+Steffenauthor=T.+Dunkelmannauthor=K.+Paarmannauthor=C.+Fr%C3%B6hlichauthor=A.+Ueckerauthor=A.+S.+Plathauthor=A.+Sommerauthor=T.+Br%C3%BCningauthor=H.+J.+Heinzeauthor=J.+Pahnke&title=ABC+Transporters+B1%2C+C1+and+G2+differentially+regulate+neuroregeneration+in+mice&doi=10.1371%2Fjournal.pone.0035613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">ABC transporters B1, C1 and G2 differentially regulate neuroregeneration in mice</span></div><div class="casAuthors">Schumacher, Toni; Krohn, Markus; Hofrichter, Jacqueline; Lange, Cathleen; Stenzel, Jan; Steffen, Johannes; Dunkelmann, Tina; Paarmann, Kristin; Froehlich, Christina; Uecker, Annekathrin; Plath, Anne-Sophie; Sommer, Alexandra; Bruening, Thomas; Heinze, Hans-Jochen; Pahnke, Jens</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e35613</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: ATP-binding cassette (ABC) transporters are essential regulators of organismic homeostasis, and are particularly important in protecting the body from potentially harmful exogenous substances.  Recently, an increasing no. of in vitro observations have indicated a functional role of ABC transporters in the differentiation and maintenance of stem cells.  Therefore, we sought to det. brain-related phenotypic changes in animals lacking the expression of distinct ABC transporters (ABCB1, ABCG2 or ABCC1).  Methodol. and Principal Findings: Analyzing adult neurogenesis in ABC transporter-deficient animals in vivo and neuronal stem/progenitor cells in vitro resulted in complex findings.  In vivo, the differentiation of neuronal progenitors was hindered in ABC transporter-deficient mice (ABCB10/0) as evidenced by lowered nos. of doublecortin+ (-36%) and calretinin+ (-37%) cells.  In vitro, we confirmed that this finding is not connected to the functional loss of single neural stem/progenitor cells (NSPCs).  Furthermore, assessment of activity, exploratory behavior, and anxiety levels revealed behavioral alterations in ABCB10/0 and ABCC10/0 mice, whereas ABCG20/0 mice were mostly unaffected.  Conclusion and Significance: Our data show that single ABC transporter-deficiency does not necessarily impair neuronal progenitor homeostasis on the single NSPC level, as suggested by previous studies.  However, loss of distinct ABC transporters impacts global brain homeostasis with far ranging consequences, leading to impaired neurogenic functions in vivo and even to distinct behavioral phenotypes.  In addn. to the known role of ABC transporters in proteopathies such as Parkinson's disease and Alzheimer's disease, our data highlight the importance of understanding the general function of ABC transporters for the brain's homeostasis and the regeneration potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt5VxqNNTz8LVg90H21EOLACvtfcHk0lh2V0Zi2UotUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslantLc%253D&md5=e91107843e33893fc32619ab1ba4a8e7</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0035613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0035613%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DT.%26aulast%3DKrohn%26aufirst%3DM.%26aulast%3DHofrichter%26aufirst%3DJ.%26aulast%3DLange%26aufirst%3DC.%26aulast%3DStenzel%26aufirst%3DJ.%26aulast%3DSteffen%26aufirst%3DJ.%26aulast%3DDunkelmann%26aufirst%3DT.%26aulast%3DPaarmann%26aufirst%3DK.%26aulast%3DFr%25C3%25B6hlich%26aufirst%3DC.%26aulast%3DUecker%26aufirst%3DA.%26aulast%3DPlath%26aufirst%3DA.%2BS.%26aulast%3DSommer%26aufirst%3DA.%26aulast%3DBr%25C3%25BCning%26aufirst%3DT.%26aulast%3DHeinze%26aufirst%3DH.%2BJ.%26aulast%3DPahnke%26aufirst%3DJ.%26atitle%3DABC%2520Transporters%2520B1%252C%2520C1%2520and%2520G2%2520differentially%2520regulate%2520neuroregeneration%2520in%2520mice%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0035613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hölzl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrowolny, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrandt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trübner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogerts, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahnke, J.</span></span> <span> </span><span class="NLM_article-title">Vascular and extravascular distribution of the ATP-binding cassette transporters ABCB1 and ABCC1 in aged human brain and pituitary</span>. <i>Mech. Ageing Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>141–142</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.mad.2014.08.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.mad.2014.08.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25218792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKqurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141%E2%80%93142&publication_year=2014&pages=12-21&author=H.+G.+Bernsteinauthor=G.+H%C3%B6lzlauthor=H.+Dobrowolnyauthor=J.+Hildebrandtauthor=K.+Tr%C3%BCbnerauthor=M.+Krohnauthor=N.+Bogertsauthor=J.+Pahnke&title=Vascular+and+extravascular+distribution+of+the+ATP-binding+cassette+transporters+ABCB1+and+ABCC1+in+aged+human+brain+and+pituitary&doi=10.1016%2Fj.mad.2014.08.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular and extravascular distribution of the ATP-binding cassette transporters ABCB1 and ABCC1 in aged human brain and pituitary</span></div><div class="casAuthors">Bernstein, Hans-Gert; Hoelzl, Gloria; Dobrowolny, Henrik; Hildebrandt, Jens; Truebner, Kurt; Krohn, Markus; Bogerts, Bernhard; Pahnke, Jens</div><div class="citationInfo"><span class="NLM_cas:title">Mechanisms of Ageing and Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">141-142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">MAGDA3</span>;
        ISSN:<span class="NLM_cas:issn">0047-6374</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">ATP-binding cassette (ABC) transporters play an increasing role in the understanding of pathol. peptide deposition in neurodegenerative diseases (NDs), such as Alzheimer's and Parkinson's.  To describe the location of the most important ABC transporters for NDs in human brain tissue, we investigated ABCB1 and ABCC1 immunohistol. in the adult human brain and pituitary.  Both transporters have similar but not identical expression patterns.  In brain regions with an established blood-brain barrier (BBB), ABCB1 and ABCC1 were ubiquitously expressed in endothelial cells of the microvasculature and in a subset of larger blood vessels (mostly venules).  Remarkably, both transporters were also found in fenestrated capillaries in circumventricular organs where the BBB is absent.  Moreover, ABCB1 and ABCC1 were also expressed in various non-endothelia cells such as pericytes, astrocytes, choroid plexus epithelia, ventricle ependymal cells, and neurons.  With regard to their neuronal expression it was shown that both transporters are located in specific nerve cell populations, which are also immunopos. for three putative cell markers of purinergic cell signalling, namely 5'-nucleotidase, adenosine deaminase and nucleoside triphosphate diphosphohydrolase-2.  Therefore, we speculate that neuronal expression of ABCB1 and ABCC1 might be linked to adenosinergic/purinergic neuromodulation.  Lastly, both transporters were obsd. in multiple adenohypophyseal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotBRARb3874bVg90H21EOLACvtfcHk0lhES3KhIRB4Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKqurrJ&md5=fb92edd6c1ebd7d2216eda5bc44c1dc9</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.mad.2014.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mad.2014.08.003%26sid%3Dliteratum%253Aachs%26aulast%3DBernstein%26aufirst%3DH.%2BG.%26aulast%3DH%25C3%25B6lzl%26aufirst%3DG.%26aulast%3DDobrowolny%26aufirst%3DH.%26aulast%3DHildebrandt%26aufirst%3DJ.%26aulast%3DTr%25C3%25BCbner%26aufirst%3DK.%26aulast%3DKrohn%26aufirst%3DM.%26aulast%3DBogerts%26aufirst%3DN.%26aulast%3DPahnke%26aufirst%3DJ.%26atitle%3DVascular%2520and%2520extravascular%2520distribution%2520of%2520the%2520ATP-binding%2520cassette%2520transporters%2520ABCB1%2520and%2520ABCC1%2520in%2520aged%2520human%2520brain%2520and%2520pituitary%26jtitle%3DMech.%2520Ageing%2520Dev.%26date%3D2014%26volume%3D141%25E2%2580%2593142%26spage%3D12%26epage%3D21%26doi%3D10.1016%2Fj.mad.2014.08.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samant, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodrich, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, W. J.</span></span> <span> </span><span class="NLM_article-title">Multi-drug resistance ABC transporters inhibition enhances murine ventral prostate ste,/progenitor cell differentiation</span>. <i>Stem Cells Dev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1236</span>– <span class="NLM_lpage">1251</span>, <span class="refDoi"> DOI: 10.1089/scd.2014.0293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1089%2Fscd.2014.0293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25567291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsVanuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1236-1251&author=M.+D.+Samantauthor=C.+M.+Jacksonauthor=C.+L.+Felixauthor=A.+J.+Jonesauthor=D.+W.+Goodrichauthor=B.+A.+Fosterauthor=W.+J.+Huss&title=Multi-drug+resistance+ABC+transporters+inhibition+enhances+murine+ventral+prostate+ste%2C%2Fprogenitor+cell+differentiation&doi=10.1089%2Fscd.2014.0293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Drug Resistance ABC Transporter Inhibition Enhances Murine Ventral Prostate Stem/Progenitor Cell Differentiation</span></div><div class="casAuthors">Samant, Mugdha D.; Jackson, Courtney M.; Felix, Carina L.; Jones, Anthony J.; Goodrich, David W.; Foster, Barbara A.; Huss, Wendy J.</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cells and Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1236-1251</span>CODEN:
                <span class="NLM_cas:coden">SCDTAE</span>;
        ISSN:<span class="NLM_cas:issn">1547-3287</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Multi-drug resistance (MDR)-ATP binding cassette (ABC) transporters, ABCB1, ABCC1, and ABCG2 participate in the efflux of steroid hormones, estrogens, and androgens, which regulate prostate development and differentiation.  The role of MDR-ABC efflux transporters in prostate epithelial proliferation and differentiation remains unclear.  We hypothesized that MDR-ABC transporters regulate prostate differentiation and epithelium regeneration.  Prostate epithelial differentiation was studied using histol., sphere formation assay, and prostate regeneration induced by cycles of repeated androgen withdrawal and replacement.  Embryonic deletion of Abcg2 resulted in a decreased no. of luminal cells in the prostate and increased sphere formation efficiency, indicating an imbalance in the prostate epithelial differentiation pattern.  Decreased luminal cell no. in the Abcg2 null prostate implies reduced differentiation.  Enhanced sphere formation efficiency in Abcg2 null prostate cells implies activation of the stem/progenitor cells.  Prostate regeneration was assocd. with profound activation of the stem/progenitor cells, indicating the role of Abcg2 in maintaining stem/progenitor cell pool.  Since embryonic deletion of Abcg2 may result in compensation by other ABC transporters, pharmacol. inhibition of MDR-ABC efflux was performed.  Pharmacol. inhibition of MDR-ABC efflux enhanced prostate epithelial differentiation in sphere culture and during prostate regeneration.  In conclusion, Abcg2 deletion leads to activation of the stem/progenitor cells and enhances differentiating divisions; and pharmacol. inhibition of MDR-ABC efflux leads to epithelial differentiation.  Our study demonstrates for the first time that MDR-ABC efflux transporter inhibition results in enhanced prostate epithelial cell differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0vFmNx4MRwrVg90H21EOLACvtfcHk0lhES3KhIRB4Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsVanuro%253D&md5=c6d7660e4a68f133c326cc0848e2bd02</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1089%2Fscd.2014.0293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fscd.2014.0293%26sid%3Dliteratum%253Aachs%26aulast%3DSamant%26aufirst%3DM.%2BD.%26aulast%3DJackson%26aufirst%3DC.%2BM.%26aulast%3DFelix%26aufirst%3DC.%2BL.%26aulast%3DJones%26aufirst%3DA.%2BJ.%26aulast%3DGoodrich%26aufirst%3DD.%2BW.%26aulast%3DFoster%26aufirst%3DB.%2BA.%26aulast%3DHuss%26aufirst%3DW.%2BJ.%26atitle%3DMulti-drug%2520resistance%2520ABC%2520transporters%2520inhibition%2520enhances%2520murine%2520ventral%2520prostate%2520ste%252C%252Fprogenitor%2520cell%2520differentiation%26jtitle%3DStem%2520Cells%2520Dev.%26date%3D2015%26volume%3D24%26spage%3D1236%26epage%3D1251%26doi%3D10.1089%2Fscd.2014.0293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed-Belkacem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macalou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Victoria, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumendjel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pietro, A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2)</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1097/00001813-200603000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1097%2F00001813-200603000-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=16520651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVGntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=239-243&author=A.+Ahmed-Belkacemauthor=A.+Pozzaauthor=S.+Macalouauthor=J.+M.+Perez-Victoriaauthor=A.+Boumendjelauthor=A.+Di+Pietro&title=Inhibitors+of+cancer+cell+multidrug+resistance+mediated+by+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29&doi=10.1097%2F00001813-200603000-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2)</span></div><div class="casAuthors">Ahmed-Belkacem, Abdelhakim; Pozza, Alexandre; Macalou, Sira; Perez-Victoria, Jose M.; Boumendjel, Ahcene; Di Pietro, Attilio</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-243</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Breast cancer resistance protein (BCRP/ABCG2) belongs to the ATP-binding cassette (ABC) transporter superfamily.  It is able to efflux a broad range of anti-cancer drugs through the cellular membrane, thus limiting their anti-proliferative effects.  Due to its relatively recent discovery in 1998, and in contrast to the other ABC transporters P-glycoprotein (MDR1/ABCB1) and multidrug resistance-assocd. protein (MRP1/ABCC1), only a few BCRP inhibitors have been reported.  This review summarizes the known classes of inhibitors that are either specific for BCRP or also inhibit the other multidrug resistance ABC transporters.  Information is presented on structure-activity relationship aspects and how modulators may interact with BCRP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo8q1_Mp1zf7Vg90H21EOLACvtfcHk0lhES3KhIRB4Fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVGntLk%253D&md5=bc8c1ba612b88026cfcb745d032d2388</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1097%2F00001813-200603000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-200603000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed-Belkacem%26aufirst%3DA.%26aulast%3DPozza%26aufirst%3DA.%26aulast%3DMacalou%26aufirst%3DS.%26aulast%3DPerez-Victoria%26aufirst%3DJ.%2BM.%26aulast%3DBoumendjel%26aufirst%3DA.%26aulast%3DDi%2BPietro%26aufirst%3DA.%26atitle%3DInhibitors%2520of%2520cancer%2520cell%2520multidrug%2520resistance%2520mediated%2520by%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2006%26volume%3D17%26spage%3D239%26epage%3D243%26doi%3D10.1097%2F00001813-200603000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, S. M.</span></span> <span> </span><span class="NLM_article-title">Multi-target ABC transporter modulators: what next and where to go?</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2353</span>– <span class="NLM_lpage">2358</span>, <span class="refDoi"> DOI: 10.4155/fmc-2019-0185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.4155%2Ffmc-2019-0185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=31516029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFWis7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=2353-2358&author=S.+M.+Stefan&title=Multi-target+ABC+transporter+modulators%3A+what+next+and+where+to+go%3F&doi=10.4155%2Ffmc-2019-0185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target ABC transporter modulators: what next and where to go?</span></div><div class="casAuthors">Stefan, Sven Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2353-2358</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review discussing multi-target ABC transporter modulators for treatment of cancer.  It also discusses that future ABC transporter modulators in particular and future medicinal chem. in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMUFK03Bl4kbVg90H21EOLACvtfcHk0lj7fF-EjXBbIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFWis7jM&md5=a8666c2d50a6ebc8899adceb3c4b4650</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2019-0185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2019-0185%26sid%3Dliteratum%253Aachs%26aulast%3DStefan%26aufirst%3DS.%2BM.%26atitle%3DMulti-target%2520ABC%2520transporter%2520modulators%253A%2520what%2520next%2520and%2520where%2520to%2520go%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D2353%26epage%3D2358%26doi%3D10.4155%2Ffmc-2019-0185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ozvegy-Laczka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegedus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varady, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ujhelly, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkadi, B.</span></span> <span> </span><span class="NLM_article-title">High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1485</span>– <span class="NLM_lpage">1495</span>, <span class="refDoi"> DOI: 10.1124/mol.65.6.1485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1124%2Fmol.65.6.1485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=15155841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ms1enug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2004&pages=1485-1495&author=C.+Ozvegy-Laczkaauthor=T.+Hegedusauthor=G.+Varadyauthor=O.+Ujhellyauthor=J.+D.+Schuetzauthor=A.+Varadiauthor=G.+Keriauthor=L.+Orfiauthor=K.+Nemetauthor=B.+Sarkadi&title=High-affinity+interaction+of+tyrosine+kinase+inhibitors+with+the+ABCG2+multidrug+transporter&doi=10.1124%2Fmol.65.6.1485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter</span></div><div class="casAuthors">Ozvegy-Laczka Csilla; Hegedus Tamas; Varady Gyorgy; Ujhelly Olga; Schuetz John D; Varadi Andras; Keri Gyorgy; Orfi Laszlo; Nemet Katalin; Sarkadi Balazs</div><div class="citationInfo"><span class="NLM_cas:title">Molecular pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1485-95</span>
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Tyrosine kinase inhibitors (TKIs) are promising new agents for specific inhibition of malignant cell growth and metastasis formation.  Because most of the TKIs have to reach an intracellular target, specific membrane transporters may significantly modulate their effectiveness.  In addition, the hydrophobic TKIs may interact with so-called multidrug transporters and thus alter the cellular distribution of unrelated pharmacological agents.  In the present work, we show that certain TKIs, already in the clinical phase of drug development, directly interact with the ABCG2 multidrug transporter protein with a high affinity.  We found that in several in vitro assay systems, STI-571 (Gleevec; imatinib mesylate), ZD1839 (Iressa; gefitinib), and N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (EKI-785) interacted with ABCG2 at submicromolar concentrations, whereas other multidrug transporters, human multidrug resistance protein (P-glycoprotein, ABCB1) and human multidrug resistance protein 1 (ABCC1), showed much lower reactivity toward these agents.  Low concentrations of the TKIs examined selectively modulated ABCG2-ATPase activity, inhibited ABCG2-dependent active drug extrusion, and significantly affected drug resistance patterns in cells expressing ABCG2.  Our results indicate that multidrug resistance protein modulation by TKIs may be an important factor in the clinical treatment of cancer patients.  These data also raise the possibility that an extrusion of TKIs by multidrug transporters, e.g., ABCG2, may be involved in tumor cell TKI resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxLklKEEpRTDToTC3aBaesfW6udTcc2eYTNPACH85QXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ms1enug%253D%253D&md5=d95324e42b206e256c0e0cb9e7474eaa</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1124%2Fmol.65.6.1485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.65.6.1485%26sid%3Dliteratum%253Aachs%26aulast%3DOzvegy-Laczka%26aufirst%3DC.%26aulast%3DHegedus%26aufirst%3DT.%26aulast%3DVarady%26aufirst%3DG.%26aulast%3DUjhelly%26aufirst%3DO.%26aulast%3DSchuetz%26aufirst%3DJ.%2BD.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DOrfi%26aufirst%3DL.%26aulast%3DNemet%26aufirst%3DK.%26aulast%3DSarkadi%26aufirst%3DB.%26atitle%3DHigh-affinity%2520interaction%2520of%2520tyrosine%2520kinase%2520inhibitors%2520with%2520the%2520ABCG2%2520multidrug%2520transporter%26jtitle%3DMol.%2520Pharmacol.%26date%3D2004%26volume%3D65%26spage%3D1485%26epage%3D1495%26doi%3D10.1124%2Fmol.65.6.1485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pawarode, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minderman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricke, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Loughlin, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span> <span> </span><span class="NLM_article-title">Differential effects of the immunosuppressive agents cyclosporine A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1007/s00280-006-0357-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1007%2Fs00280-006-0357-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=17031644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFSksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2007&pages=179-188&author=A.+Pawarodeauthor=S.+Shuklaauthor=H.+Mindermanauthor=S.+M.+Frickeauthor=E.+M.+Pinderauthor=K.+L.+O%E2%80%99Loughlinauthor=S.+V.+Ambudkarauthor=M.+R.+Baer&title=Differential+effects+of+the+immunosuppressive+agents+cyclosporine+A%2C+tacrolimus+and+sirolimus+on+drug+transport+by+multidrug+resistance+proteins&doi=10.1007%2Fs00280-006-0357-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins</span></div><div class="casAuthors">Pawarode, Attaphol; Shukla, Suneet; Minderman, Hans; Fricke, Stacy M.; Pinder, Elaine M.; O'Loughlin, Kieran L.; Ambudkar, Suresh V.; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-188</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We sought to det. the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).  Cellular content of mitoxantrone, a Pgp, MRP-1 and BCRP substrate, was measured by flow cytometry in cells overexpressing these proteins following incubation with and without CsA, tacrolimus or sirolimus.  Interaction of BCRP with these compds. was studied by photolabeling and ATPase assays.  Nuclear-cytoplasmic distribution of doxorubicin was studied by confocal microscopy in cells overexpressing LRP.  CsA increased cellular drug uptake in cells overexpressing Pgp, MRP-1 or BCRP and nuclear drug uptake in cells overexpressing LRP at the clin. achievable concn. of 2.5 μM.  Tacrolimus enhanced cellular drug uptake at 1 μM, but not at 0.08 μM, its clin. achievable concn., and did not enhance nuclear drug uptake.  Sirolimus enhanced cellular drug uptake in cells overexpressing Pgp, MRP-1 and BCRP with optimal effects at 2.5 μM, but was effective at its clin. achievable concn. of 0.25 μM if cells were pre-incubated for at least 30 min before drug exposure, and also enhanced nuclear drug uptake at 0.25 μM.  BCRP modulation by all three immunosuppressive agents was assocd. with competitive binding to the drug transport sites.  CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concns. that differ from immunosuppressive concns. and max. tolerated concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWFap9_l-cebVg90H21EOLACvtfcHk0lj7fF-EjXBbIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFSksbY%253D&md5=7a726299d0b6bcb3c7e86bd4605088f1</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1007%2Fs00280-006-0357-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-006-0357-8%26sid%3Dliteratum%253Aachs%26aulast%3DPawarode%26aufirst%3DA.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DMinderman%26aufirst%3DH.%26aulast%3DFricke%26aufirst%3DS.%2BM.%26aulast%3DPinder%26aufirst%3DE.%2BM.%26aulast%3DO%25E2%2580%2599Loughlin%26aufirst%3DK.%2BL.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DDifferential%2520effects%2520of%2520the%2520immunosuppressive%2520agents%2520cyclosporine%2520A%252C%2520tacrolimus%2520and%2520sirolimus%2520on%2520drug%2520transport%2520by%2520multidrug%2520resistance%2520proteins%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2007%26volume%3D60%26spage%3D179%26epage%3D188%26doi%3D10.1007%2Fs00280-006-0357-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ivnitski-Steele, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovato, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khawaja, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklar, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, B. S.</span></span> <span> </span><span class="NLM_article-title">High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1089/adt.2007.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1089%2Fadt.2007.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=18205550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1cXls1Kqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=263-276&author=I.+Ivnitski-Steeleauthor=R.+S.+Larsonauthor=D.+M.+Lovatoauthor=H.+M.+Khawajaauthor=S.+S.+Winterauthor=T.+I.+Opreaauthor=L.+A.+Sklarauthor=B.+S.+Edwards&title=High-throughput+flow+cytometry+to+detect+selective+inhibitors+of+ABCB1%2C+ABCC1%2C+and+ABCG2+transporters&doi=10.1089%2Fadt.2007.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters</span></div><div class="casAuthors">Ivnitski-Steele, Irena; Larson, Richard S.; Lovato, Debbie M.; Khawaja, Hadya M.; Winter, Stuart S.; Oprea, Tudor I.; Sklar, Larry A.; Edwards, Bruce S.</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-276</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Up-regulation of pump (transporter) expression and selection of resistant cancer cells result in cancer multidrug resistance to diverse substrates of these transporters.  While more than 48 members of the ATP binding cassette (ABC) transporter superfamily have been identified, up to now only three human ABC transporters-ABCB1, ABCC1, and ABCG2-have unambiguously been shown to contribute to cancer multidrug resistance.  The use of low-toxicity and high-specificity agents as a targeted transporter inhibition strategy is necessary to effectively overcome multiple drug resistance.  An objective of the present studies was to develop and validate HyperCyt (IntelliCyt, Albuquerque, NM) flow cytometry high-throughput screening assays to assess the specificity of test compds. that inhibited transporters as an integral part of the screen.  Two sep. duplex assays were constructed: one in which ABCB1 and ABCG2 transporters were evaluated in parallel using fluorescent J-aggregate-forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide as substrate, and the other in which ABCB1 and ABCC1 transporters were evaluated in parallel using fluorescent calcein acetoxymethyl ester as substrate.  ABCB1-expressing cells were color-coded to allow their distinction from cells expressing the alternate transporter.  The assays were validated in a screen of the Prestwick Chem. Library (Illkirch, France).  Three novel selective inhibitors of the ABCC1 transporter were identified in the screen, and the activity of each was confirmed in follow-up chemosensitivity shift and reversal studies.  This high-throughput screening assay provides an efficient approach for identifying selective inhibitors of individual ABC transporters, promising as probes of transporter function and therapeutic tools for treating chemotherapy-resistant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRappYyF8fXLVg90H21EOLACvtfcHk0liXp5fq22H-FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXls1Kqu70%253D&md5=4c037ba8843d29d06440df46ec7f12e3</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1089%2Fadt.2007.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2007.107%26sid%3Dliteratum%253Aachs%26aulast%3DIvnitski-Steele%26aufirst%3DI.%26aulast%3DLarson%26aufirst%3DR.%2BS.%26aulast%3DLovato%26aufirst%3DD.%2BM.%26aulast%3DKhawaja%26aufirst%3DH.%2BM.%26aulast%3DWinter%26aufirst%3DS.%2BS.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26aulast%3DEdwards%26aufirst%3DB.%2BS.%26atitle%3DHigh-throughput%2520flow%2520cytometry%2520to%2520detect%2520selective%2520inhibitors%2520of%2520ABCB1%252C%2520ABCC1%252C%2520and%2520ABCG2%2520transporters%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2008%26volume%3D6%26spage%3D263%26epage%3D276%26doi%3D10.1089%2Fadt.2007.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarulo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ancona, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Bicalutamide failure in prostate cancer treatment: involvement of multi drug resistance proteins</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>601</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2008.10.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejphar.2008.10.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=18992739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKrsbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=601&publication_year=2008&pages=38-42&author=N.+A.+Colabufoauthor=V.+Pagliaruloauthor=F.+Berardiauthor=M.+Continoauthor=C.+Ingleseauthor=M.+Nisoauthor=P.+Anconaauthor=G.+Alboauthor=A.+Pagliaruloauthor=R.+Perrone&title=Bicalutamide+failure+in+prostate+cancer+treatment%3A+involvement+of+multi+drug+resistance+proteins&doi=10.1016%2Fj.ejphar.2008.10.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Bicalutamide failure in prostate cancer treatment: Involvement of Multi Drug Resistance proteins</span></div><div class="casAuthors">Colabufo, Nicola Antonio; Pagliarulo, Vincenzo; Berardi, Francesco; Contino, Marialessandra; Inglese, Carmela; Niso, Mauro; Ancona, Patrizia; Albo, Giancarlo; Pagliarulo, Arcangelo; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">601</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">38-42</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Prolonged bicalutamide treatment induced pathol. regression although relapses with a more aggressive form of prostate cancer have been obsd.  This failure could be due to androgen receptor mutation.  In the present work we hypothesized an alternative mechanism responsible for bicalutamide failure involving activity of ATP-binding cassette (ABC) pumps such as P-glycoprotein, Breast Cancer Receptor Protein (BCRP), and Multi Resistant Proteins (MRPs) that extrude the androgen antagonist from the cell membrane.  As exptl. models androgen-dependent (LnCap) and androgen-independent (PC-3) prostate cancer cell lines have been employed.  Bicalutamide has been tested in the cell lines mentioned above in the absence and in the presence of MC18, our potent P-glycoprotein/BCRP/MRP1 inhibitor.  The results displayed that bicalutamide antiproliferative effect at 72 h was ameliorated in LnCap cells (EC50 from 51.9 ± 6.1 μM to 17.8 ± 2.6 μM in the absence and in the presence of MC18, resp.) and restored in PC-3 cells (EC50 from 150 ± 2.4 μM to 60 ± 3.5 μM in the absence and in the presence of MC18, resp.).  Moreover, we established the contribution of each transporter employing stable transfected cells (MDCK) overexpressing P-glycoprotein or BCRP or MRP1 pump.  The results displayed that P-glycoprotein and BCRP were involved in bicalutamide efflux while MRP1 was unable to bind the antiandrogen drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGxXLjsSjHvrVg90H21EOLACvtfcHk0liXp5fq22H-FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKrsbrE&md5=102ec86e344cace41ffa295e135a838c</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2008.10.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2008.10.038%26sid%3Dliteratum%253Aachs%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DPagliarulo%26aufirst%3DV.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DInglese%26aufirst%3DC.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DAncona%26aufirst%3DP.%26aulast%3DAlbo%26aufirst%3DG.%26aulast%3DPagliarulo%26aufirst%3DA.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DBicalutamide%2520failure%2520in%2520prostate%2520cancer%2520treatment%253A%2520involvement%2520of%2520multi%2520drug%2520resistance%2520proteins%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D601%26spage%3D38%26epage%3D42%26doi%3D10.1016%2Fj.ejphar.2008.10.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashby, C. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L. W.</span></span> <span> </span><span class="NLM_article-title">Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">7905</span>– <span class="NLM_lpage">7914</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-0499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1158%2F0008-5472.CAN-08-0499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=18829547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2msL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=7905-7914&author=C.+L.+Daiauthor=A.+K.+Tiwariauthor=C.+P.+Wuauthor=X.+D.+Suauthor=S.+R.+Wangauthor=D.+G.+Liuauthor=C.+R.+Ashbyauthor=Y.+Huangauthor=R.+W.+Robeyauthor=Y.+J.+Liangauthor=L.+M.+Chenauthor=C.+J.+Shiauthor=S.+V.+Ambudkarauthor=Z.+S.+Chenauthor=L.+W.+Fu&title=Lapatinib+%28Tykerb%2C+GW572016%29+reverses+multidrug+resistance+in+cancer+cells+by+inhibiting+the+activity+of+ATP-binding+cassette+subfamily+B+member+1+and+G+member+2&doi=10.1158%2F0008-5472.CAN-08-0499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2</span></div><div class="casAuthors">Dai, Chun-ling; Tiwari, Amit K.; Wu, Chung-Pu; Su, Xiao-dong; Wang, Si-Rong; Liu, Dong-geng; Ashby, Charles R., Jr.; Huang, Yan; Robey, Robert W.; Liang, Yong-ju; Chen, Li-ming; Shi, Cheng-Jun; Ambudkar, Suresh V.; Chen, Zhe-Sheng; Fu, Li-wu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7905-7914</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Lapatinib is active at the ATP-binding site of tyrosine kinases that are assocd. with the human epidermal growth factor receptor (Her-1 or ErbB1) and Her-2.  It is conceivable that lapatinib may inhibit the function of ATP-binding cassette (ABC) transporters by binding to their ATP-binding sites.  The aim of this study was to investigate the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to overexpression of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2) transporters.  Our results showed that lapatinib significantly enhanced the sensitivity to ABCB1 or ABCG2 substrates in cells expressing these transporters, although a small synergetic effect was obsd. in combining lapatinib and conventional chemotherapeutic agents in parental sensitive MCF-7 or S1 cells.  Lapatinib alone, however, did not significantly alter the sensitivity of non-ABCB1 or non-ABCG2 substrates in sensitive and resistant cells.  Addnl., lapatinib significantly increased the accumulation of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells and inhibited the transport of methotrexate and E217βG by ABCG2.  Furthermore, lapatinib stimulated the ATPase activity of both ABCB1 and ABCG2 and inhibited the photolabeling of ABCB1 or ABCG2 with [125I]iodoarylazidoprazosin in a concn.-dependent manner.  However, lapatinib did not affect the expression of these transporters at mRNA or protein levels.  Importantly, lapatinib also strongly enhanced the effect of paclitaxel on the inhibition of growth of the ABCB1-overexpressing KBv200 cell xenografts in nude mice.  Overall, we conclude that lapatinib reverses ABCB1- and ABCG2-mediated MDR by directly inhibiting their transport function.  These findings may be useful for cancer combinational therapy with lapatinib in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowPBKRO5m-O7Vg90H21EOLACvtfcHk0likDgAGLl0kFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2msL3P&md5=6dd61ea93f95ac0137055777fa53599f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-0499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-0499%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DC.%2BL.%26aulast%3DTiwari%26aufirst%3DA.%2BK.%26aulast%3DWu%26aufirst%3DC.%2BP.%26aulast%3DSu%26aufirst%3DX.%2BD.%26aulast%3DWang%26aufirst%3DS.%2BR.%26aulast%3DLiu%26aufirst%3DD.%2BG.%26aulast%3DAshby%26aufirst%3DC.%2BR.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DLiang%26aufirst%3DY.%2BJ.%26aulast%3DChen%26aufirst%3DL.%2BM.%26aulast%3DShi%26aufirst%3DC.%2BJ.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26aulast%3DFu%26aufirst%3DL.%2BW.%26atitle%3DLapatinib%2520%2528Tykerb%252C%2520GW572016%2529%2520reverses%2520multidrug%2520resistance%2520in%2520cancer%2520cells%2520by%2520inhibiting%2520the%2520activity%2520of%2520ATP-binding%2520cassette%2520subfamily%2520B%2520member%25201%2520and%2520G%2520member%25202%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D7905%26epage%3D7914%26doi%3D10.1158%2F0008-5472.CAN-08-0499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L. W.</span></span> <span> </span><span class="NLM_article-title">Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function</span>. <i>Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.2119/molmed.2014.00059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.2119%2Fmolmed.2014.00059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25105301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yrtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=390-399&author=S.+L.+Maauthor=Y.+P.+Huauthor=F.+Wangauthor=Z.+C.+Huangauthor=Y.+F.+Chenauthor=X.+K.+Wangauthor=L.+W.+Fu&title=Lapatinib+antagonizes+multidrug+resistance-associated+protein+1-mediated+multidrug+resistance+by+inhibiting+its+transport+function&doi=10.2119%2Fmolmed.2014.00059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function</span></div><div class="casAuthors">Ma, Shao-Lin; Hu, Ya-Peng; Wang, Fang; Huang, Zhen-Cong; Chen, Yi-Fan; Wang, Xiao-Kun; Fu, Li-Wu</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine (Manhasset, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">390-399, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1528-3658</span>.
    
            (<span class="NLM_cas:orgname">Feinstein Institute for Medical Research</span>)
        </div><div class="casAbstract">Lapatinib, a tyrosine kinase inhibitor, is used in the treatment of advanced or metastatic breast cancer overexpressing human epidermal receptor 2 (HER2).  Lapatinib can modulate the function of ATP-binding cassette (ABC) transporters (ABCB1 and ABCG2), which are the major mechanism responsible for multidrug resistance (MDR) in cancer.  In this study, we investigated the effect of lapatinib on multidrug resistance-assocd. protein 1 (MRP1 [ABCC1]), MRP2 (ABCC2), MRP4 (ABCC4) and lung relative resistance protein (LRP) drug efflux pumps.  We demonstrated that lapatinib could enhance the efficacy of conventional chemotherapeutic agents in MRP1-overexpressing cells in vitro and in vivo, but no effect in MRP2-, MPR4-and LRP-overexpressing cells.  Furthermore, lapatinib significantly increased the accumulation of rhodamine 123 (Rho123) and doxorubicin (DOX) in MRP1-overexpressing cells.  However, lapatinib did not alter the protein or mRNA expression levels of MRP1.  Further studies showed that the level of phosphorylation of AKT and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) were not altered at the indicated concns. of lapatinib.  In conclusion, lapatinib enhanced the efficacy of conventional chemotherapeutic agents in MRP1-overexpressing cells by inhibiting MRP1 transport function without altering the level of AKT or ERK1/2 phosphorylation.  These findings will encourage the clin. research of lapatinib combined with conventional chemotherapeutic drugs in MRP1-overexpressing cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeTcf5F8bwW7Vg90H21EOLACvtfcHk0likDgAGLl0kFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yrtr3I&md5=39440a6a97d4ed1b24bff5c6e3e042d3</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.2119%2Fmolmed.2014.00059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2119%252Fmolmed.2014.00059%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DS.%2BL.%26aulast%3DHu%26aufirst%3DY.%2BP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DZ.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BF.%26aulast%3DWang%26aufirst%3DX.%2BK.%26aulast%3DFu%26aufirst%3DL.%2BW.%26atitle%3DLapatinib%2520antagonizes%2520multidrug%2520resistance-associated%2520protein%25201-mediated%2520multidrug%2520resistance%2520by%2520inhibiting%2520its%2520transport%2520function%26jtitle%3DMol.%2520Med.%26date%3D2014%26volume%3D20%26spage%3D390%26epage%3D399%26doi%3D10.2119%2Fmolmed.2014.00059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Multi-drug-resistance-reverting agents: 2-arylazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200800329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1002%2Fcmdc.200800329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=19140144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXislWju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=188-195&author=N.+A.+Colabufoauthor=F.+Berardiauthor=M.+G.+Perroneauthor=M.+Cantoreauthor=M.+Continoauthor=C.+Ingleseauthor=M.+Nisoauthor=R.+Perrone&title=Multi-drug-resistance-reverting+agents%3A+2-arylazole+and+2-arylthiazole+derivatives+as+potent+BCRP+or+MRP1+inhibitors&doi=10.1002%2Fcmdc.200800329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors</span></div><div class="casAuthors">Colabufo, Nicola A.; Berardi, Francesco; Perrone, Maria Grazia; Cantore, Mariangela; Contino, Marialessandra; Inglese, Carmela; Niso, Mauro; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-195</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">2-Aryloxazole and 2-arylthiazole derivs. were evaluated for their inhibitory activity toward P-glycoprotein (P-gp) as well as their selectivity toward other ABC transporters involved in multidrug resistance such as BCRP and MRP1.  These derivs. have 6,7-dimethoxytetrahydroisoquinoline or cyclohexylpiperazine moieties, which are the same basic nuclei of the potent P-gp inhibitors MC70 (EC50 = 0.05 μM) and PB28 (EC50 = 0.55 μM), resp.  The results demonstrate that 2-aryloxazole and 2-arylthiazole derivs., planned as cycloisosteres of MC70, were found to be less potent than the ref. compd. in inhibiting P-gp.  These compds. were evaluated for their BCRP and MRP1 inhibitory activities.  In particular, 6,7-dimethoxytetrahydroisoquinoline derivs., unsubstituted, 3-Br, 3-Cl, and 3-OCH3 2-aryloxalzole derivs. showed the best BCRP inhibitory activity (EC50 range: 0.24-0.46 μM).  In contrast, all cyclohexylpiperazine derivs. except one (EC50 = 0.56 μM), showed decreased BCRP inhibitory activity.  All compds. tested were unable to inhibit the MRP1 pump, with the exception of the 2-OCH3 and 4-OCH3 derivs. of the 6,7-dimethoxytetrahydroisoquinoline series, which displayed high MRP1 inhibitory activity (EC50 = 0.84 and 0.90 μM, resp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprNAfet5qK9bVg90H21EOLACvtfcHk0lih8NEXX8yvBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXislWju7s%253D&md5=3a97e57563939e60a3e34485ea0a3d15</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800329%26sid%3Dliteratum%253Aachs%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPerrone%26aufirst%3DM.%2BG.%26aulast%3DCantore%26aufirst%3DM.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DInglese%26aufirst%3DC.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DMulti-drug-resistance-reverting%2520agents%253A%25202-arylazole%2520and%25202-arylthiazole%2520derivatives%2520as%2520potent%2520BCRP%2520or%2520MRP1%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D188%26epage%3D195%26doi%3D10.1002%2Fcmdc.200800329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L. W.</span></span> <span> </span><span class="NLM_article-title">Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">7981</span>– <span class="NLM_lpage">7991</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-0111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1158%2F0008-5472.CAN-10-0111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=20876799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yqs7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=7981-7991&author=Y.+J.+Miauthor=Y.+J.+Liangauthor=H.+B.+Huangauthor=H.+Y.+Zhaoauthor=C.+P.+Wuauthor=F.+Wangauthor=L.+Y.+Taoauthor=C.+Z.+Zhangauthor=C.+L.+Daiauthor=A.+K.+Tiwariauthor=X.+X.+Maauthor=K.+K.+Toauthor=S.+V.+Ambudkarauthor=Z.+S.+Chenauthor=L.+W.+Fu&title=Apatinib+%28YN968D1%29+reverses+multidrug+resistance+by+inhibiting+the+efflux+function+of+multiple+ATP-binding+cassette+transporters&doi=10.1158%2F0008-5472.CAN-10-0111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters</span></div><div class="casAuthors">Mi, Yan-jun; Liang, Yong-ju; Huang, Hong-bing; Zhao, Hong-yun; Wu, Chung-Pu; Wang, Fang; Tao, Li-yang; Zhang, Chuan-zhao; Dai, Chun-Ling; Tiwari, Amit K.; Ma, Xiao-xu; To, Kenneth Kin Wah; Ambudkar, Suresh V.; Chen, Zhe-Sheng; Fu, Li-wu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7981-7991</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Apatinib, a small-mol. multitargeted tyrosine kinase inhibitor, is in phase III clin. trial for the treatment of patients with non-small-cell lung cancer and gastric cancer in China.  In this study, we detd. the effect of apatinib on the interaction of specific antineoplastic compds. with P-glycoprotein (ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), and breast cancer resistance protein (BCRP, ABCG2).  Our results showed that apatinib significantly enhanced the cytotoxicity of ABCB1 or ABCG2 substrate drugs in KBv200, MCF-7/adr, and HEK293/ABCB1 cells overexpressing ABCB1 and in S1-M1-80, MCF-7/FLV1000, and HEK293/ABCG2-R2 cells overexpressing ABCG2 (wild-type).  In contrast, apatinib did not alter the cytotoxicity of specific substrates in the parental cells and cells overexpressing ABCC1.  Apatinib significantly increased the intracellular accumulation of rhodamine 123 and doxorubicin in the multidrug resistance (MDR) cells.  Furthermore, apatinib significantly inhibited the photoaffinity labeling of both ABCB1 and ABCG2 with [125I]iodoarylazidoprazosin in a concn.-dependent manner.  The ATPase activity of both ABCB1 and ABCG2 was significantly increased by apatinib.  However, apatinib, at a concn. that produced a reversal of MDR, did not significantly alter the ABCB1 or ABCG2 protein or mRNA expression levels or the phosphorylation of AKT and extracellular signal-regulated kinase 1/2 (ERK1/2).  Importantly, apatinib significantly enhanced the effect of paclitaxel against the ABCB1-resistant KBv200 cancer cell xenografts in nude mice.  In conclusion, apatinib reverses ABCB1- and ABCG2-mediated MDR by inhibiting their transport function, but not by blocking the AKT or ERK1/2 pathway or downregulating ABCB1 or ABCG2 expression.  Apatinib may be useful in circumventing MDR to other conventional antineoplastic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7UdIyUL3T57Vg90H21EOLACvtfcHk0lih8NEXX8yvBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yqs7nF&md5=ecf314e6eda8940a8a739398c959eb43</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-0111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-0111%26sid%3Dliteratum%253Aachs%26aulast%3DMi%26aufirst%3DY.%2BJ.%26aulast%3DLiang%26aufirst%3DY.%2BJ.%26aulast%3DHuang%26aufirst%3DH.%2BB.%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DWu%26aufirst%3DC.%2BP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DTao%26aufirst%3DL.%2BY.%26aulast%3DZhang%26aufirst%3DC.%2BZ.%26aulast%3DDai%26aufirst%3DC.%2BL.%26aulast%3DTiwari%26aufirst%3DA.%2BK.%26aulast%3DMa%26aufirst%3DX.%2BX.%26aulast%3DTo%26aufirst%3DK.%2BK.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26aulast%3DFu%26aufirst%3DL.%2BW.%26atitle%3DApatinib%2520%2528YN968D1%2529%2520reverses%2520multidrug%2520resistance%2520by%2520inhibiting%2520the%2520efflux%2520function%2520of%2520multiple%2520ATP-binding%2520cassette%2520transporters%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D7981%26epage%3D7991%26doi%3D10.1158%2F0008-5472.CAN-10-0111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krauze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinberga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasnova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adlere, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domracheva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shestakova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andzans, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duburs, G.</span></span> <span> </span><span class="NLM_article-title">Thieno[3,2-b]pyridines–a new class of multidrug resistance (MDR) modulators</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5860</span>– <span class="NLM_lpage">5870</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.09.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bmc.2014.09.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25311564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslCitLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5860-5870&author=A.+Krauzeauthor=S.+Grinbergaauthor=L.+Krasnovaauthor=I.+Adlereauthor=E.+Sokolovaauthor=I.+Domrachevaauthor=I.+Shestakovaauthor=Z.+Andzansauthor=G.+Duburs&title=Thieno%5B3%2C2-b%5Dpyridines%E2%80%93a+new+class+of+multidrug+resistance+%28MDR%29+modulators&doi=10.1016%2Fj.bmc.2014.09.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Thieno[2,3-b]pyridines-A new class of multidrug resistance (MDR) modulators</span></div><div class="casAuthors">Krauze, Aivars; Grinberga, Signe; Krasnova, Laura; Adlere, Ilze; Sokolova, Elina; Domracheva, Ilona; Shestakova, Irina; Andzans, Zigmars; Duburs, Gunars</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5860-5870</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To identify new potent multidrug resistance modulators, we have synthesized a series of novel thieno[2,3-b]pyridines and furo[2,3-b]pyridines, and examd. their structure-activity relationships.  All synthesized compds. were tested to det. BCRP1, P-gp, and MRP1 inhibitor activity, and most potent MDR modulators were also screened for their toxicity, cytotoxicity and Ca2+ channel antagonist activity.  Among these compds., thieno[2,3-b]pyridine (6r) was found to exhibit a potent P-gp inhibitory action with EC50 = 0.3 ± 0.2 μM, MRP1 inhibitory action with EC50 = 1.1 ± 0.1 μM and BCRP1 inhibitory action with EC50 = 0.2 ± 0.05 μM and may represent suitable candidate for further pharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3HnHyKtS3y7Vg90H21EOLACvtfcHk0lg5Qmfx1FGX6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslCitLrE&md5=7f648cc8771774e04e6dab83b11fd4a8</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.09.023%26sid%3Dliteratum%253Aachs%26aulast%3DKrauze%26aufirst%3DA.%26aulast%3DGrinberga%26aufirst%3DS.%26aulast%3DKrasnova%26aufirst%3DL.%26aulast%3DAdlere%26aufirst%3DI.%26aulast%3DSokolova%26aufirst%3DE.%26aulast%3DDomracheva%26aufirst%3DI.%26aulast%3DShestakova%26aufirst%3DI.%26aulast%3DAndzans%26aufirst%3DZ.%26aulast%3DDuburs%26aufirst%3DG.%26atitle%3DThieno%255B3%252C2-b%255Dpyridines%25E2%2580%2593a%2520new%2520class%2520of%2520multidrug%2520resistance%2520%2528MDR%2529%2520modulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5860%26epage%3D5870%26doi%3D10.1016%2Fj.bmc.2014.09.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teodori, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riganti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manetti, i D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanelli, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trezza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athanasios, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiga, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giampietro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dei, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">111655</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2019.111655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=31494468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslCgs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2019&pages=111655&author=E.+Teodoriauthor=M.+Continoauthor=C.+Rigantiauthor=G.+Bartolucciauthor=L.+Braconiauthor=i+D.+Manettiauthor=M.+N.+Romanelliauthor=A.+Trezzaauthor=A.+Athanasiosauthor=O.+Spigaauthor=M.+G.+Perroneauthor=R.+Giampietroauthor=E.+Gazzanoauthor=M.+Salernoauthor=N.+A.+Colabufoauthor=S.+Dei&title=Design%2C+synthesis+and+biological+evaluation+of+stereo-+and+regioisomers+of+amino+aryl+esters+as+multidrug+resistance+%28MDR%29+reversers&doi=10.1016%2Fj.ejmech.2019.111655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers</span></div><div class="casAuthors">Teodori, Elisabetta; Contino, Marialessandra; Riganti, Chiara; Bartolucci, Gianluca; Braconi, Laura; Manetti, Dina; Romanelli, Maria Novella; Trezza, Alfonso; Athanasios, Asimidis; Spiga, Ottavia; Perrone, Maria Grazia; Giampietro, Roberta; Gazzano, Elena; Salerno, Milena; Colabufo, Nicola Antonio; Dei, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111655pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Stereo- and regioisomers of a series of N,N-bis(alkanol)amine aryl ester derivs. I [Ar = Ar1 = (E)3-(3,4,5-trimethoxyphenyl)acrylic acid, 3,4,5-trimethoxybenzoicacid, anthracene-9-carboxylic acid; n = 3, 5, 7] were prepd. and studied as multidrug resistance (MDR) modulators.  In the pirarubicin uptake assay on K562/DOX cell line these compds. I showed good activity and efficacy and in many cases enantioselectivity was obsd.  Docking studies confirmed the influence of the stereocenter on the interaction in the P-gp pocket.  The P-gp interaction mechanism and selectivity towards MRP1 and BCRP were also evaluated on MDCK transfected cells overexpressing the three transporters.  Almost all these compds. inhibited both P-gp and BCRP, but only derivs. with specific structural characteristics showed MRP1 activity.  Moreover, two compds., (S)-3 and (R)-7, showed the ability to induce collateral sensitivity (CS) against MDR cells.  Therefore, these two CS-promoting agents could be considered interesting leads for the development of selective cytotoxic agents for drug-resistant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUPLjN1vaDrVg90H21EOLACvtfcHk0lg5Qmfx1FGX6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslCgs73K&md5=de524db6fbdcda6e3c2f2226ad5c53b4</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111655%26sid%3Dliteratum%253Aachs%26aulast%3DTeodori%26aufirst%3DE.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DRiganti%26aufirst%3DC.%26aulast%3DBartolucci%26aufirst%3DG.%26aulast%3DBraconi%26aufirst%3DL.%26aulast%3DManetti%26aufirst%3Di%2BD.%26aulast%3DRomanelli%26aufirst%3DM.%2BN.%26aulast%3DTrezza%26aufirst%3DA.%26aulast%3DAthanasios%26aufirst%3DA.%26aulast%3DSpiga%26aufirst%3DO.%26aulast%3DPerrone%26aufirst%3DM.%2BG.%26aulast%3DGiampietro%26aufirst%3DR.%26aulast%3DGazzano%26aufirst%3DE.%26aulast%3DSalerno%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DDei%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520stereo-%2520and%2520regioisomers%2520of%2520amino%2520aryl%2520esters%2520as%2520multidrug%2520resistance%2520%2528MDR%2529%2520reversers%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D182%26spage%3D111655%26doi%3D10.1016%2Fj.ejmech.2019.111655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manolaridis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">König, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, G.</span></span> <span> </span><span class="NLM_article-title">Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">112133</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2020.112133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=32105979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvVKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2020&pages=112133&author=F.+Antoniauthor=M.+Bauseauthor=M.+Schollerauthor=S.+Bauerauthor=S.+A.+Starkauthor=S.+M.+Jacksonauthor=I.+Manolaridisauthor=K.+P.+Locherauthor=B.+K%C3%B6nigauthor=A.+Buschauerauthor=G.+Bernhardt&title=Tariquidar-related+triazoles+as+potent%2C+selective+and+stable+inhibitors+of+ABCG2+%28BCRP%29&doi=10.1016%2Fj.ejmech.2020.112133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP)</span></div><div class="casAuthors">Antoni, Frauke; Bause, Manuel; Scholler, Matthias; Bauer, Stefanie; Stark, Simone A.; Jackson, Scott M.; Manolaridis, Ioannis; Locher, Kaspar P.; Koenig, Burkhard; Buschauer, Armin; Bernhardt, Guenther</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112133pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The current study comprises the synthesis and characterization of novel tariquidar-related inhibitors, obtained by bioisosteric replacement of the labile moieties in previous tariquidar analog UR-ME22-1.  CuAAC ("click" reaction) gave convenient access to a triazole core as a substitute for the labile amide group and the labile ester moiety was replaced by different acyl groups in a Sugasawa reaction.  A stability assay proved the enhancement of the stability in blood plasma.  Compds. UR-MB108 I (R1 = OMe) and UR-MB136 I (R1 = O(CH2CH2O)3Me) inhibited ABCG2 in a Hoechst 33342 transport assay with an IC50 value of about 80 nM and belong to the most potent ABCG2 inhibitors described so far.  Compd. I (R1 = OMe) was highly selective, whereas its PEGylated analog I (R1 = O(CH2CH2O)3Me) showed some potency at ABCB1.  Both compds. produced an ABCG2 ATPase-depressing effect which is in agreement with precedent cryo-EM study identifying I (R1 = O(CH2CH2O)3Me) as an ATPase inhibitor that exerts its effect via locking the inward-facing conformation.  Thermostabilization of ABCG2 by both compds. can be taken as a hint to comparable binding to ABCG2.  As ref. substances, both compds. allow addnl. mechanistic studies on ABCG2 inhibition.  The highly specific inhibitor (R1 = OMe) is suited for PET labeling, helping to further elucidate the (patho)physiol. role of ABCG2, e.g. at the BBB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSL6WpPUbeCrVg90H21EOLACvtfcHk0lidSbVyqbnEPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvVKhu7s%253D&md5=1b7237b3d2a389ca0c1ee8f6c5928903</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112133%26sid%3Dliteratum%253Aachs%26aulast%3DAntoni%26aufirst%3DF.%26aulast%3DBause%26aufirst%3DM.%26aulast%3DScholler%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DS.%2BA.%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DManolaridis%26aufirst%3DI.%26aulast%3DLocher%26aufirst%3DK.%2BP.%26aulast%3DK%25C3%25B6nig%26aufirst%3DB.%26aulast%3DBuschauer%26aufirst%3DA.%26aulast%3DBernhardt%26aufirst%3DG.%26atitle%3DTariquidar-related%2520triazoles%2520as%2520potent%252C%2520selective%2520and%2520stable%2520inhibitors%2520of%2520ABCG2%2520%2528BCRP%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D191%26spage%3D112133%26doi%3D10.1016%2Fj.ejmech.2020.112133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.-W.</span></span> <span> </span><span class="NLM_article-title">Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2009.01.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.canlet.2009.01.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=19232821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlejt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2009&pages=74-83&author=C.-L.+Daiauthor=Y.-J.+Liangauthor=Y.-S.+Wangauthor=A.+K.+Tiwariauthor=Y.-Y.+Yanauthor=F.+Wangauthor=Z.-S.+Chenauthor=X.-Z.+Tongauthor=L.-W.+Fu&title=Sensitization+of+ABCG2-overexpressing+cells+to+conventional+chemotherapeutic+agent+by+sunitinib+was+associated+with+inhibiting+the+function+of+ABCG2&doi=10.1016%2Fj.canlet.2009.01.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2</span></div><div class="casAuthors">Dai, Chun-Ling; Liang, Yong-Ju; Wang, Yan-Sheng; Tiwari, Amit K.; Yan, Yan-Yan; Wang, Fang; Chen, Zhe-Sheng; Tong, Xiu-Zhen; Fu, Li-Wu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-83</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Sunitinib is an ATP-competitive multi-targeted tyrosine kinase inhibitor.  In this study, we evaluated the possible interaction of sunitinib with P-glycoprotein (P-gp, ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), breast cancer resistance protein (BCRP, ABCG2) and lung-resistance protein (LRP) in vitro.  Our results showed that sunitinib completely reverse drug resistance mediated by ABCG2 at a non-toxic concn. of 2.5 μM and has no significant reversal effect on ABCB1-, ABCC1- and LRP-mediated drug resistance, although a small synergetic effect was obsd. in combining sunitinib and conventional chemotherapeutic agents in ABCB1 overexpressing MCF-7/adr and parental sensitive MCF-7 cells, ABCC1 overexpressing C-A120 and parental sensitive KB-3-1 cells.  Sunitinib significantly increased intracellular accumulation of rhodamine 123 and doxorubicin and remarkably inhibited the efflux of rhodamine 123 and methotrexate by ABCG2 in ABCG2-overexpressing cells, and also profoundly inhibited the transport of [3H]-methotrexate by ABCG2.  However, sunitinib did not affect the expression of ABCG2 at mRNA or protein levels.  In addn., sunitinib did not block the phosphorylation of Akt and Erk1/2 in ABCG2-overexpressing or parental sensitive cells.  Overall, we conclude that sunitinib reverses ABCG2-mediated MDR through inhibiting the drug efflux function of ABCG2.  These findings may be useful for cancer combinational therapy with sunitinib in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri11_oxCDuL7Vg90H21EOLACvtfcHk0lidSbVyqbnEPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlejt7w%253D&md5=3d448f3fd1ee17c338e8b7783a19ea82</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.01.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.01.027%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DC.-L.%26aulast%3DLiang%26aufirst%3DY.-J.%26aulast%3DWang%26aufirst%3DY.-S.%26aulast%3DTiwari%26aufirst%3DA.%2BK.%26aulast%3DYan%26aufirst%3DY.-Y.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.-S.%26aulast%3DTong%26aufirst%3DX.-Z.%26aulast%3DFu%26aufirst%3DL.-W.%26atitle%3DSensitization%2520of%2520ABCG2-overexpressing%2520cells%2520to%2520conventional%2520chemotherapeutic%2520agent%2520by%2520sunitinib%2520was%2520associated%2520with%2520inhibiting%2520the%2520function%2520of%2520ABCG2%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D279%26spage%3D74%26epage%3D83%26doi%3D10.1016%2Fj.canlet.2009.01.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan Sheng, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.05.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2012.05.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=22743241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWntLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=413-422&author=J.+Yuanauthor=I.+L.+Wongauthor=T.+Jiangauthor=S.+W.+Wangauthor=T.+Liuauthor=B.+J.+Wenauthor=L.+M.+Chowauthor=B.+Wan+Sheng&title=Synthesis+of+methylated+quercetin+derivatives+and+their+reversal+activities+on+P-gp-+and+BCRP-mediated+multidrug+resistance+tumour+cells&doi=10.1016%2Fj.ejmech.2012.05.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumor cells</span></div><div class="casAuthors">Yuan, Jian; Wong, Iris L. K.; Jiang, Tao; Wang, Si Wen; Liu, Tao; Bin, Jin Wen; Chow, Larry M. C.; Biao, Wan Sheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">413-422</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Three methylated quercetins and a series of O-3 substituted 5,7,3',4'-tetra-O-methylated quercetin derivs. have been synthesized and evaluated on the modulating activity of P-gp, BCRP and MRP1 in cancer cell lines.  Compd. I is the most potent P-gp modulator.  Three derivs. consistently exhibited promising BCRP-modulating activity.  Interestingly, I was found to be equipotent against both P-gp and BCRP.  Importantly, these synthetic quercetin derivs. did not exhibit any inherent cytotoxicity to cancer cell lines or normal mouse fibroblast cell lines.  These quercetin derivs. can be employed as safe and effective modulators of P-gp- or BCRP-mediated drug resistance in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfUvCzHF18QbVg90H21EOLACvtfcHk0ljCKrtbsoTMVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWntLbM&md5=b2b5d4c5949f2af31840ec6ad3a71841</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.05.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.05.026%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DI.%2BL.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DS.%2BW.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DWen%26aufirst%3DB.%2BJ.%26aulast%3DChow%26aufirst%3DL.%2BM.%26aulast%3DWan%2BSheng%26aufirst%3DB.%26atitle%3DSynthesis%2520of%2520methylated%2520quercetin%2520derivatives%2520and%2520their%2520reversal%2520activities%2520on%2520P-gp-%2520and%2520BCRP-mediated%2520multidrug%2520resistance%2520tumour%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D54%26spage%3D413%26epage%3D422%26doi%3D10.1016%2Fj.ejmech.2012.05.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flemming, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conseil, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tivnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polinsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudkov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishvanath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, D. M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, M. D.</span></span> <span> </span><span class="NLM_article-title">High-throughput screening identifies ceefourin 1 and ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2014.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bcp.2014.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=24973542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOgtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2014&pages=97-108&author=L.+Cheungauthor=C.+L.+Flemmingauthor=F.+Wattauthor=N.+Masadaauthor=D.+M.+T.+Yuauthor=T.+Huynhauthor=G.+Conseilauthor=A.+Tivnanauthor=A.+Polinskyauthor=A.+V.+Gudkovauthor=M.+A.+Munozauthor=A.+Vishvanathauthor=D.+M.+F.+Cooperauthor=M.+J.+Hendersonauthor=S.+P.+C.+Coleauthor=J.+I.+Fletcherauthor=M.+Haberauthor=M.+D.+Norris&title=High-throughput+screening+identifies+ceefourin+1+and+ceefourin+2+as+highly+selective+inhibitors+of+multidrug+resistance+protein+4+%28MRP4%29&doi=10.1016%2Fj.bcp.2014.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)</span></div><div class="casAuthors">Cheung, Leanna; Flemming, Claudia L.; Watt, Fujiko; Masada, Nanako; Yu, Denise M. T.; Huynh, Tony; Conseil, Gwenaelle; Tivnan, Amanda; Polinsky, Alexander; Gudkov, Andrei V.; Munoz, Marcia A.; Vishvanath, Anasuya; Cooper, Dermot M. F.; Henderson, Michelle J.; Cole, Susan P. C.; Fletcher, Jamie I.; Haber, Michelle; Norris, Murray D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multidrug resistance protein 4 (MRP4/ABCC4), a member of the ATP-binding cassette (ABC) transporter superfamily, is an org. anion transporter capable of effluxing a wide range of physiol. important signalling mols. and drugs.  MRP4 has been proposed to contribute to numerous functions in both health and disease; however, in most cases these links remain to be unequivocally established.  A major limitation to understanding the physiol. and pharmacol. roles of MRP4 has been the absence of specific small mol. inhibitors, with the majority of established inhibitors also targeting other ABC transporter family members, or inhibiting the prodn., function or degrdn. of important MRP4 substrates.  We therefore set out to identify more selective and well tolerated inhibitors of MRP4 that might be used to study the many proposed functions of this transporter.  Using high-throughput screening, we identified two chem. distinct small mols., Ceefourin 1 and Ceefourin 2, that inhibit transport of a broad range of MRP4 substrates, yet are highly selective for MRP4 over other ABC transporters, including P-glycoprotein (P-gp), ABCG2 (Breast Cancer Resistance Protein; BCRP) and MRP1 (multidrug resistance protein 1; ABCC1).  Both compds. are more potent MRP4 inhibitors in cellular assays than the most widely used inhibitor, MK-571, requiring lower concns. to effect a comparable level of inhibition.  Furthermore, Ceefourin 1 and Ceefourin 2 have low cellular toxicity, and high microsomal and acid stability.  These newly identified inhibitors should be of great value for efforts to better understand the biol. roles of MRP4, and may represent classes of compds. with therapeutic application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocSL--oUSDXbVg90H21EOLACvtfcHk0ljCKrtbsoTMVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOgtLrM&md5=11cf7f10449638e857c9f9379a77e778</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DCheung%26aufirst%3DL.%26aulast%3DFlemming%26aufirst%3DC.%2BL.%26aulast%3DWatt%26aufirst%3DF.%26aulast%3DMasada%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DD.%2BM.%2BT.%26aulast%3DHuynh%26aufirst%3DT.%26aulast%3DConseil%26aufirst%3DG.%26aulast%3DTivnan%26aufirst%3DA.%26aulast%3DPolinsky%26aufirst%3DA.%26aulast%3DGudkov%26aufirst%3DA.%2BV.%26aulast%3DMunoz%26aufirst%3DM.%2BA.%26aulast%3DVishvanath%26aufirst%3DA.%26aulast%3DCooper%26aufirst%3DD.%2BM.%2BF.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DCole%26aufirst%3DS.%2BP.%2BC.%26aulast%3DFletcher%26aufirst%3DJ.%2BI.%26aulast%3DHaber%26aufirst%3DM.%26aulast%3DNorris%26aufirst%3DM.%2BD.%26atitle%3DHigh-throughput%2520screening%2520identifies%2520ceefourin%25201%2520and%2520ceefourin%25202%2520as%2520highly%2520selective%2520inhibitors%2520of%2520multidrug%2520resistance%2520protein%25204%2520%2528MRP4%2529%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D91%26spage%3D97%26epage%3D108%26doi%3D10.1016%2Fj.bcp.2014.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Voruciclib, a potent CDK4/6 inhibitor, antagonizes ABCB1 and ABCG2-mediated multi-drug resistance in cancer cells</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1528</span>, <span class="refDoi"> DOI: 10.1159/000487578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1159%2F000487578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=29486476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlOgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=1515-1528&author=P.+Guptaauthor=Y.-K.+Zhangauthor=X.-Y.+Zhangauthor=Y.-J.+Wangauthor=K.+W.+Luauthor=T.+Hallauthor=R.+Pengauthor=D.-H.+Yangauthor=N.+Xieauthor=Z.-S.+Chen&title=Voruciclib%2C+a+potent+CDK4%2F6+inhibitor%2C+antagonizes+ABCB1+and+ABCG2-mediated+multi-drug+resistance+in+cancer+cells&doi=10.1159%2F000487578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells</span></div><div class="casAuthors">Gupta, Pranav; Zhang, Yun-Kai; Zhang, Xiao-Yu; Wang, Yi-Jun; Lu, Kimberly W.; Hall, Timothy; Peng, Richard; Yang, Dong-Hua; Xie, Ni; Chen, Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1515-1528</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background/Aims: The overexpression of ATP-Binding Cassette (ABC) transporters has known to be one of the major obstacles impeding the success of chemotherapy in drug resistant cancers.  In this study, we evaluated voruciclib, a CDK 4/6 inhibitor, for its chemo-sensitizing activity in ABCB1- and ABCG2- overexpressing cells.  Methods: Cytotoxicity and reversal effect of voruciclib was detd. by MTT assay.  The intracellular accumulation and efflux of ABCB1 and ABCG2 substrates were measured by scintillation counter.  The effects on expression and intracellular localization of ABCB1 and ABCG2 proteins were detd. by Western blotting and immunofluorescence, resp.  Vanadate-sensitive ATPase assay was done to det. the effect of voruciclib on the ATPase activity of ABCB1 and ABCG2.  Flow cytometric anal. was done to det. the effect of voruciclib on apoptosis of ABCB1 and ABCG2-overexpressing cells and docking anal. was done to det. the interaction of voruciclib with ABCB1 and ACBG2 protein.  Results: Voruciclib significantly potentiated the effect of paclitaxel and doxorubicin in ABCB1-overexpressing cells, as well as mitoxantrone and SN-38 in ABCG2-overexpressing cells.  Voruciclib moderately sensitized ABCC10- overexpressing cells to paclitaxel, whereas it did not alter the cytotoxicity of substrates of ABCC1.  Furthermore, voruciclib increased the intracellular accumulation and decreased the efflux of substrate anti-cancer drugs from ABCB1- or ABCG2-overexpressing cells.  However, voruciclib did not alter the expression or the sub-cellular localization of ABCB1 or ABCG2.  Voruciclib stimulated the ATPase activity of both ABCB1 and ABCG2 in a concn.-dependent manner.  Lastly, voruciclib exhibited a drug-induced apoptotic effect in ABCB1- or ABCG2- overexpressing cells.  Conclusion: Voruciclib is currently a phase I clin. trial drug.  Our findings strongly support its potential use in combination with conventional anti-cancer drugs for cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoyadf1NgenrVg90H21EOLACvtfcHk0lgwEsqnrs7mOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlOgtLo%253D&md5=03b4795bd5a136b1ea91f0403ee8fb5a</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1159%2F000487578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000487578%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.-K.%26aulast%3DZhang%26aufirst%3DX.-Y.%26aulast%3DWang%26aufirst%3DY.-J.%26aulast%3DLu%26aufirst%3DK.%2BW.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DD.-H.%26aulast%3DXie%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DZ.-S.%26atitle%3DVoruciclib%252C%2520a%2520potent%2520CDK4%252F6%2520inhibitor%252C%2520antagonizes%2520ABCB1%2520and%2520ABCG2-mediated%2520multi-drug%2520resistance%2520in%2520cancer%2520cells%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2018%26volume%3D45%26spage%3D1515%26epage%3D1528%26doi%3D10.1159%2F000487578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span> <span> </span><span class="NLM_article-title">Triazole bridged flavonoid dimers as potent, nontoxic, and highly selective breast cancer resistance protein (BCRP/ABCG2) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8578</span>– <span class="NLM_lpage">8608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00963</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00963" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12jt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8578-8608&author=X.+Zhuauthor=I.+L.+K.+Wongauthor=K.+F.+Chanauthor=J.+Cuiauthor=M.+C.+Lawauthor=T.+C.+Chongauthor=X.+Huauthor=L.+M.+C.+Chowauthor=T.+H.+Chan&title=Triazole+bridged+flavonoid+dimers+as+potent%2C+nontoxic%2C+and+highly+selective+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29+inhibitors&doi=10.1021%2Facs.jmedchem.9b00963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors</span></div><div class="casAuthors">Zhu, Xuezhen; Wong, Iris L. K.; Chan, Kin-Fai; Cui, Jiahua; Law, Man Chun; Chong, Tsz Cheung; Hu, Xuesen; Chow, Larry M. C.; Chan, Tak Hang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8578-8608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The present work describes the syntheses of diverse triazole bridged flavonoid dimers and identifies potent, nontoxic, and highly selective BCRP inhibitors.  A homodimer, Ac22(Az8)2, with m-methoxycarbonylbenzyloxy substitution at C-3 of the flavone moieties and a bis-triazole-contg. linker (21 atoms between the two flavones) showed low toxicity (IC50 toward L929, 3T3, and HFF-1 > 100 μM), potent BCRP-inhibitory activity (EC50 = 1-2 nM), and high BCRP selectivity (BCRP selectivity over MRP1 and P-gp > 455-909).  Ac22(Az8)2 inhibits BCRP-ATPase activity, blocks the drug efflux activity of BCRP, elevates the intracellular drug accumulation, and finally restores the drug sensitivity of BCRP-overexpressing cells.  It does not down-regulate the surface BCRP protein expression to enhance the drug retention.  Therefore, Ac22(Az8)2 and similar flavonoid dimers appear to be promising candidates for further development into combination therapy to overcome MDR cancers with BCRP overexpression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT5xt1YU3qdLVg90H21EOLACvtfcHk0lgwEsqnrs7mOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12jt7zI&md5=3fe2b8583391b42b77d7205b1f32555a</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00963%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DI.%2BL.%2BK.%26aulast%3DChan%26aufirst%3DK.%2BF.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DLaw%26aufirst%3DM.%2BC.%26aulast%3DChong%26aufirst%3DT.%2BC.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DChow%26aufirst%3DL.%2BM.%2BC.%26aulast%3DChan%26aufirst%3DT.%2BH.%26atitle%3DTriazole%2520bridged%2520flavonoid%2520dimers%2520as%2520potent%252C%2520nontoxic%252C%2520and%2520highly%2520selective%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8578%26epage%3D8608%26doi%3D10.1021%2Facs.jmedchem.9b00963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casciano, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W. W.</span></span> <span> </span><span class="NLM_article-title">In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">522</span>– <span class="NLM_lpage">528</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10772630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivVKgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=522-528&author=E.-J.+Wangauthor=C.+N.+Cascianoauthor=R.+P.+Clementauthor=W.+W.+Johnson&title=In+vitro+flow+cytometry+method+to+quantitatively+assess+inhibitors+of+P-glycoprotein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein</span></div><div class="casAuthors">Wang, Er-Jia; Casciano, Christopher N.; Clement, Robert P.; Johnson, William W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">522-528</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P-glycoprotein (Pgp)-mediated drug efflux is a major factor contributing to the variance of absorption and distribution of many drugs (Hall et al., 1999).  A simple and reliable in vitro method to identify inhibitors of Pgp helps to prevent the potential of drug interactions.  Using daunorubicin as a fluorescent marker and vanadate as a pos. control compd., a functional flow cytometry method for assessing the ability of a drug to inhibit Pgp-mediated drug efflux from CR1R12 multidrug-resistant cells has been evaluated.  Quantitation of the relative fluorescence was used to compare potency of individual inhibitors.  Known Pgp inhibitors, such as cyclosporin A, nicardipine, verapamil, quinidine, terfenadine, tamoxifen, and vinblastine were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin.  Cyclosporin A and terfenadine were the most potent inhibitors among the compds. tested.  Tetraphenylphosphonium and α-tocopherol had little inhibitory effect.  Progesterone produced significant inhibition at relatively high concns.  This study demonstrated that this in vitro flow cytometry method is a simple, sensitive, and quant. tool to assess the capacity of a drug to inhibit Pgp transporters, and is useful for screening or identifying inhibitors of Pgp as well as evaluation of potential for drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDfnK8-8FgsrVg90H21EOLACvtfcHk0lgufwfG7t8Kyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivVKgurs%253D&md5=f13c2d00678cdf18ec816e52dbe0d0a4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DE.-J.%26aulast%3DCasciano%26aufirst%3DC.%2BN.%26aulast%3DClement%26aufirst%3DR.%2BP.%26aulast%3DJohnson%26aufirst%3DW.%2BW.%26atitle%3DIn%2520vitro%2520flow%2520cytometry%2520method%2520to%2520quantitatively%2520assess%2520inhibitors%2520of%2520P-glycoprotein%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2000%26volume%3D28%26spage%3D522%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casciano, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W. W.</span></span> <span> </span><span class="NLM_article-title">Cooperativity in the Inhibition of P-glycoprotein-mediated daunorubicin transport: evidence for half-of-the-sites reactivity</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1006/abbi.2000.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1006%2Fabbi.2000.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11097180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot1KhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2000&pages=91-98&author=E.-J.+Wangauthor=C.+N.+Cascianoauthor=R.+P.+Clementauthor=W.+W.+Johnson&title=Cooperativity+in+the+Inhibition+of+P-glycoprotein-mediated+daunorubicin+transport%3A+evidence+for+half-of-the-sites+reactivity&doi=10.1006%2Fabbi.2000.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: Evidence for half-of-the-sites reactivity</span></div><div class="casAuthors">Wang, Er-jia; Casciano, Christopher N.; Clement, Robert P.; Johnson, William W.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-98</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">P-Glycoprotein (Pgp) is an important transport enzyme composed of two homologous domains and transports a wide range of structurally diverse xenobiotics from the cell.  Recent studies have indicated that allosteric interactions occur between the nucleotide binding domains and between the substrate binding domains of the two halves, but the extent of this interaction as well as the means by which the enzyme can transport such a wide variety of substrates has not been elucidated.  Herein, the Pgp-mediated transport of a marker substrate, daunorubicin (DNR), out of viable cells was examd. in the presence of a variety of other known substrates of Pgp.  For most of the typical Pgp substrates examd., the relation between inhibition of DNR efflux and competing substrate concn. with sigmoidal and therefore not a simple mutually exclusive competitive inhibition of transport.  The Hill coeff. ranged from about 3 to 5 for the inhibition of transport of DNR.  This neg. cooperativity in combination with recent evidence, including several examples of noncompetitive inhibition between the homologous halves of Pgp, indicates a "half-of-the-sites" reactivity.  Our data support the mechanistic proposal that substrate binding at one putative transport binding site precludes activity at another unequal site; many of the substrates examd. exert a neg. allosteric effect on the other transport site (and vice versa).  A half-of-the-sites reactivity model would account for many of these observations and may be crit. to the efficiency of Pgp substrate transport of a broad spectrum of compds.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiU9kmAbJogrVg90H21EOLACvtfcHk0lgufwfG7t8Kyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot1KhsLw%253D&md5=19284896a9c39e96651719d43ebccd30</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1006%2Fabbi.2000.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabbi.2000.2004%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DE.-J.%26aulast%3DCasciano%26aufirst%3DC.%2BN.%26aulast%3DClement%26aufirst%3DR.%2BP.%26aulast%3DJohnson%26aufirst%3DW.%2BW.%26atitle%3DCooperativity%2520in%2520the%2520Inhibition%2520of%2520P-glycoprotein-mediated%2520daunorubicin%2520transport%253A%2520evidence%2520for%2520half-of-the-sites%2520reactivity%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2000%26volume%3D383%26spage%3D91%26epage%3D98%26doi%3D10.1006%2Fabbi.2000.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kühnle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahringer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">König, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span> <span> </span><span class="NLM_article-title">Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the P-glycoprotein modulator tariquidar</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1190</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1021/jm8013822</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8013822" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Ohtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1190-1197&author=M.+K%C3%BChnleauthor=M.+Eggerauthor=C.+M%C3%BCllerauthor=A.+Mahringerauthor=G.+Bernhardtauthor=G.+Frickerauthor=B.+K%C3%B6nigauthor=A.+Buschauer&title=Potent+and+selective+inhibitors+of+breast+cancer+resistance+protein+%28ABCG2%29+derived+from+the+P-glycoprotein+modulator+tariquidar&doi=10.1021%2Fjm8013822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) Derived from the p-Glycoprotein (ABCB1) Modulator Tariquidar</span></div><div class="casAuthors">Kuehnle, Matthias; Egger, Michael; Mueller, Christine; Mahringer, Anne; Bernhardt, Gunther; Fricker, Gert; Koenig, Burkhard; Buschauer, Armin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1190-1197</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The efflux pumps ABCB1 (p-gp, MDR1) and ABCG2 (BCRP) are expressed to a high extent by endothelial cells at the blood-brain barrier (BBB) and other barrier tissues and are involved in drug resistance of tumor (stem) cells.  Whereas numerous ABCB1 inhibitors are known, only a few ABCG2 modulators with submicromolar activity have been published.  Starting from tariquidar (4) analogs as ABCB1 modulators, minimal structural modifications resulted in a drastic shift in favor of ABCG2 inhibition.  Highest potency was found when the 3,4-dimethoxy-2-(quinoline-3-carbonylamino)benzoyl moiety in 4 was replaced with a 4-methoxycarbonylbenzoyl moiety bearing a hetarylcarboxamido group in 3-position, e.g., quinoline-3-carboxamido (5, IC50: 119 nM) or quinoline-2-carboxamido (6, IC50: 60 nM, flow cytometric mitoxantrone efflux assay, topotecan-resistant MCF-7 breast cancer cells); the selectivity for ABCG2 over ABCB1 was about 100-500 fold and the compds. were inactive at ABCC2 (MRP2).  Chemosensitivity assays against MCF-7/Topo cells revealed that the nontoxic inhibitor 6 completely reverted ABCG2-mediated topotecan resistance at concns. >100 nM, whereas 5 showed ABCG2 independent cytotoxicity.  ABCG2 inhibitors might be useful for cancer treatment with respect to reversal of multidrug resistance, overcoming the BBB and targeting of tumor stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXaBXLV28GfbVg90H21EOLACvtfcHk0lh9sdNJQi4EFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Ohtrg%253D&md5=7f6e62d7e127747c08e16db192392e12</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm8013822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8013822%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BChnle%26aufirst%3DM.%26aulast%3DEgger%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DMahringer%26aufirst%3DA.%26aulast%3DBernhardt%26aufirst%3DG.%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DK%25C3%25B6nig%26aufirst%3DB.%26aulast%3DBuschauer%26aufirst%3DA.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%2520derived%2520from%2520the%2520P-glycoprotein%2520modulator%2520tariquidar%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1190%26epage%3D1197%26doi%3D10.1021%2Fjm8013822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Köhler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">HM30181 derivatives as novel potent and selective inhibitors of the breast cancer resistance protein (BCRP/ABCG2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3910</span>– <span class="NLM_lpage">3921</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjitlelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3910-3921&author=S.+C.+K%C3%B6hlerauthor=M.+Wiese&title=HM30181+derivatives+as+novel+potent+and+selective+inhibitors+of+the+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29&doi=10.1021%2Facs.jmedchem.5b00188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2)</span></div><div class="casAuthors">Kohler Sebastian C; Wiese Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3910-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The breast cancer resistance protein (BCRP, ABCG2) belongs to the superfamily of ATP binding-cassette (ABC) proteins.  In addition to other physiological functions, it transports potentially cell-damaging compounds out of the cell using the energy from ATP hydrolysis.  Certain tumors overexpressing BCRP were found to become resistant against various anticancer drugs.  In previous work, we found that tariquidar analogues lacking the tetrahydroisoquinoline moiety selectively inhibit BCRP.  In the present study, we synthesized 21 derivatives of the third-generation P-gp inhibitor HM30181, which is structurally related to tariquidar.  The compounds were tested for their inhibitory activities against BCRP and screened against P-glycoprotein (P-gp, ABCB1) and multidrug resistance protein 1 (MRP1, ABCC1) to confirm the selectivity toward BCRP.  The most potent compounds are selective toward BCRP and 2-fold more potent than the reference Ko143.  Qualitative structure-activity relationship (SAR) analysis revealed that the presence of a methoxy group in the ortho or para position of at least one phenyl ring is beneficial for inhibitory activity.  Furthermore, the cytotoxicity and multidrug resistance (MDR)-reversal ability of selected compounds were investigated.  It was shown that they have a low cytotoxicity and the ability to reverse the BCRP-mediated SN-38 resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_-1BYW7HmO9-cVm4E2RlLfW6udTcc2eZjMWcyPhAinbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjitlelsg%253D%253D&md5=777b13f427105e8909ae751d11e8c7b4</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00188%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6hler%26aufirst%3DS.%2BC.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DHM30181%2520derivatives%2520as%2520novel%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3910%26epage%3D3921%26doi%3D10.1021%2Facs.jmedchem.5b00188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraege, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köhler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Acryloylphenylcarboxamides: a new class of breast cancer resistance protein (ABCG2) modulators</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2422</span>– <span class="NLM_lpage">2436</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1002%2Fcmdc.201600341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=27735138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2422-2436&author=S.+Kraegeauthor=S.+C.+K%C3%B6hlerauthor=M.+Wiese&title=Acryloylphenylcarboxamides%3A+a+new+class+of+breast+cancer+resistance+protein+%28ABCG2%29+modulators&doi=10.1002%2Fcmdc.201600341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Acryloylphenylcarboxamides: A New Class of Breast Cancer Resistance Protein (ABCG2) Modulators</span></div><div class="casAuthors">Kraege, Stefanie; Koehler, Sebastian C.; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2422-2435</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Chalcones are easily synthesized natural precursors of secondary plant metabolites, and their derivs. show various biol. activities including inhibition of ABC transporters.  Esp., their role as inhibitors of ABCG2, the most recently discovered ABC transporter involved in multidrug resistance, inspired the synthesis of new structurally diverse derivs.  Therefore, we combined the typical chalcone moiety with several acid chlorides by using an amide linker at position 2', 3', or 4' on ring A of the chalcone.  The resulting 35 compds. covered a wide spectrum of substitution patterns, which allowed development of structure-activity relationships and to find the optimal structural features for further investigations.  Synthesized acryloylphenylcarboxamides were investigated for their inhibitory activity against ABCG2 and their behavior toward ABCB1 and ABCC1.  Furthermore, for the most promising compds., their intrinsic cytotoxicity and their ability to reverse ABCG2-mediated multidrug resistance were detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0P-lyvFfxZbVg90H21EOLACvtfcHk0lh9sdNJQi4EFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbrF&md5=9ec4f956a6b65d38723bb2ee270c4196</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600341%26sid%3Dliteratum%253Aachs%26aulast%3DKraege%26aufirst%3DS.%26aulast%3DK%25C3%25B6hler%26aufirst%3DS.%2BC.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DAcryloylphenylcarboxamides%253A%2520a%2520new%2520class%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%2520modulators%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D2422%26epage%3D2436%26doi%3D10.1002%2Fcmdc.201600341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraege, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köhler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of acryloylphenylcarboxamides as inhibitors of ABCG2 and comparison with acryloylphenylcarboxylates</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2547</span>– <span class="NLM_lpage">2559</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1002%2Fcmdc.201600455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=27785905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCrs7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2547-2559&author=S.+Kraegeauthor=K.+Stefanauthor=S.+C.+K%C3%B6hlerauthor=M.+Wiese&title=Optimization+of+acryloylphenylcarboxamides+as+inhibitors+of+ABCG2+and+comparison+with+acryloylphenylcarboxylates&doi=10.1002%2Fcmdc.201600455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates</span></div><div class="casAuthors">Kraege, Stefanie; Stefan, Katja; Koehler, Sebastian C.; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2547-2558</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">ABCG2 belongs to the superfamily of ATP binding cassette (ABC) proteins and is assocd. with the limited success of anticancer chemotherapy, given its responsibility for the cross-resistance of tumor cells, known as multidrug resistance (MDR).  Several classes of ABCG2 inhibitors were developed for increasing the efficacy of chemotherapy.  A series of chalcones coupled to an addnl. arom. residue was synthesized and investigated for their inhibition of ABC transporters.  In the authors' previous work the authors detd. the preferred position of the linker on the A-ring to be ortho, and found several substitution patterns at the addnl. ring that improved potency.  In this study the authors investigated whether a methoxy group that improved the inhibitory activity of chalcones would also be beneficial for the acryloylphenylcarboxamide scaffold.  Indeed, this modification led to highly potent ABCG2 inhibitors.  To support the hypothesis of a beneficial effect of the amide linker, six acryloylphenylcarboxylates were synthesized and investigated for their inhibitory activity.  Replacement of the amide linker with an ester group resulted in decreased inhibition.  Mol. modeling showed that the conformational preference of both series differs, thereby explaining the pos. effect of the amide linker.  Several compds. were characterized in detail by investigating their intrinsic cytotoxicity and capacity to reverse MDR in MTT assays and their effect on vanadate-sensitive ATPase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSSOhTSZbrG7Vg90H21EOLACvtfcHk0ljz9KShfhuhTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCrs7nL&md5=43572ddfbc073331704e4950b109bcf4</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600455%26sid%3Dliteratum%253Aachs%26aulast%3DKraege%26aufirst%3DS.%26aulast%3DStefan%26aufirst%3DK.%26aulast%3DK%25C3%25B6hler%26aufirst%3DS.%2BC.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520acryloylphenylcarboxamides%2520as%2520inhibitors%2520of%2520ABCG2%2520and%2520comparison%2520with%2520acryloylphenylcarboxylates%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D2547%26epage%3D2559%26doi%3D10.1002%2Fcmdc.201600455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnier-Suillerot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbeuf-Gueye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loetchutinat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalczyk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priebe, W.</span></span> <span> </span><span class="NLM_article-title">Analysis of drug transport kinetics in multidrug-resistant cells. Implications for drug action</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.2174/0929867013373967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.2174%2F0929867013373967" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11172692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVSgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=51-64&author=A.+Garnier-Suillerotauthor=C.+Marbeuf-Gueyeauthor=M.+Salernoauthor=C.+Loetchutinatauthor=I.+Foktauthor=M.+Krawczykauthor=T.+Kowalczykauthor=W.+Priebe&title=Analysis+of+drug+transport+kinetics+in+multidrug-resistant+cells.+Implications+for+drug+action&doi=10.2174%2F0929867013373967"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action</span></div><div class="casAuthors">Garnier-Suillerot, Arlette; Marbeuf-Gueye, Carole; Salerno, Milena; Loetchutinat, Chatchanok; Fokt, Izabela; Krawczyk, Marta; Kowalczyk, Teresa; Priebe, Waldemar</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-64</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review with 80 refs.  Multidrug resistance (MDR) in model systems is known to be conferred by two different integral proteins--the 170-kDa P-glycoprotein (P-gp) and the 190-kDa multidrug resistance-assocd. protein (MRP1)--that pump drugs out of MDR cells.  The intracellular level of a drug, which influences the drug's cytotoxic effect, is a function of the amt. of drug transported inside the cell (influx) and the amt. of drug expelled from the cell (efflux).  One possible pharmacol. approach to overcoming drug resistance is the use of specific inhibitors that enhance the cytotoxicity of known antineoplastic agents.  Many compds. have been proven to be very efficient in inhibiting P-gp activity, but only some of them can inhibit MRP1.  However, the clin. results obtained so far by this approach have been rather disappointing.  The other likely approach is based on the design and synthesis of new non-cross-resistant drugs whose physicochem. properties favor the uptake of such drug by resistant cells.  Our recent studies have shown that whereas the P-gp- and MRP1-mediated efflux of different anthracycline-based drugs may not differ considerably, their kinetics of uptake do.  Thus, the high uptake of drug by cells may lead to concns. at the cellular target site high enough to achieve the needed cytotoxicity against MDR cells.  Therefore, increased drug lipophilicity might be one factor in improving drug cytotoxicity in MDR cells.  In vitro studies have shown that idarubicin, an analog of daunorub cin, is more effective than daunorubicin and doxorubicin against MDR tumor cell lines and that this increased effectiveness is related in part to the increased lipophilicity of idarubicin.  Other studies have also confirmed the strong impact of lipophilicity on the uptake and retention of anthracyclines in MDR cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouku4IcN0vOLVg90H21EOLACvtfcHk0ljz9KShfhuhTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVSgsbY%253D&md5=312caa47b349690cdb759a21e9ccf323</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.2174%2F0929867013373967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867013373967%26sid%3Dliteratum%253Aachs%26aulast%3DGarnier-Suillerot%26aufirst%3DA.%26aulast%3DMarbeuf-Gueye%26aufirst%3DC.%26aulast%3DSalerno%26aufirst%3DM.%26aulast%3DLoetchutinat%26aufirst%3DC.%26aulast%3DFokt%26aufirst%3DI.%26aulast%3DKrawczyk%26aufirst%3DM.%26aulast%3DKowalczyk%26aufirst%3DT.%26aulast%3DPriebe%26aufirst%3DW.%26atitle%3DAnalysis%2520of%2520drug%2520transport%2520kinetics%2520in%2520multidrug-resistant%2520cells.%2520Implications%2520for%2520drug%2520action%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2001%26volume%3D8%26spage%3D51%26epage%3D64%26doi%3D10.2174%2F0929867013373967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Pyrrolopyrimidine derivatives and purine analogs as novel activators of multidrug resistance-associated protein 1 (MRP1, ABCC1)</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1859</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.bbamem.2016.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bbamem.2016.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=27810353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKksbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1859&publication_year=2017&pages=69-79&author=S.+M.+Schmittauthor=K.+Stefanauthor=M.+Wiese&title=Pyrrolopyrimidine+derivatives+and+purine+analogs+as+novel+activators+of+multidrug+resistance-associated+protein+1+%28MRP1%2C+ABCC1%29&doi=10.1016%2Fj.bbamem.2016.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1)</span></div><div class="casAuthors">Schmitt, Sven Marcel; Stefan, Katja; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1859</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-79</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) is the main cause of diminished success in cancer chemotherapy.  ABC transport proteins are considered to be one important factor of MDR.  Besides P-glycoprotein (P-gp, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2), Multidrug Resistance-assocd. Protein 1 (MRP1, ABCC1) is assocd. with nonresponse to chemotherapy in different cancers.  While considerable effort was spent in overcoming MDR during the last two decades, almost nothing is known with respect to activators of transport proteins.  In this work the authors present certain pyrrolo[3,2-d]pyrimidine derivs. with variations at positions 4 and 5 and purine analogs with variations at position 6 as novel activators of MRP1-mediated transport of the MRP1 substrate calcein AM and the anticancer drug daunorubicin in low nanomolar concn. range.  Two different MRP1 overexpressing cell lines were used, the doxorubicin-selected human lung cancer cell line H69 AR and the transfected Madin-Darby Canine Kidney cell line MDCK II MRP1.  No effect was obsd. in the sensitive counterparts H69 and MDCK II wild type (wt.).  Derivs. with higher mol. wt. possessed also inhibitory properties at low micromolar concns., although most compds. were rather poor MRP1 inhibitors.  Purine analogs derived from potent MRP1 inhibitors of the pyrrolopyrimidine class showed equal activating, but no inhibiting effects at all.  All tested compds. were nontoxic and had only minor impact on P-gp or BCRP, showing no inhibition or activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiRhn6QKwRzbVg90H21EOLACvtfcHk0ljz9KShfhuhTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKksbvO&md5=f471a639c01cedfac35c1bbbd9e1d2c1</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2016.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2016.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DS.%2BM.%26aulast%3DStefan%26aufirst%3DK.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DPyrrolopyrimidine%2520derivatives%2520and%2520purine%2520analogs%2520as%2520novel%2520activators%2520of%2520multidrug%2520resistance-associated%2520protein%25201%2520%2528MRP1%252C%2520ABCC1%2529%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2017%26volume%3D1859%26spage%3D69%26epage%3D79%26doi%3D10.1016%2Fj.bbamem.2016.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9800"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9800'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit9800"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silbermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juvale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9800/cit9800&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2018.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9800/cit9800&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=30594677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9800/cit9800&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlt1Sh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=193-213&author=K.+Silbermannauthor=C.+P.+Shahauthor=N.+U.+Sahuauthor=K.+Juvaleauthor=S.+M.+Stefanauthor=P.+S.+Kharkarauthor=M.+Wiese&title=Novel+chalcone+and+flavone+derivatives+as+selective+and+dual+inhibitors+of+the+transport+proteins+ABCB1+and+ABCG2&doi=10.1016%2Fj.ejmech.2018.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9800R"><div class="casContent"><span class="casTitleNuber">9800</span><div class="casTitle"><span class="NLM_cas:atitle">Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2</span></div><div class="casAuthors">Silbermann, Katja; Shah, Chetan P.; Sahu, Niteshkumar U.; Juvale, Kapil; Stefan, Sven Marcel; Kharkar, Prashant S.; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">193-213</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">During cancer chemotherapy, certain cancers may become cross-resistant to structurally diverse antineoplastic agents.  This so-called multidrug resistance (MDR) is highly assocd. with the overexpression of ATP-binding cassette (ABC) transport proteins.  These membrane-bound efflux pumps export a broad range of structurally diverse endo- and xenobiotics, including chem. unrelated anticancer agents.  This translocation of drugs from the inside to the outside of cancer cells is mediated at the expense of ATP.  In the last 40 years, three ABC transporters - ABCB1 (P-gp), ABCC1 (MRP1), and ABCG2 (BCRP) - have mainly been attributed to the occurrence of MDR in cancer cells.  One of the strategies to overcome MDR is to inhibit the efflux transporter function by small-mol. inhibitors.  In this work, we investigated new chalcone- and flavone-based compds. for selective as well as broad-spectrum inhibition of the stated transport proteins.  These include substituted chalcones with variations at rings A and B, and flavones with acetamido linker at position 3.  The synthesized mols. were evaluated for their inhibitory potential against ABCB1, ABCC1, and ABCG2 in calcein AM and pheophorbide A assays.  In further investigations with the most promising candidates from each class, we proved that ABCB1- and ABCG2-mediated MDR could be reversed by the compds.  Moreover, their intrinsic toxicity was found to be negligible in most cases.  Altogether, our findings contribute to the understanding of ABC transport proteins and reveal new compds. for ongoing evaluation in the field of ABC transporter-mediated MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm76_aHKScf7Vg90H21EOLACvtfcHk0lgGCS4UQuq_rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlt1Sh&md5=142434225d1c45fc9e8c66ee74606b15</span></div><a href="/servlet/linkout?suffix=cit9800&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DSilbermann%26aufirst%3DK.%26aulast%3DShah%26aufirst%3DC.%2BP.%26aulast%3DSahu%26aufirst%3DN.%2BU.%26aulast%3DJuvale%26aufirst%3DK.%26aulast%3DStefan%26aufirst%3DS.%2BM.%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DNovel%2520chalcone%2520and%2520flavone%2520derivatives%2520as%2520selective%2520and%2520dual%2520inhibitors%2520of%2520the%2520transport%2520proteins%2520ABCB1%2520and%2520ABCG2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D193%26epage%3D213%26doi%3D10.1016%2Fj.ejmech.2018.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kruijtzer, C. M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Bokkel Huinink, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span> <span> </span><span class="NLM_article-title">Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2943</span>– <span class="NLM_lpage">2950</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.12.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1200%2FJCO.2002.12.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=12089223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlslyrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=2943-2950&author=C.+M.+F.+Kruijtzerauthor=J.+H.+Beijnenauthor=H.+Rosingauthor=W.+W.+ten+Bokkel+Huininkauthor=M.+Schotauthor=R.+C.+Jewellauthor=E.+M.+Paulauthor=J.+H.+M.+Schellens&title=Increased+oral+bioavailability+of+topotecan+in+combination+with+the+breast+cancer+resistance+protein+and+P-glycoprotein+inhibitor+GF120918&doi=10.1200%2FJCO.2002.12.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918</span></div><div class="casAuthors">Kruijtzer, C. M. F.; Beijnen, J. H.; Rosing, H.; ten Bokkel Huinink, W. W.; Schot, M.; Jewell, R. C.; Paul, E. M.; Schellens, J. H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2943-2950</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We discovered that breast cancer resistance protein (BCRP), a recently identified ATP-binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(-/-) P-glycoprotein (P-gp) knockout and wild-type mice.  GF120918 is a potent inhibitor of BCRP and P-gp.  The aim was to increase the bioavailability of topotecan by GF120918.  In cohort A, eight patients received 1.0 mg/m2 oral topotecan with or without coadministration of one single oral dose of 1,000 mg GF120918 (day 1 or day 8).  In cohort B, eight other patients received 1.0 mg/m2 i.v. topotecan with or without 1,000 mg oral GF120918 to study the effect of GF120918 on the systemic clearance of topotecan.  After oral topotecan, the mean area under the plasma concn.-time curve (AUC) of total topotecan increased significantly from 32.4±9.6 μg·h/L without GF120918 to 78.7±20.6 μg·h/L when GF120918 was coadministered (P =.008).  The mean max. plasma concn. of total topotecan increased from 4.1±1.5 μg/L without GF120918 to 11.5±2.4 μg/L with GF120918 (P =.008).  The apparent bioavailability in this cohort increased significantly from 40.0% (range, 32% to 47%) to 97.1 % (range, 91 to 120%) (P =.008).  Interpatient variability of the apparent bioavailability was 17% without and 11% with GF120918.  After i.v. administration of topotecan, coadministration of oral GF120918 had a small but statistically significant effect on the AUC and systemic clearance of total topotecan but no statistically significant effect on max. plasma concn. and terminal half-life of total topotecan.  Coadministration of the BCRP and P-gp inhibitor GF120918 resulted in a significant increase of the systemic exposure of oral topotecan.  The apparent oral bioavailability increased from 40.0% without to 97.1 % with GF120918.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRDASB6HJiOrVg90H21EOLACvtfcHk0lgGCS4UQuq_rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlslyrt7w%253D&md5=c9d91c4360028e1d8ab13267d187d6ac</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.12.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.12.116%26sid%3Dliteratum%253Aachs%26aulast%3DKruijtzer%26aufirst%3DC.%2BM.%2BF.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DRosing%26aufirst%3DH.%26aulast%3Dten%2BBokkel%2BHuinink%26aufirst%3DW.%2BW.%26aulast%3DSchot%26aufirst%3DM.%26aulast%3DJewell%26aufirst%3DR.%2BC.%26aulast%3DPaul%26aufirst%3DE.%2BM.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DIncreased%2520oral%2520bioavailability%2520of%2520topotecan%2520in%2520combination%2520with%2520the%2520breast%2520cancer%2520resistance%2520protein%2520and%2520P-glycoprotein%2520inhibitor%2520GF120918%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D2943%26epage%3D2950%26doi%3D10.1200%2FJCO.2002.12.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, N. M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manolaridis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, K. P.</span></span> <span> </span><span class="NLM_article-title">Structure of the human multidrug transporter ABCG2</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">504</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1038/nature22345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fnature22345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=28554189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosFWntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=504-509&author=N.+M.+I.+Taylorauthor=I.+Manolaridisauthor=S.+M.+Jacksonauthor=J.+Kowalauthor=H.+Stahlbergauthor=K.+P.+Locher&title=Structure+of+the+human+multidrug+transporter+ABCG2&doi=10.1038%2Fnature22345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human multidrug transporter ABCG2</span></div><div class="casAuthors">Taylor, Nicholas M. I.; Manolaridis, Ioannis; Jackson, Scott M.; Kowal, Julia; Stahlberg, Henning; Locher, Kaspar P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7659</span>),
    <span class="NLM_cas:pages">504-509</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">ABCG2 is a constitutively expressed ATP-binding cassette (ABC) transporter that protects many tissues against xenobiotic mols.  Its activity affects the pharmacokinetics of commonly used drugs and limits the delivery of therapeutics into tumor cells, thus contributing to multidrug resistance.  Here we present the structure of human ABCG2 detd. by cryo-electron microscopy, providing the first high-resoln. insight into a human multidrug transporter.  We visualize ABCG2 in complex with two antigen-binding fragments of the human-specific, inhibitory antibody 5D3 that recognizes extracellular loops of the transporter.  We observe two cholesterol mols. bound in the multidrug-binding pocket that is located in a central, hydrophobic, inward-facing translocation pathway between the transmembrane domains.  Combined with functional in vitro analyses, our results suggest a multidrug recognition and transport mechanism of ABCG2, rationalize disease-causing single nucleotide polymorphisms (SNP) and the allosteric inhibition by the 5D3 antibody, and provide the structural basis of cholesterol recognition by other G-subfamily ABC transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOlfrPNtVhrVg90H21EOLACvtfcHk0lgGCS4UQuq_rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosFWntbk%253D&md5=a3fd5157f639d2958e5abd996e2a6470</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnature22345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22345%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DN.%2BM.%2BI.%26aulast%3DManolaridis%26aufirst%3DI.%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DKowal%26aufirst%3DJ.%26aulast%3DStahlberg%26aufirst%3DH.%26aulast%3DLocher%26aufirst%3DK.%2BP.%26atitle%3DStructure%2520of%2520the%2520human%2520multidrug%2520transporter%2520ABCG2%26jtitle%3DNature%26date%3D2017%26volume%3D546%26spage%3D504%26epage%3D509%26doi%3D10.1038%2Fnature22345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manolaridis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zechner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, N. M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomaeus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, K. P.</span></span> <span> </span><span class="NLM_article-title">Structural basis of small-molecule inhibition of human multidrug transporter ABCG2</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0049-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fs41594-018-0049-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=29610494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOjsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=333-340&author=S.+M.+Jacksonauthor=I.+Manolaridisauthor=J.+Kowalauthor=M.+Zechnerauthor=N.+M.+I.+Taylorauthor=M.+Bauseauthor=S.+Bauerauthor=R.+Bartholomaeusauthor=G.+Bernhardtauthor=B.+Koenigauthor=A.+Buschauerauthor=H.+Stahlbergauthor=K.-H.+Altmannauthor=K.+P.+Locher&title=Structural+basis+of+small-molecule+inhibition+of+human+multidrug+transporter+ABCG2&doi=10.1038%2Fs41594-018-0049-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of small-molecule inhibition of human multidrug transporter ABCG2</span></div><div class="casAuthors">Jackson, Scott M.; Manolaridis, Ioannis; Kowal, Julia; Zechner, Melanie; Taylor, Nicholas M. I.; Bause, Manuel; Bauer, Stefanie; Bartholomaeus, Ruben; Bernhardt, Guenther; Koenig, Burkhard; Buschauer, Armin; Stahlberg, Henning; Altmann, Karl-Heinz; Locher, Kaspar P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">333-340</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">ABCG2 is an ATP-binding cassette (ABC) transporter that protects tissues against xenobiotics, affects the pharmacokinetics of drugs and contributes to multidrug resistance.  Although many inhibitors and modulators of ABCG2 have been developed, understanding their structure-activity relationship requires high-resoln. structural insight.  Here, we present cryo-EM structures of human ABCG2 bound to synthetic derivs. of the fumitremorgin C-related inhibitor Ko143 or the multidrug resistance modulator tariquidar.  Both compds. are bound to the central, inward-facing cavity of ABCG2, blocking access for substrates and preventing conformational changes required for ATP hydrolysis.  The high resolns. allowed for de novo building of the entire transporter and also revealed tightly bound phospholipids and cholesterol interacting with the lipid-exposed surface of the transmembrane domains (TMDs).  Extensive chem. modifications of the Ko143 scaffold combined with in vitro functional analyses revealed the details of ABCG2 interactions with this compd. family and provide a basis for the design of novel inhibitors and modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJBdcwrlGmAbVg90H21EOLACvtfcHk0ljbsf5LEYImAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOjsr7M&md5=b892ceb7a3ede9784a09c2cc98042d03</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0049-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0049-1%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DManolaridis%26aufirst%3DI.%26aulast%3DKowal%26aufirst%3DJ.%26aulast%3DZechner%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DN.%2BM.%2BI.%26aulast%3DBause%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DBartholomaeus%26aufirst%3DR.%26aulast%3DBernhardt%26aufirst%3DG.%26aulast%3DKoenig%26aufirst%3DB.%26aulast%3DBuschauer%26aufirst%3DA.%26aulast%3DStahlberg%26aufirst%3DH.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DLocher%26aufirst%3DK.%2BP.%26atitle%3DStructural%2520basis%2520of%2520small-molecule%2520inhibition%2520of%2520human%2520multidrug%2520transporter%2520ABCG2%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D333%26epage%3D340%26doi%3D10.1038%2Fs41594-018-0049-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pavek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagenaar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolscher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span> <span> </span><span class="NLM_article-title">Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.073916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1124%2Fjpet.104.073916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=15365089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2005&pages=144-152&author=P.+Pavekauthor=G.+Merinoauthor=E.+Wagenaarauthor=E.+Bolscherauthor=M.+Novotnaauthor=J.+W.+Jonkerauthor=A.+H.+Schinkel&title=Human+breast+cancer+resistance+protein%3A+interactions+with+steroid+drugs%2C+hormones%2C+the+dietary+carcinogen+2-amino-1-methyl-6-phenylimidazo%284%2C5-b%29pyridine%2C+and+transport+of+cimetidine&doi=10.1124%2Fjpet.104.073916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Human breast cancer resistance protein: Interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine</span></div><div class="casAuthors">Pavek, Petr; Merino, Gracia; Wagenaar, Els; Bolscher, Ellen; Novotna, Martina; Jonker, Johan W.; Schinkel, Alfred H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-152</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The breast cancer resistance protein (BCRP/ABCG2) is an ATP-binding cassette drug efflux transporter that extrudes xenotoxins from cells, mediating drug resistance and affecting the pharmacol. behavior of many compds.  To study the interaction of human wild-type BCRP with steroid drugs, hormones, and the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP), we expressed human BCRP in the murine MEF3.8 fibroblast cell line, which lacks Mdr1a/1b P-glycoprotein and Mrp1, and in the polarized epithelial MDCKII cell line.  We show that PhIP was efficiently transported by human BCRP in MDCKII-BCRP cells, as was found previously for murine Bcrp1.  Furthermore, we show that six out of nine glucocorticoid drugs, corticosterone, and digoxin increased the accumulation of mitoxantrone in the MEF3.8-BCRP cell line, indicating inhibition of BCRP.  In contrast, aldosterone and ursodeoxycholic acid had no significant effect on BCRP.  The four most efficiently reversing glucocorticoid drugs (beclomethasone, 6α-methylprednisolone, dexamethasone, and triamcinolone) and 17β-estradiol showed a significantly reduced BCRP-mediated transepithelial transport of PhIP by MDCKII-BCRP cells, with the highest redn. of PhIP transport ratio for beclomethasone (from 25.0±1.1 to 2.7±0.0).  None of the tested endogenous steroids or synthetic glucocorticoids or digoxin, however, were transported substrates of BCRP.  We also identified the H2-receptor antagonist drug cimetidine as a novel efficiently transported substrate for human BCRP and mouse Bcrp1.  The generated BCRP-expressing cell lines thus provide valuable tools to study pharmacol. and toxicol. interactions mediated by BCRP and to identify new BCRP substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxbdxUda3-ErVg90H21EOLACvtfcHk0ljbsf5LEYImAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWmt7c%253D&md5=0f1615781de79b8fa8eaa1e7bc12d617</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.073916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.073916%26sid%3Dliteratum%253Aachs%26aulast%3DPavek%26aufirst%3DP.%26aulast%3DMerino%26aufirst%3DG.%26aulast%3DWagenaar%26aufirst%3DE.%26aulast%3DBolscher%26aufirst%3DE.%26aulast%3DNovotna%26aufirst%3DM.%26aulast%3DJonker%26aufirst%3DJ.%2BW.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26atitle%3DHuman%2520breast%2520cancer%2520resistance%2520protein%253A%2520interactions%2520with%2520steroid%2520drugs%252C%2520hormones%252C%2520the%2520dietary%2520carcinogen%25202-amino-1-methyl-6-phenylimidazo%25284%252C5-b%2529pyridine%252C%2520and%2520transport%2520of%2520cimetidine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D312%26spage%3D144%26epage%3D152%26doi%3D10.1124%2Fjpet.104.073916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Köhler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silbermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Phenyltetrazolyl-phenylamides: substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2016.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=27676469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC2svktFejtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=881-895&author=S.+C.+K%C3%B6hlerauthor=K.+Silbermannauthor=M.+Wiese&title=Phenyltetrazolyl-phenylamides%3A+substituent+impact+on+modulation+capability+and+selectivity+toward+the+efflux+protein+ABCG2+and+investigation+of+interaction+with+the+transporter&doi=10.1016%2Fj.ejmech.2016.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter</span></div><div class="casAuthors">Kohler Sebastian C; Silbermann Katja; Wiese Michael</div><div class="citationInfo"><span class="NLM_cas:title">European journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">881-895</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We recently presented a novel class of ABCG2 modulators based on the third-generation ABCB1 inhibitor tariquidar bearing a 2,5-linked tetrazole instead of an amid linker.  We investigated the modulating potential of the compound class by enlarging the substitution pattern on the outer phenyl rings of the scaffold.  To identify the structural conditions for achieving a high response, we decided to determine the individual influence of substituents on the scaffold using monosubstituted derivatives.  While electron withdrawing groups (with a few exceptions) and bulky moieties decreased the modulating potency, small electron donating groups ensured a high activity level.  Interestingly, the unsubstituted derivative 32 reached a similar inhibitory potential as the best derivatives in the previous study.  Enzyme kinetic assays indicated that our derivatives have the same binding site as reference inhibitor Ko143.  They were found to interact competitively and non-competitively with the substrates Hoechst 33342 and pheophorbide A, respectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKMUV9LEUjjRwLZxei1HN8fW6udTcc2eZltkn3mFYbGbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svktFejtQ%253D%253D&md5=b13d7cae45b24d33faee9720a6ccd781</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6hler%26aufirst%3DS.%2BC.%26aulast%3DSilbermann%26aufirst%3DK.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DPhenyltetrazolyl-phenylamides%253A%2520substituent%2520impact%2520on%2520modulation%2520capability%2520and%2520selectivity%2520toward%2520the%2520efflux%2520protein%2520ABCG2%2520and%2520investigation%2520of%2520interaction%2520with%2520the%2520transporter%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D881%26epage%3D895%26doi%3D10.1016%2Fj.ejmech.2016.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit103"><span> <i>Molecular Operating
Environment (MOE)</i>, version <span class="NLM_edition">2018.01</span>; <span class="NLM_publisher-name">Chemical Computing Group ULC</span> (<span class="NLM_publisher-loc">1010
Sherbooke Street, West, Suite No. 910, Montreal,
QC, H3A 2R7, Canada</span>), <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Molecular+Operating%0AEnvironment+%28MOE%29%2C+version+2018.01%3B+Chemical+Computing+Group+ULC+%281010%0ASherbooke+Street%2C+West%2C+Suite+No.+910%2C+Montreal%2C%0AQC%2C+H3A+2R7%2C+Canada%29%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Operating%250AEnvironment%2520%2528MOE%2529%26pub%3DChemical%2520Computing%2520Group%2520ULC%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit104"><span> <i>LeadIT</i>, version <span class="NLM_edition">2.3.2</span>; <span class="NLM_publisher-name">BioSolveIT GmbH</span>: <span class="NLM_publisher-loc">Sankt Augustin,
Germany</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+LeadIT%2C+version+2.3.2%3B+BioSolveIT+GmbH%3A+Sankt+Augustin%2C%0AGermany%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DLeadIT%26pub%3DBioSolveIT%2520GmbH%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rarey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebe, G.</span></span> <span> </span><span class="NLM_article-title">A fast flexible docking method using an incremental construction algorithm</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1996.0477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1006%2Fjmbi.1996.0477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=8780787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADyaK28XltlKisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1996&pages=470-489&author=M.+Rareyauthor=B.+Kramerauthor=T.+Lengauerauthor=G.+Klebe&title=A+fast+flexible+docking+method+using+an+incremental+construction+algorithm&doi=10.1006%2Fjmbi.1996.0477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">A fast flexible docking method using an incremental construction algorithm</span></div><div class="casAuthors">Rarey, Matthias; Kramer, Bernd; Lengauer, Thomas; Klebe, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">470-489</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">We present an automatic method for docking org. ligands into protein binding sites.  The method can be used in the design process of specific protein ligands.  It combines an appropriate model of the physico-chem. properties of the docked mols. with efficient methods for sampling the conformational space of the ligand.  If the ligand is flexible, it can adopt a large variety of different conformations.  Each such min. in conformational space presents a potential candidate for the conformation of the ligand in the complexed state.  Our docking method samples the conformation space of the ligand on the basis of a discrete model and uses a tree-search technique for placing the ligand incrementally into the active site.  For placing the first fragment of the ligand into the protein, we use hashing techniques adapted from computer vision.  The incremental construction algorithm is based on a greedy strategy combined with efficient methods for overlap detection and for the search of new interactions.  We present results on 19 complexes of which the binding geometry has been crystallog. detd.  All considered ligands are docked in at most three minutes on a current workstation.  The exptl. obsd. binding mode of the ligand is reproduced with 0.5 to 1.2 Å rms deviation.  It is almost always found among the highest-ranking conformations computed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx9N2sFXkOfLVg90H21EOLACvtfcHk0ljCPj9HY0x4hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XltlKisLo%253D&md5=8cd8f384906ed90e894d118399e4dc4a</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1996.0477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1996.0477%26sid%3Dliteratum%253Aachs%26aulast%3DRarey%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3DLengauer%26aufirst%3DT.%26aulast%3DKlebe%26aufirst%3DG.%26atitle%3DA%2520fast%2520flexible%2520docking%2520method%2520using%2520an%2520incremental%2520construction%2520algorithm%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1996%26volume%3D261%26spage%3D470%26epage%3D489%26doi%3D10.1006%2Fjmbi.1996.0477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref9800':['cit9800'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Vigneshwaran Namasivayam, Katja Silbermann, Michael Wiese, Jens Pahnke, <span class="NLM_string-name hlFld-ContribAuthor">Sven Marcel Stefan</span>. </span><span class="cited-content_cbyCitation_article-title"><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="3774776776">[email protected]</a>: Computer-Aided Pattern Analysis to Predict Multitarget ABC Transporter Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 3350-3366. <a href="https://doi.org/10.1021/acs.jmedchem.0c02199" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02199</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02199%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DC%252540PA%25253A%252BComputer-Aided%252BPattern%252BAnalysis%252Bto%252BPredict%252BMultitarget%252BABC%252BTransporter%252BInhibitors%26aulast%3DNamasivayam%26aufirst%3DVigneshwaran%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D20122020%26date%3D16032021%26volume%3D64%26issue%3D6%26spage%3D3350%26epage%3D3366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mehdi  Khalaj</span>, <span class="hlFld-ContribAuthor ">Mahboubeh  Taherkhani</span>, <span class="hlFld-ContribAuthor ">Mehdi  Kalhor</span>. </span><span class="cited-content_cbyCitation_article-title">Preparation of some chromeno[4,3-
              d
              ]pyrido[1,2-
              a
              ]pyrimidine derivatives by ultrasonic irradiation using NiFe
              2
              O
              4
              @SiO
              2
              grafted di(3-propylsulfonic acid) nanoparticles. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2021,</strong> <em>45 </em>
                                    (24)
                                     , 10718-10724. <a href="https://doi.org/10.1039/D1NJ01676H" title="DOI URL">https://doi.org/10.1039/D1NJ01676H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1NJ01676H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1NJ01676H%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DPreparation%252Bof%252Bsome%252Bchromeno%25255B4%25252C3-%252Bd%252B%25255Dpyrido%25255B1%25252C2-%252Ba%252B%25255Dpyrimidine%252Bderivatives%252Bby%252Bultrasonic%252Birradiation%252Busing%252BNiFe%252B2%252BO%252B4%252B%252540SiO%252B2%252Bgrafted%252Bdi%2525283-propylsulfonic%252Bacid%252529%252Bnanoparticles%26aulast%3DKhalaj%26aufirst%3DMehdi%26date%3D2021%26date%3D2021%26volume%3D45%26issue%3D24%26spage%3D10718%26epage%3D10724" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katja  Silbermann</span>, <span class="hlFld-ContribAuthor ">Jiyang  Li</span>, <span class="hlFld-ContribAuthor ">Vigneshwaran  Namasivayam</span>, <span class="hlFld-ContribAuthor ">Sven Marcel  Stefan</span>, <span class="hlFld-ContribAuthor ">Michael  Wiese</span>. </span><span class="cited-content_cbyCitation_article-title">Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>212 </em>, 113045. <a href="https://doi.org/10.1016/j.ejmech.2020.113045" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113045%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252Bdrug%252Bdesign%252Bof%252B6-substituted%252B4-anilino-2-phenylpyrimidines%252Bfor%252Bexploration%252Bof%252Bnovel%252BABCG2%252Bbinding%252Bsite%26aulast%3DSilbermann%26aufirst%3DKatja%26date%3D2021%26volume%3D212%26spage%3D113045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vigneshwaran  Namasivayam</span>, <span class="hlFld-ContribAuthor ">Katja  Silbermann</span>, <span class="hlFld-ContribAuthor ">Jens  Pahnke</span>, <span class="hlFld-ContribAuthor ">Michael  Wiese</span>, <span class="hlFld-ContribAuthor ">Sven Marcel  Stefan</span>. </span><span class="cited-content_cbyCitation_article-title">Scaffold fragmentation and substructure hopping reveal potential, robustness, and limits of computer-aided pattern analysis (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="a4e7e4f4e5">[email protected]</a>). </span><span class="cited-content_cbyCitation_journal-name">Computational and Structural Biotechnology Journal</span><span> <strong>2021,</strong> <em>19 </em>, 3269-3283. <a href="https://doi.org/10.1016/j.csbj.2021.05.018" title="DOI URL">https://doi.org/10.1016/j.csbj.2021.05.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.csbj.2021.05.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.csbj.2021.05.018%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520and%2520Structural%2520Biotechnology%2520Journal%26atitle%3DScaffold%252Bfragmentation%252Band%252Bsubstructure%252Bhopping%252Breveal%252Bpotential%25252C%252Brobustness%25252C%252Band%252Blimits%252Bof%252Bcomputer-aided%252Bpattern%252Banalysis%252B%252528C%252540PA%252529%26aulast%3DNamasivayam%26aufirst%3DVigneshwaran%26date%3D2021%26volume%3D19%26spage%3D3269%26epage%3D3283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katja  Stefan</span>, <span class="hlFld-ContribAuthor ">Lionel Yi  Wen Leck</span>, <span class="hlFld-ContribAuthor ">Vigneshwaran  Namasivayam</span>, <span class="hlFld-ContribAuthor ">Pablo  Bascuñana</span>, <span class="hlFld-ContribAuthor ">Michael Li-Hsuan  Huang</span>, <span class="hlFld-ContribAuthor ">Patrick Johannes  Riss</span>, <span class="hlFld-ContribAuthor ">Jens  Pahnke</span>, <span class="hlFld-ContribAuthor ">Patric Jan  Jansson</span>, <span class="hlFld-ContribAuthor ">Sven Marcel  Stefan</span>. </span><span class="cited-content_cbyCitation_article-title">Vesicular ATP-binding cassette transporters in human disease: relevant aspects of their organization for future drug development. </span><span class="cited-content_cbyCitation_journal-name">Future Drug Discovery</span><span> <strong>2020,</strong> <em>2 </em>
                                    (4)
                                     , FDD51. <a href="https://doi.org/10.4155/fdd-2020-0025" title="DOI URL">https://doi.org/10.4155/fdd-2020-0025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fdd-2020-0025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffdd-2020-0025%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Drug%2520Discovery%26atitle%3DVesicular%252BATP-binding%252Bcassette%252Btransporters%252Bin%252Bhuman%252Bdisease%25253A%252Brelevant%252Baspects%252Bof%252Btheir%252Borganization%252Bfor%252Bfuture%252Bdrug%252Bdevelopment%26aulast%3DStefan%26aufirst%3DKatja%26date%3D2020%26volume%3D2%26issue%3D4%26spage%3DFDD51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Compound <b>1</b> and its derivatives commonly used in second-line anticancer regimens.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Depiction of inhibitor- and MDR reverser-development regarding ABCG2-mediated drug transport: compound <b>5</b>, the very first TKI associated with inhibition of ABCG2 and reversal of ABCG2-mediated compound <b>1</b> analog resistance;<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> compound <b>6</b>, the most active TKI regarding MDR reversal against compound <b>2</b> in ABCG2-overexpressing cells (EC<sub>50</sub> ≈ 65 nM);<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> compound <b>7</b>, one of the first reported HTS-derived quinazolines as ABCG2 inhibitors;<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a> compound <b>8</b>, exceptional representative of a triple ABCB1/ABCC1/ABCG2 inhibitor;<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> compound <b>9</b>, one of the most potent ABCG2-mediated MDR reversers known until today (EC<sub>50</sub> = 12.7 nM);<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> compound <b>10</b>, one of only seven synthesized pyrimidine derivatives as ABCG2 inhibitors.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Reported triple reversers of ABCB1-, ABCC1-, and ABCG2-mediated MDR that proved to exert their effect due to inhibition of ABCB1, ABCC1, and ABCG2: 9-deazapurine 55 (<b>11</b>)<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> and thienopyrimidine 14 (<b>12</b>).<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0016.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis of 4-Anilino-6-methyl-2-phenylpyrimidine Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaOEt/EtOH, reflux, overnight; (b) POCl<sub>3</sub> reflux, 8–9 h; (c) <i>i</i>-PrOH, microwave, 110 °C, 30 min.</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Concentration–effect curves of compound <b>22</b> (■, IC<sub>50</sub> = 0.0522 μM) in comparison to reference inhibitor <b>41</b> (●, IC<sub>50</sub> = 0.220 μM) in the Hoechst 33342 assay. (B) Concentration–effect curves of compound <b>30</b> (■, IC<sub>50</sub> = 0.0594 μM) in comparison to reference inhibitor <b>41</b> (●, IC<sub>50</sub> = 0.274 μM) in the pheophorbide A assay. Shown is the mean ± SEM of at least three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibitory effect of screened compounds at 10 μM against ABCB1 using the ABCB1-overexpressing cell line A2780/ADR (A) and ABCC1 using the ABCC1-overexpressing cell line MDCK II MRP1 (B) applying a calcein AM assay. Data were normalized by defining the effect of 10 μM cyclosporine A as positive control (100%) and buffer medium as negative control (0%). Shown is the mean ± SEM of at least three independent experiments with duplicate measurements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) MDR reversal assay obtained in a MTT-based cell viability assay for compound <b>19</b>. The curves show sensitization of ABCG2-overexpressing MDCK II BCRP cells with regard to compound <b>4</b>. Compound <b>19</b> was used at concentrations of 0 μM (●), 0.001 μM (■), 0.010 μM (▲), 0.100 μM (▼), and 1.000 μM (◆) and was compared to the wild type cell line without compound addition (○). Shown is the mean ± SEM of at least three independent experiments with duplicate measurements. (B) Calculated resistance factors derived from GI<sub>50</sub> values of graph (A) were plotted against the used concentrations of compound <b>19</b>. A nonlinear regression of the obtained curve yielded an EC<sub>50</sub> of 11 nM. Shown is the mean ± SEM of at least three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Time-dependent MDR reversal assay using a MTT-based approach. (A, B) Compound <b>19</b> was used at a concentration of 10 nM and was combined with 0.5 μM compound <b>4</b> over a period of 7 days. Shown is the mean ± SEM of at least three independent experiments with triplicate measurements. (A) Normalization was conducted on the effect-value of cells in pure cell culture medium without addition of compound <b>4</b> and/or compound <b>19</b>. (B) Normalization was conducted on the effect-value of compound <b>4</b> alone at the corresponding day. Significance was calculated applying multiple <i>t</i>-test and is given as the following: ∗, <i>p</i> ≤ 0.05; ∗∗, <i>p</i> ≤ 0.01; ∗∗∗, <i>p</i> ≤ 0.001; ∗∗∗∗, <i>p</i> ≤ 0.0001. (C) Cell viability versus time assay using 0.5 μM compound <b>4</b> and 0 nM (●), 10 nM (■), 25 nM (▲), 50 nM (▼) compound <b>19</b>. Shown is the mean ± SEM of at least three independent experiments with triplicate measurements. (D) The inflection points derived from the curves in graphic (C) have been plotted against the used concentration of compound <b>19</b>. Nonlinear regression revealed that when using 0.5 μM compound <b>4</b> in combination with compound <b>19</b>, the latter is able to accelerate half-maximal cell death by a factor of 1.7 (∼4.25 days vs ∼7.25 days). The half-maximal cell death acceleration concentration of compound <b>19</b> was ∼17.25 nM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Sensitization of ABCB1-overexpressing A2780/ADR cells against daunorubicin by compound <b>37</b> at concentrations of 0 μM (●), 0.5 μM (■), 1.0 μM (▲), 5.0 μM (▼), and 10 μM (◆) compared to the wild type cell line A2780 (○). (B) Resulting resistance factors derived from GI<sub>50</sub> values of graph (A) were plotted against the used concentrations of compound <b>37</b>. A nonlinear regression of the obtained curve yielded an EC<sub>50</sub> of 8.41 μM. (C) Sensitization of ABCC1-overexpressing MDCK II MRP1 cells against daunorubicin by compound <b>37</b> at concentrations of 0 μM (●), 0.5 μM (■), 1.0 μM (▲), 5.0 μM (▼), and 10 μM (◆) compared to the wild type cell line MDCK II (○). (D) Resulting resistance factors derived from GI<sub>50</sub> of graph (C) were plotted against the used concentrations of compound <b>37</b>. A nonlinear regression of the obtained curve yielded an EC<sub>50</sub> of 5.15 μM. (E) Sensitization of ABCG2-overexpressing MDCK II BCRP cells against compound <b>4</b> by compound <b>37</b> at concentrations of 0 μM (●), 0.001 μM (■), 0.010 μM (▲), 0.100 μM (▼), and 1.000 μM (◆) compared to the wild type cell line MDCK II (○). (F) Resulting resistance factors derived from GI<sub>50</sub> of graph (E) were plotted against the used concentrations of compound <b>37</b>. A nonlinear regression of the obtained curve yielded an EC<sub>50</sub> of 0.0164 μM. In all cases, the mean ± SEM of at least three independent experiments with duplicate measurements is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Bar chart showing the influence of the studied compounds (10 μM) on the cell viability of MDCK II BCRP (black) and MDCK II wild type (gray) cells. The data were obtained by a MTT-based assay defining culture medium as negative control (100%) and 10% DMSO as positive control (0%). Shown is the mean ± SEM of at least three independent experiments with duplicate measurements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0010.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. MTT-based viability assays of compounds <b>29</b> (■) and <b>36</b> (●) using the MDCK II BCRP (closed) and wild type (open) cells. 10% DMSO and culture medium were used to define 0 and 100%, respectively. Shown is the mean ± SEM of at least three independent experiments with duplicate measurements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0011.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Confocal laser scanning microscopy analysis of accumulation of fluorescent compound <b>38</b> (A, B) or pheophorbide A (C, D, E) in ABCG2-overexpressing MCF-7/MX (A, C, E) or parental MCF-7 (B, D) cells: (A) compound <b>38</b> (1 μM) in ABCG2-overexpressing MCF-7/MX cells; (B) compound <b>38</b> (1 μM) in parental MCF-7 cells; (C) pheophorbide A (0.5 μM) in ABCG2-overexpressing MCF-7/MX cells; (D) pheophorbide A (0.5 μM) in parental MCF-7 cells; (E) pheophorbide A (0.5 μM) in the presence of compound <b>38</b> (1 μM) in ABCG2-overexpressing MCF-7/MX cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0012.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Determination of mode of inhibition by compound <b>19</b> using ABCG2-overexpressing MDCK II BCRP cells. (A) Lineweaver–Burk plot of ABCG2-mediated Hoechst 33342 transport at concentrations of 0.3, 0.4, 0.5, 0.6, 0.7, and 1.0 μM. Compound <b>19</b> was used at concentrations of 0 μM (○), 0.056 μM (●), 0.100 μM (■), 0.316 μM (▲), and 1.000 μM (▼). (B) Cornish–Bowden plot generated from direct plot of data, in which <i>K</i><sub>m</sub> (●) increases while <i>v</i><sub>max</sub> (■) remains constant. Depicted are representative experiments out of three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0013.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Binding sites (A) and poses of MZ29 (B) as well as Hoechst 33342 (C) in human ABCG2, which is displayed in cartoon representation (chain A: light gray; chain B: dark gray). Both MZ29 (A) and Hoechst 33342 (B) are shown as stick models. (A) The putative binding sites obtained from the cryo-EM structure of human ABCG2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FFC">6FFC</a>) are schematically indicated as S1 and S2. (B) Binding pose of MZ29, an analog of compound <b>41</b> (carbon colored green) in the binding pocket of human ABCG2. (C) Docked pose of the ABCG2 substrate Hoechst 33342 (carbon colored magenta) in the binding pocket of human ABCG2. Oxygen atoms are colored in red and nitrogen atoms in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0014.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Putative binding poses of compound <b>19</b>: (A) top 100 docked poses of <b>19</b> (carbon colored cyan) observed in the cryo-EM structure of human ABCG2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FFC">6FFC</a>). (B) best scoring pose of <b>19</b> in the S2 binding site. (C) 2D interaction diagram. Oxygen atoms are colored in red and nitrogen atoms in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/medium/jm0c00961_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0015.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Western blot analysis of ABCG2 protein expression in MDCK II BCRP cells exposed to compound <b>19</b> (10 nM) and/or compound <b>4</b> (0.5 μM) for 4 (left) and 7 days (right), respectively. Bands were normalized by stain-free total protein normalization and related to each untreated control sample. Shown is the mean ± SEM of at least three independent experiments. Significance was calculated by applying one-sample <i>t</i>-test and is given as the following: ∗, <i>p</i> ≤ 0.05; ∗∗, <i>p</i> ≤ 0.01; ∗∗∗, <i>p</i> ≤ 0.001; ∗∗∗∗, <i>p</i> ≤ 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-18/acs.jmedchem.0c00961/20200918/images/large/jm0c00961_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00961&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i69">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62356" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62356" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 106 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stavrovskaya, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybalkina, E. Y.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the studies of molecular mechanisms regulating multidrug resistance in cancer cells</span>. <i>Biochemistry (Moscow)</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1134/S0006297918070015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1134%2FS0006297918070015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=30200862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlamtbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2018&pages=779-786&author=A.+A.+Stavrovskayaauthor=E.+Y.+Rybalkina&title=Recent+advances+in+the+studies+of+molecular+mechanisms+regulating+multidrug+resistance+in+cancer+cells&doi=10.1134%2FS0006297918070015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Studies of Molecular Mechanisms Regulating Multidrug Resistance in Cancer Cells</span></div><div class="casAuthors">Stavrovskaya, A. A.; Rybalkina, E. Yu.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry (Moscow)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">779-786</span>CODEN:
                <span class="NLM_cas:coden">BIORAK</span>;
        ISSN:<span class="NLM_cas:issn">0006-2979</span>.
    
            (<span class="NLM_cas:orgname">Pleiades Publishing, Ltd.</span>)
        </div><div class="casAbstract">Abstr.-Here we present new approaches to better understanding multidrug resistance (MDR) development in cancer cells, such as identification of components of a complex process of MDR evolution.  Recent advances in the studies of MDR are discussed: 1) chemotherapy agents might be involved in the selection of cancer stem cells resulting in the elevated drug resistance and enhanced tumorigenicity; 2) cell-cell interactions have a great effect on the MDR emergence and evolution; 3) mechanotransduction is an important signaling mechanism in cell-cell interactions; 4) proteins of the ABC transporter family which are often involved in MDR might be transferred between cells via microvesicles (epigenetic MDR regulation); 5) proteins providing cell-to-cell transfer of functional P-glycoprotein (MDR1 protein) via microvesicles have been investigated; 6) P-glycoprotein may serve to regulate apoptosis, as well as transcription and translation of target genes/proteins.  Although proving once again that MDR is a complex multi-faceted process, these data open new approaches to overcoming it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMeoL1idltcbVg90H21EOLACvtfcHk0liM-S6dxtZWcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlamtbnN&md5=1ba527d30126b6c7eb86093371f4bf34</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1134%2FS0006297918070015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1134%252FS0006297918070015%26sid%3Dliteratum%253Aachs%26aulast%3DStavrovskaya%26aufirst%3DA.%2BA.%26aulast%3DRybalkina%26aufirst%3DE.%2BY.%26atitle%3DRecent%2520advances%2520in%2520the%2520studies%2520of%2520molecular%2520mechanisms%2520regulating%2520multidrug%2520resistance%2520in%2520cancer%2520cells%26jtitle%3DBiochemistry%2520%2528Moscow%2529%26date%3D2018%26volume%3D83%26spage%3D779%26epage%3D786%26doi%3D10.1134%2FS0006297918070015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Triller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korosec, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosnik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debeljak, A.</span></span> <span> </span><span class="NLM_article-title">Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2006.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.lungcan.2006.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=16934363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BD28ros1Shsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2006&pages=235-240&author=N.+Trillerauthor=P.+Korosecauthor=I.+Kernauthor=M.+Kosnikauthor=A.+Debeljak&title=Multidrug+resistance+in+small+cell+lung+cancer%3A+expression+of+P-glycoprotein%2C+multidrug+resistance+protein+1+and+lung+resistance+protein+in+chemo-naive+patients+and+in+relapsed+disease&doi=10.1016%2Fj.lungcan.2006.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease</span></div><div class="casAuthors">Triller Nadja; Korosec Peter; Kern Izidor; Kosnik Mitja; Debeljak Andrej</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">235-40</span>
        ISSN:<span class="NLM_cas:issn">0169-5002</span>.
    </div><div class="casAbstract">The aim of this study was to investigate the expression of multidrug resistance-associated proteins in metastatic small cell lung cancer (SCLC) cells correlated to cisplatin/etoposide chemotherapy response and the level of those proteins in relapsed disease.  Samples were obtained by transbronchial fine needle aspiration biopsy (TBNA) of enlarged mediastinal lymph nodes in 17 patients.  After cytological confirmation of SCLC, cells were stained by a panel of mAbs against internal epitopes of P-gp (JSB-1), MRP1 (MRPr1), LRP (LRP-56) and cytokeratin (MNF116) and analyzed by flow cytometry.  We observed a significant negative correlation for better response rate to chemotherapy with individual expression of P-gp (r=-0.93, P<0.0001; Pearson correlation) and MRP1 (r=-0.78, P=0.0002; Pearson correlation) in chemo-naive SCLC cells and a non-significant correlation for LRP expression.  P-gp and MRP1 expression was markedly increased in metastatic cells in four out of five patients with relapsed disease (4-12 months after starting chemotherapy), in comparison to their chemo-naive values.  In conclusion, the results suggest that P-gp and MRP1 might be associated with SCLC cell survival during metastasis and chemotherapy, and that overexpression of those transporters in relapsed disease could assist short-term chemotherapy efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ8V0qFoinzNzC850By6mxpfW6udTcc2eYpY0Y1jUzThrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28ros1Shsw%253D%253D&md5=94ddf42d81411857b149e3def0578cb7</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2006.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2006.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DTriller%26aufirst%3DN.%26aulast%3DKorosec%26aufirst%3DP.%26aulast%3DKern%26aufirst%3DI.%26aulast%3DKosnik%26aufirst%3DM.%26aulast%3DDebeljak%26aufirst%3DA.%26atitle%3DMultidrug%2520resistance%2520in%2520small%2520cell%2520lung%2520cancer%253A%2520expression%2520of%2520P-glycoprotein%252C%2520multidrug%2520resistance%2520protein%25201%2520and%2520lung%2520resistance%2520protein%2520in%2520chemo-naive%2520patients%2520and%2520in%2520relapsed%2520disease%26jtitle%3DLung%2520Cancer%26date%3D2006%26volume%3D54%26spage%3D235%26epage%3D240%26doi%3D10.1016%2Fj.lungcan.2006.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sedlakova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caltova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervinka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tosner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezac, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spacek, J.</span></span> <span> </span><span class="NLM_article-title">Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer</span>. <i>Int. J. Gynecol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1097/IGC.0000000000000354</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1097%2FIGC.0000000000000354" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25594141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC2MvmvVansA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=236-243&author=I.+Sedlakovaauthor=J.+Lacoauthor=K.+Caltovaauthor=M.+Cervinkaauthor=J.+Tosnerauthor=A.+Rezacauthor=J.+Spacek&title=Clinical+significance+of+the+resistance+proteins+LRP%2C+Pgp%2C+MRP1%2C+MRP3%2C+and+MRP5+in+epithelial+ovarian+cancer&doi=10.1097%2FIGC.0000000000000354"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer</span></div><div class="casAuthors">Sedlakova Iva; Laco Jan; Caltova Katerina; Cervinka Miroslav; Tosner Jindrich; Rezac Adam; Spacek Jiri</div><div class="citationInfo"><span class="NLM_cas:title">International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study aimed to evaluate the correlation between the expressions of lung resistance protein (LRP), P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP)-1, MRP3, and MRP5 and histopathological parameters and clinical outcome, and to determine the predictive and prognostic value of these transport proteins in patients with ovarian cancer.  METHODS:  Tumor samples from 111 chemonaive patients with epithelial ovarian cancer who underwent primary surgery from 2006 to 2010 were immunohistochemically stained for LRP, Pgp, MRP1, MRP3, and MRP5 expressions.  RESULTS:  MRP1 expression was greater among patients with late disease than among patients with early stage ovarian cancer [International Federation of Gynecology and Obstetrics (FIGO) I + II, 71.6% (confidence interval, 60-100); FIGO III + IV, 83.6% (confidence interval, 100-100); P = 0.03].  The histological subtype correlated with the expressions of LRP, Pgp, MRP1, and MRP3.  Relapse of disease during the next 24 months occurred more often among patients with higher Pgp and MRP1 than among patients with lower Pgp and MRP1 expressions.  FIGO stage, histological type, debulking efficiency, strong Pgp expression, and strong MRP1 expression correlated significantly with shorter progression-free survival (log-rank test, P = 0.001, P = 0.004, P = 0.001, P = 0.051, and P = 0.046, respectively).  FIGO stage, histological type, debulking efficiency, and strong MRP1 expression correlated with poor patient survival (log-rank test, P = 0.001, P = 0.042, P = 0.005, and P = 0.018, respectively).  CONCLUSIONS:  Pgp and MRP1 expressions were clinically significant in patients with ovarian cancer.  Pgp and MRP1 may be reliable, independent predictive and prognostic factors regarding the clinical outcome of ovarian cancer.  MRP3 is less important as a predictive and prognostic factor than MRP1 expression.  MRP5 and LRP expressions were not applicable prognostic parameters regarding ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRloUC4h7yBUUH3Rlp_k91zfW6udTcc2ebeM_T7SXpnxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvmvVansA%253D%253D&md5=e321a5e3d73ded729f1b07504a615f30</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1097%2FIGC.0000000000000354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FIGC.0000000000000354%26sid%3Dliteratum%253Aachs%26aulast%3DSedlakova%26aufirst%3DI.%26aulast%3DLaco%26aufirst%3DJ.%26aulast%3DCaltova%26aufirst%3DK.%26aulast%3DCervinka%26aufirst%3DM.%26aulast%3DTosner%26aufirst%3DJ.%26aulast%3DRezac%26aufirst%3DA.%26aulast%3DSpacek%26aufirst%3DJ.%26atitle%3DClinical%2520significance%2520of%2520the%2520resistance%2520proteins%2520LRP%252C%2520Pgp%252C%2520MRP1%252C%2520MRP3%252C%2520and%2520MRP5%2520in%2520epithelial%2520ovarian%2520cancer%26jtitle%3DInt.%2520J.%2520Gynecol.%2520Cancer%26date%3D2015%26volume%3D25%26spage%3D236%26epage%3D243%26doi%3D10.1097%2FIGC.0000000000000354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, P.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pen, X.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.-H.</span></span> <span> </span><span class="NLM_article-title">Analysis of drug resistance-associated proteins expressions of patients with the recurrent of acute leukemia via protein microarray technology</span>. <i>Eur. Rev. Med. Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">537</span>– <span class="NLM_lpage">543</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=24615181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC2crhsl2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2014&pages=537-543&author=D.-F.+Zengauthor=J.+Zhangauthor=L.-D.+Zhuauthor=P.-Y.+Kongauthor=J.-P.+Liauthor=X.+Zhangauthor=W.+Xuauthor=J.-L.+Wangauthor=X.-G.+Penauthor=P.+Wangauthor=S.-H.+Liu&title=Analysis+of+drug+resistance-associated+proteins+expressions+of+patients+with+the+recurrent+of+acute+leukemia+via+protein+microarray+technology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of drug resistance-associated proteins expressions of patients with the recurrent of acute leukemia via protein microarray technology</span></div><div class="casAuthors">Zeng D-F; Zhang J; Zhu L-D; Kong P-Y; Li J-P; Zhang X; Xu W; Wang J-L; Pen X-G; Wang P; Liu S-H</div><div class="citationInfo"><span class="NLM_cas:title">European review for medical and pharmacological sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">537-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  To detect the expressions of drug-resistance related proteins in bone marrow mononuclear cells of acute leukemia (AL) patients using protein microarray and to analyze the clinical value of protein microarray in predicting prognosis of AL patients.  PATIENTS AND METHODS:  A total of 48 AL patients received chemotherapy were divided into four groups: recurrent acute myeloid leukemia group (R-AML; n=15); AML continue remission group (AML-CR; n = 13); recurrent acute lymphocytic leukemia group (R-ALL; n=13); and ALL-CR group (n=7).  Fifteen age-matched patients with non-hematologic disease were used as controls.  RESULTS:  Expression levels of P-gp, LRP/MVP, BCL-2, GST-π, PCNA, CXCR4 were increased significantly in both AML-R and ALL-R groups (p < 0.05).  Besides, LFA-1 and TRAIL-R were also up-expressed significantly in ALL-R group (p < 0.05).  In addition, the levels of P-gp, GST-π expressed in AML-R group were higher than those in AML-CR group (p < 0.05) and P-gp, LRP/MVP, GST-π, LFA-1 and CXCR4 in ALL-R were expressed higher than those in ALL-CR group (p < 0.05).  CONCLUSIONS:  The recurrent of AL were related closely to the over expression of drug resistance-related proteins.  Protein microarray can be used in the prediction of AL recurrence and would be beneficial in guiding individual therapy and patient prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSC-_lB5JAgGOqrn-c4Of3KfW6udTcc2ebeM_T7SXpnxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crhsl2jsg%253D%253D&md5=1a92d313e7934696a5a3d4e9258d0d46</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DD.-F.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DL.-D.%26aulast%3DKong%26aufirst%3DP.-Y.%26aulast%3DLi%26aufirst%3DJ.-P.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DJ.-L.%26aulast%3DPen%26aufirst%3DX.-G.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DS.-H.%26atitle%3DAnalysis%2520of%2520drug%2520resistance-associated%2520proteins%2520expressions%2520of%2520patients%2520with%2520the%2520recurrent%2520of%2520acute%2520leukemia%2520via%2520protein%2520microarray%2520technology%26jtitle%3DEur.%2520Rev.%2520Med.%2520Pharmacol.%2520Sci.%26date%3D2014%26volume%3D18%26spage%3D537%26epage%3D543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spier, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matzner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, W. S.</span></span> <span> </span><span class="NLM_article-title">P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">490</span>– <span class="NLM_lpage">495</span>, <span class="refDoi"> DOI: 10.1182/blood.V81.2.490.490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1182%2Fblood.V81.2.490.490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=8093668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADyaK3s7js1Cguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1993&pages=490-495&author=T.+M.+Groganauthor=C.+M.+Spierauthor=S.+E.+Salmonauthor=M.+Matznerauthor=J.+Rybskiauthor=R.+S.+Weinsteinauthor=R.+J.+Scheperauthor=W.+S.+Dalton&title=P-glycoprotein+expression+in+human+plasma+cell+myeloma%3A+correlation+with+prior+chemotherapy&doi=10.1182%2Fblood.V81.2.490.490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy</span></div><div class="casAuthors">Grogan T M; Spier C M; Salmon S E; Matzner M; Rybski J; Weinstein R S; Scheper R J; Dalton W S</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">490-5</span>
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    </div><div class="casAbstract">Multidrug-resistant (MDR) myeloma patients failing chemotherapy may express P-glycoprotein (PGP), which serves as an efflux pump protecting the neoplastic cells.  Unknown is whether PGP expression might relate to prior cytotoxic drug exposure.  To address this question, we studied 106 consecutive bone marrow samples from 104 myeloma patients with samples studied either before or after therapy and at the time of relapse.  We performed an established immunocytochemical assay of PGP using an MDR-1-specific monoclonal antibody and correlated PGP status with prior chemotherapy dosage.  Myeloma patients with no prior therapy had a low incidence of PGP expression (6%, 3/47), whereas those receiving chemotherapy had a significantly higher incidence (43%, 21/49) (P < .0001).  A substantially higher incidence of PGP expression (50%, 83%, respectively) occurred when the total vincristine dose exceeded 20 mg and when doxorubicin exceeded 340 mg.  In the 11 patients who received both high vincristine and doxorubicin dosages (> 20 mg, > 340 mg total dose) there was 100% incidence of PGP expression in the tumor cells.  These data provided the basis for a predictive mathematical model from which dose-related PGP expression normograms were generated.  Time with myeloma for PGP-negative patients (mean 33 months) had overlapping confidence limits with PGP-positive patients (mean 42 months), suggesting that disease duration was not a significant variable.  PGP expression did not correlate with other clinical factors or immunophenotypic factors.  Our findings indicate a strong correlation between PGP expression in myeloma and past chemotherapy in myeloma, in particular, related to prior exposure to the natural product agents vincristine and doxorubicin.  Additionally, the proportion of PGP-positive plasma cells was significantly higher in the doxorubicin-treated patients than the nondoxorubicin-treated patients (87.7% v 65.17%; P = .013).  Combined high vincristine and doxorubicin total dosage appear highly predictive of PGP expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJCAe_N__UvMSzjBFCN0BJfW6udTcc2ebeM_T7SXpnxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s7js1Cguw%253D%253D&md5=5a29133423a74402e938706923c94f35</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1182%2Fblood.V81.2.490.490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V81.2.490.490%26sid%3Dliteratum%253Aachs%26aulast%3DGrogan%26aufirst%3DT.%2BM.%26aulast%3DSpier%26aufirst%3DC.%2BM.%26aulast%3DSalmon%26aufirst%3DS.%2BE.%26aulast%3DMatzner%26aufirst%3DM.%26aulast%3DRybski%26aufirst%3DJ.%26aulast%3DWeinstein%26aufirst%3DR.%2BS.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DDalton%26aufirst%3DW.%2BS.%26atitle%3DP-glycoprotein%2520expression%2520in%2520human%2520plasma%2520cell%2520myeloma%253A%2520correlation%2520with%2520prior%2520chemotherapy%26jtitle%3DBlood%26date%3D1993%26volume%3D81%26spage%3D490%26epage%3D495%26doi%3D10.1182%2Fblood.V81.2.490.490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sell, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zintl, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerbrey, A.</span></span> <span> </span><span class="NLM_article-title">BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1443</span>– <span class="NLM_lpage">1447</span>, <span class="refDoi"> DOI: 10.1038/sj.leu.2402541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fsj.leu.2402541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=12145683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1Wqs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2002&pages=1443-1447&author=D.+Steinbachauthor=W.+Sellauthor=A.+Voigtauthor=J.+Hermannauthor=F.+Zintlauthor=A.+Sauerbrey&title=BCRP+gene+expression+is+associated+with+a+poor+response+to+remission+induction+therapy+in+childhood+acute+myeloid+leukemia&doi=10.1038%2Fsj.leu.2402541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia</span></div><div class="casAuthors">Steinbach, D.; Sell, W.; Voigt, A.; Hermann, J.; Zintl, F.; Sauerbrey, A.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1443-1447</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Breast cancer resistance protein (BCRP), also known as mitoxantrone resistance protein (MRX) or placenta ABC protein (ABC-P), is the second member of the ABCG subfamily of ABC transport proteins (gene symbol ABCG2).  Transfection and enforced expression of BCRP in drug-sensitive cells confers resistance to mitoxantrone, doxorubicin, daunorubicin and topotecan.  In this study the expression of BCRP gene was measured using TaqMan real-time PCR in 59 children with newly diagnosed AML.  Nine patients were also analyzed in relapse.  The median of BCRP gene expression was more than 10 times higher in patients who did not achieve remission after the first phase of chemotherapy (n = 24) as compared to patients who did achieve remission at this stage (n = 21; P = 0.012).  In first relapse the expression of the BCRP gene was higher than at diagnosis (P = 0.038).  Although high levels of BCRP gene expression were more frequent in subtypes of AML with a favorable prognosis, we found that within both risk groups (high and low risk), patients who expressed high levels of BCRP had a worse prognosis (P = 0.023).  Our results strongly suggest that the expression of the BCRP gene reduces the response to chemotherapy in AML and that BCRP expression is higher at the time of relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYUOHDoO_UbLVg90H21EOLACvtfcHk0ljc28XWi56T3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1Wqs7c%253D&md5=019751e7474b806321731eaea698786f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2402541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2402541%26sid%3Dliteratum%253Aachs%26aulast%3DSteinbach%26aufirst%3DD.%26aulast%3DSell%26aufirst%3DW.%26aulast%3DVoigt%26aufirst%3DA.%26aulast%3DHermann%26aufirst%3DJ.%26aulast%3DZintl%26aufirst%3DF.%26aulast%3DSauerbrey%26aufirst%3DA.%26atitle%3DBCRP%2520gene%2520expression%2520is%2520associated%2520with%2520a%2520poor%2520response%2520to%2520remission%2520induction%2520therapy%2520in%2520childhood%2520acute%2520myeloid%2520leukemia%26jtitle%3DLeukemia%26date%3D2002%26volume%3D16%26spage%3D1443%26epage%3D1447%26doi%3D10.1038%2Fsj.leu.2402541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Damiani, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tribelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calistri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geromin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarvesio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelutti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanin, R.</span></span> <span> </span><span class="NLM_article-title">The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">825</span>– <span class="NLM_lpage">828</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=16704962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD28XntF2jtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2006&pages=825-828&author=D.+Damianiauthor=M.+Tribelliauthor=E.+Calistriauthor=A.+Gerominauthor=A.+Chiarvesioauthor=A.+Micheluttiauthor=M.+Cavallinauthor=R.+Fanin&title=The+prognostic+value+of+P-glycoprotein+%28ABCB%29+and+breast+cancer+resistance+protein+%28ABCG2%29+in+adults+with+de+novo+acute+myeloid+leukemia+with+normal+karyotype"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype</span></div><div class="casAuthors">Damiani, Daniela; Tiribelli, Mario; Calistri, Elisabetta; Geromin, Antonella; Chiarvesio, Alexsia; Michelutti, Angela; Cavallin, Margherita; Fanin, Renato</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">825-828</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">0390-6078</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Multidrug resistance is a major cause of treatment failure in acute myeloid leukemia (AML).  P-glycoprotein (PGP) over-expression has an unfavorable prognostic significance, while the role of breast cancer resistance protein (BCRP) is less clear, esp. in AML patients with a normal karyotype.  We studied 73 consecutive AML patients with a normal karyotype.  BCRP was over-expressed in 24 patients (33%) and was significantly co-expressed with PGP (13/24 vs 11/49, p=0.006) and with CD56.  Only PGP, along with age and CD34, affected the achievement of complete remission (p=0.02), while BCRP-pos. cases showed an increased risk of relapse (p=0.005) and a shorter disease-free survival (p=0.027).  BCRP over-expression did not influence the achievement of remission, but significantly affected the duration of complete remissions.  BCRP may, therefore, be regarded as a prognostic factor in patients with normal karyotype AML, for the design of risk-adapted post-remission therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWiSxJTSBaMbVg90H21EOLACvtfcHk0ljc28XWi56T3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntF2jtb4%253D&md5=4b2f18005b2632f631525de2981b8578</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDamiani%26aufirst%3DD.%26aulast%3DTribelli%26aufirst%3DM.%26aulast%3DCalistri%26aufirst%3DE.%26aulast%3DGeromin%26aufirst%3DA.%26aulast%3DChiarvesio%26aufirst%3DA.%26aulast%3DMichelutti%26aufirst%3DA.%26aulast%3DCavallin%26aufirst%3DM.%26aulast%3DFanin%26aufirst%3DR.%26atitle%3DThe%2520prognostic%2520value%2520of%2520P-glycoprotein%2520%2528ABCB%2529%2520and%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%2520in%2520adults%2520with%2520de%2520novo%2520acute%2520myeloid%2520leukemia%2520with%2520normal%2520karyotype%26jtitle%3DHaematologica%26date%3D2006%26volume%3D91%26spage%3D825%26epage%3D828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H.-S.</span></span> <span> </span><span class="NLM_article-title">Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients</span>. <i>Pathol. Int.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">175</span>, <span class="refDoi"> DOI: 10.1111/j.1440-1827.2011.02772.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1111%2Fj.1440-1827.2011.02772.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=22360504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC383lvFCrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=167-175&author=S.+H.+Leeauthor=H.+Kimauthor=J.-H.+Hwangauthor=H.+S.+Leeauthor=J.+Y.+Choauthor=Y.-S.+Yoonauthor=H.-S.+Han&title=Breast+cancer+resistance+protein+expression+is+associated+with+early+recurrence+and+decreased+survival+in+resectable+pancreatic+cancer+patients&doi=10.1111%2Fj.1440-1827.2011.02772.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients</span></div><div class="casAuthors">Lee Sang Hyub; Kim Haeryoung; Hwang Jin-Hyeok; Lee Hye Seung; Cho Jai Young; Yoon Yoo-Seok; Han Ho-Seong</div><div class="citationInfo"><span class="NLM_cas:title">Pathology international</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The prognosis of pancreatic ductal adenocarcinoma (PDAC) remains dismal even after complete resection, with most recurrences occurring within 1-2 years postoperatively.  Adenosine triphosphate (ATP)-binding cassette (ABC) transporters have been demonstrated to play major roles in multidrug resistance (MDR) of cancers.  In this study, we evaluated the expression statuses and the clinical significance of MDR1 (ABCB1), MDR-associated proteins (MRPs/ABCC) 1, 2 and 3, and breast cancer resistance protein (BCRP/ABCG2) in 67 surgically resected PDACs by immunohistochemistry.  MDR1, MRP1, MRP2, MRP3 and BCRP were expressed in 35 (52.2%), 56 (83.6%), 61 (91.0%), 49 (73.1%) and 49 (73.1%) out of 67 cases, respectively.  The expression statuses of the MDR-related proteins were positively correlated with each other (P < 0.05).  Tumors expressing MRP1 (P= 0.015), MRP2 (P= 0.022) and MRP3 (P < 0.001) demonstrated more frequent perineural invasion.  MDR1 expression was significantly correlated with lymphatic invasion (P= 0.047).  High BCRP expression in PDAC was a significant prognostic factor for early tumor recurrence (HR = 2.43, P= 0.003) and poor survival (HR = 2.63, P= 0.001).  MDR-related proteins are frequently expressed in PDAC, and high BCRP expression is a significant independent predictor for early recurrence and poor survival.  Immunohistochemical analysis for BCRP expression in PDAC may be a useful test in identifying a subgroup of patients with a poor prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTweVYj99EDj4NpW7w2tapOfW6udTcc2ealBGrEcVK_7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383lvFCrug%253D%253D&md5=4c10b59d6b30b8664e12e62edeacc920</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1827.2011.02772.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1827.2011.02772.x%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DHwang%26aufirst%3DJ.-H.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DCho%26aufirst%3DJ.%2BY.%26aulast%3DYoon%26aufirst%3DY.-S.%26aulast%3DHan%26aufirst%3DH.-S.%26atitle%3DBreast%2520cancer%2520resistance%2520protein%2520expression%2520is%2520associated%2520with%2520early%2520recurrence%2520and%2520decreased%2520survival%2520in%2520resectable%2520pancreatic%2520cancer%2520patients%26jtitle%3DPathol.%2520Int.%26date%3D2012%26volume%3D62%26spage%3D167%26epage%3D175%26doi%3D10.1111%2Fj.1440-1827.2011.02772.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Prognostic value and implication for chemotherapy treatment of ABCB1 in epithelial ovarian cancer: a meta-analysis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0166058</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0166058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1371%2Fjournal.pone.0166058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=27812204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFKls77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0166058&author=S.+Sunauthor=J.+Caiauthor=Q.+Yangauthor=Y.+Zhuauthor=S.+Zhaoauthor=Z.+Wang&title=Prognostic+value+and+implication+for+chemotherapy+treatment+of+ABCB1+in+epithelial+ovarian+cancer%3A+a+meta-analysis&doi=10.1371%2Fjournal.pone.0166058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic value and implication for chemotherapy treatment of ABCB1 in epithelial ovarian cancer: a meta-analysis</span></div><div class="casAuthors">Sun, Si; Cai, Jing; Yang, Qiang; Zhu, Yapei; Zhao, Simei; Wang, Zehua</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e0166058/1-e0166058/24</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background Chemotherapy resistance is reported to correlate with up-regulation of anti-tumor agent transporter ABCB1 (p-gp) in epithelial ovarian cancer (EOC), but the results remain controversial.  To reconcile the results, a systematic review followed by meta-anal. was performed to assess the assocn. between high ABCB1 status or ABCB1 gene variants and overall survival (OS), progression free survival (PFS), and total response rate (TR) in patients with EOC.  Materials and Methods Electronic searches were performed using Pubmed, EMBASE, Web of Science and Chinese Wanfang databases from Jan. 1990 to Feb. 2016.  Summary hazard ratio (HR), risk ratio (RR) and 95% confidence intervals (CIs) were combined using fixed or random- effects models as appropriate.  Results Thirty-eight retrospective studies of 8607 cases qualified for meta-anal. were identified.  Our results suggested that ABCB1 over-expression was significantly assocd. with unfavorable OS (HR = 1.54; 95% CI, 1.25-1.90), PFS (HR = 1.49; 95% CI, 1.22-1.82) and TR (RR = 0.63; 95% CI, 0.54-0.75).  After adjustment for age, clin. stage, residual disease, histol. type and tumor grade, high ABCB1 status remained to be a significant risk factor for adverse OS and PFS.  Patients with recurrent ABCB1 positivity suffered from poorer OS than those with primary ABCB1 positivity.  However, stratified by chemotherapy regimen, inverse correlation between high ABCB1 status and poor OS, PFS and TR were only found in patients underwent platinum-based chemotherapy but not in patients received std. platinum/paclitaxel-based chemotherapy.  No evidence was found for any assocn. between ABCB1 gene polymorphisms and OS, PFS or TR.  Conclusion High ABCB1 status is significantly assocd. with chemo-resistance and poor prognosis in patients with EOC.  Large-scale, prospective studies are needed to assess the clin. value of ABCB1 expression in EOC more accurately.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ90v9n7RX1rVg90H21EOLACvtfcHk0lhvRDq7fQZ5Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFKls77O&md5=32f1162b3048950590031c384629cd68</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0166058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0166058%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DPrognostic%2520value%2520and%2520implication%2520for%2520chemotherapy%2520treatment%2520of%2520ABCB1%2520in%2520epithelial%2520ovarian%2520cancer%253A%2520a%2520meta-analysis%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0166058%26doi%3D10.1371%2Fjournal.pone.0166058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gregorcyk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolm, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, R. R.</span></span> <span> </span><span class="NLM_article-title">P-glycoprotein expression as a predictor of breast cancer recurrence</span>. <i>Ann. Surg. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">8</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1007/BF02409045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1007%2FBF02409045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=8770296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADyaK28zms1Wiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1996&pages=8-14&author=S.+Gregorcykauthor=Y.+Kangauthor=D.+Brandtauthor=P.+Kolmauthor=G.+Singerauthor=R.+R.+Perry&title=P-glycoprotein+expression+as+a+predictor+of+breast+cancer+recurrence&doi=10.1007%2FBF02409045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">p-Glycoprotein expression as a predictor of breast cancer recurrence</span></div><div class="casAuthors">Gregorcyk S; Kang Y; Brandt D; Kolm P; Singer G; Perry R R</div><div class="citationInfo"><span class="NLM_cas:title">Annals of surgical oncology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-14</span>
        ISSN:<span class="NLM_cas:issn">1068-9265</span>.
    </div><div class="casAbstract">BACKGROUND:  Many new prognostic factors for breast cancer have been described, and yet the ability to predict patient outcomes remains poor.  Overexpression of p-glycoprotein (p-gp), the multidrug resistance efflux pump, confers a worse prognosis to patients with certain leukemias and other tumors.  The purpose of this study was to analyze the potential usefulness of p-gp expression as a prognostic factor in patients with breast cancer.  METHODS:  Paraffin blocks were obtained from 55 previously untreated patients who underwent surgery between 1987 and 1988.  To determine p-gp expression, tumor cell suspensions were incubated with the p-gp-specific C219 monoclonal antibody and analyzed using an indirect immunofluorescent flow cytometric assay.  RESULTS:  Twenty-four (44%) of the tumors were p-gp positive and 31 (56%) were p-gp negative.  Among the p-gp positive patients, 65% had recurrence of their disease, whereas only 13% of the p-gp negative patients experienced recurrence (p = 0.0001).  The 5-year disease-free rate for p-gp positive patients was 39% compared with 83% for p-gp negative patients (p = 0.0001).  In univariate analysis examining 10 different variables, significant predictors of recurrence were p-gp, stage, and tumor size.  Multivariate analysis using Cox Proportional Hazards regression showed that only p-gp and stage were significant independent predictors of recurrence (p = 0.0002).  CONCLUSIONS:  p-gp is frequently expressed in patients with untreated breast cancer, with p-gp-positive patients being at significantly greater risk for disease recurrence. p-gp appears to be a useful prognostic factor in breast cancer and could potentially help guide management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_ypUREnYfDIxhnOQkIHOxfW6udTcc2ealBGrEcVK_7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28zms1Wiuw%253D%253D&md5=9f054d023b41325bd45ebccad3624528</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2FBF02409045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02409045%26sid%3Dliteratum%253Aachs%26aulast%3DGregorcyk%26aufirst%3DS.%26aulast%3DKang%26aufirst%3DY.%26aulast%3DBrandt%26aufirst%3DD.%26aulast%3DKolm%26aufirst%3DP.%26aulast%3DSinger%26aufirst%3DG.%26aulast%3DPerry%26aufirst%3DR.%2BR.%26atitle%3DP-glycoprotein%2520expression%2520as%2520a%2520predictor%2520of%2520breast%2520cancer%2520recurrence%26jtitle%3DAnn.%2520Surg.%2520Oncol.%26date%3D1996%26volume%3D3%26spage%3D8%26epage%3D14%26doi%3D10.1007%2FBF02409045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filipits, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietze, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lax, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grill, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zielinski, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hausmaninger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubista, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samonigg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jakesz, R.</span></span> <span> </span><span class="NLM_article-title">Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian breast and colorectal cancer study group</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1161</span>– <span class="NLM_lpage">1168</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.03.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1200%2FJCO.2005.03.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=15718312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitl2gurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=1161-1168&author=M.+Filipitsauthor=G.+Pohlauthor=M.+Rudasauthor=O.+Dietzeauthor=S.+Laxauthor=R.+Grillauthor=R.+Pirkerauthor=C.+C.+Zielinskiauthor=H.+Hausmaningerauthor=E.+Kubistaauthor=H.+Samoniggauthor=R.+Jakesz&title=Clinical+role+of+multidrug+resistance+protein+1+expression+in+chemotherapy+resistance+in+early-stage+breast+cancer%3A+the+Austrian+breast+and+colorectal+cancer+study+group&doi=10.1200%2FJCO.2005.03.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: The Austrian Breast and Colorectal Cancer Study Group</span></div><div class="casAuthors">Filipits, Martin; Pohl, Gudrun; Rudas, Margaretha; Dietze, Otto; Lax, Sigurd; Grill, Renate; Pirker, Robert; Zielinski, Christoph C.; Hausmaninger, Hubert; Kubista, Ernst; Samonigg, Hellmut; Jakesz, Raimund</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1161-1168</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: The multidrug resistance protein 1 (MRP1) is expressed in human breast cancer cells and may contribute to the clin. drug resistance of breast cancer patients.  Therefore, we detd. the impact of MRP1 expression on the clin. outcome of adjuvant therapy in patients with early-stage breast cancer.  Patients and Methods: Immunostaining for MRP1 was performed on tissue sections from 516 premenopausal, hormone receptor-pos. breast cancer patients with stage I and II disease.  Statistical analyses were performed to assess the effect of MRP1 expression on survival and to test for interaction between MRP1 expression and treatment.  Results: MRP1 expression independently predicted shorter relapse-free survival (RFS) and overall survival (OS) in patients treated with cyclophosphamide, methotrexate, and fluorouracil (CMF; RFS: hazard ratio [HR] = 1.48; 95% CI, 1.16 to 1.88; P = .002; OS: HR = 1.82; 95% CI, 1.10 to 3.01; P = .02), but it did not predict shorter RFS and OS in patients who received tamoxifen plus goserelin (RFS: HR = 0.99; 95% CI, 0.74 to 1.31; P = .9; OS: HR = 0.68; 95% CI, 0.40 to 1.15; P = .1).  Tests for interaction between MRP1 expression and treatment were statistically significant for both RFS (P = .04) and OS (P = .006).  Conclusion: Our data suggest that MRP1 expression plays an important role in the clin. resistance to adjuvant CMF chemotherapy but does not seem to affect response to adjuvant endocrine treatment with tamoxifen plus goserelin.  Thus, MRP1 may be a useful marker for the selection of patients with early-stage breast cancer for the appropriate adjuvant therapy after prospective confirmatory evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlUpaouxrMy7Vg90H21EOLACvtfcHk0lhPK4NrBXsENQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitl2gurw%253D&md5=a2ed9f4db2046dc66f99306eeb6d98e4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.03.033%26sid%3Dliteratum%253Aachs%26aulast%3DFilipits%26aufirst%3DM.%26aulast%3DPohl%26aufirst%3DG.%26aulast%3DRudas%26aufirst%3DM.%26aulast%3DDietze%26aufirst%3DO.%26aulast%3DLax%26aufirst%3DS.%26aulast%3DGrill%26aufirst%3DR.%26aulast%3DPirker%26aufirst%3DR.%26aulast%3DZielinski%26aufirst%3DC.%2BC.%26aulast%3DHausmaninger%26aufirst%3DH.%26aulast%3DKubista%26aufirst%3DE.%26aulast%3DSamonigg%26aufirst%3DH.%26aulast%3DJakesz%26aufirst%3DR.%26atitle%3DClinical%2520role%2520of%2520multidrug%2520resistance%2520protein%25201%2520expression%2520in%2520chemotherapy%2520resistance%2520in%2520early-stage%2520breast%2520cancer%253A%2520the%2520Austrian%2520breast%2520and%2520colorectal%2520cancer%2520study%2520group%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D1161%26epage%3D1168%26doi%3D10.1200%2FJCO.2005.03.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eno, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahzad, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenshein, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A. K.</span></span> <span> </span><span class="NLM_article-title">Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer</span>. <i>Am. J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">488</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1097/COC.0b013e3181ec5f4b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1097%2FCOC.0b013e3181ec5f4b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=20921883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WkurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2011&pages=488-493&author=K.+Matsuoauthor=M.+L.+Enoauthor=E.+H.+Ahnauthor=M.+M.+Shahzadauthor=D.+D.+Imauthor=N.+B.+Rosensheinauthor=A.+K.+Sood&title=Multidrug+resistance+gene+%28MDR-1%29+and+risk+of+brain+metastasis+in+epithelial+ovarian%2C+fallopian+tube%2C+and+peritoneal+cancer&doi=10.1097%2FCOC.0b013e3181ec5f4b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug Resistance Gene (MDR-1) and Risk of Brain Metastasis in Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer</span></div><div class="casAuthors">Matsuo, Koji; Eno, Michele L.; Ahn, Edward H.; Shahzad, Mian M. K.; Im, Dwight D.; Rosenshein, Neil B.; Sood, Anil K.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">488-493</span>CODEN:
                <span class="NLM_cas:coden">AJCODI</span>;
        ISSN:<span class="NLM_cas:issn">0277-3732</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: To evaluate risk factors that predict brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.  Methods: All patients with FIGO stage I to IV who underwent initial cytoreductive surgery between Jan. 1995 and Jan. 2009 were evaluated.  The tumor samples were evaluated for 7 markers including multidrug resistance gene (MDR-1), DNA aneuploidity and S-phase fraction, human epidermal growth factor receptor 2, estrogen receptor, progesterone receptor, p53 mutation, epidermal growth factor receptor, and CD31.  Biomarker expression was evaluated as a predictor of hematogenous metastasis to the following locations: (i) liver and spleen, (ii) lung, and (iii) brain.  Results: There were 309 cases identified during the period.  Of those, 5 (1.6%, 95% CI: 0.2%-3.0%) women developed brain metastasis.  Time to onset of brain metastasis was significantly longer than that for other recurrent sites (median time to recurrence after initial cytoredn., brain vs. lung vs. liver, 21.4 vs. 12.6 vs. 11.0 mo, P< 0.05).  Significantly increased expression of MDR-1 was seen in tumors from women who developed brain metastasis (brain vs. nonbrain sites, 80% vs. 4.2%-24.3%, P= 0.004).  In multivariate anal., MDR-1 was the only significant variable assocd. with the risk of brain metastasis.  MDR-1 expression predicted brain metastasis (receiver-operator-characteristic curve anal., AUC 0.808, P= 0.018), and with a 10% pos. expression of MDR-1 as the cutoff value, sensitivity, specificity, pos. predictive value, neg. predictive value, accuracy of prediction of brain metastasis were 80%, 86.1%, 15.4%, 99.3%, and 85.9%, resp. (odds ratio: 24.7, 95% CI: 2.64-232, P= 0.002).  Conclusions: Increased expression of MDR-1 in the tumor tissue obtained at initial cytoredn. is assocd. with increased risk of developing brain metastases in women with epithelial ovarian, fallopian tube, or peritoneal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_xRbjF-3nabVg90H21EOLACvtfcHk0lhPK4NrBXsENQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WkurbL&md5=905a59d23e27d5124dcdfe2cbff2da1a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1097%2FCOC.0b013e3181ec5f4b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCOC.0b013e3181ec5f4b%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuo%26aufirst%3DK.%26aulast%3DEno%26aufirst%3DM.%2BL.%26aulast%3DAhn%26aufirst%3DE.%2BH.%26aulast%3DShahzad%26aufirst%3DM.%2BM.%26aulast%3DIm%26aufirst%3DD.%2BD.%26aulast%3DRosenshein%26aufirst%3DN.%2BB.%26aulast%3DSood%26aufirst%3DA.%2BK.%26atitle%3DMultidrug%2520resistance%2520gene%2520%2528MDR-1%2529%2520and%2520risk%2520of%2520brain%2520metastasis%2520in%2520epithelial%2520ovarian%252C%2520fallopian%2520tube%252C%2520and%2520peritoneal%2520cancer%26jtitle%3DAm.%2520J.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D34%26spage%3D488%26epage%3D493%26doi%3D10.1097%2FCOC.0b013e3181ec5f4b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polgar, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeken, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span> <span> </span><span class="NLM_article-title">ABCG2: determining its relevance in clinical drug resistance</span>. <i>Cancer Metastasis Rev.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1007/s10555-007-9042-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1007%2Fs10555-007-9042-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=17323127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1KqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=39-57&author=R.+W.+Robeyauthor=O.+Polgarauthor=J.+Deekenauthor=K.+W.+Toauthor=S.+E.+Bates&title=ABCG2%3A+determining+its+relevance+in+clinical+drug+resistance&doi=10.1007%2Fs10555-007-9042-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">ABCG2: determining its relevance in clinical drug resistance</span></div><div class="casAuthors">Robey, Robert W.; Polgar, Orsolya; Deeken, John; To, Kin Wah; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer and Metastasis Reviews</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-57</span>CODEN:
                <span class="NLM_cas:coden">CMRED4</span>;
        ISSN:<span class="NLM_cas:issn">0167-7659</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Multidrug resistance is a major obstacle to successful cancer treatment.  One mechanism by which cells can become resistant to chemotherapy is the expression of ABC transporters that use the energy of ATP hydrolysis to transport a wide variety of substrates across the cell membrane.  There are three human ABC transporters primarily assocd. with the multidrug resistance phenomenon, namely Pgp, MRP1, and ABCG2.  All three have broad and, to a certain extent, overlapping substrate specificities, transporting the major drugs currently used in cancer chemotherapy.  ABCG2 is the most recently described of the three major multidrug-resistance pumps, and its substrates include mitoxantrone, topotecan, irinotecan, flavopiridol, and methotrexate.  Despite several studies reporting ABCG2 expression in normal and malignant tissues, no trials have thus far addressed the role of ABCG2 in clin. drug resistance.  This gives us an opportunity to critically review the disappointing results of past clin. trials targeting Pgp and to propose strategies for ABCG2.  We need to know in which tumor types ABCG2 contributes to the resistance phenotype.  We also need to develop standardized assays to detect ABCG2 expression in vivo and to carefully select the chemotherapeutic agents and clin. trial designs.  This review focuses on our current knowledge about normal tissue distribution, tumor expression profiles, and substrates and inhibitors of ABCG2, together with lessons learned from clin. trials with Pgp inhibitors.  Implications of SNPs in the ABCG2 gene affecting the pharmacokinetics of substrate drugs, including many non-chemotherapy agents and ABCG2 expression in the SP population of stem cells are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohVW7mqrWFVLVg90H21EOLACvtfcHk0lg9lX4_JStKwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1KqtL0%253D&md5=fd6e32da8ddccc75c8f1c6d92bb0bd56</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs10555-007-9042-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-007-9042-6%26sid%3Dliteratum%253Aachs%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DPolgar%26aufirst%3DO.%26aulast%3DDeeken%26aufirst%3DJ.%26aulast%3DTo%26aufirst%3DK.%2BW.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DABCG2%253A%2520determining%2520its%2520relevance%2520in%2520clinical%2520drug%2520resistance%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2007%26volume%3D26%26spage%3D39%26epage%3D57%26doi%3D10.1007%2Fs10555-007-9042-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unadkat, J. D.</span></span> <span> </span><span class="NLM_article-title">Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport – an update</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1208/s12248-014-9668-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1208%2Fs12248-014-9668-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25236865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFygu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=65-82&author=Q.+Maoauthor=J.+D.+Unadkat&title=Role+of+the+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29+in+drug+transport+%E2%80%93+an+update&doi=10.1208%2Fs12248-014-9668-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport-an update</span></div><div class="casAuthors">Mao, Qingcheng; Unadkat, Jashvant D.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-82</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The human breast cancer resistance protein (BCRP, gene symbol ABCG2) is an ATP-binding cassette (ABC) efflux transporter.  It was so named because it was initially cloned from a multidrug-resistant breast cancer cell line where it was found to confer resistance to chemotherapeutic agents such as mitoxantrone and topotecan.  Since its discovery in 1998, the substrates of BCRP have been rapidly expanding to include not only therapeutic agents but also physiol. substances such as estrone-3-sulfate, 17β-estradiol 17-(β-D-glucuronide) and uric acid.  Likewise, at least hundreds of BCRP inhibitors have been identified.  Among normal human tissues, BCRP is highly expressed on the apical membranes of the placental syncytiotrophoblasts, the intestinal epithelium, the liver hepatocytes, the endothelial cells of brain microvessels, and the renal proximal tubular cells, contributing to the absorption, distribution, and elimination of drugs and endogenous compds. as well as tissue protection against xenobiotic exposure.  As a result, BCRP has now been recognized by the FDA to be one of the key drug transporters involved in clin. relevant drug disposition.  We published a highly-accessed review article on BCRP in 2005, and much progress has been made since then.  In this review, we provide an update of current knowledge on basic biochem. and pharmacol. functions of BCRP as well as its relevance to drug resistance and drug disposition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojBFIoPBT7CbVg90H21EOLACvtfcHk0lg9lX4_JStKwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFygu7fM&md5=c4b8d6e1286fc6340cf4a8159f525c22</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1208%2Fs12248-014-9668-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-014-9668-6%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DQ.%26aulast%3DUnadkat%26aufirst%3DJ.%2BD.%26atitle%3DRole%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%2520in%2520drug%2520transport%2520%25E2%2580%2593%2520an%2520update%26jtitle%3DAAPS%2520J.%26date%3D2015%26volume%3D17%26spage%3D65%26epage%3D82%26doi%3D10.1208%2Fs12248-014-9668-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hardwick, L. J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velamakanni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Veen, H. W.</span></span> <span> </span><span class="NLM_article-title">The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2)</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fsj.bjp.0707218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=17375082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Wku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2007&pages=163-174&author=L.+J.+A.+Hardwickauthor=S.+Velamakanniauthor=H.+W.+van+Veen&title=The+emerging+pharmacotherapeutic+significance+of+the+breast+cancer+resistance+protein+%28ABCG2%29&doi=10.1038%2Fsj.bjp.0707218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2)</span></div><div class="casAuthors">Hardwick, L. J. A.; Velamakanni, S.; van Veen, H. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-174</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The breast cancer resistance protein (also termed ABCG2) is an ATP-binding cassette transporter, which mediates the extrusion of toxic compds. from the cell, and which was originally identified in relation to the development of multidrug resistance of cancer cells.  ABCG2 interacts with a range of substrates including clin. drugs but also substances such as sterols, porphyrins and a variety of dietary compds.  Physiol. functions of ABCG2 at both cellular and systemic levels are reviewed.  For example, ABCG2 expression in erythrocytes may function in porphyrin homeostasis.  In addn., ABCG2 expression at apical membranes of cells such as hepatocytes, enterocytes, endothelial and syncytiotrophoblast cells may correlate to protective barrier or secretory functions against environmental or clin. administered substances.  ABCG2 also appears influential in the inter-patient variation and generally poor oral bioavailability of certain chemotherapeutic drugs such as topotecan.  As this often precludes an oral drug administration strategy, genotypic and environmental factors altering ABCG2 expression and activity are considered.  Finally, clin. modulation of ABCG2 activity is discussed.  Some of the more recent strategies include co-administered modulating agents, hammerhead ribozymes or antisense oligonucleotides, and with specificity in cell targeting, these may be used to reduce drug resistance and increase drug bioavailability to improve the profile of chemotherapeutic efficacy vs. toxicity.  While many such strategies remain in relative infancy at present, increased knowledge of modulators of ABCG2 could hold the key to novel approaches in medical treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom3w5nPxaNRLVg90H21EOLACvtfcHk0lg9lX4_JStKwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Wku74%253D&md5=fdd17189ef8fdb4a95c21d96fd0fd7a5</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707218%26sid%3Dliteratum%253Aachs%26aulast%3DHardwick%26aufirst%3DL.%2BJ.%2BA.%26aulast%3DVelamakanni%26aufirst%3DS.%26aulast%3Dvan%2BVeen%26aufirst%3DH.%2BW.%26atitle%3DThe%2520emerging%2520pharmacotherapeutic%2520significance%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D151%26spage%3D163%26epage%3D174%26doi%3D10.1038%2Fsj.bjp.0707218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Möbus, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfaff, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volm, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreienberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaubitzsch, S.</span></span> <span> </span><span class="NLM_article-title">Long time therapy with topotecan in patients with recurrence of ovarian carcinoma</span>. <i>Anticancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3551</span>– <span class="NLM_lpage">3556</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11848522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvFGmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=3551-3556&author=V.+M%C3%B6busauthor=P.+N.+Pfaffauthor=T.+Volmauthor=R.+Kreienbergauthor=S.+Kaubitzsch&title=Long+time+therapy+with+topotecan+in+patients+with+recurrence+of+ovarian+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Long time therapy with topotecan in patients with recurrence of ovarian carcinoma</span></div><div class="casAuthors">Mobus, Volker; Pfaff, Peter N.; Volm, Tanja; Kreienberg, Rolf; Kaubitzsch, Sabine</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3551-3556</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">In several phase II and III topotecan studies the large no. of patients with stable disease is striking.  Since no severe organ toxicity has been described for topotecan, long-term therapy with topotecan seems to be reasonable.  In this summary we present evidence, that long-term topotecan therapy can be managed without cumulative hematol. and non-hematol. toxicity.  Thirty-three patients with recurrent ovarian cancer, who were treated with at least 7 courses of topotecan, were evaluated in this retrospective study (patient database from SmithKline Beecham, Germany).  Most of the patients had more than 2 previous courses of chemotherapy.  The starting dose was between 1.0 and 1.5 mg/m2 topotecan administered for 5 days every 3 wk as an i.v. infusion.  All patients were evaluated for toxicity, 32 patients for response.  The 33 patients received 343 courses of topotecan, an av. of more than 10 courses per patient.  The highest no. of courses given to a single patient was 33.  The hematotoxicity was in the expected range, but toxicity was not cumulative.  The no. of interventions for growth factors and blood cell transfusions were const. over the whole therapy.  Dose redns. were conducted in more than 75% of the patients as early as in course two.  There was no grade 3 or 4 non-hematol. toxicity.  Alopecia was the only toxicity to be cumulative.  Remissions were obsd. in 12 out of 32 eligible patients.  The remissions were achieved after an av. of 4.3 courses (range 2-7).  The median time to progression was 33 wk.  Long-term therapy with topotecan is reasonable and can be conducted without cumulative hematol. toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3zVaZdTuIQbVg90H21EOLACvtfcHk0lgw33MM_r2mlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvFGmsb0%253D&md5=4ef623f52cfcdfcc6d5229b9ad5d6870</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25B6bus%26aufirst%3DV.%26aulast%3DPfaff%26aufirst%3DP.%2BN.%26aulast%3DVolm%26aufirst%3DT.%26aulast%3DKreienberg%26aufirst%3DR.%26aulast%3DKaubitzsch%26aufirst%3DS.%26atitle%3DLong%2520time%2520therapy%2520with%2520topotecan%2520in%2520patients%2520with%2520recurrence%2520of%2520ovarian%2520carcinoma%26jtitle%3DAnticancer%2520Res.%26date%3D2001%26volume%3D21%26spage%3D3551%26epage%3D3556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckardt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramlau, R.</span></span> <span> </span><span class="NLM_article-title">Recent advances with topotecan in the treatment of lung cancer</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1194</span>– <span class="NLM_lpage">1204</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.12-10-1194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1634%2Ftheoncologist.12-10-1194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=17962613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=1194-1204&author=M.+O%E2%80%99Brienauthor=J.+Eckardtauthor=R.+Ramlau&title=Recent+advances+with+topotecan+in+the+treatment+of+lung+cancer&doi=10.1634%2Ftheoncologist.12-10-1194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances with topotecan in the treatment of lung cancer</span></div><div class="casAuthors">O'Brien, Mary; Eckardt, John; Ramlau, Rodryg</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1194-1204</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">A review.  Topotecan is a semisynthetic deriv. of camptothecin that specifically targets topoisomerase I.  It has well-established antineoplastic properties and has been successfully combined with other antineoplastic agents with activity dependent on DNA disruption, such as cisplatin and etoposide.  Topotecan is indicated for the treatment of small cell lung cancer (SCLC) sensitive disease after failure of first-line chemotherapy and metastatic ovarian carcinoma after failure of initial or subsequent chemotherapy.  Since the approval of topotecan for the second-line treatment of SCLC, studies have been conducted in the first-line setting.  Recent studies demonstrate the utility of i.v. topotecan in combination with cisplatin for untreated SCLC.  Further, an oral formulation of topotecan is currently under investigation and may provide added convenience for patients.  Oral topotecan has been studied in the first- and second-line settings for both SCLC and non-small cell lung cancer (NSCLC).  Three recent phase III trials have demonstrated the activity of oral topotecan.  In the first study of chemotherapy-naive patients with extensive-disease SCLC, oral topotecan plus cisplatin provided efficacy and safety similar to those of etoposide plus cisplatin.  In a second study of patients with relapsed SCLC, treatment with oral topotecan showed a statistically significant and clin. meaningful longer overall survival time and improvement in dyspnea and quality of life compared with best supportive care alone in all prognostic groups.  Finally, in previously treated patients with NSCLC, single-agent oral topotecan was shown to be noninferior in 1-yr survival rate relative to the current std. of i.v. docetaxel.  In future studies, oral topotecan will represent a good candidate for combination therapy with other i.v. or oral chemotherapy agents, monoclonal antibodies, and small mol. tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM0akGR-WUlrVg90H21EOLACvtfcHk0lgw33MM_r2mlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOmurrP&md5=ca58348a79672414db1fd9fcbf55e5e1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.12-10-1194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.12-10-1194%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DM.%26aulast%3DEckardt%26aufirst%3DJ.%26aulast%3DRamlau%26aufirst%3DR.%26atitle%3DRecent%2520advances%2520with%2520topotecan%2520in%2520the%2520treatment%2520of%2520lung%2520cancer%26jtitle%3DOncologist%26date%3D2007%26volume%3D12%26spage%3D1194%26epage%3D1204%26doi%3D10.1634%2Ftheoncologist.12-10-1194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galdy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cella, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spada, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murgioni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frezza, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravenda, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampino, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazio, N.</span></span> <span> </span><span class="NLM_article-title">Systematic therapy beyond first-line in advanced gastric cancer: an overview of the main randomized clinical trials</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2015.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.critrevonc.2015.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=26697987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC28rkt1KjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2016&pages=1-12&author=S.+Galdyauthor=C.+A.+Cellaauthor=F.+Spadaauthor=S.+Murgioniauthor=A.+M.+Frezzaauthor=S.+P.+Ravendaauthor=M.+G.+Zampinoauthor=N.+Fazio&title=Systematic+therapy+beyond+first-line+in+advanced+gastric+cancer%3A+an+overview+of+the+main+randomized+clinical+trials&doi=10.1016%2Fj.critrevonc.2015.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials</span></div><div class="casAuthors">Galdy Salvatore; Cella Chiara Alessandra; Spada Francesca; Murgioni Sabina; Frezza Anna Maria; Ravenda Simona Paola; Zampino Maria Giulia; Fazio Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Following progression on first-line platinum and fluoropyrimidine-based chemotherapy, prognosis for advanced gastric cancer patients is extremely poor.  Thus, new and effective treatments are required.  Based on positive results of recent randomized controlled trials, second-line monochemotherapies with either irinotecan or taxanes confer a median overall survival of approximately 5 months in gastro-esophageal and gastric adenocarcinoma.  Combination of weekly paclitaxel and ramucirumab, a novel anti-angiogenic VEGFR2 antibody, pushes the overall survival up to over 9.5 months, whereas apatinib, a novel oral VEGFR2 tyrosine kinase inhibitor, seems to be promising in heavily pretreated patients.  In contrast, the role of EGFR/HER2 and mTOR inhibitors is controversial.  Studies are heterogeneous for tumor population, geographical areas, quality of life assessment, type of first-line therapy and response to that, making clinical practice application of the trial results difficult.  Furthermore, sustainability is challenging due to high cost of novel biotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTD8kRPQnDjf7t7lRqEFUJVfW6udTcc2ebgCIW6-fQU6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rkt1KjsQ%253D%253D&md5=c1bb5df45446bf3fd0745769f60e74f8</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2015.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2015.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DGaldy%26aufirst%3DS.%26aulast%3DCella%26aufirst%3DC.%2BA.%26aulast%3DSpada%26aufirst%3DF.%26aulast%3DMurgioni%26aufirst%3DS.%26aulast%3DFrezza%26aufirst%3DA.%2BM.%26aulast%3DRavenda%26aufirst%3DS.%2BP.%26aulast%3DZampino%26aufirst%3DM.%2BG.%26aulast%3DFazio%26aufirst%3DN.%26atitle%3DSystematic%2520therapy%2520beyond%2520first-line%2520in%2520advanced%2520gastric%2520cancer%253A%2520an%2520overview%2520of%2520the%2520main%2520randomized%2520clinical%2520trials%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2016%26volume%3D99%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.critrevonc.2015.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawabata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiozawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatomi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikegami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamihira, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doyle, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, S.</span></span> <span> </span><span class="NLM_article-title">Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>280</i></span>,  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1223</span>, <span class="refDoi"> DOI: 10.1006/bbrc.2001.4267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1006%2Fbbrc.2001.4267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11162657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptlCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2001&pages=1216-1223&author=S.+Kawabataauthor=M.+Okaauthor=K.+Shiozawaauthor=K.+Tsukamotoauthor=K.+Nakatomiauthor=H.+Sodaauthor=M.+Fukudaauthor=Y.+Ikegamiauthor=K.+Sugaharaauthor=Y.+Yamadaauthor=S.+Kamihiraauthor=L.+A.+Doyleauthor=D.+D.+Rossauthor=S.+Kohno&title=Breast+cancer+resistance+protein+directly+confers+SN-38+resistance+of+lung+cancer+cells&doi=10.1006%2Fbbrc.2001.4267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Breast Cancer Resistance Protein Directly Confers SN-38 Resistance of Lung Cancer Cells</span></div><div class="casAuthors">Kawabata, Shigeru; Oka, Mikio; Shiozawa, Ken; Tsukamoto, Kazuhiro; Nakatomi, Katsumi; Soda, Hiroshi; Fukuda, Minoru; Ikegami, Yoji; Sugahara, Kazuyuki; Yamada, Yasuaki; Kamihira, Shimeru; Doyle, L. Austin; Ross, Douglas D.; Kohno, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1216-1223</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Breast cancer resistance protein (BCRP), an ABC half-transporter, is overexpressed in cancer cell lines selected with doxorubicin/verapamil, topotecan, or mitoxantrone.  BCRP-overexpressing cells show cross-resistance to camptothecin derivs. such as irinotecan, SN-38 (the active metabolite of irinotecan), and topotecan.  To test whether BCRP confers SN-38 resistance, we selected two SN-38 resistant sublines from PC-6 human small-cell lung cancer cells by SN-38, and then characterized these cells.  Compared to PC-6 cells, the resistant sublines PC-6/SN2-5 and PC-6/SN2-5H were approx. 18- and 34-fold resistant, resp.  The intracellular SN-38 accumulation was reduced in the sublines, and BCRP mRNA was overexpressed in proportion to the degree of SN-38 resistance.  These findings suggest that BCRP confers SN-38 resistance in the sublines.  To confirm this hypothesis, PC-6/SN2-5 cells were transfected with antisense oligonucleotides complementary to portions of BCRP mRNA.  The antisense oligonucleotides significantly suppressed BCRP mRNA expression, and enhanced SN-38 sensitivity in the subline.  These data indicate that BCRP is directly involved with SN-38 resistance, by efflux transport of SN-38.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp94jSgfFuPnrVg90H21EOLACvtfcHk0lh66h9st6KLOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptlCrsg%253D%253D&md5=d3e2199a04430e59605416d693b567fd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.2001.4267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.2001.4267%26sid%3Dliteratum%253Aachs%26aulast%3DKawabata%26aufirst%3DS.%26aulast%3DOka%26aufirst%3DM.%26aulast%3DShiozawa%26aufirst%3DK.%26aulast%3DTsukamoto%26aufirst%3DK.%26aulast%3DNakatomi%26aufirst%3DK.%26aulast%3DSoda%26aufirst%3DH.%26aulast%3DFukuda%26aufirst%3DM.%26aulast%3DIkegami%26aufirst%3DY.%26aulast%3DSugahara%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DKamihira%26aufirst%3DS.%26aulast%3DDoyle%26aufirst%3DL.%2BA.%26aulast%3DRoss%26aufirst%3DD.%2BD.%26aulast%3DKohno%26aufirst%3DS.%26atitle%3DBreast%2520cancer%2520resistance%2520protein%2520directly%2520confers%2520SN-38%2520resistance%2520of%2520lung%2520cancer%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2001%26volume%3D280%26spage%3D1216%26epage%3D1223%26doi%3D10.1006%2Fbbrc.2001.4267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maliepaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gastelen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Waardenburg, R. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruevekamp-Helmers, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floot, B. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span> <span> </span><span class="NLM_article-title">Overexpression of the <i>BCRP/MXR/ABCP</i> gene in a topotecan-selected ovarian tumor cell line</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4559</span>– <span class="NLM_lpage">4563</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10493507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADyaK1MXmtVKksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1999&pages=4559-4563&author=M.+Maliepaardauthor=M.+A.+van+Gastelenauthor=L.+A.+de+Jongauthor=D.+Pluimauthor=R.+A.+M.+van+Waardenburgauthor=M.+C.+Ruevekamp-Helmersauthor=B.+G.+J.+Flootauthor=J.+H.+M.+Schellens&title=Overexpression+of+the+BCRP%2FMXR%2FABCP+gene+in+a+topotecan-selected+ovarian+tumor+cell+line"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line</span></div><div class="casAuthors">Maliepaard, Marc; Van Gastelen, Margot A.; De Jong, Laurina A.; Pluim, Dick; Van Waardenburg, Robert C. A. M.; Ruevekamp-Helmers, Marjan C.; Floot, Ben G. J.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4559-4563</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">AACR Subscription Office</span>)
        </div><div class="casAbstract">Topotecan- or mitoxantrone-selected cell lines (T8 and MX3, resp.), derived from the human IGROV1 ovarian cancer cell line, were resistant to the topoisomerase I inhibitors topotecan, SN-38 (the active metabolite of irinotecan), and 9-aminocamptothecin, as well as to the topoisomerase II drug mitoxantrone.  In both resistant cell lines, decreased accumulation of topotecan and mitoxantrone was obsd., caused by enhanced energy-dependent efflux of the drugs involved.  In both cell lines, we found that the breast cancer resistance protein/mitoxantrone resistance/placenta-specific ATP binding cassette (BCRP/MXR/ABCP) gene was overexpressed.  Furthermore, BCRP/MXR/ABCP expression levels in various partially revertant T8 cells correlated with the levels of resistance to topotecan, SN-38, and mitoxantrone, strongly suggesting BCRP/MXR/ABCP to be the transporter responsible for the enhanced efflux.  Pharmacodynamic anal. demonstrated that BCRP/MXR/ABCP is a very efficient transporter of topotecan; in vitro, 70% of the intracellular topotecan pool was transported out of the T8 or MX3 cells within 30 s.  In conclusion, we report for the first time that BCRP/MXR/ABCP can also be upregulated upon exposure of tumor cells to the clin. important drug topotecan, and that BCRP-mediated efflux of topotecan is very efficient.  This highly efficient efflux of topotecan by BCRP/MXR/ABCP may have clin. relevance for patients being treated with topotecan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkkbyzfYDaxrVg90H21EOLACvtfcHk0lh66h9st6KLOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmtVKksbo%253D&md5=626719a6e276cde3b86e5a83427a51b8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaliepaard%26aufirst%3DM.%26aulast%3Dvan%2BGastelen%26aufirst%3DM.%2BA.%26aulast%3Dde%2BJong%26aufirst%3DL.%2BA.%26aulast%3DPluim%26aufirst%3DD.%26aulast%3Dvan%2BWaardenburg%26aufirst%3DR.%2BA.%2BM.%26aulast%3DRuevekamp-Helmers%26aufirst%3DM.%2BC.%26aulast%3DFloot%26aufirst%3DB.%2BG.%2BJ.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DOverexpression%2520of%2520the%2520BCRP%252FMXR%252FABCP%2520gene%2520in%2520a%2520topotecan-selected%2520ovarian%2520tumor%2520cell%2520line%26jtitle%3DCancer%2520Res.%26date%3D1999%26volume%3D59%26spage%3D4559%26epage%3D4563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dexheimer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sordet, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavielle, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">Novel-E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">3229</span>– <span class="NLM_lpage">3238</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-0441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1158%2F1535-7163.MCT-07-0441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=18089716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=3229-3238&author=K.+Takagiauthor=T.+S.+Dexheimerauthor=C.+Redonauthor=O.+Sordetauthor=K.+Agamaauthor=G.+Lavielleauthor=A.+Pierreauthor=S.+E.+Batesauthor=Y.+Pommier&title=Novel-E-ring+camptothecin+keto+analogues+%28S38809+and+S39625%29+are+stable%2C+potent%2C+and+selective+topoisomerase+I+inhibitors+without+being+substrates+of+drug+efflux+transporters&doi=10.1158%2F1535-7163.MCT-07-0441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters</span></div><div class="casAuthors">Takagi, Kazutaka; Dexheimer, Thomas S.; Redon, Christophe; Sordet, Olivier; Agama, Keli; Lavielle, Gilbert; Pierre, Alain; Bates, Susan E.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">3229-3238</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Camptothecin (CPT) analogs are powerful anticancer agents but are chem. unstable due to their α-hydroxylactone six-membered E-ring structure, which is essential for trapping topoisomerase I (Top1)-DNA cleavage complexes.  To stabilize the E-ring, CPT keto analogs with a five-membered E-ring lacking the oxygen of the lactone ring (S38809 and S39625) have been synthesized.  S39625 has been selected for advanced preclin. development based on its promising activity in tumor models.  Here, we show that both keto analogs are active against purified Top1 and selective against Top1 in yeast and human cancer cells.  The keto analogs show improved cytotoxicity toward colon, breast, and prostate cancer cells and leukemia cells compared with CPT.  The drug-induced Top1-DNA cleavage complexes induced by the keto analogs show remarkable persistence both with purified Top1 and in cells following 1-h drug treatments.  Moreover, we find that S39625 is not a substrate for either the ABCB1 (multidrug resistance-1/P-glycoprotein) or ABCG2 (mitoxantrone resistance/breast cancer resistance protein) drug efflux transporters, which sets S39625 apart from the clin. used CPT analogs topotecan or SN-38 (active metabolite of irinotecan).  Finally, we show that nanomolar concns. of S38809 or S39625 induce intense and persistent histone γ-H2AX.  The chem. stability of the keto analogs and the ability of S39625 to produce high levels of persistent Top1-DNA cleavage complex and its potent antiproliferative activity against human cancer cell lines make S39625 a promising new anticancer drug candidate.  Histone γ-H2AX could be used as a biomarker for the upcoming clin. trials of S39625.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsAvXCcUmkvLVg90H21EOLACvtfcHk0lhRK4LxvhDzkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjsr3L&md5=3a428d2a4871232a86096569c4550fb2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-0441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-0441%26sid%3Dliteratum%253Aachs%26aulast%3DTakagi%26aufirst%3DK.%26aulast%3DDexheimer%26aufirst%3DT.%2BS.%26aulast%3DRedon%26aufirst%3DC.%26aulast%3DSordet%26aufirst%3DO.%26aulast%3DAgama%26aufirst%3DK.%26aulast%3DLavielle%26aufirst%3DG.%26aulast%3DPierre%26aufirst%3DA.%26aulast%3DBates%26aufirst%3DS.%2BE.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DNovel-E-ring%2520camptothecin%2520keto%2520analogues%2520%2528S38809%2520and%2520S39625%2529%2520are%2520stable%252C%2520potent%252C%2520and%2520selective%2520topoisomerase%2520I%2520inhibitors%2520without%2520being%2520substrates%2520of%2520drug%2520efflux%2520transporters%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D3229%26epage%3D3238%26doi%3D10.1158%2F1535-7163.MCT-07-0441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volk, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocchi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-C.</span></span> <span> </span><span class="NLM_article-title">BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">831</span>– <span class="NLM_lpage">837</span>, <span class="refDoi"> DOI: 10.1016/S0006-2952(00)00396-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2FS0006-2952%2800%2900396-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10930538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltlWgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2000&pages=831-837&author=C.-H.+Yangauthor=E.+Schneiderauthor=M.-L.+Kuoauthor=E.+L.+Volkauthor=E.+Rocchiauthor=Y.-C.+Chen&title=BCRP%2FMXR%2FABCP+expression+in+topotecan-resistant+human+breast+carcinoma+cells&doi=10.1016%2FS0006-2952%2800%2900396-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells</span></div><div class="casAuthors">Yang, C.-H.; Schneider, E.; Kuo, M.-L.; Volk, E. L.; Rocchi, E.; Chen, Y.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">831-837</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">We have previously described a mitoxantrone-resistant MCF7 cell line that is cross-resistant to topotecan, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11), and 9-aminocamptothecin, but not to camptothecin.  A novel mechanism that resulted in decreased topotecan accumulation in MCF7/MX cells was proposed (Yang, C.J.; et al., 1995).  We now have developed a topotecan-resistant cancer cell line from wild-type MCF7 cells.  MCF7/TPT300 cells were 68.9-fold resistant to topotecan, 68.3-fold to 10-hydroxy-7-ethylcamptothecin (SN-38), and 116-fold to mitoxantrone, but only 4.1-fold to camptothecin.  Topotecan efflux was increased in MCF7/TPT300 cells compared with MCF7/WT cells, and this increase was reversed upon ATP depletion by sodium azide, suggesting an energy-dependent drug efflux mechanism.  However, MCF7/TPT300 cells did not overexpress P-glycoprotein or the multidrug resistance-assocd. protein (MRP1).  In contrast, overexpression of the breast cancer resistance protein (BCRP/MXR/ABCP) was obsd. in MCF7/TPT300 cells as well as DNA topoisomerase I down-regulation.  Our data suggest that enhanced topotecan efflux contributes partly to topotecan resistance in MCF7/TPT300 cells, possibly mediated by BCRP/MXR/ABCP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoItOCSF823urVg90H21EOLACvtfcHk0lhRK4LxvhDzkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltlWgtL4%253D&md5=2debb1cb7ab8782a7928341d556c1d1a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2800%2900396-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252800%252900396-8%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.-H.%26aulast%3DSchneider%26aufirst%3DE.%26aulast%3DKuo%26aufirst%3DM.-L.%26aulast%3DVolk%26aufirst%3DE.%2BL.%26aulast%3DRocchi%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DY.-C.%26atitle%3DBCRP%252FMXR%252FABCP%2520expression%2520in%2520topotecan-resistant%2520human%2520breast%2520carcinoma%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2000%26volume%3D60%26spage%3D831%26epage%3D837%26doi%3D10.1016%2FS0006-2952%2800%2900396-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maliepaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span> <span> </span><span class="NLM_article-title">Transport of topoisomerase I inhibitors by the breast cancer resistance protein</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>922</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">194</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2000.tb07037.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1111%2Fj.1749-6632.2000.tb07037.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11193894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntVCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=922&publication_year=2000&pages=188-194&author=J.+H.+M.+Schellensauthor=M.+Maliepaardauthor=R.+J.+Scheperauthor=G.+L.+Schefferauthor=J.+W.+Jonkerauthor=J.+W.+Smitauthor=J.+H.+Beijnenauthor=A.+H.+Schinkel&title=Transport+of+topoisomerase+I+inhibitors+by+the+breast+cancer+resistance+protein&doi=10.1111%2Fj.1749-6632.2000.tb07037.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Transport of topoisomerase I inhibitors by the breast cancer resistance protein: Potential clinical implications</span></div><div class="casAuthors">Schellens, Jan H. M.; Maliepaard, Marc; Scheper, Rik J.; Scheffer, George L.; Jonker, Johan W.; Smit, Johan W.; Beijnen, Jos H.; Schinkel, Alfred H.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">922</span>
        (<span class="NLM_cas:issue">Camptothecins</span>),
    <span class="NLM_cas:pages">188-194</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">New York Academy of Sciences</span>)
        </div><div class="casAbstract">The multidrug resistance protein BCRP (breast cancer resistance protein) is a member of the ATP-binding cassette family of drug transporters.  Overexpression of BCRP caused by exposure of cells to mitoxantrone (MX) or doxorubicin/verapamil resulted in a resistance pattern that is different from what is generally seen in the case of P-glycoprotein and MRP1 overexpression.  Recently, the BCRP gene has been described in ovarian, breast, colon, and gastric cancer and fibrosarcoma cell lines.  Our human tumor cells T8 and MX3, derived from the ovarian cancer cell line IGROV1 by stepwise increased exposure to topotecan and MX, are resistant to topotecan, CPT11, SN38, and 9-aminocamptothecin as well as MX.  Increased energy-dependent efflux of affected drugs was noted.  BCRP is a very efficient transporter of topotecan.  Our recent studies, using the monoclonal antibody (mAb) BXP34, revealed that BCRP is located in the plasma membrane of the T8 and MX3 cell lines.  Preliminary results of staining of human tumor cells showed low or absent levels of BCRP in a panel of solid tumors and acute myeloid leukemia cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPn0QwPct2nLVg90H21EOLACvtfcHk0lhRK4LxvhDzkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntVCrsA%253D%253D&md5=868dbe4d966603c1e7f523a4539b2fe7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2000.tb07037.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2000.tb07037.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DMaliepaard%26aufirst%3DM.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DJonker%26aufirst%3DJ.%2BW.%26aulast%3DSmit%26aufirst%3DJ.%2BW.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26atitle%3DTransport%2520of%2520topoisomerase%2520I%2520inhibitors%2520by%2520the%2520breast%2520cancer%2520resistance%2520protein%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2000%26volume%3D922%26spage%3D188%26epage%3D194%26doi%3D10.1111%2Fj.1749-6632.2000.tb07037.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwahana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsui, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imagawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohgo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejima, A.</span></span> <span> </span><span class="NLM_article-title">Growth inhibitory effect if a new campthotecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell Line PC6</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1097/00001813-200006000-00005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1097%2F00001813-200006000-00005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10912951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3cXltVegtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2000&pages=353-362&author=M.+Ishiiauthor=M.+Iwahanaauthor=I.+Mitsuiauthor=M.+Minamiauthor=S.+Imagawaauthor=A.+Tohgoauthor=A.+Ejima&title=Growth+inhibitory+effect+if+a+new+campthotecin+analog%2C+DX-8951f%2C+on+various+drug-resistant+sublines+including+BCRP-mediated+camptothecin+derivative-resistant+variants+derived+from+the+human+lung+cancer+cell+Line+PC6&doi=10.1097%2F00001813-200006000-00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6</span></div><div class="casAuthors">Ishii, Mineko; Iwahana, Michio; Mitsui, Ikuo; Minami, Megumi; Imagawa, Setsuko; Tohgo, Akiko; Ejima, Akio</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-362</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">DX-8951f, a new water-sol. camptothecin (CPT) deriv., has been reported to show potent antitumor effects against various tumors in vitro and in vivo.  We further evaluated the cytotoxic effect of DX-8951f against eight drug-resistant sublines derived by stepwise exposure of human oat cell carcinoma PC-6 to various drugs.  In paclitaxel-, adriamycin-, vincristine- and etoposide-resistant cells, over-expression of P-glycoprotein (P-gp) and a correlative redn. in drug accumulation and typical drug-sensitivity pattern were confirmed.  The etoposide-resistant line with the highest P-gp level was cross-resistant also to SN-38, CPT-11 and topotecan (TPT), but not to 9-aminocamptothecin (9-AC), CPT and DX-8951f.  SN-38- and CPT-11-resistant cells, of which topoisomerase I activities and levels were similar to those of the parent cells, showed cross-resistance clearly to TPT, 9-AC and mitoxantrone, but hardly to DX-8951f.  In these two resistant sublines, the intracellular topotecan level was significantly lower than that in parental PC-6 and the reduced accumulation was mediated by breast cancer resistant protein (BCRP).  The cisplatin-resistant variant, which had a 2-fold increase in glutathione content, showed no cross-resistance and the 5-fluorouracil-resistant variant, which had a 50% decrease in glutathione content, exhibited collateral sensitivity to most of the other anticancer agents including DX-8951f.  We concluded that DX-8951f showed a potent cytotoxic effect on various types of drug-resistant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHN95P5NWZALVg90H21EOLACvtfcHk0lgifE5-vPSu-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXltVegtLc%253D&md5=2734e7e280f96a907f6ba8c448653985</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2F00001813-200006000-00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-200006000-00005%26sid%3Dliteratum%253Aachs%26aulast%3DIshii%26aufirst%3DM.%26aulast%3DIwahana%26aufirst%3DM.%26aulast%3DMitsui%26aufirst%3DI.%26aulast%3DMinami%26aufirst%3DM.%26aulast%3DImagawa%26aufirst%3DS.%26aulast%3DTohgo%26aufirst%3DA.%26aulast%3DEjima%26aufirst%3DA.%26atitle%3DGrowth%2520inhibitory%2520effect%2520if%2520a%2520new%2520campthotecin%2520analog%252C%2520DX-8951f%252C%2520on%2520various%2520drug-resistant%2520sublines%2520including%2520BCRP-mediated%2520camptothecin%2520derivative-resistant%2520variants%2520derived%2520from%2520the%2520human%2520lung%2520cancer%2520cell%2520Line%2520PC6%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2000%26volume%3D11%26spage%3D353%26epage%3D362%26doi%3D10.1097%2F00001813-200006000-00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bessho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achiwa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muramatsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niimi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, R.</span></span> <span> </span><span class="NLM_article-title">Role of ABCG2 as biomarker for predicting resistance to CPT11/SN-38 in lung cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1111/j.1349-7006.2006.00164.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1111%2Fj.1349-7006.2006.00164.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=16542215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs1Omurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2006&pages=192-198&author=Y.+Besshoauthor=T.+Oguriauthor=H.+Achiwaauthor=H.+Muramatsuauthor=H.+Maedaauthor=T.+Niimiauthor=S.+Satoauthor=R.+Ueda&title=Role+of+ABCG2+as+biomarker+for+predicting+resistance+to+CPT11%2FSN-38+in+lung+cancer&doi=10.1111%2Fj.1349-7006.2006.00164.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer</span></div><div class="casAuthors">Bessho, Yuji; Oguri, Tetsuya; Achiwa, Hiroyuki; Muramatsu, Hideki; Maeda, Hiroyoshi; Niimi, Takashi; Sato, Shigeki; Ueda, Ryuzo</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">192-198</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Asia Pty Ltd.</span>)
        </div><div class="casAbstract">To examine the mechanism of resistance to 7-ethyl-10-hydroxycamptothecin (SN-38) in lung cancer, we continuously exposed the non-small-cell lung cancer (NSCLC) cell line NCI-H23 to SN-38 and selected the SN-38-resistant clone H23/SN-38.  After 2 mo of culturing in SN-38-free conditions, H23/SN-38 cells recovered their sensitivity to SN-38 and were subsequently established as the revertant H23/SN-38REV cell line.  Because H23/SN-38 cells show cross resistance to certain anticancer drugs, such as topotecan, etoposide, doxorubicin and mitoxantrone, we examd. the gene and protein expression levels of drug efflux transporters of the ATP-binding cassette (ABC) family.  We found that both gene and protein expression of ABCG2/BCRP (ABCG2) in H23/SN-38 cells was increased compared with that in NCI-H23 cells and H23/SN-38REV cells.  The cellular accumulation of topotecan in H23/SN-38 cells was decreased compared with that in NCI-H23 and H23/SN-38REV cells, and treatment with reserpine (an inhibitor of ABCG2) increased the cellular accumulation of topotecan in H23/SN-38 cells.  Furthermore, treatment with reserpine also altered the sensitivity of H23/SN-38 cells to SN-38.  These results indicate that the upregulation of ABCG2 was functional, and related to the resistance of H23/SN-38 cells to SN-38.  Moreover, we found that gene expression levels of ABCG2 were significantly correlated with the concn. of SN-38 for 50% cell survival in 13 NSCLC cells (r = 0.592, P < 0.05).  The present results indicate that the induction of ABCG2 by SN-38 does confer acquired resistance to CPT-11/SN-38, but the induction of ABCG2 and subsequent drug resistance are reversible.  However, the expression level of ABCG2 may be a useful indicator of CPT-11/SN-38 activity in lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLxN5ZFT5Rw7Vg90H21EOLACvtfcHk0lgifE5-vPSu-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs1Omurk%253D&md5=55a3c2b03ac4efa18d0268a4fdb60c07</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2006.00164.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2006.00164.x%26sid%3Dliteratum%253Aachs%26aulast%3DBessho%26aufirst%3DY.%26aulast%3DOguri%26aufirst%3DT.%26aulast%3DAchiwa%26aufirst%3DH.%26aulast%3DMuramatsu%26aufirst%3DH.%26aulast%3DMaeda%26aufirst%3DH.%26aulast%3DNiimi%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DUeda%26aufirst%3DR.%26atitle%3DRole%2520of%2520ABCG2%2520as%2520biomarker%2520for%2520predicting%2520resistance%2520to%2520CPT11%252FSN-38%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2006%26volume%3D97%26spage%3D192%26epage%3D198%26doi%3D10.1111%2Fj.1349-7006.2006.00164.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagashima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiozawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yabuuchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, S.</span></span> <span> </span><span class="NLM_article-title">BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1007/s00280-006-0212-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1007%2Fs00280-006-0212-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=16520985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1SmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=594-600&author=S.+Nagashimaauthor=H.+Sodaauthor=M.+Okaauthor=T.+Kitazakiauthor=K.+Shiozawaauthor=Y.+Nakamuraauthor=M.+Takemuraauthor=H.+Yabuuchiauthor=M.+Fukudaauthor=K.+Tsukamotoauthor=S.+Kohno&title=BCRP%2FABCG2+levels+account+for+the+resistance+to+topoisomerase+I+inhibitors+and+reversal+effects+by+gefitinib+in+non-small+cell+lung+cancer&doi=10.1007%2Fs00280-006-0212-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer</span></div><div class="casAuthors">Nagashima, Seiji; Soda, Hiroshi; Oka, Mikio; Kitazaki, Takeshi; Shiozawa, Ken; Nakamura, Yoichi; Takemura, Masaaki; Yabuuchi, Hikaru; Fukuda, Minoru; Tsukamoto, Kazuhiro; Kohno, Shigeru</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">594-600</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Breast cancer resistance protein (BCRP) confers resistance against topoisomerase I inhibitors in cancer cells.  Very recently, the authors reported that gefitinib reverses BCRP-mediated drug resistance by direct inhibition.  However, it remains undetd. how much BCRP contributes to the resistance to topoisomerase I inhibitors in non-small cell lung cancer (NSCLC).  The present study was designed to examine whether BCRP levels in NSCLC cells are correlated with the resistance to topoisomerase I inhibitors and the reversal effect by gefitinib.  Methods: BCRP levels and its function were evaluated by Western blotting and flow-cytometry, resp.  Gefitinib-insensitive NSCLC cells expressed various levels of BCRP, which were closely correlated not only with the IC50 values of SN-38 (r=0.874, P<0.05) and those of topotecan (r=0.968, P<0.001), but also with the reversal effects of 1 μM gefitinib on SN-38 resistance (r=0.956, P<0.001) and topotecan resistance (r=0.977, P=0.0001).  Results: BCRP levels accounted for between 80 and 90% of the variation in the resistance to topoisomerase I inhibitors and the reversal effects by gefitinib.  Also, gefitinib increased intracellular topotecan accumulation in proportion to the BCRP levels.  Conclusions: These findings suggest that BCRP is the most important mol. responsible for topoisomerase I inhibitor resistance, and that the development of BCRP inhibitors is an effective approach for overcoming this resistance.  In addn., the examn. of BCRP levels in NSCLC tissues may identify an optimal patient population for treatment with topoisomerase I inhibitors alone or in combination with BCRP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13sMpfTcgPLVg90H21EOLACvtfcHk0lgifE5-vPSu-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1SmsLs%253D&md5=2eeab9a906ca519fcfcc5d7ba4140b77</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs00280-006-0212-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-006-0212-y%26sid%3Dliteratum%253Aachs%26aulast%3DNagashima%26aufirst%3DS.%26aulast%3DSoda%26aufirst%3DH.%26aulast%3DOka%26aufirst%3DM.%26aulast%3DKitazaki%26aufirst%3DT.%26aulast%3DShiozawa%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DTakemura%26aufirst%3DM.%26aulast%3DYabuuchi%26aufirst%3DH.%26aulast%3DFukuda%26aufirst%3DM.%26aulast%3DTsukamoto%26aufirst%3DK.%26aulast%3DKohno%26aufirst%3DS.%26atitle%3DBCRP%252FABCG2%2520levels%2520account%2520for%2520the%2520resistance%2520to%2520topoisomerase%2520I%2520inhibitors%2520and%2520reversal%2520effects%2520by%2520gefitinib%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2006%26volume%3D58%26spage%3D594%26epage%3D600%26doi%3D10.1007%2Fs00280-006-0212-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina-Perez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhagen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antony, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadjem, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span> <span> </span><span class="NLM_article-title">ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin and homocamptothecins</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">836</span>– <span class="NLM_lpage">842</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.063149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1124%2Fjpet.103.063149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=15075385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVykt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2004&pages=836-842&author=S.+E.+Batesauthor=M.+Medina-Perezauthor=G.+Kohlhagenauthor=S.+Antonyauthor=T.+Nadjemauthor=R.+W.+Robeyauthor=Y.+Pommier&title=ABCG2+mediates+differential+resistance+to+SN-38+%287-ethyl-10-hydroxycamptothecin+and+homocamptothecins&doi=10.1124%2Fjpet.103.063149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins</span></div><div class="casAuthors">Bates, Susan E.; Medina-Perez, Wilma Y.; Kohlhagen, Glenda; Antony, Smitha; Nadjem, Tim; Robey, Robert W.; Pommier, Yves</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">836-842</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">One activity potentially limiting the efficacy of camptothecin anticancer agents is their cellular efflux by the ATP-binding cassette half-transporter, ABCG2.  Homocamptothecins are novel anticancer drugs that inhibit topoisomerase 1 with a greater potency than camptothecins.  Homocamptothecins differ from camptothecins by their E-ring, which is seven-membered instead of the six-membered ring of camptothecins.  We report herein that, like camptothecins, homocamptothecin and its difluoro deriv. BN80915 are substrates for ABCG2.  However, the resistance of three selected cell lines overexpressing wild-type or mutant ABCG2 to homocamptothecin or BN80915 was less than resistance to SN-38 (7-ethyl-10-hydroxycamptothecin), indicating that both the seven-membered E-ring present in homocamptothecin and the A- and B-ring modifications present in SN-38 are involved in substrate recognition by ABCG2.  HEK-293 cells transfected with vectors encoding wild-type or mutant ABCG2 were less resistant to both homocamptothecins than to SN-38.  However, transfectants overexpressing mutant ABCG2 had relative resistance values for homocamptothecin and BN80915 4- to 14-fold higher than cells expressing wild-type ABCG2, suggesting that the gain of function resulting from mutation at amino acid 482, although not affecting SN-38, extends to the homocamptothecins.  Resistance was reversed by the ABCG2 inhibitor fumitremorgin C.  BN80915 was 17-fold more potent than SN-38 in wild-type ABCG2-transfected cells, suggesting that BN80915 has the potential to overcome ABCG2-related resistance to SN-38, the active metabolite of CPT-11 (irinotecan).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZClD9Z5kQgLVg90H21EOLACvtfcHk0liCgmigKduXgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVykt7g%253D&md5=274f9c9ba24d1d4cc1843e614725004e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.063149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.063149%26sid%3Dliteratum%253Aachs%26aulast%3DBates%26aufirst%3DS.%2BE.%26aulast%3DMedina-Perez%26aufirst%3DM.%26aulast%3DKohlhagen%26aufirst%3DG.%26aulast%3DAntony%26aufirst%3DS.%26aulast%3DNadjem%26aufirst%3DT.%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DPommier%26aufirst%3DY.%26atitle%3DABCG2%2520mediates%2520differential%2520resistance%2520to%2520SN-38%2520%25287-ethyl-10-hydroxycamptothecin%2520and%2520homocamptothecins%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D310%26spage%3D836%26epage%3D842%26doi%3D10.1124%2Fjpet.103.063149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perego, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Cesare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Isabella, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carenini, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beggiolin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezzoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plumbo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tartiglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratesi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carminati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunino, F.</span></span> <span> </span><span class="NLM_article-title">A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6034</span>– <span class="NLM_lpage">6037</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2011&pages=6034-6037&author=P.+Peregoauthor=M.+De+Cesareauthor=P.+De+Isabellaauthor=N.+Careniniauthor=G.+Beggiolinauthor=G.+Pezzoniauthor=M.+Plumboauthor=L.+Tartigliaauthor=G.+Pratesiauthor=C.+Pisanoauthor=P.+Carminatiauthor=G.+L.+Schefferauthor=F.+Zunino&title=A+novel+7-modified+camptothecin+analog+overcomes+breast+cancer+resistance+protein-associated+resistance+in+a+mitoxantrone-selected+colon+carcinoma+cell+line"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPerego%26aufirst%3DP.%26aulast%3DDe%2BCesare%26aufirst%3DM.%26aulast%3DDe%2BIsabella%26aufirst%3DP.%26aulast%3DCarenini%26aufirst%3DN.%26aulast%3DBeggiolin%26aufirst%3DG.%26aulast%3DPezzoni%26aufirst%3DG.%26aulast%3DPlumbo%26aufirst%3DM.%26aulast%3DTartiglia%26aufirst%3DL.%26aulast%3DPratesi%26aufirst%3DG.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DCarminati%26aufirst%3DP.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DZunino%26aufirst%3DF.%26atitle%3DA%2520novel%25207-modified%2520camptothecin%2520analog%2520overcomes%2520breast%2520cancer%2520resistance%2520protein-associated%2520resistance%2520in%2520a%2520mitoxantrone-selected%2520colon%2520carcinoma%2520cell%2520line%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D61%26spage%3D6034%26epage%3D6037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maliepaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Gastelen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohgo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hausheer, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Waardenburg, R. C. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Jong, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span> <span> </span><span class="NLM_article-title">Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins <i>in vitro</i> using non-substrate drugs or the BCRP inhibitor GF120918</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">941</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11309344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjs1elsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=935-941&author=M.+Maliepaardauthor=M.+A.+van+Gastelenauthor=A.+Tohgoauthor=F.+H.+Hausheerauthor=R.+C.+A.+M.+van+Waardenburgauthor=L.+A.+de+Jongauthor=D.+Pluimauthor=J.+H.+Beijnenauthor=J.+H.+M.+Schellens&title=Circumvention+of+breast+cancer+resistance+protein+%28BCRP%29-mediated+resistance+to+camptothecins+in+vitro+using+non-substrate+drugs+or+the+BCRP+inhibitor+GF120918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using nonsubstrate drugs or the BCRP inhibitor GF 120918</span></div><div class="casAuthors">Maliepaard, Mare; van Gastelen, Margot A.; Tohgo, Akiko; Hausheer, Frederick H.; van Waardenburg, Robert C. A. M.; de Jong, Laurina A.; Pluim, Dick; Beijnen, Jos H.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">935-941</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8 and MX3 to camptothecins more extensively and investigating whether resistance can be reversed by inhibiting BCRP by GF120918.  Camptothecins studied were topotecan, CPT-11, and its active metabolite SN-38, 9-aminocamptothecin, and the novel exptl. camptothecins NX211, DX8951f, and BNP1350.  Notably, DX8951f and BNP1350 appeared to be very poor substrates for BCRP, with much lower resistance factors obsd. both in T8 and MX3 cells than obsd. for the other camptothecins tested.  In the presence of a nontoxic dose level of GF120918, the intracellular accumulation of topotecan in the T8 and MX3 cells was completely restored to the intracellular levels obsd. in the sensitive IGROV1 parental cell line.  This resulted in almost complete reversal of drug resistance to topotecan and to most of the other topoisomerase I drugs tested in the T8 cell line and to complete reversal in the MX3 cells.  However, coincubation of DX8951f or BNP1350 with GF120918 did not affect the cytotoxicity of either of these drugs significantly.  From the combined data, we conclude that the affinities of topoisomerase I drugs for BCRP are, in decreasing order: SN-38 > topotecan > 9-aminocamptothecin ∼ CPT-11 > NX211 > DX8951f > BNP1350.  Furthermore, GF120918 appears to be a potent reversal agent of BCRP-mediated resistance to camptothecins, with almost complete reversal noted at 100 nM.  Potential BCRP-mediated resistance to topoisomerase I inhibitors can also be avoided by using the BCRP-insensitive drugs DX8951f or BNP1350.  This observation may have important clin. implications for future development of novel camptothecins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn1KA-rPrFobVg90H21EOLACvtfcHk0liCgmigKduXgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjs1elsbo%253D&md5=b381852cab5ffd4959526f22b64290e8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMaliepaard%26aufirst%3DM.%26aulast%3Dvan%2BGastelen%26aufirst%3DM.%2BA.%26aulast%3DTohgo%26aufirst%3DA.%26aulast%3DHausheer%26aufirst%3DF.%2BH.%26aulast%3Dvan%2BWaardenburg%26aufirst%3DR.%2BC.%2BA.%2BM.%26aulast%3Dde%2BJong%26aufirst%3DL.%2BA.%26aulast%3DPluim%26aufirst%3DD.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DCircumvention%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%2529-mediated%2520resistance%2520to%2520camptothecins%2520in%2520vitro%2520using%2520non-substrate%2520drugs%2520or%2520the%2520BCRP%2520inhibitor%2520GF120918%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D935%26epage%3D941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Hattum, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoogsteen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlüper, H. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maliepaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheper, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlhagen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinedo, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boven, E.</span></span> <span> </span><span class="NLM_article-title">Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumor activity</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6600508</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fsj.bjc.6600508" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=12237778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD38XntVGqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2002&pages=665-672&author=A.+H.+van%0AHattumauthor=J.+J.+Hoogsteenauthor=H.+M.+M.+Schl%C3%BCperauthor=M.+Maliepaardauthor=G.+L.+Schefferauthor=R.+J.+Scheperauthor=G.+Kohlhagenauthor=Y.+Pommierauthor=H.+M.+Pinedoauthor=E.+Boven&title=Induction+of+breast+cancer+resistance+protein+by+the+camptothecin+derivative+DX-8951f+is+associated+with+minor+reduction+of+antitumor+activity&doi=10.1038%2Fsj.bjc.6600508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity</span></div><div class="casAuthors">van Hattum, A. H.; Hoogsteen, I. J.; Schlueper, H. M. M.; Maliepaard, M.; Scheffer, G. L.; Scheper, R. J.; Kohlhagen, G.; Pommier, Y.; Pinedo, H. M.; Boven, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">665-672</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">DX-8951f (exatecan mesylate), a new water-sol. deriv. of camptothecin, is currently being evaluated in phase II clin. trials.  Resistance may be acquired when treating cancer patients with DX-8951f.  Therefore, the authors selected a subline of the human ovarian cancer cell line A2780 for resistance against DX-8951f to investigate possible mechanisms of resistance.  This DX-8951f-resistant subline, designated 2780DX8 (resistance factor = 9.3), displayed a typical cross-resistance pattern including compds., such as topotecan (resistance factor = 34), SN-38 (resistance factor = 47), mitoxantrone (resistance factor = 59) and doxorubicin (resistance factor = 2.9), which have previously been assocd. with the expression of breast cancer resistance protein.  2780DX8 cells did not show changes in the topoisomerase I gene, in topoisomerase I protein levels or catalytic activity.  Overexpression of breast cancer resistance protein could be detected, both at the mRNA and protein level, while staining for Pgp, MRP1, or LRP was neg.  GF120918, an inhibitor of breast cancer resistance protein, was able to reverse the DX-8951f-induced resistance in 2780DX8 cells.  In vivo expts. in well-established 2780DX8 human tumor xenografts demonstrated that the growth inhibition induced by CPT-11 was more affected by breast cancer resistance protein expression than that of DX-8951f.  These data indicate for the first time that DX-8951f is able to induce breast cancer resistance protein as a mechanism of resistance.  Breast cancer resistance protein, however, results in only minor redn. of antitumor activity of DX-8951f which is an advantage over topotecan and CPT-11/SN-38.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSpTsPOcp8QbVg90H21EOLACvtfcHk0lgHk6NocHHmzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntVGqu7g%253D&md5=5eb7b6b36d3f89d830d69ff095e8f57f</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600508%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BHattum%26aufirst%3DA.%2BH.%26aulast%3DHoogsteen%26aufirst%3DJ.%2BJ.%26aulast%3DSchl%25C3%25BCper%26aufirst%3DH.%2BM.%2BM.%26aulast%3DMaliepaard%26aufirst%3DM.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DScheper%26aufirst%3DR.%2BJ.%26aulast%3DKohlhagen%26aufirst%3DG.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26aulast%3DBoven%26aufirst%3DE.%26atitle%3DInduction%2520of%2520breast%2520cancer%2520resistance%2520protein%2520by%2520the%2520camptothecin%2520derivative%2520DX-8951f%2520is%2520associated%2520with%2520minor%2520reduction%2520of%2520antitumor%2520activity%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2002%26volume%3D87%26spage%3D665%26epage%3D672%26doi%3D10.1038%2Fsj.bjc.6600508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Hattum, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlüper, H. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hausheer, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinedo, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boven, E.</span></span> <span> </span><span class="NLM_article-title">Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1002/ijc.10434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1002%2Fijc.10434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=12115582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVGntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2002&pages=22-29&author=A.+H.+van%0AHattumauthor=H.+M.+M.+Schl%C3%BCperauthor=F.+H.+Hausheerauthor=H.+M.+Pinedoauthor=E.+Boven&title=Novel+camptothecin+derivative+BNP1350+in+experimental+human+ovarian+cancer%3A+determination+of+efficacy+and+possible+mechanisms+of+resistance&doi=10.1002%2Fijc.10434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance</span></div><div class="casAuthors">Van Hattum, Annemarie H.; Schluper, Hennie M. M.; Hausheer, Frederick H.; Pinedo, Herbert M.; Boven, Epie</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-29</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The novel camptothecin deriv. BNP1350 ((7-[2-trimethylsilyl)ethyl]-20(S)-camptothecin), also known as Karenitecin, has been developed for superior oral bioavailability and increased lactone stability.  In our study, we describe the antiproliferative effects of BNP1350, SN-38 and topotecan in 4 human ovarian cancer cell lines.  BNP1350 was slightly more potent than SN-38 (p<0.01) and was considerably more potent than topotecan (p<0.01).  We extended these studies to well-established human ovarian cancer xenografts in which we compared the growth inhibition induced by BNP1350 with that of topotecan given in equitoxic schedules.  The growth inhibition in all 3 xenografts induced by BNP1350 was ≥75%, which was significantly better than that resulting from topotecan (p<0.05).  We then selected BNP1350-resistant variants of the A2780 human ovarian cancer cell line, 2780K4 (resistance factor: 41) and 2780K32 (resistance factor: 90), to analyze possible resistance mechanisms.  These variants exhibited cross-resistance against all camptothecins tested.  In comparison with 2780K4 cells, 2780K32 cells were relatively more resistant against SN-38, topotecan, DX-8951f and BNP1350.  In addn., 2780K32 cells were highly cross-resistant against mitoxantrone.  In both 2780K4 and 2780K32, the amt. of topoisomerase I was not changed but the catalytic activity was reduced.  Furthermore, 2780K32 cells clearly overexpressed the breast cancer resistance protein (BCRP), as demonstrated for both the gene and the protein.  In contrast to topotecan, BNP1350 proved not to be a good substrate for BCRP.  Overall, we conclude that BNP1350 offers advantages over topotecan expressed by high efficacy in exptl. human ovarian cancer and poor affinity for BCRP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopTHWO4MpXH7Vg90H21EOLACvtfcHk0lgHk6NocHHmzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVGntLg%253D&md5=19bc250d6b7cfe4dbbbffe47f3a73ed5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fijc.10434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.10434%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BHattum%26aufirst%3DA.%2BH.%26aulast%3DSchl%25C3%25BCper%26aufirst%3DH.%2BM.%2BM.%26aulast%3DHausheer%26aufirst%3DF.%2BH.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26aulast%3DBoven%26aufirst%3DE.%26atitle%3DNovel%2520camptothecin%2520derivative%2520BNP1350%2520in%2520experimental%2520human%2520ovarian%2520cancer%253A%2520determination%2520of%2520efficacy%2520and%2520possible%2520mechanisms%2520of%2520resistance%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2002%26volume%3D100%26spage%3D22%26epage%3D29%26doi%3D10.1002%2Fijc.10434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erlichman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boerner, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallgren, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spieker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffer, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maliepaard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bible, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufmann, S. H.</span></span> <span> </span><span class="NLM_article-title">The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 6-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance-mediated drug efflux</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">739</span>– <span class="NLM_lpage">748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11212277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3MXht1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=739-748&author=C.+Erlichmanauthor=S.+A.+Boernerauthor=C.+G.+Hallgrenauthor=R.+Spiekerauthor=X.-Y.+Wangauthor=C.+D.+Jamesauthor=G.+L.+Schefferauthor=M.+Maliepaardauthor=D.+D.+Rossauthor=K.+C.+Bibleauthor=S.+H.+Kaufmann&title=The+HER+tyrosine+kinase+inhibitor+CI1033+enhances+cytotoxicity+of+6-ethyl-10-hydroxycamptothecin+and+topotecan+by+inhibiting+breast+cancer+resistance-mediated+drug+efflux"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux</span></div><div class="casAuthors">Erlichman, Charles; Boerner, Scott A.; Hallgren, Christopher G.; Spieker, Rebecca; Wang, Xiao-Yang; James, C. David; Scheffer, George L.; Maliepaard, Marc; Ross, Douglas D.; Bible, Keith C.; Kaufmann, Scott H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">739-748</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Because the activities of HER family members are elevated and/or aberrant in a variety of human neoplasms, these cell surface receptors are receiving increasing attention as potential therapeutic targets.  In the present study, we examd. the effect of combining the HER family tyrosine kinase inhibitor CI1033 (PD 183805) with the topoisomerase (topo) I poison 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan, in a no. of different cell lines.  Colony-forming assays revealed that the antiproliferative effects of simultaneous treatment with CI1033 and SN-38 were synergistic in T98G glioblastoma cells and HCT8 colorectal carcinoma cells, whereas sequential treatments were additive at best.  In addnl. studies examg. the mechanistic basis for these findings in T98G cells, immunoblotting revealed that the inhibitory effects of CI1033 on epidermal growth factor receptor autophosphorylation were unaffected by SN-38.  Likewise, CI1033 had no effect on topo I polypeptide levels, localization, or activity.  Nonetheless, CI1033 markedly enhanced the no. of covalent topo I-DNA complexes stabilized by SN-38 or the related agent topotecan (TPT).  Anal. of intracellular SN-38 levels by high-performance liq. chromatog. and intracellular TPT levels by flow microfluorometry revealed that CI1033 increased the steady-state accumulation of SN-38 and TPT by 9.4 ± 1.9- and 1.8 ± 0.2-fold, resp.  Further evaluation revealed that the initial rate of TPT uptake was unaffected by CI1033, whereas the rate of efflux was markedly diminished.  Addnl. studies demonstrated that T98G and HCT8 cells express the breast cancer resistance protein (BCRP), a recently cloned ATP binding cassette transporter.  Moreover, CI1033 enhanced the uptake and cytotoxicity of SN-38 and TPT in cells transfected with BCRP but not empty vector.  Conversely, CI1033 accumulation was diminished in cells expressing BCRP, suggesting that CI1033 is a substrate for this efflux pump.  These results indicate that CI1033 can modulate the accumulation and subsequent cytotoxicity of two widely used topo I poisons in cells that have no history of previous exposure to these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgpLth6O-Z0LVg90H21EOLACvtfcHk0lgHk6NocHHmzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXht1Gmt74%253D&md5=93b4e887dde792b70d881bc94b6793ca</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DHallgren%26aufirst%3DC.%2BG.%26aulast%3DSpieker%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.-Y.%26aulast%3DJames%26aufirst%3DC.%2BD.%26aulast%3DScheffer%26aufirst%3DG.%2BL.%26aulast%3DMaliepaard%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DD.%2BD.%26aulast%3DBible%26aufirst%3DK.%2BC.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26atitle%3DThe%2520HER%2520tyrosine%2520kinase%2520inhibitor%2520CI1033%2520enhances%2520cytotoxicity%2520of%25206-ethyl-10-hydroxycamptothecin%2520and%2520topotecan%2520by%2520inhibiting%2520breast%2520cancer%2520resistance-mediated%2520drug%2520efflux%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D739%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.-W.</span></span> <span> </span><span class="NLM_article-title">Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">11971</span>– <span class="NLM_lpage">11985</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.18632%2Foncotarget.2647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25436978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC2MzhslWhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=11971-11985&author=X.-K.+Wangauthor=K.+K.+W.+Toauthor=L.-Y.+Huangauthor=J.-H.+Xuauthor=K.+Yangauthor=F.+Wangauthor=Z.-C.+Huangauthor=S.+Yeauthor=L.-W.+Fu&title=Afatinib+circumvents+multidrug+resistance+via+dually+inhibiting+ATP+binding+cassette+subfamily+G+member+2+in+vitro+and+in+vivo&doi=10.18632%2Foncotarget.2647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo</span></div><div class="casAuthors">Wang Xiao-Kun; Huang Li-Yan; Yang Ke; Wang Fang; Huang Zhen-Cong; Fu Li-Wu; To Kenneth Kin Wah; Xu Jing-Hong; Ye Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11971-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multidrug resistance (MDR) to chemotherapeutic drugs is a formidable barrier to the success of cancer chemotherapy.  Expressions of ATP-binding cassette (ABC) transporters contribute to clinical MDR phenotype.  In this study, we found that afatinib, a small molecule tyrosine kinase inhibitor (TKI) targeting EGFR, HER-2 and HER-4, reversed the chemoresistance mediated by ABCG2 in vitro, but had no effect on that mediated by multidrug resistance protein ABCB1 and ABCC1.  In addition, afatinib, in combination with topotecan, significantly inhibited the growth of ABCG2- overexpressing cell xenograft tumors in vivo.  Mechanistic investigations exhibited that afatinib significantly inhibited ATPase activity of ABCG2 and downregulated expression level of ABCG2, which resulted in the suppression of efflux activity of ABCG2 in parallel to the increase of intracellular accumulation of ABCG2 substrate anticancer agents.  Taken together, our findings may provide a new and useful combinational therapeutic strategy of afatinib with chemotherapeutical drug for the patients with ABCG2 overexpressing cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSrZfMDjQbKJmhHGZei4OW9fW6udTcc2eZZu9w4mA3VCbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzhslWhtA%253D%253D&md5=8f91286a39ee9f15f2a87287e794ec96</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2647%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.-K.%26aulast%3DTo%26aufirst%3DK.%2BK.%2BW.%26aulast%3DHuang%26aufirst%3DL.-Y.%26aulast%3DXu%26aufirst%3DJ.-H.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DZ.-C.%26aulast%3DYe%26aufirst%3DS.%26aulast%3DFu%26aufirst%3DL.-W.%26atitle%3DAfatinib%2520circumvents%2520multidrug%2520resistance%2520via%2520dually%2520inhibiting%2520ATP%2520binding%2520cassette%2520subfamily%2520G%2520member%25202%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D11971%26epage%3D11985%26doi%3D10.18632%2Foncotarget.2647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance <i>in vitro</i>, <i>in vivo</i> and <i>ex vivo</i></span>. <i>Exp. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">e303</span>, <span class="refDoi"> DOI: 10.1038/emm.2016.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Femm.2016.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=28303028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVWms7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2017&pages=e303&author=K.+Yangauthor=Y.+Chenauthor=K.+K.+W.+Toauthor=F.+Wangauthor=D.+Liauthor=L.+Chenauthor=L.+Fu&title=Alectinib+%28CH5424802%29+antagonizes+ABCB1-+and+ABCG2-mediated+multidrug+resistance+in+vitro%2C+in+vivo+and+ex+vivo&doi=10.1038%2Femm.2016.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo</span></div><div class="casAuthors">Yang, Ke; Chen, Yifan; To, Kenneth Kin Wah; Wang, Fang; Li, Delan; Chen, Likun; Fu, Liwu</div><div class="citationInfo"><span class="NLM_cas:title">Experimental & Molecular Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e303</span>CODEN:
                <span class="NLM_cas:coden">EMMEF3</span>;
        ISSN:<span class="NLM_cas:issn">2092-6413</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Alectinib, an inhibitor of anaplastic lymphoma kinase (ALK), was approved by the Food and Drug Administration (FDA) for the treatment of patients with ALK-pos. non-small cell lung cancer (NSCLC).  Here we investigated the reversal effect of alectinib on multidrug resistance (MDR) induced by ATP-binding cassette (ABC) transporters, which is the primary cause of chemotherapy failure.  We provide the first evidence that alectinib increases the sensitivity of ABCB1- and ABCG2-overexpressing cells to chemotherapeutic agents in vitro and in vivo.  Mechanistically, alectinib increased the intracellular accumulation of ABCB1/ABCG2 substrates such as doxorubicin (DOX) and Rhodamine 123 (Rho 123) by inhibiting the efflux function of the transporters in ABCB1- or ABCG2-overexpressing cells but not in their parental sensitive cells.  Furthermore, alectinib stimulated ATPase activity and competed with substrates of ABCB1 or ABCG2 and competed with [125I] iodoarylazidoprazosin (IAAP) photolabeling bound to ABCB1 or ABCG2 but neither altered the expression and localization of ABCB1 or ABCG2 nor the phosphorylation levels of AKT and ERK.  Alectinib also enhanced the cytotoxicity of DOX and the intracellular accumulation of Rho 123 in ABCB1-overexpressing primary leukemia cells.  These findings suggest that alectinib combined with traditional chemotherapy may be beneficial to patients with ABCB1- or ABCG2-mediated MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovC2uTLcj2vLVg90H21EOLACvtfcHk0ljWc8DaMks-sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVWms7o%253D&md5=3307b29638f0965d215784981011e9eb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Femm.2016.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femm.2016.168%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTo%26aufirst%3DK.%2BK.%2BW.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DAlectinib%2520%2528CH5424802%2529%2520antagonizes%2520ABCB1-%2520and%2520ABCG2-mediated%2520multidrug%2520resistance%2520in%2520vitro%252C%2520in%2520vivo%2520and%2520ex%2520vivo%26jtitle%3DExp.%2520Mol.%2520Med.%26date%3D2017%26volume%3D49%26spage%3De303%26doi%3D10.1038%2Femm.2016.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbuti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, A.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurpel, J. N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) inhibitor cabozantinib</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.01.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.phrs.2017.01.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=28131876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXisFSmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2017&pages=89-98&author=G.-N.+Zhangauthor=Y.-K.+Zhangauthor=Y.-J.+Wangauthor=A.+M.+Barbutiauthor=X.-J.+Zhuauthor=X.-Y.+Yuauthor=A.-W.+Wenauthor=J.+N.+D.+Wurpelauthor=Z.-S.+Chen&title=Modulating+the+function+of+ATP-binding+cassette+subfamily+G+member+2+%28ABCG2%29+inhibitor+cabozantinib&doi=10.1016%2Fj.phrs.2017.01.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib</span></div><div class="casAuthors">Zhang, Guan-Nan; Zhang, Yun-Kai; Wang, Yi-Jun; Barbuti, Anna Maria; Zhu, Xi-Jun; Yu, Xin-Yue; Wen, Ai-Wen; Wurpel, John N. D.; Chen, Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-98</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cabozantinib (XL184) is a small mol. tyrosine kinase receptor inhibitor, which targets c-Met and VEGFR2.  Cabozantinib has been approved by the Food and Drug Administration to treat advanced medullary thyroid cancer and renal cell carcinoma.  In the present study, we evaluated the ability of cabozantinib to modulate the function of the ATP-binding cassette subfamily G member 2 (ABCG2) by sensitizing cells that are resistant to ABCG2 substrate antineoplastic drugs.  We used a drug-selected resistant cell line H460/MX20 and three ABCG2 stable transfected cell lines ABCG2-482-R2, ABCG2-482-G2, and ABCG2-482-T7, which overexpress ABCG2.  Cabozantinib, at non-toxic concns. (3 or 5 μM), sensitized the ABCG2-overexpressing cells to mitoxantrone, SN-38, and topotecan.  Our results indicate that cabozantinib reverses ABCG2-mediated multidrug resistance by antagonizing the drug efflux function of the ABCG2 transporter instead of downregulating its expression.  The mol. docking anal. indicates that cabozantinib binds to the drug-binding site of the ABCG2 transporter.  Overall, our findings demonstrate that cabozantinib inhibits the ABCG2 transporter function and consequently enhances the effect of the antineoplastic agents that are substrates of ABCG2.  Cabozantinib may be a useful agent in anticancer treatment regimens for patients who are resistant to ABCG2 substrate drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdkxleAdX6tbVg90H21EOLACvtfcHk0ljWc8DaMks-sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXisFSmur8%253D&md5=81e2b494db185b4e91c2d31fccbea3dc</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.01.024%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DG.-N.%26aulast%3DZhang%26aufirst%3DY.-K.%26aulast%3DWang%26aufirst%3DY.-J.%26aulast%3DBarbuti%26aufirst%3DA.%2BM.%26aulast%3DZhu%26aufirst%3DX.-J.%26aulast%3DYu%26aufirst%3DX.-Y.%26aulast%3DWen%26aufirst%3DA.-W.%26aulast%3DWurpel%26aufirst%3DJ.%2BN.%2BD.%26aulast%3DChen%26aufirst%3DZ.-S.%26atitle%3DModulating%2520the%2520function%2520of%2520ATP-binding%2520cassette%2520subfamily%2520G%2520member%25202%2520%2528ABCG2%2529%2520inhibitor%2520cabozantinib%26jtitle%3DPharmacol.%2520Res.%26date%3D2017%26volume%3D119%26spage%3D89%26epage%3D98%26doi%3D10.1016%2Fj.phrs.2017.01.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, Q.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldblatt, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">781</span>– <span class="NLM_lpage">793</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2008.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bcp.2008.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=19059384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitVOmurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2009&pages=781-793&author=Z.+Shiauthor=A.+K.+Tiwariauthor=S.+Shuklaauthor=R.+W.+Robeyauthor=I.-W.+Kimauthor=S.+Parmarauthor=S.+E.+Batesauthor=Q.-S.+Siauthor=C.+S.+Goldblattauthor=I.+Abrahamauthor=L.-W.+Fuauthor=S.+V.+Ambudkarauthor=Z.-S.+Chen&title=Inhibiting+the+function+of+ABCB1+and+ABCG2+by+the+EGFR+tyrosine+kinase+inhibitor+AG1478&doi=10.1016%2Fj.bcp.2008.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478</span></div><div class="casAuthors">Shi, Zhi; Tiwari, Amit K.; Shukla, Suneet; Robey, Robert W.; Kim, In-Wha; Parmar, Smitaben; Bates, Susan E.; Si, Qiu-Sheng; Goldblatt, Curtis S.; Abraham, Ioana; Fu, Li-Wu; Ambudkar, Suresh V.; Chen, Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">781-793</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The tyrphostin 4-(3-chloroanilino)-6,7-dimethoxyquinazoline (AG1478) is a potent and specific EGFR tyrosine kinase inhibitor (TKI); its promising pre-clin. results have led to clin. trials.  Overexpression of ATP-binding cassette (ABC) transporters such as ABCB1, ABCC1 and ABCG2 is one of the main causes of multidrug resistance (MDR) and usually results in the failure of cancer chemotherapy.  However, the interaction of AG1478 with these ABC transporters is still unclear.  In the present study, we have investigated this interaction and found that AG1478 has differential effects on these transporters.  In ABCB1-overexpressing cells, non-toxic doses of AG1478 were found to partially inhibit resistance to ABCB1 substrate anticancer drugs as well as increase intracellular accumulation of [3H]-paclitaxel.  Similarly, in ABCG2-overexpressing cells, AG1478 significantly reversed resistance to ABCG2 substrate anticancer drugs and increased intracellular accumulation of [3H]-mitoxantrone as well as fluorescent compd. BODIPY-prazosin.  AG1478 also profoundly inhibited the transport of [3H]-E217βG and [3H]-methotrexate by ABCG2.  We also found that AG1478 slightly stimulated ABCB1 ATPase activity and significantly stimulated ABCG2 ATPase activity.  Interestingly, AG1478 did not inhibit the photolabeling of ABCB1 or ABCG2 with [125I]-iodoarylazidoprazosin.  Addnl., AG1478 did not alter the sensitivity of parental, ABCB1- or ABCG2-overexpressing cells to non-ABCB1 and non-ABCG2 substrate drug and had no effect on the function of ABCC1.  Overall, we conclude that AG1478 is able to inhibit the function of ABCB1 and ABCG2, with a more pronounced effect on ABCG2.  Our findings provide valuable contributions to the development of safer and more effective EGFR TKIs for use as anticancer agents in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYeG-aGqdzKbVg90H21EOLACvtfcHk0lg5Nau6H2VyoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitVOmurs%253D&md5=51f7053a870d2e67f300b892947eb89d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2008.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2008.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DTiwari%26aufirst%3DA.%2BK.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DKim%26aufirst%3DI.-W.%26aulast%3DParmar%26aufirst%3DS.%26aulast%3DBates%26aufirst%3DS.%2BE.%26aulast%3DSi%26aufirst%3DQ.-S.%26aulast%3DGoldblatt%26aufirst%3DC.%2BS.%26aulast%3DAbraham%26aufirst%3DI.%26aulast%3DFu%26aufirst%3DL.-W.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DChen%26aufirst%3DZ.-S.%26atitle%3DInhibiting%2520the%2520function%2520of%2520ABCB1%2520and%2520ABCG2%2520by%2520the%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520AG1478%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2009%26volume%3D77%26spage%3D781%26epage%3D793%26doi%3D10.1016%2Fj.bcp.2008.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span>; <span class="NLM_string-name">Yang, N.</span>; <span class="NLM_string-name">Cai, C.-Y.</span>; <span class="NLM_string-name">Lei, Z.-Y.</span>; <span class="NLM_string-name">Wang, J.-Q.</span>; <span class="NLM_string-name">Gupta, P.</span>; <span class="NLM_string-name">Teng, Q.-X.</span>; <span class="NLM_string-name">Chen, Z.-S.</span>; <span class="NLM_string-name">Kong, D.</span>; <span class="NLM_string-name">Yang, D.-H.</span></span> <span> </span><span class="NLM_article-title">VS-4718 antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells by inhibiting the efflux function of ABC transporters</span>.  <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.3389%2Ffphar.2018.01236" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Ji&author=N.+Yang&author=C.-Y.+Cai&author=Z.-Y.+Lei&author=J.-Q.+Wang&author=P.+Gupta&author=Q.-X.+Teng&author=Z.-S.+Chen&author=D.+Kong&author=D.-H.+Yang&title=VS-4718+antagonizes+multidrug+resistance+in+ABCB1-+and+ABCG2-overexpressing+cancer+cells+by+inhibiting+the+efflux+function+of+ABC+transporters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01236%26sid%3Dliteratum%253Aachs%26aulast%3DJi%26aufirst%3DY.%26atitle%3DVS-4718%2520antagonizes%2520multidrug%2520resistance%2520in%2520ABCB1-%2520and%2520ABCG2-overexpressing%2520cancer%2520cells%2520by%2520inhibiting%2520the%2520efflux%2520function%2520of%2520ABC%2520transporters%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">44643</span>– <span class="NLM_lpage">44659</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.5989</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.18632%2Foncotarget.5989" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=26556876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC28vgvFaisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=44643-44659&author=J.+Huauthor=X.+Zhangauthor=F.+Wangauthor=X.+Wangauthor=K.+Yangauthor=M.+Xuauthor=K.+K.+W.+Toauthor=Q.+Liauthor=L.+Fu&title=Effect+of+ceritinib+%28LDK378%29+on+enhancement+of+chemotherapeutic+agents+in+ABCB1+and+ABCG2+overexpressing+cells+in+vitro+and+in+vivo&doi=10.18632%2Foncotarget.5989"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo</span></div><div class="casAuthors">Hu Jing; Li Qingshan; Hu Jing; Zhang Xu; Wang Fang; Wang Xiaokun; Yang Ke; Xu Meng; Fu Liwu; To Kenneth K W</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">44643-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Multidrug resistance (MDR) is the leading cause of treatment failure in cancer chemotherapy.  The overexpression of ATP-binding cassette (ABC) transporters, particularly ABCB1, ABCC1 and ABCG2, play a key role in mediating MDR by pumping anticancer drugs out from cancer cells.  Ceritinib (LDK378) is a second-generation tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) currently in phase III clinical trial for the treatment of non-small cell lung cancer.  Here, we found that ceritinib remarkably enhanced the efficacy of chemotherapeutic drugs in ABCB1 or ABCG2 over-expressing cancer cells in vitro and in vivo.  Ceritinib significantly increased the intracellular accumulation of chemotherapeutic agents such as doxorubicin (DOX) by inhibiting ABCB1 or ABCG2-mediated drug efflux in the transporters-overexpressing cells.  Mechanistically, ceritinib is likely a competitive inhibitor of ABCB1 and ABCG2 because it competed with [(125)I]-iodoarylazidoprazosin for photo affinity labeling of the transporters.  On the other hand, at the transporters-inhibiting concentrations, ceritinib did not alter the expression level of ABCB1 and ABCG2, and phosphorylation status of AKT and ERK1/2.  Thus the findings advocate further clinical investigation of combination chemotherapy of ceritinib and other conventional chemotherapeutic drugs in chemo-refractory cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_pzeWjl0LuWgRQsDqrjW_fW6udTcc2eZSa5zFpj-99rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vgvFaisQ%253D%253D&md5=90f4dd647cca64bf7b847959e59ef980</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.5989&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.5989%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DTo%26aufirst%3DK.%2BK.%2BW.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DEffect%2520of%2520ceritinib%2520%2528LDK378%2529%2520on%2520enhancement%2520of%2520chemotherapeutic%2520agents%2520in%2520ABCB1%2520and%2520ABCG2%2520overexpressing%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D44643%26epage%3D44659%26doi%3D10.18632%2Foncotarget.5989" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donfrancesco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ioris, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pasquale, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ilari, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cialfi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Laurentis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominici, C.</span></span> <span> </span><span class="NLM_article-title">Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response</span>. <i>Pediatr. Blood. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/pbc.22219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1002%2Fpbc.22219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=19821523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BD1Mjmt1GmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=55-61&author=A.+Donfrancescoauthor=M.+A.+De+Iorisauthor=H.+P.+McDowellauthor=M.+D.+De+Pasqualeauthor=I.+Ilariauthor=A.+Jenknerauthor=A.+Castellanoauthor=S.+Cialfiauthor=C.+De+Laurentisauthor=C.+Dominici&title=Gefitinib+in+combination+with+oral+topotecan+and+cyclophosphamide+in+relapsed+neuroblastoma%3A+pharmacological+rationale+and+clinical+response&doi=10.1002%2Fpbc.22219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response</span></div><div class="casAuthors">Donfrancesco Alberto; De Ioris Maria Antonietta; McDowell Heather Prudence; De Pasquale Maria Debora; Ilari Ilaria; Jenkner Alessandro; Castellano Aurora; Cialfi Samantha; De Laurentis Clementina; Dominici Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric blood & cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIM:  Activity and toxiciy of gefitinib in combination with topotecan and cyclophosphamide (CPA) were evaluated in a case-series of relapsed neuroblastoma (NB) patients.  The in vitro activity of the combination was also assessed.  PROCEDURE:  Gefitinib (250 mg/day), topotecan (0.8 mg/m(2)/day), and CPA (50 mg/m(2)/day) (GTC) were administered orally for 14 consecutive days out of 28 days.  Antitumor activity of gefitinib as single agent and in combination with either topotecan or CPA was assessed in a panel of NB cell lines.  RESULTS:  Ninety-two courses were given in 10 patients.  Grade 4 neutropenia was observed in 7/92 courses (8%) and grade 4 thrombocytopenia in 8/92 (9%).  Two patients had a grade 2 liver toxicity, four a grade 1/2 skin toxicity, and two a grade 1/2 diarrhea.  Dose reduction of topotecan and/or CPA was required in eight patients.  After four courses, three patients were in partial response (PR) and four with a stable disease (SD), while three experienced a progressive disease (PD).  Time to progression (TTP) was 9 months (range, 1-27).  After a median follow-up of 16 months (range 5-54), seven patients are died of disease (DOD) and three alive with disease (AWD).  All but one patient discontinued oral chemotherapy because of a PD, whilst one patient stopped chemotherapy after 27 months with a SD.  In vitro, gefitinib was synergistic with topotecan and additive with CPA.  CONCLUSION:  The GTC combination was well tolerated and the TTP was encouraging.  These promising results, also supported by in vitro evidence, should be further confirmed in a phase II study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTr-dJ9m_ZXzz0SWnHPWbmmfW6udTcc2eb9O6lCoH4oybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mjmt1GmtQ%253D%253D&md5=22d2f0551cbdc2af97d971d1e0aa1719</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fpbc.22219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.22219%26sid%3Dliteratum%253Aachs%26aulast%3DDonfrancesco%26aufirst%3DA.%26aulast%3DDe%2BIoris%26aufirst%3DM.%2BA.%26aulast%3DMcDowell%26aufirst%3DH.%2BP.%26aulast%3DDe%2BPasquale%26aufirst%3DM.%2BD.%26aulast%3DIlari%26aufirst%3DI.%26aulast%3DJenkner%26aufirst%3DA.%26aulast%3DCastellano%26aufirst%3DA.%26aulast%3DCialfi%26aufirst%3DS.%26aulast%3DDe%2BLaurentis%26aufirst%3DC.%26aulast%3DDominici%26aufirst%3DC.%26atitle%3DGefitinib%2520in%2520combination%2520with%2520oral%2520topotecan%2520and%2520cyclophosphamide%2520in%2520relapsed%2520neuroblastoma%253A%2520pharmacological%2520rationale%2520and%2520clinical%2520response%26jtitle%3DPediatr.%2520Blood.%2520Cancer%26date%3D2010%26volume%3D54%26spage%3D55%26epage%3D61%26doi%3D10.1002%2Fpbc.22219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lheureux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pautier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selle, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgeois, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lortholary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plantade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilquin, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarisse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanc-Fournier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, F.</span></span> <span> </span><span class="NLM_article-title">Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial</span>. <i>Int. J. Gynecol. Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1483</span>– <span class="NLM_lpage">1488</span>, <span class="refDoi"> DOI: 10.1097/IGC.0b013e31826d1438</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1097%2FIGC.0b013e31826d1438" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=23027040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252Fhs1Whtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1483-1488&author=S.+Lheureuxauthor=S.+Kriegerauthor=B.+Weberauthor=P.+Pautierauthor=M.+Fabbroauthor=F.+Selleauthor=H.+Bourgeoisauthor=T.+Petitauthor=A.+Lortholaryauthor=A.+Plantadeauthor=M.+Briandauthor=A.+Leconteauthor=N.+Richardauthor=O.+Vilquinauthor=B.+Clarisseauthor=C.+Blanc-Fournierauthor=F.+Joly&title=Expected+benefits+of+topotecan+combined+with+lapatinib+in+recurrent+ovarian+cancer+according+to+biological+profile%3A+a+phase+2+trial&doi=10.1097%2FIGC.0b013e31826d1438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial</span></div><div class="casAuthors">Lheureux Stephanie; Krieger Sophie; Weber Beatrice; Pautier Patricia; Fabbro Michel; Selle Frederic; Bourgeois Hugues; Petit Thierry; Lortholary Alain; Plantade Anne; Briand Melanie; Leconte Alexandra; Richard Nicolas; Vilquin Paul; Clarisse Benedicte; Blanc-Fournier Cecile; Joly Florence</div><div class="citationInfo"><span class="NLM_cas:title">International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1483-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Lapatinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), also inhibits breast cancer resistance protein (BCRP) involved in resistance to topotecan.  The aim of this multicenter study was to assess the efficacy of the combination topotecan-lapatinib in epithelial ovarian cancer relapsing after a first line of chemotherapy.  METHODS:  Patients having relapsed within 6 months (n = 20) or between 6 and 12 months (n = 19) received weekly topotecan (3.2 mg/m given intravenously on days 1, 8, and 15) and daily oral lapatinib (1250 mg).  Translational studies were performed on tumor and serum.  RESULTS:  An objective (partial) response was observed for 5 patients (14%), all with late relapse.  The rates of overall benefits, including responses and stabilizations, were 37% and 62% in patients having relapsed within or after 6 months, respectively.  Corresponding median time to progression were 58 and 94 days.  The most frequent toxicity was hematological, including grade 4 neutropenia (18%) and thrombocytopenia (3%).  None of the tumors overexpressed HER2 or EGFR, and no mutation was found.  Two Kras mutations were identified.  Positive expressions of BCRP and cyclin A (median, 70% and 40%) were not correlated to the response to treatment.  CONCLUSIONS:  This study failed to demonstrate a clinical benefit of lapatinib-topotecan compared to previously described activity with topotecan alone in a context of low levels of EGFR and HER2 expressions, and no biomarkers could be identified.  The absence of correlation between BCRP expression and clinical outcomes suggests that other mechanisms of resistance to topotecan could predominate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT36k4GOwlqSUBuFdjgVNKSfW6udTcc2eaznYtx29B8Qrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252Fhs1Whtg%253D%253D&md5=30fb57fca073a2de9d6ee67d3853038a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1097%2FIGC.0b013e31826d1438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FIGC.0b013e31826d1438%26sid%3Dliteratum%253Aachs%26aulast%3DLheureux%26aufirst%3DS.%26aulast%3DKrieger%26aufirst%3DS.%26aulast%3DWeber%26aufirst%3DB.%26aulast%3DPautier%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DM.%26aulast%3DSelle%26aufirst%3DF.%26aulast%3DBourgeois%26aufirst%3DH.%26aulast%3DPetit%26aufirst%3DT.%26aulast%3DLortholary%26aufirst%3DA.%26aulast%3DPlantade%26aufirst%3DA.%26aulast%3DBriand%26aufirst%3DM.%26aulast%3DLeconte%26aufirst%3DA.%26aulast%3DRichard%26aufirst%3DN.%26aulast%3DVilquin%26aufirst%3DO.%26aulast%3DClarisse%26aufirst%3DB.%26aulast%3DBlanc-Fournier%26aufirst%3DC.%26aulast%3DJoly%26aufirst%3DF.%26atitle%3DExpected%2520benefits%2520of%2520topotecan%2520combined%2520with%2520lapatinib%2520in%2520recurrent%2520ovarian%2520cancer%2520according%2520to%2520biological%2520profile%253A%2520a%2520phase%25202%2520trial%26jtitle%3DInt.%2520J.%2520Gynecol.%2520Cancer.%26date%3D2012%26volume%3D22%26spage%3D1483%26epage%3D1488%26doi%3D10.1097%2FIGC.0b013e31826d1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weroha, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberg, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegler, K. L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakhilm, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, D. F.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeney, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peethambaram, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, P.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma</span>. <i>Gynecol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.ygyno.2011.03.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ygyno.2011.03.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=21514634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslOns7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2011&pages=116-120&author=S.+J.+Werohaauthor=A.+L.+Obergauthor=K.+L.+A.+Zieglerauthor=S.+R.+Dakhilmauthor=K.+M.+Rowlandauthor=L.+C.+Hartmannauthor=D.+F.+Mooreauthor=G.+L.+Keeneyauthor=P.+P.+Peethambaramauthor=P.+Haluska&title=Phase+II+trial+of+lapatinib+and+topotecan+%28LapTop%29+in+patients+with+platinum-refractory%2Fresistant+ovarian+and+primary+peritoneal+carcinoma&doi=10.1016%2Fj.ygyno.2011.03.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma</span></div><div class="casAuthors">Weroha, S. John; Oberg, Ann L.; Ziegler, Katie L. Allen; Dakhilm, Shaker R.; Rowland, Kendrith M.; Hartmann, Lynn C.; Moore, Dennis F., Jr.; Keeney, Gary L.; Peethambaram, Prema P.; Haluska, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-120</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Resistance to chemotherapy is a major challenge in the treatment of ovarian/peritoneal cancer.  One purported mechanism of topotecan resistance is the breast cancer resistance protein (BCRP) and P-glycoprotein (Pgp).  We designed a phase II clin. trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small mol. pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan.  Patients with platinum-refractory or resistant epithelial ovarian/peritoneal cancer were treated with topotecan 3.2 mg/m2 IV on Day 1, 8 and 15 and lapatinib 1250 mg PO daily, continuously in 28 day cycles.  The primary endpoint was response rate.  For correlative studies, archived tissue was assessed for expression of EGFR, HER2, HIF-1α, CD31, and BCRP.  18 Patients were enrolled and treated.  Four experienced evidence of clin. benefit: one partial response and three with stable disease.  Using a two-stage Simon design, the trial was stopped after the first stage due to insufficient activity.  Grades 3+ and 4+ adverse events (AE) were experienced in 14 and 4 patients, resp.  The most common grade 3/4 AE were neutropenia (56%), thrombocytopenia (28%), and diarrhea (22%).  The combination of lapatinib plus topotecan for the treatment of platinum refractory/resistant epithelial ovarian cancer lacks sufficient activity to warrant further investigation.  In particular, hematol. adverse events were substantial.  Expression of correlative study markers did not reveal patterns of predicted benefit or toxicity.  Disruption of erbB signaling and BCRP/Pgp efflux with lapatinib was insufficient for overcoming topotecan resistance, suggesting alternative mechanisms of resistance are involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQxhyz5fb5xbVg90H21EOLACvtfcHk0lhE1iB3h4QqiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslOns7c%253D&md5=3acf75d974638693616fca43ea28091c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2011.03.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2011.03.030%26sid%3Dliteratum%253Aachs%26aulast%3DWeroha%26aufirst%3DS.%2BJ.%26aulast%3DOberg%26aufirst%3DA.%2BL.%26aulast%3DZiegler%26aufirst%3DK.%2BL.%2BA.%26aulast%3DDakhilm%26aufirst%3DS.%2BR.%26aulast%3DRowland%26aufirst%3DK.%2BM.%26aulast%3DHartmann%26aufirst%3DL.%2BC.%26aulast%3DMoore%26aufirst%3DD.%2BF.%26aulast%3DKeeney%26aufirst%3DG.%2BL.%26aulast%3DPeethambaram%26aufirst%3DP.%2BP.%26aulast%3DHaluska%26aufirst%3DP.%26atitle%3DPhase%2520II%2520trial%2520of%2520lapatinib%2520and%2520topotecan%2520%2528LapTop%2529%2520in%2520patients%2520with%2520platinum-refractory%252Fresistant%2520ovarian%2520and%2520primary%2520peritoneal%2520carcinoma%26jtitle%3DGynecol.%2520Oncol.%26date%3D2011%26volume%3D122%26spage%3D116%26epage%3D120%26doi%3D10.1016%2Fj.ygyno.2011.03.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span> <span> </span><span class="NLM_article-title">A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma</span>. <i>Medicine (Philadelphia, PA, U. S.)</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">e9053</span>, <span class="refDoi"> DOI: 10.1097/MD.0000000000009053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1097%2FMD.0000000000009053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2luro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=e9053&author=L.+Wangauthor=L.+Liangauthor=T.+Yangauthor=Y.+Qiaoauthor=Y.+Xiaauthor=L.+Liuauthor=C.+Liauthor=P.+Luauthor=X.+Jiang&title=A+pilot+clinical+study+of+apatinib+plus+irinotecan+in+patients+with+recurrent+high-grade+glioma&doi=10.1097%2FMD.0000000000009053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical Trial/Experimental Study</span></div><div class="casAuthors">Wang, Lei; Liang, Lijun; Yang, Tao; Qiao, Yun; Xia, Youyou; Liu, Liang; Li, Chao; Lu, Peizhi; Jiang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Medicine (Philadelphia, PA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">e9053</span>CODEN:
                <span class="NLM_cas:coden">MEDIAV</span>;
        ISSN:<span class="NLM_cas:issn">0025-7974</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Malignant glioma is the most common primary malignant brain tumor that displays high vascularity, making vascular endothelial growth factor receptors become promising targets.  This study was conducted to evaluate the efficacy and safety of apatinib, a new potent oral small-mol. tyrosine kinase inhibitor targeted vascular endothelial growth factor receptor 2, combined with irinotecan, in patients with recurrent malignant glioma.  Methods: Ten patients with recurrent malignant glioma who were experiencing relapse after treatment of temozolomide were enrolled in this study.  They received oral apatinib (500mg qd) in conjunction with irinotecan (340 mg/m2 or 125 mg/m2 depending on use of enzyme-inducing antiepileptic drugs) for 6 cycles.  After that the patients continued to take apatinib as maintenance.  Dosage adjustment occurred in only 3 (30.0%) patients.  Results: Among the 10 patients, 9 were available for the efficacy evaluation.  There were 5 with partial response, 2 with stable disease and 2 with progressive disease.  The objective response rate and the disease control rate (DCR) were 55% (5/9) and 78% (7/9), resp.  The median progress free survival time was 8.3 mo.  As for safety anal., the most 3 common adverse events were gastrointestinal reaction (31.8%), hypertension (22.7%), and myelosuppression (18.0%).  Conclusion: Apatinib combined with irinotecan seems to be a promising therapeutic option for recurrent malignant glioma patients.  Perspective clin. studies with adequate sample size are required to validate our results.  Trial registration: NCT02848794/Ahead-BG306.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV8bypxFNfW7Vg90H21EOLACvtfcHk0lhE1iB3h4QqiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2luro%253D&md5=502fad5077f271b1312373b915bbce37</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1097%2FMD.0000000000009053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMD.0000000000009053%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DQiao%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DX.%26atitle%3DA%2520pilot%2520clinical%2520study%2520of%2520apatinib%2520plus%2520irinotecan%2520in%2520patients%2520with%2520recurrent%2520high-grade%2520glioma%26jtitle%3DMedicine%2520%2528Philadelphia%252C%2520PA%252C%2520U.%2520S.%2529%26date%3D2017%26volume%3D96%26spage%3De9053%26doi%3D10.1097%2FMD.0000000000009053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furman, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navid, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daw, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarville, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spunt, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Galindo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panetta, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajjar, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houghton, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santana, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, C. F.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4599</span>– <span class="NLM_lpage">4604</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.19.6642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1200%2FJCO.2008.19.6642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=19687340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCns7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4599-4604&author=W.+L.+Furmanauthor=F.+Navidauthor=N.+C.+Dawauthor=M.+B.+McCarvilleauthor=L.+M.+McGregorauthor=S.+L.+Spuntauthor=C.+Rodriguez-Galindoauthor=J.+C.+Panettaauthor=K.+R.+Crewsauthor=J.+Wuauthor=A.+J.+Gajjarauthor=P.+J.+Houghtonauthor=V.+M.+Santanaauthor=C.+F.+Stewart&title=Tyrosine+kinase+inhibitor+enhances+the+bioavailability+of+oral+irinotecan+in+pediatric+patients+with+refractory+solid+tumors&doi=10.1200%2FJCO.2008.19.6642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors</span></div><div class="casAuthors">Furman, Wayne L.; Navid, Fariba; Daw, Najat C.; McCarville, M. Beth; McGregor, Lisa M.; Spunt, Sheri L.; Rodriguez-Galindo, Carlos; Panetta, John C.; Crews, Kristine R.; Wu, Jianrong; Gajjar, Amar J.; Houghton, Peter J.; Santana, Victor M.; Stewart, Clinton F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4599-4604</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">To assess the max.-tolerated dosages (MTDs), and dose-limiting toxicities (DLTs) of the epidermal growth factor receptor inhibitor gefitinib and of i.v. irinotecan when administered together in children with refractory solid tumors.  To assess the effect of gefitinib on the pharmacokinetics of i.v. irinotecan and on the bioavailability of a single oral dose of irinotecan.  I.v. irinotecan (15 or 20 mg/m2) was given daily for 5 days of 2 consecutive weeks.  Oral gefitinib (150 or 112.5 mg/m2) was concomitantly given daily for 12 or 21 days.  A single oral dose of irinotecan was given on day 9 of course 2 to allow pharmacokinetic anal.  The study enrolled 29 patients with recurrent solid tumors.  The 21-day regimen of oral gefitinib with irinotecan was not tolerated.  Diarrhea was the most common DLT.  The MTD of the combination regimen was 15 mg/m2/d of i.v. irinotecan for 5 days of 2 consecutive weeks and 112.5 mg/m2/d of gefitinib given for 12 days.  Gefitinib increased the bioavailability of oral irinotecan by four-fold over that obsd. in historical controls (median, 0.09 v 0.42; P < .000001), reducing the apparent clearance (an inverse measure of exposure) of irinotecan and SN-38 by 37% and 38%, resp. (P < .0001).  A partial response was obsd. in a patient with refractory Ewing sarcoma.  I.v. irinotecan given with 12 days of oral gefitinib is well tolerated in children.  We obsd. one partial response.  Gefitinib significantly enhances the bioavailability of oral irinotecan.  This combination warrants further investigation, particularly with orally administered irinotecan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp7zdd78C72bVg90H21EOLACvtfcHk0lgn95P7cyc27w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCns7%252FJ&md5=6c3fae6c49642dbf2cd410b321baa1f7</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.19.6642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.19.6642%26sid%3Dliteratum%253Aachs%26aulast%3DFurman%26aufirst%3DW.%2BL.%26aulast%3DNavid%26aufirst%3DF.%26aulast%3DDaw%26aufirst%3DN.%2BC.%26aulast%3DMcCarville%26aufirst%3DM.%2BB.%26aulast%3DMcGregor%26aufirst%3DL.%2BM.%26aulast%3DSpunt%26aufirst%3DS.%2BL.%26aulast%3DRodriguez-Galindo%26aufirst%3DC.%26aulast%3DPanetta%26aufirst%3DJ.%2BC.%26aulast%3DCrews%26aufirst%3DK.%2BR.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGajjar%26aufirst%3DA.%2BJ.%26aulast%3DHoughton%26aufirst%3DP.%2BJ.%26aulast%3DSantana%26aufirst%3DV.%2BM.%26aulast%3DStewart%26aufirst%3DC.%2BF.%26atitle%3DTyrosine%2520kinase%2520inhibitor%2520enhances%2520the%2520bioavailability%2520of%2520oral%2520irinotecan%2520in%2520pediatric%2520patients%2520with%2520refractory%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4599%26epage%3D4604%26doi%3D10.1200%2FJCO.2008.19.6642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoff, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogaard, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldrum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbruzzese, J. L.</span></span> <span> </span><span class="NLM_article-title">A phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma</span>. <i>Jpn. J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">100</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1093/jjco/hyi229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1093%2Fjjco%2Fhyi229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=16449240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BD287jtVertQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2006&pages=100-103&author=P.+M.+Hoffauthor=R.+A.+Wolffauthor=K.+Bogaardauthor=S.+Waldrumauthor=J.+L.+Abbruzzese&title=A+phase+I+study+of+escalating+doses+of+the+tyrosine+kinase+inhibitor+semaxanib+%28SU5416%29+in+combination+with+irinotecan+in+patients+with+advanced+colorectal+carcinoma&doi=10.1093%2Fjjco%2Fhyi229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma</span></div><div class="casAuthors">Hoff Paulo M; Wolff Robert A; Bogaard Karla; Waldrum Sherry; Abbruzzese James L</div><div class="citationInfo"><span class="NLM_cas:title">Japanese journal of clinical oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-3</span>
        ISSN:<span class="NLM_cas:issn">0368-2811</span>.
    </div><div class="casAbstract">BACKGROUND:  One of the most studied pro-angiogenic factors involved in the development of colorectal cancer is the vascular endothelial growth factor (VEGF).  The small molecule tyrosine kinase inhibitor semaxanib (SU5416) is one of the several agents targeting the VEGF signaling pathway, and its development centered mostly in the treatment of colorectal cancer.  METHODS:  We designed and conducted an NCI-sponsored trial to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of semaxanib given twice weekly in combination with weekly irinotecan in patients with advanced colorectal cancer who had failed at least one prior treatment.  The irinotecan dose was fixed at 125 mg/m(2) given weekly for 4 weeks followed by 2 weeks of rest.  Patients with prior pelvic irradiation received a reduced dose of 100 mg/m(2).  The semaxanib dose was escalated, going from 85 to 110 mg/m(2) and finally to 145 mg/m(2).  RESULTS:  Ten patients were treated in our study and all were evaluable for toxicity.  There were no drug-related Grade 4 toxicities.  There was one episode of Grade 3 headache and one episode of Grade 3 vomiting.  The most common Grades 1 and 2 toxicities included diarrhea, abdominal cramping, anemia and nausea.  Nine patients completed at least one 6 week cycle of treatment and were considered evaluable for response.  Among those nine, two had a partial response, three had stable disease and four had progressive disease after the first cycle.  CONCLUSIONS:  Both irinotecan and semaxanib could be given at their full single-agent recommended doses without significant toxicity, and the combination showed signs of clinical activity.  However, owing to discouraging results from Phase III trials, it is unlikely that this combination will be further explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQI6NH5C7JgwmHOrQ6qeX-mfW6udTcc2eZtoNELDrWcHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD287jtVertQ%253D%253D&md5=0c60fd64a89368f4ac5adc7c5b6ef760</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1093%2Fjjco%2Fhyi229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjjco%252Fhyi229%26sid%3Dliteratum%253Aachs%26aulast%3DHoff%26aufirst%3DP.%2BM.%26aulast%3DWolff%26aufirst%3DR.%2BA.%26aulast%3DBogaard%26aufirst%3DK.%26aulast%3DWaldrum%26aufirst%3DS.%26aulast%3DAbbruzzese%26aufirst%3DJ.%2BL.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520escalating%2520doses%2520of%2520the%2520tyrosine%2520kinase%2520inhibitor%2520semaxanib%2520%2528SU5416%2529%2520in%2520combination%2520with%2520irinotecan%2520in%2520patients%2520with%2520advanced%2520colorectal%2520carcinoma%26jtitle%3DJpn.%2520J.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D36%26spage%3D100%26epage%3D103%26doi%3D10.1093%2Fjjco%2Fhyi229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boven, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armand, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartog, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brega, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Countouriotis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span> <span> </span><span class="NLM_article-title">A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumors</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">1000</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6605852</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fsj.bjc.6605852" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=20717111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1WlsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2010&pages=993-1000&author=E.+Bovenauthor=C.+Massardauthor=J.+P.+Armandauthor=C.+Tillierauthor=V.+Hartogauthor=N.+M.+Bregaauthor=A.+M.+Countouriotisauthor=A.+Ruiz-Garciaauthor=J.+C.+Soria&title=A+phase+I%2C+dose-finding+study+of+sunitinib+in+combination+with+irinotecan+in+patients+with+advanced+solid+tumors&doi=10.1038%2Fsj.bjc.6605852"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours</span></div><div class="casAuthors">Boven, E.; Massard, C.; Armand, J. P.; Tillier, C.; Hartog, V.; Brega, N. M.; Countouriotis, A. M.; Ruiz-Garcia, A.; Soria, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">993-1000</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Sunitinib is a multitargeted, oral tyrosine kinase inhibitor with antitumor and antiangiogenic activity.  We investigated the safety and pharmacokinetics of sunitinib in combination with irinotecan in patients with advanced, refractory solid tumors.  Methods: Sunitinib was initially administered once daily at 37.5 mg per day on days 1-14 of a 21-day cycle, in which irinotecan 250 mg m-2 was given on day 1.  In a second cohort, the sunitinib dose was reduced to 25 mg per day.  Blood samples were collected for pharmacokinetic studies.  Results: In the sunitinib 37.5 mg per day cohort, 3 out of 10 evaluable patients had objective responses, but dose-limiting toxicities (DLTs) of neutropenia, pneumococcal sepsis, and fatigue were obsd.  There were no DLTs in the sunitinib 25 mg per day cohort.  Paired observations of pharmacokinetic parameter values of sunitinib and irinotecan alone vs the combination did not reveal significant drug-drug interactions.  The max. tolerated dose was defined as sunitinib 25 mg per day (days 1-14) with irinotecan 250 mg m-2 (day 1), but no activity was obsd. at this dose.  Conclusion: Although a higher sunitinib dose of 37.5 mg per day (days 1-14) with irinotecan showed preliminary evidence of antitumor activity, this dose was poorly tolerated.  Therefore, this particular combination will not be pursued for further studies.  British Journal of Cancer (2010) 103, 993-1000; doi:10.1038/sj.bjc.6605852 www.bjcancer.com Published online 17 August 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSLdbu3rXbFrVg90H21EOLACvtfcHk0lgE5U7w0cqUfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1WlsrfN&md5=0a8ce1112c4faef025cbf4ed7a7d241b</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605852%26sid%3Dliteratum%253Aachs%26aulast%3DBoven%26aufirst%3DE.%26aulast%3DMassard%26aufirst%3DC.%26aulast%3DArmand%26aufirst%3DJ.%2BP.%26aulast%3DTillier%26aufirst%3DC.%26aulast%3DHartog%26aufirst%3DV.%26aulast%3DBrega%26aufirst%3DN.%2BM.%26aulast%3DCountouriotis%26aufirst%3DA.%2BM.%26aulast%3DRuiz-Garcia%26aufirst%3DA.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26atitle%3DA%2520phase%2520I%252C%2520dose-finding%2520study%2520of%2520sunitinib%2520in%2520combination%2520with%2520irinotecan%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D103%26spage%3D993%26epage%3D1000%26doi%3D10.1038%2Fsj.bjc.6605852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reardon, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vredenburgh, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desjardins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gururangan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathornsumetee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herndon, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, H. S.</span></span> <span> </span><span class="NLM_article-title">Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma</span>. <i>J. Neuro-Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1007/s11060-011-0631-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1007%2Fs11060-011-0631-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=21744079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyrtLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=621-627&author=D.+A.+Reardonauthor=J.+J.+Vredenburghauthor=A.+Coanauthor=A.+Desjardinsauthor=K.+B.+Petersauthor=S.+Gururanganauthor=S.+Sathornsumeteeauthor=J.+N.+Richauthor=J.+E.+Herndonauthor=H.+S.+Friedman&title=Phase+I+study+of+sunitinib+and+irinotecan+for+patients+with+recurrent+malignant+glioma&doi=10.1007%2Fs11060-011-0631-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma</span></div><div class="casAuthors">Reardon, David A.; Vredenburgh, James J.; Coan, April; Desjardins, Annick; Peters, Katherine B.; Gururangan, Sridharan; Sathornsumetee, Sith; Rich, Jeremy N.; Herndon, James E.; Friedman, Henry S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">621-627</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We detd. the max. tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, sunitinib, when administered with irinotecan among recurrent malignant glioma (MG) patients.  For each 42-day cycle, sunitinib was administered once a day for four consecutive weeks followed by a 2 wk rest.  Irinotecan was administered i.v. every other week.  Each agent was alternatively escalated among cohorts of 3-6 patients enrolled at each dose level.  Patients on CYP3A-inducing anti-epileptic drugs were not eligible.  Twenty-five patients with recurrent MG were enrolled, including 15 (60%) with glioblastoma (GBM) and 10 (40%) with grade 3 MG.  Five patients progressed previously on bevacizumab and two had received prior VEGFR tyrosine kinase inhibitor therapy.  The MTD was 50 mg of sunitinib combined with 75 mg/m2 of irinotecan.  DLT were primarily hematol. and included grade 4 neutropenia in 3 patients and one patient with grade 4 thrombocytopenia.  Non-hematol. DLT included grade 3 mucositis (n = 1) and grade 3 dehydration (n = 1).  Progression-free survival (PFS)-6 was 24% and only one patient achieved a radiog. response.  The combination of sunitinib and irinotecan was assocd. with moderate toxicity and limited anti-tumor activity.  Further studies with this regimen using the dosing schedules evaluated in this study are not warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8tDSqIYAxZ7Vg90H21EOLACvtfcHk0lgE5U7w0cqUfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyrtLfK&md5=a0f07732c407a80b4f742b5b1da09622</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs11060-011-0631-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-011-0631-4%26sid%3Dliteratum%253Aachs%26aulast%3DReardon%26aufirst%3DD.%2BA.%26aulast%3DVredenburgh%26aufirst%3DJ.%2BJ.%26aulast%3DCoan%26aufirst%3DA.%26aulast%3DDesjardins%26aufirst%3DA.%26aulast%3DPeters%26aufirst%3DK.%2BB.%26aulast%3DGururangan%26aufirst%3DS.%26aulast%3DSathornsumetee%26aufirst%3DS.%26aulast%3DRich%26aufirst%3DJ.%2BN.%26aulast%3DHerndon%26aufirst%3DJ.%2BE.%26aulast%3DFriedman%26aufirst%3DH.%2BS.%26atitle%3DPhase%2520I%2520study%2520of%2520sunitinib%2520and%2520irinotecan%2520for%2520patients%2520with%2520recurrent%2520malignant%2520glioma%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2011%26volume%3D105%26spage%3D621%26epage%3D627%26doi%3D10.1007%2Fs11060-011-0631-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trombetta, L. D.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>421</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.01.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.canlet.2018.01.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=29331420" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslOgtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=421&publication_year=2018&pages=186-198&author=Y.+F.+Fanauthor=W.+Zhangauthor=L.+Zengauthor=Z.+N.+Leiauthor=C.+Y.+Caiauthor=P.+Guptaauthor=D.+H.+Yangauthor=Q.+Cuiauthor=Z.+D.+Qinauthor=Z.+S.+Chenauthor=L.+D.+Trombetta&title=Dacomitinib+antagonizes+multidrug+resistance+%28MDR%29+in+cancer+cells+by+inhibiting+the+efflux+activity+of+ABCB1+and+ABCG2+transporters&doi=10.1016%2Fj.canlet.2018.01.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters</span></div><div class="casAuthors">Fan, Ying-Fang; Zhang, Wei; Zeng, Leli; Lei, Zi-Ning; Cai, Chao-Yun; Gupta, Pranav; Yang, Dong-Hua; Cui, Qingbin; Qin, Zuo-Dong; Chen, Zhe-Sheng; Trombetta, Louis D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">421</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">186-198</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The development of multidrug resistance (MDR) to chemotherapy remains a major challenge in the treatment of cancer.  Numerous mechanisms have been recognized that cause MDR, but one of the most important mechanisms is overexpression of ATP-binding cassette transporters, through which the efflux of various anticancer drugs against their concn. gradients is powered by ATP.  At the same time, some TKIs have been shown to be capable of inhibiting ABC transporter-mediated MDR.  As many TKIs are substrates or inhibitors of ABC transporters, this study investigates whether dacomitinib could interact with ABC subfamily members that mediate MDR, including ABCB1, ABCG2 (BCRP) and ABCC1.  The results showed that dacomitinib at 1.0μM significantly reversed drug resistance mediated by ABCB1 and ABCG2, but not ABCC1, doing so by antagonizing the drug efflux function in ABCB1- and ABCG2-overexpressing cell lines.  Therefore, the mechanisms of this modulating effect are likely to be the following: first, as an inhibitor of ABCB1 or ABCG2 transporters, dacomitinib binds to drug-substrate site in transmembrane domains (TMD) stably in a noncompetitive manner; or second, dacomitinib inhibits ATPase activity and maintains the stability of TMD conformation in a concn.-dependent manner thereby inhibiting the drug efflux function of ABCB1 or ABCG2 transporter.  This study provides a useful combinational therapeutic strategy with dacomitinib and substrates of ABCB1 and/or ABCG2 transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNoQc-zmcdSrVg90H21EOLACvtfcHk0ljTpZlctKVSng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslOgtLs%253D&md5=ff4b80d0070530e60588ac50cd4b2cf0</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.01.021%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DY.%2BF.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DZ.%2BN.%26aulast%3DCai%26aufirst%3DC.%2BY.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DD.%2BH.%26aulast%3DCui%26aufirst%3DQ.%26aulast%3DQin%26aufirst%3DZ.%2BD.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26aulast%3DTrombetta%26aufirst%3DL.%2BD.%26atitle%3DDacomitinib%2520antagonizes%2520multidrug%2520resistance%2520%2528MDR%2529%2520in%2520cancer%2520cells%2520by%2520inhibiting%2520the%2520efflux%2520activity%2520of%2520ABCB1%2520and%2520ABCG2%2520transporters%26jtitle%3DCancer%2520Lett.%26date%3D2018%26volume%3D421%26spage%3D186%26epage%3D198%26doi%3D10.1016%2Fj.canlet.2018.01.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span> <span> </span><span class="NLM_article-title">Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">4089</span>– <span class="NLM_lpage">4106</span>, <span class="refDoi"> DOI: 10.1111/bph.13189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1111%2Fbph.13189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25988710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOhurnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=4089-4106&author=K.+K.+Toauthor=D.+C.+Poonauthor=Y.+Weiauthor=F.+Wangauthor=G.+Linauthor=L.+Fu&title=Pelitinib+%28EKB-569%29+targets+the+up-regulation+of+ABCB1+and+ABCG2+induced+by+hyperthermia+to+eradicate+lung+cancer&doi=10.1111%2Fbph.13189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer</span></div><div class="casAuthors">To, Kenneth K. W.; Poon, Daniel C.; Wei, Yuming; Wang, Fang; Lin, Ge; Fu, Liwu</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4089-4106</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Pelitinib is a potent irreversible EGFR TK inhibitor currently in clin. trials for the treatment of lung cancer.  Hyperthermia has been applied concomitantly with chemotherapy and radiotherapy to enhance treatment outcome.  In this study, we investigated the ability of the combination of pelitinib with other conventional anticancer drugs to specifically target cancer cells with up-regulated efflux transporters ABCB1/ABCG2 after hyperthermia as a novel way to eradicate the cancer stem-like cells responsible for cancer recurrence.  Exptl. Approach : Alterations in intracellular topotecan accumulation, the efflux of fluorescent probe substrates, expression and ATPase activity of ABCB1/ABCG2 and tumorsphere formation capacity of side population (SP) cells sorted after hyperthermia were examd. to elucidate the mechanism of pelitinib-induced chemosensitization.  Key Results : While pelitinib did not modulate ABCB1/ABCG2 expressions, the combination of pelitinib with transporter substrate anticancer drugs induced more marked apoptosis, specifically in cells exposed to hyperthermia.  The flow cytometric assay showed that both ABCB1- and ABCG2-mediated drug effluxes were significantly inhibited by pelitinib in a concn.-dependent manner.  The inhibition kinetics suggested that pelitinib is a competitive inhibitor of ABCB1/ABCG2, which is consistent with its ability to stimulate their ATPase activity.  SP cells sorted after hyperthermia were found to be more resistant to anticancer drugs, presumably due to the up-regulation of ABCB1 and ABCG2.  Importantly, pelitinib specifically enhanced the chemosensitivity but reduced the tumorsphere formation capacity of these SP cells.  Conclusions and Implications : This study demonstrated a novel approach, exploiting drug resistance, to selectively kill cancer stem-like cells after hyperthermia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbh7vkVQ2dtbVg90H21EOLACvtfcHk0ljTpZlctKVSng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOhurnN&md5=d84e534bd828820f4e05cd9afa940a0d</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1111%2Fbph.13189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13189%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DK.%2BK.%26aulast%3DPoon%26aufirst%3DD.%2BC.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DFu%26aufirst%3DL.%26atitle%3DPelitinib%2520%2528EKB-569%2529%2520targets%2520the%2520up-regulation%2520of%2520ABCB1%2520and%2520ABCG2%2520induced%2520by%2520hyperthermia%2520to%2520eradicate%2520lung%2520cancer%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D4089%26epage%3D4106%26doi%3D10.1111%2Fbph.13189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathias, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doshi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span> <span> </span><span class="NLM_article-title">The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations</span>. <i>Invest. New Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1007/s10637-015-0205-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1007%2Fs10637-015-0205-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25597754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWnsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=300-309&author=T.+J.+Mathiasauthor=K.+Natarajanauthor=S.+Shuklaauthor=K.+A.+Doshiauthor=Z.+N.+Singhauthor=S.+V.+Ambudkarauthor=M.+R.+Baer&title=The+FLT3+and+PDGFR+inhibitor+crenolanib+is+a+substrate+of+the+multidrug+resistance+protein+ABCB1+but+does+not+inhibit+transport+function+at+pharmacologically+relevant+concentrations&doi=10.1007%2Fs10637-015-0205-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations</span></div><div class="casAuthors">Mathias, Trevor J.; Natarajan, Karthika; Shukla, Suneet; Doshi, Kshama A.; Singh, Zeba N.; Ambudkar, Suresh V.; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">300-309</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Crenolanib (crenolanib besylate, 4-piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]-, monobenzenesulfonate) is a potent and specific type I inhibitor of fms-like tyrosine kinase 3 (FLT3) that targets the active kinase conformation and is effective against FLT3 with internal tandem duplication (ITD) with point mutations induced by, and conferring resistance to, type II FLT3 inhibitors in acute myeloid leukemia (AML) cells.  Crenolanib is also an inhibitor of platelet-derived growth factor receptor alpha and beta and is in clin. trials in both gastrointestinal stromal tumors and gliomas.  We tested crenolanib interactions with the multidrug resistance-assocd. ATP-binding cassette proteins ABCB1 (P-glycoprotein), ABCG2 (breast cancer resistance protein) and ABCC1 (multidrug resistance-assocd. protein 1), which are expressed on AML cells and other cancer cells and are important components of the blood-brain barrier.  We found that crenolanib is a substrate of ABCB1, as evidenced by approx. five-fold resistance of ABCB1-overexpressing cells to crenolanib, reversal of this resistance by the ABCB1-specific inhibitor PSC-833 and stimulation of ABCB1 ATPase activity by crenolanib.  In contrast, crenolanib was not a substrate of ABCG2 or ABCC1.  Addnl., it did not inhibit substrate transport by ABCB1, ABCG2 or ABCC1, at pharmacol. relevant concns.  Finally, incubation of the FLT3-ITD AML cell lines MV4-11 and MOLM-14 with crenolanib at a pharmacol. relevant concn. of 500 nM did not induce upregulation of ABCB1 cell surface expression.  Thus ABCB1 expression confers resistance to crenolanib and likely limits crenolanib penetration of the central nervous system, but crenolanib at therapeutic concns. should not alter cellular exposure to ABC protein substrate chemotherapy drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE_ac0g0ThIbVg90H21EOLACvtfcHk0lhxryyXM0ilKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWnsrk%253D&md5=6de25ffa46c1a3cdac6cdb1154baa28c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1007%2Fs10637-015-0205-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-015-0205-y%26sid%3Dliteratum%253Aachs%26aulast%3DMathias%26aufirst%3DT.%2BJ.%26aulast%3DNatarajan%26aufirst%3DK.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DDoshi%26aufirst%3DK.%2BA.%26aulast%3DSingh%26aufirst%3DZ.%2BN.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DThe%2520FLT3%2520and%2520PDGFR%2520inhibitor%2520crenolanib%2520is%2520a%2520substrate%2520of%2520the%2520multidrug%2520resistance%2520protein%2520ABCB1%2520but%2520does%2520not%2520inhibit%2520transport%2520function%2520at%2520pharmacologically%2520relevant%2520concentrations%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2015%26volume%3D33%26spage%3D300%26epage%3D309%26doi%3D10.1007%2Fs10637-015-0205-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, Q. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span> <span> </span><span class="NLM_article-title">Olmutinib (BI1482694/HM61713), a novel epidermal growth factor receptor tyrosine kinase inhibitor, reverses ABCG2-mediated multidrug resistance in cancer cells</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1097</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.3389%2Ffphar.2018.01097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=30356705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpt1Wqtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1097&author=W.+Zhangauthor=Y.+F.+Fanauthor=C.+Y.+Caiauthor=J.+Q.+Wangauthor=Q.+X.+Tengauthor=Z.+N.+Leiauthor=L.+Zengauthor=P.+Guptaauthor=Z.+S.+Chen&title=Olmutinib+%28BI1482694%2FHM61713%29%2C+a+novel+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor%2C+reverses+ABCG2-mediated+multidrug+resistance+in+cancer+cells&doi=10.3389%2Ffphar.2018.01097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Olmutinib (BI1482694/HM61713), a novel epidermal growth factor receptor tyrosine kinase inhibitor, reverses ABCG2-mediated multidrug resistance in cancer cells</span></div><div class="casAuthors">Zhang, Wei; Fan, Ying-Fang; Cai, Chao-Yun; Wang, Jing-Quan; Teng, Qiu-Xu; Lei, Zi-Ning; Zeng, Leli; Gupta, Pranav; Chen, Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1097</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The main characteristic of tumor cell resistance is multidrug resistance (MDR).  MDR is the principle cause of the decline in clin. efficacy of chemotherapeutic drugs.  There are several mechanisms that could cause MDR.  Among these, one of the most important mechanisms underlying MDR is the overexpression of ATP (ATP)-binding cassette (ABC) super-family of transporters, which effectively pump out cytotoxic agents and targeted anticancer drugs across the cell membrane.  In recent years, studies found that ABC transporters and tyrosine kinase inhibitors (TKIs) interact with each other.  TKIs may behave as substrates or inhibitors depending on the expression of specific pumps, drug concn., their affinity for the transporters and types of co-administered agents.  Therefore, we performed in vitro expts. to observe whether olmutinib could reverse MDR in cancer cells overexpressing ABCB1, ABCG2, or ABCC1 transporters.  The results showed that olmutinib at 3 μM significantly reversed drug resistance mediated by ABCG2, but not by ABCB1 and ABCC1, by antagonizing the drug efflux function in ABCG2-overexpressing cells.  In addn., olmutinib at reversal concn. affected neither the protein expression level nor the localization of ABCG2.  The results obsd. from the accumulation/efflux study of olmutinib showed that olmutinib reversed ABCG2-mediated MDR with an increasing intracellular drug accumulation due to inhibited drug efflux.  We also had consistent results with the ATPase assay that olmutinib stimulated ATPase activity of ABCG2 up to 3.5-fold.  Addnl., the mol. interaction between olmutinib and ABCG2 was identified by docking simulation.  Olmutinib not only interacts directly with ABCG2 but also works as a competitive inhibitor of the transport protein.  In conclusion, olmutinib could reverse ABCG2-mediated MDR.  The reversal effect of olmutinib on ABCG2-mediated MDR cells is not due to ABCG2 expression or intracellular localization, but rather related to its interaction with ABCG2 protein resulting in drug efflux inhibition and ATPase stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW7PCUH2QHK7Vg90H21EOLACvtfcHk0lhxryyXM0ilKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpt1Wqtrs%253D&md5=1dc98b10f7f196fcc2fe29ed32cc7e47</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01097%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DFan%26aufirst%3DY.%2BF.%26aulast%3DCai%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BQ.%26aulast%3DTeng%26aufirst%3DQ.%2BX.%26aulast%3DLei%26aufirst%3DZ.%2BN.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26atitle%3DOlmutinib%2520%2528BI1482694%252FHM61713%2529%252C%2520a%2520novel%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%252C%2520reverses%2520ABCG2-mediated%2520multidrug%2520resistance%2520in%2520cancer%2520cells%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1097%26doi%3D10.3389%2Ffphar.2018.01097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, Q. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Z. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span> <span> </span><span class="NLM_article-title">Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2019.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bcp.2019.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=31078601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvFyjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2019&pages=120-127&author=Z.+X.+Wuauthor=Q.+X.+Tengauthor=C.+Y.+Caiauthor=J.+Q.+Wangauthor=Z.+N.+Leiauthor=Y.+Yangauthor=Y.+F.+Fanauthor=J.+Y.+Zhangauthor=J.+Liauthor=Z.+S.+Chen&title=Tepotinib+reverses+ABCB1-mediated+multidrug+resistance+in+cancer+cells&doi=10.1016%2Fj.bcp.2019.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells</span></div><div class="casAuthors">Wu, Zhuo-Xun; Teng, Qiu-Xu; Cai, Chao-Yun; Wang, Jing-Quan; Lei, Zi-Ning; Yang, Yuqi; Fan, Ying-Fang; Zhang, Jian-Ye; Li, Jun; Chen, Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">120-127</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Overexpression of ABCB1 transporters plays a crucial role in mediating multidrug resistance (MDR).  Therefore, it is important to inhibit ABCB1 activity in order to maintain an effective intracellular level of chemotherapeutic drugs.  Tepotinib is a MET tyrosine kinase inhibitor with potential anticancer effect and it is currently in clin. trials.  In this study, we investigated whether tepotinib could antagonize ABC transporters-mediated MDR.  Our results suggest that tepotinib significantly reversed ABCB1-mediated MDR but not ABCG2- or ABCC1-mediated MDR.  Mechanistic studies show that tepotinib significantly reversed ABCB1-mediated MDR by attenuating the efflux activity of ABCB1 transporter.  The ATPase assay showed that tepotinib inhibited the ATPase activity of ABCB1 in a concn.-dependent manner.  Furthermore, treatment with tepotinib did not change protein expression or subcellular localization of ABCB1.  Docking anal. indicated that tepotinib interacted with the drug-binding site of the ABCB1 transporter.  Our study provides a potential chemotherapeutic strategy of co-administrating tepotinib with other conventional chemotherapeutic agents to overcome MDR and improve therapeutic effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplnqcY4M5vZrVg90H21EOLACvtfcHk0lglwALitnHwvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvFyjsb0%253D&md5=3bdd1fc5ab757748269d5468710bf06a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%2BX.%26aulast%3DTeng%26aufirst%3DQ.%2BX.%26aulast%3DCai%26aufirst%3DC.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BQ.%26aulast%3DLei%26aufirst%3DZ.%2BN.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DY.%2BF.%26aulast%3DZhang%26aufirst%3DJ.%2BY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26atitle%3DTepotinib%2520reverses%2520ABCB1-mediated%2520multidrug%2520resistance%2520in%2520cancer%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2019%26volume%3D166%26spage%3D120%26epage%3D127%26doi%3D10.1016%2Fj.bcp.2019.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L. W.</span></span> <span> </span><span class="NLM_article-title">Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cells to chemotherapy under hypoxia</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2015.06.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bcp.2015.06.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=26206183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1SqtrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=27-37&author=K.+K.+Toauthor=D.+C.+Poonauthor=Y.+Weiauthor=F.+Wangauthor=G.+Linauthor=L.+W.+Fu&title=Vatalanib+sensitizes+ABCB1+and+ABCG2-overexpressing+multidrug+resistant+colon+cells+to+chemotherapy+under+hypoxia&doi=10.1016%2Fj.bcp.2015.06.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia</span></div><div class="casAuthors">To, Kenneth K. W.; Poon, Daniel C.; Wei, Yuming; Wang, Fang; Lin, Ge; Fu, Li-wu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cancer microenvironment is characterized by significantly lower oxygen concn.  This hypoxic condition is known to reduce drug responsiveness to cancer chemotherapy via multiple mechanisms, among which the upregulation of the ATP-binding cassette (ABC) efflux transporters confers resistance to a wide variety of structurally unrelated anticancer drugs.  Vatalanib (PTK787/ZK22584) is a multitargeted tyrosine kinase inhibitor for all isoforms of VEGFR, PDGFR and c-Kit, which exhibit potent anticancer activity in vitro and in vivo.  The authors investigated the potentiation effect of vatalanib on the anticancer activity of conventional cytotoxic drugs in colon cancer cell lines under both normoxic and hypoxic conditions.  Mechanistically, vatalanib was found to inhibit ABCG2 and ABCB1 efflux activity, presumably by acting as a competitive inhibitor and interfering with their ATPase activity.  Under hypoxic growth condition, ABCG2 and ABCB1-overexpressing cells sorted out by FACS technique as side population (SP) were found to be significantly more responsive to SN-38 (ABCG2 and ABCB1 substrate anticancer drug) in the presence of vatalanib.  The anchorage independent soft agar colony formation capacity of the SP cells was remarkably reduced upon treatment with a combination of SN-38 and vatalanib, compared to SN-38 alone.  However, vatalanib, at concns. that produced the circumvention of the transporters-mediated resistance, did not appreciably alter ABCG2/ABCB1 mRNA or protein expression levels or the phosphorylation of Akt and extracellular signal-regulated kinase (ERK1/2).  The authors' study thus advocates the further investigation of vatalanib for use in combination chemotherapy to eradicate drug-resistant cancer cells under hypoxia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq6tmHFlXBbbVg90H21EOLACvtfcHk0lglwALitnHwvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1SqtrzO&md5=331ffaccd4a3e14d8e139b8150f4ad70</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.06.034%26sid%3Dliteratum%253Aachs%26aulast%3DTo%26aufirst%3DK.%2BK.%26aulast%3DPoon%26aufirst%3DD.%2BC.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DFu%26aufirst%3DL.%2BW.%26atitle%3DVatalanib%2520sensitizes%2520ABCB1%2520and%2520ABCG2-overexpressing%2520multidrug%2520resistant%2520colon%2520cells%2520to%2520chemotherapy%2520under%2520hypoxia%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2015%26volume%3D97%26spage%3D27%26epage%3D37%26doi%3D10.1016%2Fj.bcp.2015.06.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juvale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">4-Substituted-2-phenylquinazolines as inhibitors of BCRP</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6766</span>– <span class="NLM_lpage">6769</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bmcl.2012.08.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=23017888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVSjsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6766-6769&author=K.+Juvaleauthor=M.+Wiese&title=4-Substituted-2-phenylquinazolines+as+inhibitors+of+BCRP&doi=10.1016%2Fj.bmcl.2012.08.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">4-Substituted-2-phenylquinazolines as inhibitors of BCRP</span></div><div class="casAuthors">Juvale, Kapil; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6766-6769</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We investigated several 2-phenylquinazolines with different substitutions at position 4 for their BCRP inhibition.  Compds. with Ph ring attached via an amine-contg. linker at position 4 were found to be potent inhibitors of BCRP.  In general compds. with meta substitution of Ph ring at position 4 were found to have higher inhibitory effect, compd. 12 being the most potent and selective towards BCRP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf-v9OH4Nxr7Vg90H21EOLACvtfcHk0lhWOaKtKy5h-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVSjsrbJ&md5=e96d4566ff6ae54c8e454bda7b50c873</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.024%26sid%3Dliteratum%253Aachs%26aulast%3DJuvale%26aufirst%3DK.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3D4-Substituted-2-phenylquinazolines%2520as%2520inhibitors%2520of%2520BCRP%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6766%26epage%3D6769%26doi%3D10.1016%2Fj.bmcl.2012.08.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juvale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Investigation of quinazolines as inhibitors of breast cancer resistance protein</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7858</span>– <span class="NLM_lpage">7873</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bmc.2013.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=24184213" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWmsb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=7858-7873&author=K.+Juvaleauthor=J.+Gallusauthor=M.+Wiese&title=Investigation+of+quinazolines+as+inhibitors+of+breast+cancer+resistance+protein&doi=10.1016%2Fj.bmc.2013.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2)</span></div><div class="casAuthors">Juvale, Kapil; Gallus, Jennifer; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7858-7873</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chemotherapy is one of the major forms of cancer treatment.  Unfortunately, tumors are prone to multidrug resistance leading to failure of treatment.  Breast cancer resistance protein (BCRP), the second member of ABC transporter subfamily G, has been found to play a major role in drug efflux and hence multidrug resistance.  Until now, very few potent and selective BCRP inhibitors like Ko143 have been identified.  In the search for more potent and selective BCRP inhibitors, we synthesized and investigated a series of differently substituted quinazoline compds.  Several variations at positions 2, 4, 6 and 7 of the quinazoline scaffold were carried out to develop a structure-activity-relationship anal. for these compds.  It was found that compds. bearing a Ph substituent at position 2 of the 4-anilinoquinazoline scaffold were most potent.  On the aniline ring at position 4 of the quinazoline moiety substituents like NO2, CN, CF3 led to very high BCRP inhibition potencies.  The most potent compds. were further investigated for their intrinsic cytotoxicity and their ability to reverse the multidrug resistance.  Compd. 20, an anilinoquinazoline bearing a Ph ring at position 2 and meta-nitro substitution on the 4-anilino ring, was found to have the highest therapeutic ratio.  The most active compds. from each variation were also investigated for their effect on BCRP expression.  It was found that compd. 20 has no significant effect on BCRP expression, while compd. 31 decreased the surface BCRP expression.  The only difference in the two compds. was the presence of a 3,4-dimethoxyphenyl ring in compd. 31 instead of Ph substitution at position 2 of the quinazoline moiety.  From the study of all target compds., compd. 20 was the most prominent compd. having inhibitory potency even higher than Ko143, the most potent BCRP inhibitor known.  Compd. 20 was also found to be selective towards BCRP with a very high therapeutic ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwQG7UwDr2PrVg90H21EOLACvtfcHk0lhWOaKtKy5h-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWmsb3P&md5=45a1d684ff3849c478498ede66d0cda8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DJuvale%26aufirst%3DK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DInvestigation%2520of%2520quinazolines%2520as%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D7858%26epage%3D7873%26doi%3D10.1016%2Fj.bmc.2013.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 4-anilino-quinazolines and -quinolines as inhibitors of breast cancer resistance protein (ABCG2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5449</span>– <span class="NLM_lpage">5461</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00330</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00330" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlCnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5449-5461&author=M.+K.+Krapfauthor=M.+Wiese&title=Synthesis+and+biological+evaluation+of+4-anilino-quinazolines+and+-quinolines+as+inhibitors+of+breast+cancer+resistance+protein+%28ABCG2%29&doi=10.1021%2Facs.jmedchem.6b00330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2)</span></div><div class="casAuthors">Krapf, Michael K.; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5449-5461</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chemotherapeutic treatment of cancer often fails due to overexpression of the ATP-binding cassette (ABC) transport proteins, like ABCG2, triggering active efflux of various structurally unrelated drugs.  This so-called multidrug resistance (MDR) may be reversed by selective, potent, and nontoxic inhibitors of ABCG2.  As only a few potent inhibitors are known, new compds. based on a 4-substituted-2-phenylquinazoline scaffold were investigated.  Substitution with hydroxy, cyano, nitro, acetamido, and fluoro, e.g., I, led to high inhibitory activities toward ABCG2.  The ability to reverse MDR of the most active compds. was confirmed in a MTT efficacy assay.  Moreover, a negligibly low intrinsic cytotoxicity was found resulting in a high therapeutic ratio.  Investigations of the inhibitory activity toward ABCB1 and ABCC1 yielded a high selectivity toward ABCG2 for the quinazoline compds.  Quinoline-based analogs showed lower inhibitory activity and selectivity.  The study yielded a variety of promising compds., some with superior properties compared to those of the std. inhibitor Ko143.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdz9Uvqz3i6rVg90H21EOLACvtfcHk0lifoIjXyMGG3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlCnurY%253D&md5=a127c60fe7ecf9d5fc76a13903e794db</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00330%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25204-anilino-quinazolines%2520and%2520-quinolines%2520as%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5449%26epage%3D5461%26doi%3D10.1021%2Facs.jmedchem.6b00330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">611</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.08.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2017.08.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=28841513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOrs7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=587-611&author=M.+K.+Krapfauthor=J.+Gallusauthor=M.+Wiese&title=Synthesis+and+biological+investigation+of+2%2C4-substituted+quinazolines+as+highly+potent+inhibitors+of+breast+cancer+resistance+protein&doi=10.1016%2Fj.ejmech.2017.08.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2)</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">587-611</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Expression of ABCG2, a member of the ABC transporter superfamily, was correlated to the clin. outcome of multiple cancers and is often assocd. with the occurrence of multidrug resistance (MDR) in chemotherapy.  Inhibition of the transport protein by potent and selective inhibitors might be a way to treat cancer more efficiently and improve the therapy of cancer patients.  Recently the authors reported the synthesis of new inhibitors based on a quinazoline scaffold.  In the present study more structural variations were explored.  Compds. with 3,4-dimethoxy groups and meta or para nitro substituents are highly potent inhibitors of ABCG2.  The most potent compd. was more than five-fold more potent than Ko143, one of the best inhibitors of ABCG2.  To det. the new compds. selectivity toward ABCG2 their inhibitory effects on ABCB1 and ABCC1 were also studied identifying selective as well as broadspectrum inhibitors.  Furthermore, intrinsic cytotoxicity and efficacy regarding the reversal of multidrug resistance toward SN-38 and mitoxantrone were explored.  The most potent compds. were able to reverse the resistance toward the cytostatic agents with EC50 values <20 nM.  Addnl., the type of interaction between inhibitors and the ABCG2 substrate Hoechst 33342 was studied yielding competitive and non-competitive interactions suggesting different modes of binding.  Finally the effect of the derivs. on vanadate-sensitive ATPase activity of ABCG2 was detd.  According to the different effects on ATPase activity the authors conclude the existence of different binding sites.  This study provides the structural requirements for high potency inhibition and elucidates the interaction with ABCG2 setting the basis for further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE5dQXb6qJ5bVg90H21EOLACvtfcHk0lifoIjXyMGG3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOrs7jM&md5=d0fb787cddc361a521b402ea76d2bb51</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.08.020%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520investigation%2520of%25202%252C4-substituted%2520quinazolines%2520as%2520highly%2520potent%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D587%26epage%3D611%26doi%3D10.1016%2Fj.ejmech.2017.08.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">4-Anilino-2-pyridylquinazolines and -pyrimidines as highly potent and nontoxic inhibitors of breast cancer resistance protein (ABCG2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4474</span>– <span class="NLM_lpage">4495</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00441</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00441" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFSks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4474-4495&author=M.+K.+Krapfauthor=J.+Gallusauthor=M.+Wiese&title=4-Anilino-2-pyridylquinazolines+and+-pyrimidines+as+highly+potent+and+nontoxic+inhibitors+of+breast+cancer+resistance+protein+%28ABCG2%29&doi=10.1021%2Facs.jmedchem.7b00441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2)</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4474-4495</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transport proteins remains a major problem in the chemotherapeutic treatment of cancer and might be overcome by inhibition of the transporter.  Because of the lack of understanding, the complex mechanisms involved in the transport process, in particular for breast cancer resistance protein (BCRP/ABCG2), there is a persistent need for studies of inhibitors of ABCG2.  In this study, the authors investigated a systematic series of 4-substituted-2-pyridylquinazolines in terms of their inhibitory potency as well as selectivity toward ABCG2.  For comparison, the quinazoline scaffold was reduced to the significantly smaller 4-methylpyrimidine basic structure.  Furthermore, the cytotoxicity and the ability to reverse MDR was tested with the chemotherapeutic agents SN-38 and mitoxantrone (MX).  Interaction of the compds. with ABCG2 was investigated by a colorimetric ATPase assay.  Enzyme kinetic studies were carried out with Hoechst 33342 as fluorescent dye and substrate of ABCG2 to elucidate the compds. binding modes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBVIj0DPElPrVg90H21EOLACvtfcHk0lggSx0Ou4lXiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFSks7k%253D&md5=cd9380f0b33fb110c3cde721345f6fe5</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00441%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3D4-Anilino-2-pyridylquinazolines%2520and%2520-pyrimidines%2520as%2520highly%2520potent%2520and%2520nontoxic%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4474%26epage%3D4495%26doi%3D10.1021%2Facs.jmedchem.7b00441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraege, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juvale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmes, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.03.067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2016.03.067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=27100033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsFyms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2016&pages=212-229&author=S.+Kraegeauthor=K.+Stefanauthor=K.+Juvaleauthor=T.+Rossauthor=T.+Willmesauthor=M.+Wiese&title=The+combination+of+quinazoline+and+chalcone+moieties+leads+to+novel+potent+heterodimeric+modulators+of+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29&doi=10.1016%2Fj.ejmech.2016.03.067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2)</span></div><div class="casAuthors">Kraege, Stefanie; Stefan, Katja; Juvale, Kapil; Ross, Thomas; Willmes, Thomas; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">212-229</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">During the last decade it has been found that chalcones and quinazolines are promising inhibitors of ABCG2.  The combination of these two scaffolds offers a new class of heterocyclic compds. with potentially high inhibitory activity against ABCG2.  For this purpose we investigated 22 different heterodimeric derivs.  In this series only methoxy groups were used as substituents as these had been proven superior for inhibitory activity of chalcones.  All compds. were tested for their inhibitory activity, specificity and cytotoxicity.  The most potent ABCG2 inhibitor in this series showed an IC50 value of 0.19 μM.  It possesses low cytotoxicity (GI50 = 93 μM), the ability to reverse MDR and is nearly selective toward ABCG2.  Most compds. contg. dimethoxy groups showed slight activity against ABCB1 too.  Among these three compds. (17, 19 and 24) showed even higher activity toward ABCB1 than ABCG2.  All inhibitors were further screened for their effect on basal ATPase activity.  Although the basal ATPase activity was partially stimulated, the compds. were not transported by ABCG2.  Thus, quinazoline-chalcones are a new class of effective ABCG2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAiBrpQVZkPrVg90H21EOLACvtfcHk0lggSx0Ou4lXiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsFyms7Y%253D&md5=91877b15d0301ec2bbcd468f63ea1a2b</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.03.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.03.067%26sid%3Dliteratum%253Aachs%26aulast%3DKraege%26aufirst%3DS.%26aulast%3DStefan%26aufirst%3DK.%26aulast%3DJuvale%26aufirst%3DK.%26aulast%3DRoss%26aufirst%3DT.%26aulast%3DWillmes%26aufirst%3DT.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DThe%2520combination%2520of%2520quinazoline%2520and%2520chalcone%2520moieties%2520leads%2520to%2520novel%2520potent%2520heterodimeric%2520modulators%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D117%26spage%3D212%26epage%3D229%26doi%3D10.1016%2Fj.ejmech.2016.03.067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">2,4,6-Substituted quinazolines with extraordinary inhibitory potency toward ABCG2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7952</span>– <span class="NLM_lpage">7976</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVChtbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7952-7976&author=M.+K.+Krapfauthor=J.+Gallusauthor=V.+Namasivayamauthor=M.+Wiese&title=2%2C4%2C6-Substituted+quinazolines+with+extraordinary+inhibitory+potency+toward+ABCG2&doi=10.1021%2Facs.jmedchem.8b01011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">2,4,6-Substituted Quinazolines with Extraordinary Inhibitory Potency toward ABCG2</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Namasivayam, Vigneshwaran; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7952-7976</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several members of the ABC transporter superfamily play a decisive role in the development of multidrug resistance (MDR) in cancer.  One of these MDR assocd. efflux transporters is ABCG2.  One way to overcome this MDR is the coadministration of potent inhibitors of ABCG2.  In this study, we identified novel inhibitors contg. a 2,4,6-substituted quinazoline scaffold.  Introduction of a 6-nitro function led to extraordinarily potent compds. that were highly selective for ABCG2 and also able to reverse the MDR toward the chemotherapeutic drugs SN-38 and mitoxantrone.  The binding of substrate Hoechst 33342 and the two potent inhibitors 31 and 41 which differ in their mechanism of inhibition was rationalized using the recently published cryo-EM structures of ABCG2.  For a better understanding of the interaction between the inhibitors and ABCG2, addnl. investigations regarding the ATPase activity, the interaction with Hoechst 33342, and with the conformational sensitive 5D3 antibody were carried out.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHoikCuvyt-bVg90H21EOLACvtfcHk0ljLp73sw8sLKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVChtbjO&md5=376bdc61d3a65d7ea6877e7b69ca0d74</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01011%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3D2%252C4%252C6-Substituted%2520quinazolines%2520with%2520extraordinary%2520inhibitory%2520potency%2520toward%2520ABCG2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7952%26epage%3D7976%26doi%3D10.1021%2Facs.jmedchem.8b01011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahdati, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">New inhibitors of breast cancer resistance protein (ABCG2) containing a 2,4-disubstituted pyridopyrimidine scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3389</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltVGlsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3389-3408&author=M.+K.+Krapfauthor=J.+Gallusauthor=S.+Vahdatiauthor=M.+Wiese&title=New+inhibitors+of+breast+cancer+resistance+protein+%28ABCG2%29+containing+a+2%2C4-disubstituted+pyridopyrimidine+scaffold&doi=10.1021%2Facs.jmedchem.7b01012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">New Inhibitors of Breast Cancer Resistance Protein (ABCG2) Containing a 2,4-Disubstituted Pyridopyrimidine Scaffold</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Vahdati, Sahel; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3389-3408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) occurring during cancer chemotherapy is a major obstacle for effectiveness and response to therapy and is often caused by ATP-binding cassette (ABC) efflux transporters.  Belonging to the family of ABC transporters, breast cancer resistance protein is getting more and more in the spotlight of research.  As a strategy to overcome MDR, inhibitors of ABC transporters were synthesized, which could be applied in combination with cytostatic drugs.  For this purpose, 2,4-disubstituted pyridopyrimidine derivs. were synthesized.  The investigations confirmed three key characteristics of good inhibitors: a low intrinsic cytotoxicity and a high potency and selectivity toward ABCG2.  For selected compds. the interaction with ABCG2 was elucidated and their effect on ATPase activity and conformation sensitive 5D3 antibody binding was investigated.  Their ability to reverse MDR in coadministration with the active metabolite of irinotecan and mitoxantron was confirmed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1PrWr1uAkvLVg90H21EOLACvtfcHk0ljLp73sw8sLKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltVGlsro%253D&md5=aa27ba46b274bcb0501e596b92973efa</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01012%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DVahdati%26aufirst%3DS.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DNew%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%2520containing%2520a%25202%252C4-disubstituted%2520pyridopyrimidine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3389%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.7b01012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krapf, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spindler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of quinazoline derivatives - a SAR study of novel inhibitors of ABCG2</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">525</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2018.10.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=30390439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2019&pages=506-525&author=M.+K.+Krapfauthor=J.+Gallusauthor=A.+Spindlerauthor=M.+Wiese&title=Synthesis+and+biological+evaluation+of+quinazoline+derivatives+-+a+SAR+study+of+novel+inhibitors+of+ABCG2&doi=10.1016%2Fj.ejmech.2018.10.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2</span></div><div class="casAuthors">Krapf, Michael K.; Gallus, Jennifer; Spindler, Anna; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">506-525</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) is a major obstacle for effective chemotherapeutic treatment of cancer frequently leading to failure of the therapy.  MDR is often assocd. with the overexpression of ABC transport proteins like ABCB1 or ABCG2 which efflux harmful substances out of cells at the cost of ATP hydrolysis.  One way to overcome MDR is to apply potent inhibitors of ABC transporters to restore the sensitivity of the cells toward cytostatic agents.  This study focusses on the synthesis and evaluation of novel 2,4-disubstituted quinazoline derivs. regarding the structure-activity-relationship (SAR), their ability to reverse MDR and their mode of interaction with ABCG2.  Hence, the inhibitory potency and selectivity toward ABCG2 was detd.  Moreover, the intrinsic cytotoxicity and the reversal of MDR were investigated.  Interaction type studies with the substrate Hoechst 33342 and conformational analyses of ABCG2 with 5D3 monoclonal antibody were performed for a better understanding of the underlying mechanisms.  In our study we could further enhance the inhibitory effect against ABCG2 (compd. I, IC50: 55 nM) and identify the structural features that are crucial for inhibitory potency, the impact on transport activity and binding to the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpRCSRKm5X7bVg90H21EOLACvtfcHk0ljLp73sw8sLKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qsLvJ&md5=0199c580e5f555ebfac47322c1adf7a2</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DKrapf%26aufirst%3DM.%2BK.%26aulast%3DGallus%26aufirst%3DJ.%26aulast%3DSpindler%26aufirst%3DA.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520quinazoline%2520derivatives%2520-%2520a%2520SAR%2520study%2520of%2520novel%2520inhibitors%2520of%2520ABCG2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D161%26spage%3D506%26epage%3D525%26doi%3D10.1016%2Fj.ejmech.2018.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinkhammer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Specific inhibitors of the breast cancer resistance protein (BCRP)</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1498</span>– <span class="NLM_lpage">1505</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201000216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1002%2Fcmdc.201000216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=20632361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFWgsbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=1498-1505&author=A.+Pickauthor=W.+Klinkhammerauthor=M.+Wiese&title=Specific+inhibitors+of+the+breast+cancer+resistance+protein+%28BCRP%29&doi=10.1002%2Fcmdc.201000216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Inhibitors of the Breast Cancer Resistance Protein (BCRP)</span></div><div class="casAuthors">Pick, Anne; Klinkhammer, Werner; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1498-1505</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A new class of specific breast cancer resistance protein (BCRP) inhibitors was identified, showing no inhibition of the ATP binding cassette (ABC) transporters P-gp and MRP1.  Some of these modulators inhibit BCRP with high potency; they are only slightly less potent than Ko143 and could serve as promising lead structures for the design of novel effective BCRP inhibitors.  These inhibitors are structurally related to tariquidar (XR9576) and belong to a library of multidrug-resistance modulators synthesized by our research group.  The absence of the tetrahydroisoquinoline substructure appears to play a crucial role for specificity; we found that the presence of this substructure is not essential for interaction with BCRP.  To det. the type of interaction between pheophorbide A and compds. with and without the tetrahydroisoquinoline substructure, various substrate pheophorbide A concns. were used in enzyme kinetics assays.  The resulting data show that these compds. share a noncompetitive-type interaction with pheophorbide A.  Expts. with imatinib and pheophorbide A revealed a mixed-type interaction.  The combination of imatinib and compds. with and without the tetrahydroisoquinoline substructure resulted in a pos. cooperative effect, indicating that imatinib engages a binding site distinct from that of the new compds. on one side and distinct from that of pheophorbide A on the other side as well.  The results of this study suggest that the category of BCRP-specific inhibitors, which includes only fumitremorgin C, Ko143 and analogs, and novobiocin needs to be extended by this new class of inhibitors, which possess three key characteristics: specificity, potency, and low toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdbFkR4oCa3bVg90H21EOLACvtfcHk0lixivBZIjZF0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFWgsbnK&md5=751e5cb7fb4a5db8645196ff3b3ae28a</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000216%26sid%3Dliteratum%253Aachs%26aulast%3DPick%26aufirst%3DA.%26aulast%3DKlinkhammer%26aufirst%3DW.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DSpecific%2520inhibitors%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%2529%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D1498%26epage%3D1505%26doi%3D10.1002%2Fcmdc.201000216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Pyrrolopyrimidine derivatives as novel inhibitors of multidrug resistance-associated Protein 1 (MRP1, ABCC1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3018</span>– <span class="NLM_lpage">3033</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01644</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01644" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjs1SqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3018-3033&author=S.+M.+Schmittauthor=K.+Stefanauthor=M.+Wiese&title=Pyrrolopyrimidine+derivatives+as+novel+inhibitors+of+multidrug+resistance-associated+Protein+1+%28MRP1%2C+ABCC1%29&doi=10.1021%2Facs.jmedchem.5b01644"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1)</span></div><div class="casAuthors">Schmitt, Sven Marcel; Stefan, Katja; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3018-3033</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Five series of pyrrolo[3,2-d]pyrimidines were synthesized and evaluated with respect to potency and selectivity toward multidrug resistance-assocd. protein 1 (MRP1, ABCC1).  This transport protein is a major target to overcome multidrug resistance in cancer patients.  We investigated differently substituted pyrrolopyrimidines using the doxorubicin selected and MRP1 overexpressing small cell lung cancer cell line H69 AR in a calcein AM and daunorubicin cell accumulation assay.  New compds. with high potency and selectivity were identified.  Piperazine residues at position 4 bearing large phenylalkyl side chains proved to be beneficial for MRP1 inhibition.  Its replacement by an amino group led to decreased activity.  Aliph. and aliph.-arom. variations at position 5 and 6 revealed compds. with IC50 values in high nanomolar range.  All investigated compds. had low affinity toward P-glycoprotein (P-gp, ABCB1).  Pyrrolopyrimidines with small substituents showed moderate inhibition against breast cancer resistance protein (BCRP, ABCG2).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc-LdtLQMGi7Vg90H21EOLACvtfcHk0lixivBZIjZF0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjs1SqsrY%253D&md5=a7ef32c9b2c134621d9d56f296397a9c</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01644&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01644%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DS.%2BM.%26aulast%3DStefan%26aufirst%3DK.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DPyrrolopyrimidine%2520derivatives%2520as%2520novel%2520inhibitors%2520of%2520multidrug%2520resistance-associated%2520Protein%25201%2520%2528MRP1%252C%2520ABCC1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3018%26epage%3D3033%26doi%3D10.1021%2Facs.jmedchem.5b01644" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juvale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">115</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.06.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2013.06.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=23851114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVeis73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2013&pages=115-126&author=K.+Juvaleauthor=K.+Stefanauthor=M.+Wiese&title=Synthesis+and+biological+evaluation+of+flavones+and+benzoflavones+as+inhibitors+of+BCRP%2FABCG2&doi=10.1016%2Fj.ejmech.2013.06.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2</span></div><div class="casAuthors">Juvale, Kapil; Stefan, Katja; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">115-126</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) often leads to a failure of cancer chemotherapy.  Breast Cancer Resistance Protein (BCRP/ABCG2), a member of the superfamily of ATP binding cassette proteins has been found to confer MDR in cancer cells by transporting mols. with amphiphilic character out of the cells using energy from ATP hydrolysis.  Inhibiting BCRP can be a soln. to overcome MDR.  The authors synthesized a series of flavones, 7,8-benzoflavones and 5,6-benzoflavones with varying substituents at positions 3, 3' and 4' of the (benzo)flavone structure.  All synthesized compds. were tested for BCRP inhibition in Hoechst 33342 and pheophorbide A accumulation assays using MDCK cells expressing BCRP.  All the compds. were further screened for their P-glycoprotein (P-gp) and Multidrug resistance-assocd. protein 1 (MRP1) inhibitory activity by calcein AM accumulation assay to check the selectivity towards BCRP.  In addn. most active compds. were investigated for their cytotoxicity.  It was obsd. that in most cases 7,8-benzoflavones are more potent in comparison to the 5,6-benzoflavones.  In general it was found that presence of a 3-OCH3 substituent leads to increase in activity in comparison to presence of OH or no substitution at position 3.  Also, it was found that presence of 3',4'-OCH3 on Ph ring lead to increase in activity as compared to other substituents.  Compd. 24, a 7,8-benzoflavone deriv. was found to be most potent being 50 times selective for BCRP and showing very low cytotoxicity at higher concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoep2o4_wG7XrVg90H21EOLACvtfcHk0limyzL3IgtXhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVeis73E&md5=961e1899a816717d108c5c8e71944f70</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.06.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.06.035%26sid%3Dliteratum%253Aachs%26aulast%3DJuvale%26aufirst%3DK.%26aulast%3DStefan%26aufirst%3DK.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520flavones%2520and%2520benzoflavones%2520as%2520inhibitors%2520of%2520BCRP%252FABCG2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D67%26spage%3D115%26epage%3D126%26doi%3D10.1016%2Fj.ejmech.2013.06.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">9-Deazapurines as broad-spectrum inhibitors of the ABC transport proteins P-glycoprotein, multidrug resistance-associated protein 1, and breast cancer resistance protein</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8758</span>– <span class="NLM_lpage">8780</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Cit7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=8758-8780&author=K.+Stefanauthor=S.+M.+Schmittauthor=M.+Wiese&title=9-Deazapurines+as+broad-spectrum+inhibitors+of+the+ABC+transport+proteins+P-glycoprotein%2C+multidrug+resistance-associated+protein+1%2C+and+breast+cancer+resistance+protein&doi=10.1021%2Facs.jmedchem.7b00788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein</span></div><div class="casAuthors">Stefan, Katja; Schmitt, Sven Marcel; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8758-8780</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P-Glycoprotein (P-gp, ABCB1), multidrug resistance-assocd. protein 1 (MRP1, ABCC1), and breast cancer resistance protein (BCRP, ABCG2) are the three major ABC transport proteins conferring resistance to many structurally diverse anticancer agents, leading to the phenomenon called multidrug resistance (MDR).  Much effort has been put into the development of clin. useful compds. to reverse MDR.  Broad-spectrum inhibitors of ABC transport proteins can be of great use in cancers that simultaneously coexpress two or three transporters.  In this work, the authors continued the effort to generate new, potent, nontoxic, and multiply effective inhibitors of the three major ABC transporters.  The best compd. (I) was active in a very low micromolar concn. range against all three transporters and restored sensitivity toward daunorubicin (P-gp and MRP1) and SN-38 (BCRP) in A2780/ADR (P-gp), H69AR (MRP1), and MDCK II BCRP cells.  Addnl., the compd. is a noncompetitive inhibitor of daunorubicin (MRP1), calcein AM (P-gp), and pheophorbide A (BCRP) transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq07xlNCwYzL7Vg90H21EOLACvtfcHk0limyzL3IgtXhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Cit7%252FL&md5=a4c6a3553f7c885f1ae24d3f974ce448</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00788%26sid%3Dliteratum%253Aachs%26aulast%3DStefan%26aufirst%3DK.%26aulast%3DSchmitt%26aufirst%3DS.%2BM.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3D9-Deazapurines%2520as%2520broad-spectrum%2520inhibitors%2520of%2520the%2520ABC%2520transport%2520proteins%2520P-glycoprotein%252C%2520multidrug%2520resistance-associated%2520protein%25201%252C%2520and%2520breast%2520cancer%2520resistance%2520protein%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D8758%26epage%3D8780%26doi%3D10.1021%2Facs.jmedchem.7b00788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silbermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elshawadfy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Identification of thienopyrimidine scaffold as inhibitor of the ABC transport protein ABCC1 (MRP1) and related transporters using a combined virtual screening approach</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4383</span>– <span class="NLM_lpage">4400</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01821</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01821" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlWisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4383-4400&author=K.+Silbermannauthor=S.+M.+Stefanauthor=R.+Elshawadfyauthor=V.+Namasivayamauthor=M.+Wiese&title=Identification+of+thienopyrimidine+scaffold+as+inhibitor+of+the+ABC+transport+protein+ABCC1+%28MRP1%29+and+related+transporters+using+a+combined+virtual+screening+approach&doi=10.1021%2Facs.jmedchem.8b01821"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening Approach</span></div><div class="casAuthors">Silbermann, Katja; Stefan, Sven Marcel; Elshawadfy, Randa; Namasivayam, Vigneshwaran; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4383-4400</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A virtual screening protocol with combination of similarity search and pharmacophore modeling was applied to virtually screen a large compd. library to gain new scaffolds regarding ABCC1 inhibition.  Biol. investigation of promising candidates revealed four compds. as ABCC1 inhibitors, three of them with scaffolds not assocd. with ABCC1 inhibition until now.  The best hit mol.-a thienopyrimidine-was a moderately potent, competitive inhibitor of the ABCC1-mediated transport of calcein AM which also sensitized ABCC1-overexpressing cells toward daunorubicin.  Further evaluation showed that it was a moderately potent, competitive inhibitor of the ABCB1-mediated transport of calcein AM, and noncompetitive inhibitor of the ABCG2-mediated pheophorbide A transport.  In addn., the thienopyrimidine could also sensitize ABCB1- as well as ABCG2-overexpressing cells toward daunorubicin and SN-38, resp., in concn. ranges that qualified it as one of the ten best triple ABCC1/ABCB1/ABCG2 inhibitors in the literature.  Besides, three more new multitarget inhibitors were identified by this virtual screening approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriD8it8lIcF7Vg90H21EOLACvtfcHk0lg60-1QhrUHMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlWisbs%253D&md5=f02035affb6b17b0b4962758565b63cb</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01821%26sid%3Dliteratum%253Aachs%26aulast%3DSilbermann%26aufirst%3DK.%26aulast%3DStefan%26aufirst%3DS.%2BM.%26aulast%3DElshawadfy%26aufirst%3DR.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520thienopyrimidine%2520scaffold%2520as%2520inhibitor%2520of%2520the%2520ABC%2520transport%2520protein%2520ABCC1%2520%2528MRP1%2529%2520and%2520related%2520transporters%2520using%2520a%2520combined%2520virtual%2520screening%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4383%26epage%3D4400%26doi%3D10.1021%2Facs.jmedchem.8b01821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pluchino, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fojo, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bates, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span> <span> </span><span class="NLM_article-title">Revisiting the role of ABC transporters in multidrug-resistance cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.1038/s41568-018-0005-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fs41568-018-0005-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=29643473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=452-464&author=R.+W.+Robeyauthor=K.+M.+Pluchinoauthor=M.+D.+Hallauthor=A.+T.+Fojoauthor=S.+E.+Batesauthor=M.+M.+Gottesman&title=Revisiting+the+role+of+ABC+transporters+in+multidrug-resistance+cancer&doi=10.1038%2Fs41568-018-0005-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting the role of ABC transporters in multidrug-resistant cancer</span></div><div class="casAuthors">Robey, Robert W.; Pluchino, Kristen M.; Hall, Matthew D.; Fojo, Antonio T.; Bates, Susan E.; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">452-464</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Most patients who die of cancer have disseminated disease that has become resistant to multiple therapeutic modalities.  Ample evidence suggests that the expression of ATP-binding cassette (ABC) transporters, esp. the multidrug resistance protein 1 (MDR1, also known as P-glycoprotein or P-gp), which is encoded by ABC subfamily B member 1 (ABCB1), can confer resistance to cytotoxic and targeted chemotherapy.  However, the development of MDR1 as a therapeutic target has been unsuccessful.  At the time of its discovery, appropriate tools for the characterization and clin. development of MDR1 as a therapeutic target were lacking.  Thirty years after the initial cloning and characterization of MDR1 and the implication of two addnl. ABC transporters, the multidrug resistance-assocd. protein 1 (MRP1; encoded by ABCC1)), and ABCG2, in multidrug resistance, interest in investigating these transporters as therapeutic targets has waned.  However, with the emergence of new data and advanced techniques, we propose to re-evaluate whether these transporters play a clin. role in multidrug resistance.  With this Opinion article, we present recent evidence indicating that it is time to revisit the investigation into the role of ABC transporters in efficient drug delivery in various cancer types and at the blood-brain barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTrmO71Nb38rVg90H21EOLACvtfcHk0lg60-1QhrUHMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgt7Y%253D&md5=9c4b00f17a7ae98158862504bf1a8292</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fs41568-018-0005-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41568-018-0005-8%26sid%3Dliteratum%253Aachs%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DPluchino%26aufirst%3DK.%2BM.%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DFojo%26aufirst%3DA.%2BT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DRevisiting%2520the%2520role%2520of%2520ABC%2520transporters%2520in%2520multidrug-resistance%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2018%26volume%3D18%26spage%3D452%26epage%3D464%26doi%3D10.1038%2Fs41568-018-0005-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span> <span> </span><span class="NLM_article-title">Co-expression of ATP binding cassette transporters is associated with poor prognosis in acute myleoid leukemia</span>. <i>Oncol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">452</span>– <span class="NLM_lpage">464</span>, <span class="refDoi"> DOI: 10.3892/ol.2018.8095</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.3892%2Fol.2018.8095" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=452-464&author=B.+Liuauthor=L.-J.+Liauthor=X.+Gongauthor=W.+Zhangauthor=H.+Zhangauthor=L.+Zhao&title=Co-expression+of+ATP+binding+cassette+transporters+is+associated+with+poor+prognosis+in+acute+myleoid+leukemia&doi=10.3892%2Fol.2018.8095"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.3892%2Fol.2018.8095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fol.2018.8095%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DL.-J.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DL.%26atitle%3DCo-expression%2520of%2520ATP%2520binding%2520cassette%2520transporters%2520is%2520associated%2520with%2520poor%2520prognosis%2520in%2520acute%2520myleoid%2520leukemia%26jtitle%3DOncol.%2520Lett.%26date%3D2018%26volume%3D15%26spage%3D452%26epage%3D464%26doi%3D10.3892%2Fol.2018.8095" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofrichter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenzel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunkelmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paarmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhlich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uecker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plath, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brüning, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinze, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahnke, J.</span></span> <span> </span><span class="NLM_article-title">ABC Transporters B1, C1 and G2 differentially regulate neuroregeneration in mice</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e35613</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0035613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1371%2Fjournal.pone.0035613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=22545122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslantLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=T.+Schumacherauthor=M.+Krohnauthor=J.+Hofrichterauthor=C.+Langeauthor=J.+Stenzelauthor=J.+Steffenauthor=T.+Dunkelmannauthor=K.+Paarmannauthor=C.+Fr%C3%B6hlichauthor=A.+Ueckerauthor=A.+S.+Plathauthor=A.+Sommerauthor=T.+Br%C3%BCningauthor=H.+J.+Heinzeauthor=J.+Pahnke&title=ABC+Transporters+B1%2C+C1+and+G2+differentially+regulate+neuroregeneration+in+mice&doi=10.1371%2Fjournal.pone.0035613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">ABC transporters B1, C1 and G2 differentially regulate neuroregeneration in mice</span></div><div class="casAuthors">Schumacher, Toni; Krohn, Markus; Hofrichter, Jacqueline; Lange, Cathleen; Stenzel, Jan; Steffen, Johannes; Dunkelmann, Tina; Paarmann, Kristin; Froehlich, Christina; Uecker, Annekathrin; Plath, Anne-Sophie; Sommer, Alexandra; Bruening, Thomas; Heinze, Hans-Jochen; Pahnke, Jens</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e35613</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: ATP-binding cassette (ABC) transporters are essential regulators of organismic homeostasis, and are particularly important in protecting the body from potentially harmful exogenous substances.  Recently, an increasing no. of in vitro observations have indicated a functional role of ABC transporters in the differentiation and maintenance of stem cells.  Therefore, we sought to det. brain-related phenotypic changes in animals lacking the expression of distinct ABC transporters (ABCB1, ABCG2 or ABCC1).  Methodol. and Principal Findings: Analyzing adult neurogenesis in ABC transporter-deficient animals in vivo and neuronal stem/progenitor cells in vitro resulted in complex findings.  In vivo, the differentiation of neuronal progenitors was hindered in ABC transporter-deficient mice (ABCB10/0) as evidenced by lowered nos. of doublecortin+ (-36%) and calretinin+ (-37%) cells.  In vitro, we confirmed that this finding is not connected to the functional loss of single neural stem/progenitor cells (NSPCs).  Furthermore, assessment of activity, exploratory behavior, and anxiety levels revealed behavioral alterations in ABCB10/0 and ABCC10/0 mice, whereas ABCG20/0 mice were mostly unaffected.  Conclusion and Significance: Our data show that single ABC transporter-deficiency does not necessarily impair neuronal progenitor homeostasis on the single NSPC level, as suggested by previous studies.  However, loss of distinct ABC transporters impacts global brain homeostasis with far ranging consequences, leading to impaired neurogenic functions in vivo and even to distinct behavioral phenotypes.  In addn. to the known role of ABC transporters in proteopathies such as Parkinson's disease and Alzheimer's disease, our data highlight the importance of understanding the general function of ABC transporters for the brain's homeostasis and the regeneration potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt5VxqNNTz8LVg90H21EOLACvtfcHk0lhzvOsPpsHYBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslantLc%253D&md5=e91107843e33893fc32619ab1ba4a8e7</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0035613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0035613%26sid%3Dliteratum%253Aachs%26aulast%3DSchumacher%26aufirst%3DT.%26aulast%3DKrohn%26aufirst%3DM.%26aulast%3DHofrichter%26aufirst%3DJ.%26aulast%3DLange%26aufirst%3DC.%26aulast%3DStenzel%26aufirst%3DJ.%26aulast%3DSteffen%26aufirst%3DJ.%26aulast%3DDunkelmann%26aufirst%3DT.%26aulast%3DPaarmann%26aufirst%3DK.%26aulast%3DFr%25C3%25B6hlich%26aufirst%3DC.%26aulast%3DUecker%26aufirst%3DA.%26aulast%3DPlath%26aufirst%3DA.%2BS.%26aulast%3DSommer%26aufirst%3DA.%26aulast%3DBr%25C3%25BCning%26aufirst%3DT.%26aulast%3DHeinze%26aufirst%3DH.%2BJ.%26aulast%3DPahnke%26aufirst%3DJ.%26atitle%3DABC%2520Transporters%2520B1%252C%2520C1%2520and%2520G2%2520differentially%2520regulate%2520neuroregeneration%2520in%2520mice%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0035613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hölzl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrowolny, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hildebrandt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trübner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogerts, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahnke, J.</span></span> <span> </span><span class="NLM_article-title">Vascular and extravascular distribution of the ATP-binding cassette transporters ABCB1 and ABCC1 in aged human brain and pituitary</span>. <i>Mech. Ageing Dev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>141–142</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1016/j.mad.2014.08.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.mad.2014.08.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25218792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKqurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141%E2%80%93142&publication_year=2014&pages=12-21&author=H.+G.+Bernsteinauthor=G.+H%C3%B6lzlauthor=H.+Dobrowolnyauthor=J.+Hildebrandtauthor=K.+Tr%C3%BCbnerauthor=M.+Krohnauthor=N.+Bogertsauthor=J.+Pahnke&title=Vascular+and+extravascular+distribution+of+the+ATP-binding+cassette+transporters+ABCB1+and+ABCC1+in+aged+human+brain+and+pituitary&doi=10.1016%2Fj.mad.2014.08.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular and extravascular distribution of the ATP-binding cassette transporters ABCB1 and ABCC1 in aged human brain and pituitary</span></div><div class="casAuthors">Bernstein, Hans-Gert; Hoelzl, Gloria; Dobrowolny, Henrik; Hildebrandt, Jens; Truebner, Kurt; Krohn, Markus; Bogerts, Bernhard; Pahnke, Jens</div><div class="citationInfo"><span class="NLM_cas:title">Mechanisms of Ageing and Development</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">141-142</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12-21</span>CODEN:
                <span class="NLM_cas:coden">MAGDA3</span>;
        ISSN:<span class="NLM_cas:issn">0047-6374</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">ATP-binding cassette (ABC) transporters play an increasing role in the understanding of pathol. peptide deposition in neurodegenerative diseases (NDs), such as Alzheimer's and Parkinson's.  To describe the location of the most important ABC transporters for NDs in human brain tissue, we investigated ABCB1 and ABCC1 immunohistol. in the adult human brain and pituitary.  Both transporters have similar but not identical expression patterns.  In brain regions with an established blood-brain barrier (BBB), ABCB1 and ABCC1 were ubiquitously expressed in endothelial cells of the microvasculature and in a subset of larger blood vessels (mostly venules).  Remarkably, both transporters were also found in fenestrated capillaries in circumventricular organs where the BBB is absent.  Moreover, ABCB1 and ABCC1 were also expressed in various non-endothelia cells such as pericytes, astrocytes, choroid plexus epithelia, ventricle ependymal cells, and neurons.  With regard to their neuronal expression it was shown that both transporters are located in specific nerve cell populations, which are also immunopos. for three putative cell markers of purinergic cell signalling, namely 5'-nucleotidase, adenosine deaminase and nucleoside triphosphate diphosphohydrolase-2.  Therefore, we speculate that neuronal expression of ABCB1 and ABCC1 might be linked to adenosinergic/purinergic neuromodulation.  Lastly, both transporters were obsd. in multiple adenohypophyseal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotBRARb3874bVg90H21EOLACvtfcHk0lhzvOsPpsHYBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKqurrJ&md5=fb92edd6c1ebd7d2216eda5bc44c1dc9</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.mad.2014.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mad.2014.08.003%26sid%3Dliteratum%253Aachs%26aulast%3DBernstein%26aufirst%3DH.%2BG.%26aulast%3DH%25C3%25B6lzl%26aufirst%3DG.%26aulast%3DDobrowolny%26aufirst%3DH.%26aulast%3DHildebrandt%26aufirst%3DJ.%26aulast%3DTr%25C3%25BCbner%26aufirst%3DK.%26aulast%3DKrohn%26aufirst%3DM.%26aulast%3DBogerts%26aufirst%3DN.%26aulast%3DPahnke%26aufirst%3DJ.%26atitle%3DVascular%2520and%2520extravascular%2520distribution%2520of%2520the%2520ATP-binding%2520cassette%2520transporters%2520ABCB1%2520and%2520ABCC1%2520in%2520aged%2520human%2520brain%2520and%2520pituitary%26jtitle%3DMech.%2520Ageing%2520Dev.%26date%3D2014%26volume%3D141%25E2%2580%2593142%26spage%3D12%26epage%3D21%26doi%3D10.1016%2Fj.mad.2014.08.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samant, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodrich, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huss, W. J.</span></span> <span> </span><span class="NLM_article-title">Multi-drug resistance ABC transporters inhibition enhances murine ventral prostate ste,/progenitor cell differentiation</span>. <i>Stem Cells Dev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1236</span>– <span class="NLM_lpage">1251</span>, <span class="refDoi"> DOI: 10.1089/scd.2014.0293</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1089%2Fscd.2014.0293" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25567291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsVanuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1236-1251&author=M.+D.+Samantauthor=C.+M.+Jacksonauthor=C.+L.+Felixauthor=A.+J.+Jonesauthor=D.+W.+Goodrichauthor=B.+A.+Fosterauthor=W.+J.+Huss&title=Multi-drug+resistance+ABC+transporters+inhibition+enhances+murine+ventral+prostate+ste%2C%2Fprogenitor+cell+differentiation&doi=10.1089%2Fscd.2014.0293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Drug Resistance ABC Transporter Inhibition Enhances Murine Ventral Prostate Stem/Progenitor Cell Differentiation</span></div><div class="casAuthors">Samant, Mugdha D.; Jackson, Courtney M.; Felix, Carina L.; Jones, Anthony J.; Goodrich, David W.; Foster, Barbara A.; Huss, Wendy J.</div><div class="citationInfo"><span class="NLM_cas:title">Stem Cells and Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1236-1251</span>CODEN:
                <span class="NLM_cas:coden">SCDTAE</span>;
        ISSN:<span class="NLM_cas:issn">1547-3287</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Multi-drug resistance (MDR)-ATP binding cassette (ABC) transporters, ABCB1, ABCC1, and ABCG2 participate in the efflux of steroid hormones, estrogens, and androgens, which regulate prostate development and differentiation.  The role of MDR-ABC efflux transporters in prostate epithelial proliferation and differentiation remains unclear.  We hypothesized that MDR-ABC transporters regulate prostate differentiation and epithelium regeneration.  Prostate epithelial differentiation was studied using histol., sphere formation assay, and prostate regeneration induced by cycles of repeated androgen withdrawal and replacement.  Embryonic deletion of Abcg2 resulted in a decreased no. of luminal cells in the prostate and increased sphere formation efficiency, indicating an imbalance in the prostate epithelial differentiation pattern.  Decreased luminal cell no. in the Abcg2 null prostate implies reduced differentiation.  Enhanced sphere formation efficiency in Abcg2 null prostate cells implies activation of the stem/progenitor cells.  Prostate regeneration was assocd. with profound activation of the stem/progenitor cells, indicating the role of Abcg2 in maintaining stem/progenitor cell pool.  Since embryonic deletion of Abcg2 may result in compensation by other ABC transporters, pharmacol. inhibition of MDR-ABC efflux was performed.  Pharmacol. inhibition of MDR-ABC efflux enhanced prostate epithelial differentiation in sphere culture and during prostate regeneration.  In conclusion, Abcg2 deletion leads to activation of the stem/progenitor cells and enhances differentiating divisions; and pharmacol. inhibition of MDR-ABC efflux leads to epithelial differentiation.  Our study demonstrates for the first time that MDR-ABC efflux transporter inhibition results in enhanced prostate epithelial cell differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0vFmNx4MRwrVg90H21EOLACvtfcHk0liHHV2ujEOv9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsVanuro%253D&md5=c6d7660e4a68f133c326cc0848e2bd02</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1089%2Fscd.2014.0293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fscd.2014.0293%26sid%3Dliteratum%253Aachs%26aulast%3DSamant%26aufirst%3DM.%2BD.%26aulast%3DJackson%26aufirst%3DC.%2BM.%26aulast%3DFelix%26aufirst%3DC.%2BL.%26aulast%3DJones%26aufirst%3DA.%2BJ.%26aulast%3DGoodrich%26aufirst%3DD.%2BW.%26aulast%3DFoster%26aufirst%3DB.%2BA.%26aulast%3DHuss%26aufirst%3DW.%2BJ.%26atitle%3DMulti-drug%2520resistance%2520ABC%2520transporters%2520inhibition%2520enhances%2520murine%2520ventral%2520prostate%2520ste%252C%252Fprogenitor%2520cell%2520differentiation%26jtitle%3DStem%2520Cells%2520Dev.%26date%3D2015%26volume%3D24%26spage%3D1236%26epage%3D1251%26doi%3D10.1089%2Fscd.2014.0293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed-Belkacem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macalou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Victoria, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boumendjel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pietro, A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2)</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1097/00001813-200603000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1097%2F00001813-200603000-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=16520651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD28XitVGntLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=239-243&author=A.+Ahmed-Belkacemauthor=A.+Pozzaauthor=S.+Macalouauthor=J.+M.+Perez-Victoriaauthor=A.+Boumendjelauthor=A.+Di+Pietro&title=Inhibitors+of+cancer+cell+multidrug+resistance+mediated+by+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29&doi=10.1097%2F00001813-200603000-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2)</span></div><div class="casAuthors">Ahmed-Belkacem, Abdelhakim; Pozza, Alexandre; Macalou, Sira; Perez-Victoria, Jose M.; Boumendjel, Ahcene; Di Pietro, Attilio</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-243</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Breast cancer resistance protein (BCRP/ABCG2) belongs to the ATP-binding cassette (ABC) transporter superfamily.  It is able to efflux a broad range of anti-cancer drugs through the cellular membrane, thus limiting their anti-proliferative effects.  Due to its relatively recent discovery in 1998, and in contrast to the other ABC transporters P-glycoprotein (MDR1/ABCB1) and multidrug resistance-assocd. protein (MRP1/ABCC1), only a few BCRP inhibitors have been reported.  This review summarizes the known classes of inhibitors that are either specific for BCRP or also inhibit the other multidrug resistance ABC transporters.  Information is presented on structure-activity relationship aspects and how modulators may interact with BCRP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo8q1_Mp1zf7Vg90H21EOLACvtfcHk0liHHV2ujEOv9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XitVGntLk%253D&md5=bc8c1ba612b88026cfcb745d032d2388</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1097%2F00001813-200603000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-200603000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DAhmed-Belkacem%26aufirst%3DA.%26aulast%3DPozza%26aufirst%3DA.%26aulast%3DMacalou%26aufirst%3DS.%26aulast%3DPerez-Victoria%26aufirst%3DJ.%2BM.%26aulast%3DBoumendjel%26aufirst%3DA.%26aulast%3DDi%2BPietro%26aufirst%3DA.%26atitle%3DInhibitors%2520of%2520cancer%2520cell%2520multidrug%2520resistance%2520mediated%2520by%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2006%26volume%3D17%26spage%3D239%26epage%3D243%26doi%3D10.1097%2F00001813-200603000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, S. M.</span></span> <span> </span><span class="NLM_article-title">Multi-target ABC transporter modulators: what next and where to go?</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2353</span>– <span class="NLM_lpage">2358</span>, <span class="refDoi"> DOI: 10.4155/fmc-2019-0185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.4155%2Ffmc-2019-0185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=31516029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFWis7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=2353-2358&author=S.+M.+Stefan&title=Multi-target+ABC+transporter+modulators%3A+what+next+and+where+to+go%3F&doi=10.4155%2Ffmc-2019-0185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target ABC transporter modulators: what next and where to go?</span></div><div class="casAuthors">Stefan, Sven Marcel</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2353-2358</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review discussing multi-target ABC transporter modulators for treatment of cancer.  It also discusses that future ABC transporter modulators in particular and future medicinal chem. in general.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMUFK03Bl4kbVg90H21EOLACvtfcHk0lj5wLB8-VOASA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFWis7jM&md5=a8666c2d50a6ebc8899adceb3c4b4650</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2019-0185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2019-0185%26sid%3Dliteratum%253Aachs%26aulast%3DStefan%26aufirst%3DS.%2BM.%26atitle%3DMulti-target%2520ABC%2520transporter%2520modulators%253A%2520what%2520next%2520and%2520where%2520to%2520go%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D2353%26epage%3D2358%26doi%3D10.4155%2Ffmc-2019-0185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ozvegy-Laczka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegedus, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varady, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ujhelly, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orfi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nemet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkadi, B.</span></span> <span> </span><span class="NLM_article-title">High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1485</span>– <span class="NLM_lpage">1495</span>, <span class="refDoi"> DOI: 10.1124/mol.65.6.1485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1124%2Fmol.65.6.1485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=15155841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ms1enug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2004&pages=1485-1495&author=C.+Ozvegy-Laczkaauthor=T.+Hegedusauthor=G.+Varadyauthor=O.+Ujhellyauthor=J.+D.+Schuetzauthor=A.+Varadiauthor=G.+Keriauthor=L.+Orfiauthor=K.+Nemetauthor=B.+Sarkadi&title=High-affinity+interaction+of+tyrosine+kinase+inhibitors+with+the+ABCG2+multidrug+transporter&doi=10.1124%2Fmol.65.6.1485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter</span></div><div class="casAuthors">Ozvegy-Laczka Csilla; Hegedus Tamas; Varady Gyorgy; Ujhelly Olga; Schuetz John D; Varadi Andras; Keri Gyorgy; Orfi Laszlo; Nemet Katalin; Sarkadi Balazs</div><div class="citationInfo"><span class="NLM_cas:title">Molecular pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1485-95</span>
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">Tyrosine kinase inhibitors (TKIs) are promising new agents for specific inhibition of malignant cell growth and metastasis formation.  Because most of the TKIs have to reach an intracellular target, specific membrane transporters may significantly modulate their effectiveness.  In addition, the hydrophobic TKIs may interact with so-called multidrug transporters and thus alter the cellular distribution of unrelated pharmacological agents.  In the present work, we show that certain TKIs, already in the clinical phase of drug development, directly interact with the ABCG2 multidrug transporter protein with a high affinity.  We found that in several in vitro assay systems, STI-571 (Gleevec; imatinib mesylate), ZD1839 (Iressa; gefitinib), and N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (EKI-785) interacted with ABCG2 at submicromolar concentrations, whereas other multidrug transporters, human multidrug resistance protein (P-glycoprotein, ABCB1) and human multidrug resistance protein 1 (ABCC1), showed much lower reactivity toward these agents.  Low concentrations of the TKIs examined selectively modulated ABCG2-ATPase activity, inhibited ABCG2-dependent active drug extrusion, and significantly affected drug resistance patterns in cells expressing ABCG2.  Our results indicate that multidrug resistance protein modulation by TKIs may be an important factor in the clinical treatment of cancer patients.  These data also raise the possibility that an extrusion of TKIs by multidrug transporters, e.g., ABCG2, may be involved in tumor cell TKI resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxLklKEEpRTDToTC3aBaesfW6udTcc2eYYKcC0yYGF8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ms1enug%253D%253D&md5=d95324e42b206e256c0e0cb9e7474eaa</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1124%2Fmol.65.6.1485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.65.6.1485%26sid%3Dliteratum%253Aachs%26aulast%3DOzvegy-Laczka%26aufirst%3DC.%26aulast%3DHegedus%26aufirst%3DT.%26aulast%3DVarady%26aufirst%3DG.%26aulast%3DUjhelly%26aufirst%3DO.%26aulast%3DSchuetz%26aufirst%3DJ.%2BD.%26aulast%3DVaradi%26aufirst%3DA.%26aulast%3DKeri%26aufirst%3DG.%26aulast%3DOrfi%26aufirst%3DL.%26aulast%3DNemet%26aufirst%3DK.%26aulast%3DSarkadi%26aufirst%3DB.%26atitle%3DHigh-affinity%2520interaction%2520of%2520tyrosine%2520kinase%2520inhibitors%2520with%2520the%2520ABCG2%2520multidrug%2520transporter%26jtitle%3DMol.%2520Pharmacol.%26date%3D2004%26volume%3D65%26spage%3D1485%26epage%3D1495%26doi%3D10.1124%2Fmol.65.6.1485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pawarode, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minderman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricke, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinder, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Loughlin, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, M. R.</span></span> <span> </span><span class="NLM_article-title">Differential effects of the immunosuppressive agents cyclosporine A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1007/s00280-006-0357-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1007%2Fs00280-006-0357-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=17031644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFSksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2007&pages=179-188&author=A.+Pawarodeauthor=S.+Shuklaauthor=H.+Mindermanauthor=S.+M.+Frickeauthor=E.+M.+Pinderauthor=K.+L.+O%E2%80%99Loughlinauthor=S.+V.+Ambudkarauthor=M.+R.+Baer&title=Differential+effects+of+the+immunosuppressive+agents+cyclosporine+A%2C+tacrolimus+and+sirolimus+on+drug+transport+by+multidrug+resistance+proteins&doi=10.1007%2Fs00280-006-0357-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins</span></div><div class="casAuthors">Pawarode, Attaphol; Shukla, Suneet; Minderman, Hans; Fricke, Stacy M.; Pinder, Elaine M.; O'Loughlin, Kieran L.; Ambudkar, Suresh V.; Baer, Maria R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-188</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We sought to det. the effects of the immunosuppressants, cyclosporin A (CsA), tacrolimus and sirolimus, on drug transport by the ATP-binding cassette proteins, P-glycoprotein (Pgp; ABCB1), multidrug resistance protein-1 (MRP-1; ABCC1) and breast cancer resistance protein (BCRP; ABCG2), and the major vault protein lung resistance protein (LRP).  Cellular content of mitoxantrone, a Pgp, MRP-1 and BCRP substrate, was measured by flow cytometry in cells overexpressing these proteins following incubation with and without CsA, tacrolimus or sirolimus.  Interaction of BCRP with these compds. was studied by photolabeling and ATPase assays.  Nuclear-cytoplasmic distribution of doxorubicin was studied by confocal microscopy in cells overexpressing LRP.  CsA increased cellular drug uptake in cells overexpressing Pgp, MRP-1 or BCRP and nuclear drug uptake in cells overexpressing LRP at the clin. achievable concn. of 2.5 μM.  Tacrolimus enhanced cellular drug uptake at 1 μM, but not at 0.08 μM, its clin. achievable concn., and did not enhance nuclear drug uptake.  Sirolimus enhanced cellular drug uptake in cells overexpressing Pgp, MRP-1 and BCRP with optimal effects at 2.5 μM, but was effective at its clin. achievable concn. of 0.25 μM if cells were pre-incubated for at least 30 min before drug exposure, and also enhanced nuclear drug uptake at 0.25 μM.  BCRP modulation by all three immunosuppressive agents was assocd. with competitive binding to the drug transport sites.  CsA, tacrolimus and sirolimus modulate drug transport by Pgp, MRP-1 and BCRP and CsA and sirolimus modulate drug transport by LRP at concns. that differ from immunosuppressive concns. and max. tolerated concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWFap9_l-cebVg90H21EOLACvtfcHk0lgPn5xlablAJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFSksbY%253D&md5=7a726299d0b6bcb3c7e86bd4605088f1</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1007%2Fs00280-006-0357-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-006-0357-8%26sid%3Dliteratum%253Aachs%26aulast%3DPawarode%26aufirst%3DA.%26aulast%3DShukla%26aufirst%3DS.%26aulast%3DMinderman%26aufirst%3DH.%26aulast%3DFricke%26aufirst%3DS.%2BM.%26aulast%3DPinder%26aufirst%3DE.%2BM.%26aulast%3DO%25E2%2580%2599Loughlin%26aufirst%3DK.%2BL.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26atitle%3DDifferential%2520effects%2520of%2520the%2520immunosuppressive%2520agents%2520cyclosporine%2520A%252C%2520tacrolimus%2520and%2520sirolimus%2520on%2520drug%2520transport%2520by%2520multidrug%2520resistance%2520proteins%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2007%26volume%3D60%26spage%3D179%26epage%3D188%26doi%3D10.1007%2Fs00280-006-0357-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ivnitski-Steele, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovato, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khawaja, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oprea, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklar, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, B. S.</span></span> <span> </span><span class="NLM_article-title">High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1089/adt.2007.107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1089%2Fadt.2007.107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=18205550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1cXls1Kqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2008&pages=263-276&author=I.+Ivnitski-Steeleauthor=R.+S.+Larsonauthor=D.+M.+Lovatoauthor=H.+M.+Khawajaauthor=S.+S.+Winterauthor=T.+I.+Opreaauthor=L.+A.+Sklarauthor=B.+S.+Edwards&title=High-throughput+flow+cytometry+to+detect+selective+inhibitors+of+ABCB1%2C+ABCC1%2C+and+ABCG2+transporters&doi=10.1089%2Fadt.2007.107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters</span></div><div class="casAuthors">Ivnitski-Steele, Irena; Larson, Richard S.; Lovato, Debbie M.; Khawaja, Hadya M.; Winter, Stuart S.; Oprea, Tudor I.; Sklar, Larry A.; Edwards, Bruce S.</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-276</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Up-regulation of pump (transporter) expression and selection of resistant cancer cells result in cancer multidrug resistance to diverse substrates of these transporters.  While more than 48 members of the ATP binding cassette (ABC) transporter superfamily have been identified, up to now only three human ABC transporters-ABCB1, ABCC1, and ABCG2-have unambiguously been shown to contribute to cancer multidrug resistance.  The use of low-toxicity and high-specificity agents as a targeted transporter inhibition strategy is necessary to effectively overcome multiple drug resistance.  An objective of the present studies was to develop and validate HyperCyt (IntelliCyt, Albuquerque, NM) flow cytometry high-throughput screening assays to assess the specificity of test compds. that inhibited transporters as an integral part of the screen.  Two sep. duplex assays were constructed: one in which ABCB1 and ABCG2 transporters were evaluated in parallel using fluorescent J-aggregate-forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide as substrate, and the other in which ABCB1 and ABCC1 transporters were evaluated in parallel using fluorescent calcein acetoxymethyl ester as substrate.  ABCB1-expressing cells were color-coded to allow their distinction from cells expressing the alternate transporter.  The assays were validated in a screen of the Prestwick Chem. Library (Illkirch, France).  Three novel selective inhibitors of the ABCC1 transporter were identified in the screen, and the activity of each was confirmed in follow-up chemosensitivity shift and reversal studies.  This high-throughput screening assay provides an efficient approach for identifying selective inhibitors of individual ABC transporters, promising as probes of transporter function and therapeutic tools for treating chemotherapy-resistant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRappYyF8fXLVg90H21EOLACvtfcHk0lgPn5xlablAJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXls1Kqu70%253D&md5=4c037ba8843d29d06440df46ec7f12e3</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1089%2Fadt.2007.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2007.107%26sid%3Dliteratum%253Aachs%26aulast%3DIvnitski-Steele%26aufirst%3DI.%26aulast%3DLarson%26aufirst%3DR.%2BS.%26aulast%3DLovato%26aufirst%3DD.%2BM.%26aulast%3DKhawaja%26aufirst%3DH.%2BM.%26aulast%3DWinter%26aufirst%3DS.%2BS.%26aulast%3DOprea%26aufirst%3DT.%2BI.%26aulast%3DSklar%26aufirst%3DL.%2BA.%26aulast%3DEdwards%26aufirst%3DB.%2BS.%26atitle%3DHigh-throughput%2520flow%2520cytometry%2520to%2520detect%2520selective%2520inhibitors%2520of%2520ABCB1%252C%2520ABCC1%252C%2520and%2520ABCG2%2520transporters%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2008%26volume%3D6%26spage%3D263%26epage%3D276%26doi%3D10.1089%2Fadt.2007.107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarulo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ancona, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagliarulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Bicalutamide failure in prostate cancer treatment: involvement of multi drug resistance proteins</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>601</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2008.10.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejphar.2008.10.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=18992739" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKrsbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=601&publication_year=2008&pages=38-42&author=N.+A.+Colabufoauthor=V.+Pagliaruloauthor=F.+Berardiauthor=M.+Continoauthor=C.+Ingleseauthor=M.+Nisoauthor=P.+Anconaauthor=G.+Alboauthor=A.+Pagliaruloauthor=R.+Perrone&title=Bicalutamide+failure+in+prostate+cancer+treatment%3A+involvement+of+multi+drug+resistance+proteins&doi=10.1016%2Fj.ejphar.2008.10.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Bicalutamide failure in prostate cancer treatment: Involvement of Multi Drug Resistance proteins</span></div><div class="casAuthors">Colabufo, Nicola Antonio; Pagliarulo, Vincenzo; Berardi, Francesco; Contino, Marialessandra; Inglese, Carmela; Niso, Mauro; Ancona, Patrizia; Albo, Giancarlo; Pagliarulo, Arcangelo; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">601</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">38-42</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Prolonged bicalutamide treatment induced pathol. regression although relapses with a more aggressive form of prostate cancer have been obsd.  This failure could be due to androgen receptor mutation.  In the present work we hypothesized an alternative mechanism responsible for bicalutamide failure involving activity of ATP-binding cassette (ABC) pumps such as P-glycoprotein, Breast Cancer Receptor Protein (BCRP), and Multi Resistant Proteins (MRPs) that extrude the androgen antagonist from the cell membrane.  As exptl. models androgen-dependent (LnCap) and androgen-independent (PC-3) prostate cancer cell lines have been employed.  Bicalutamide has been tested in the cell lines mentioned above in the absence and in the presence of MC18, our potent P-glycoprotein/BCRP/MRP1 inhibitor.  The results displayed that bicalutamide antiproliferative effect at 72 h was ameliorated in LnCap cells (EC50 from 51.9 ± 6.1 μM to 17.8 ± 2.6 μM in the absence and in the presence of MC18, resp.) and restored in PC-3 cells (EC50 from 150 ± 2.4 μM to 60 ± 3.5 μM in the absence and in the presence of MC18, resp.).  Moreover, we established the contribution of each transporter employing stable transfected cells (MDCK) overexpressing P-glycoprotein or BCRP or MRP1 pump.  The results displayed that P-glycoprotein and BCRP were involved in bicalutamide efflux while MRP1 was unable to bind the antiandrogen drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGxXLjsSjHvrVg90H21EOLACvtfcHk0liS-ep9UxTMNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKrsbrE&md5=102ec86e344cace41ffa295e135a838c</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2008.10.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2008.10.038%26sid%3Dliteratum%253Aachs%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DPagliarulo%26aufirst%3DV.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DInglese%26aufirst%3DC.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DAncona%26aufirst%3DP.%26aulast%3DAlbo%26aufirst%3DG.%26aulast%3DPagliarulo%26aufirst%3DA.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DBicalutamide%2520failure%2520in%2520prostate%2520cancer%2520treatment%253A%2520involvement%2520of%2520multi%2520drug%2520resistance%2520proteins%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D601%26spage%3D38%26epage%3D42%26doi%3D10.1016%2Fj.ejphar.2008.10.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashby, C. R.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robey, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L. W.</span></span> <span> </span><span class="NLM_article-title">Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">7905</span>– <span class="NLM_lpage">7914</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-0499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1158%2F0008-5472.CAN-08-0499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=18829547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtF2msL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=7905-7914&author=C.+L.+Daiauthor=A.+K.+Tiwariauthor=C.+P.+Wuauthor=X.+D.+Suauthor=S.+R.+Wangauthor=D.+G.+Liuauthor=C.+R.+Ashbyauthor=Y.+Huangauthor=R.+W.+Robeyauthor=Y.+J.+Liangauthor=L.+M.+Chenauthor=C.+J.+Shiauthor=S.+V.+Ambudkarauthor=Z.+S.+Chenauthor=L.+W.+Fu&title=Lapatinib+%28Tykerb%2C+GW572016%29+reverses+multidrug+resistance+in+cancer+cells+by+inhibiting+the+activity+of+ATP-binding+cassette+subfamily+B+member+1+and+G+member+2&doi=10.1158%2F0008-5472.CAN-08-0499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2</span></div><div class="casAuthors">Dai, Chun-ling; Tiwari, Amit K.; Wu, Chung-Pu; Su, Xiao-dong; Wang, Si-Rong; Liu, Dong-geng; Ashby, Charles R., Jr.; Huang, Yan; Robey, Robert W.; Liang, Yong-ju; Chen, Li-ming; Shi, Cheng-Jun; Ambudkar, Suresh V.; Chen, Zhe-Sheng; Fu, Li-wu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7905-7914</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Lapatinib is active at the ATP-binding site of tyrosine kinases that are assocd. with the human epidermal growth factor receptor (Her-1 or ErbB1) and Her-2.  It is conceivable that lapatinib may inhibit the function of ATP-binding cassette (ABC) transporters by binding to their ATP-binding sites.  The aim of this study was to investigate the ability of lapatinib to reverse tumor multidrug resistance (MDR) due to overexpression of ABC subfamily B member 1 (ABCB1) and ABC subfamily G member 2 (ABCG2) transporters.  Our results showed that lapatinib significantly enhanced the sensitivity to ABCB1 or ABCG2 substrates in cells expressing these transporters, although a small synergetic effect was obsd. in combining lapatinib and conventional chemotherapeutic agents in parental sensitive MCF-7 or S1 cells.  Lapatinib alone, however, did not significantly alter the sensitivity of non-ABCB1 or non-ABCG2 substrates in sensitive and resistant cells.  Addnl., lapatinib significantly increased the accumulation of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells and inhibited the transport of methotrexate and E217βG by ABCG2.  Furthermore, lapatinib stimulated the ATPase activity of both ABCB1 and ABCG2 and inhibited the photolabeling of ABCB1 or ABCG2 with [125I]iodoarylazidoprazosin in a concn.-dependent manner.  However, lapatinib did not affect the expression of these transporters at mRNA or protein levels.  Importantly, lapatinib also strongly enhanced the effect of paclitaxel on the inhibition of growth of the ABCB1-overexpressing KBv200 cell xenografts in nude mice.  Overall, we conclude that lapatinib reverses ABCB1- and ABCG2-mediated MDR by directly inhibiting their transport function.  These findings may be useful for cancer combinational therapy with lapatinib in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowPBKRO5m-O7Vg90H21EOLACvtfcHk0liS-ep9UxTMNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtF2msL3P&md5=6dd61ea93f95ac0137055777fa53599f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-0499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-0499%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DC.%2BL.%26aulast%3DTiwari%26aufirst%3DA.%2BK.%26aulast%3DWu%26aufirst%3DC.%2BP.%26aulast%3DSu%26aufirst%3DX.%2BD.%26aulast%3DWang%26aufirst%3DS.%2BR.%26aulast%3DLiu%26aufirst%3DD.%2BG.%26aulast%3DAshby%26aufirst%3DC.%2BR.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DLiang%26aufirst%3DY.%2BJ.%26aulast%3DChen%26aufirst%3DL.%2BM.%26aulast%3DShi%26aufirst%3DC.%2BJ.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26aulast%3DFu%26aufirst%3DL.%2BW.%26atitle%3DLapatinib%2520%2528Tykerb%252C%2520GW572016%2529%2520reverses%2520multidrug%2520resistance%2520in%2520cancer%2520cells%2520by%2520inhibiting%2520the%2520activity%2520of%2520ATP-binding%2520cassette%2520subfamily%2520B%2520member%25201%2520and%2520G%2520member%25202%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D7905%26epage%3D7914%26doi%3D10.1158%2F0008-5472.CAN-08-0499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L. W.</span></span> <span> </span><span class="NLM_article-title">Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function</span>. <i>Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.2119/molmed.2014.00059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.2119%2Fmolmed.2014.00059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25105301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yrtr3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=390-399&author=S.+L.+Maauthor=Y.+P.+Huauthor=F.+Wangauthor=Z.+C.+Huangauthor=Y.+F.+Chenauthor=X.+K.+Wangauthor=L.+W.+Fu&title=Lapatinib+antagonizes+multidrug+resistance-associated+protein+1-mediated+multidrug+resistance+by+inhibiting+its+transport+function&doi=10.2119%2Fmolmed.2014.00059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function</span></div><div class="casAuthors">Ma, Shao-Lin; Hu, Ya-Peng; Wang, Fang; Huang, Zhen-Cong; Chen, Yi-Fan; Wang, Xiao-Kun; Fu, Li-Wu</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Medicine (Manhasset, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">390-399, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">MOMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1528-3658</span>.
    
            (<span class="NLM_cas:orgname">Feinstein Institute for Medical Research</span>)
        </div><div class="casAbstract">Lapatinib, a tyrosine kinase inhibitor, is used in the treatment of advanced or metastatic breast cancer overexpressing human epidermal receptor 2 (HER2).  Lapatinib can modulate the function of ATP-binding cassette (ABC) transporters (ABCB1 and ABCG2), which are the major mechanism responsible for multidrug resistance (MDR) in cancer.  In this study, we investigated the effect of lapatinib on multidrug resistance-assocd. protein 1 (MRP1 [ABCC1]), MRP2 (ABCC2), MRP4 (ABCC4) and lung relative resistance protein (LRP) drug efflux pumps.  We demonstrated that lapatinib could enhance the efficacy of conventional chemotherapeutic agents in MRP1-overexpressing cells in vitro and in vivo, but no effect in MRP2-, MPR4-and LRP-overexpressing cells.  Furthermore, lapatinib significantly increased the accumulation of rhodamine 123 (Rho123) and doxorubicin (DOX) in MRP1-overexpressing cells.  However, lapatinib did not alter the protein or mRNA expression levels of MRP1.  Further studies showed that the level of phosphorylation of AKT and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) were not altered at the indicated concns. of lapatinib.  In conclusion, lapatinib enhanced the efficacy of conventional chemotherapeutic agents in MRP1-overexpressing cells by inhibiting MRP1 transport function without altering the level of AKT or ERK1/2 phosphorylation.  These findings will encourage the clin. research of lapatinib combined with conventional chemotherapeutic drugs in MRP1-overexpressing cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeTcf5F8bwW7Vg90H21EOLACvtfcHk0li8Ay6M4Kd8Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yrtr3I&md5=39440a6a97d4ed1b24bff5c6e3e042d3</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.2119%2Fmolmed.2014.00059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2119%252Fmolmed.2014.00059%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DS.%2BL.%26aulast%3DHu%26aufirst%3DY.%2BP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DZ.%2BC.%26aulast%3DChen%26aufirst%3DY.%2BF.%26aulast%3DWang%26aufirst%3DX.%2BK.%26aulast%3DFu%26aufirst%3DL.%2BW.%26atitle%3DLapatinib%2520antagonizes%2520multidrug%2520resistance-associated%2520protein%25201-mediated%2520multidrug%2520resistance%2520by%2520inhibiting%2520its%2520transport%2520function%26jtitle%3DMol.%2520Med.%26date%3D2014%26volume%3D20%26spage%3D390%26epage%3D399%26doi%3D10.2119%2Fmolmed.2014.00059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantore, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglese, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Multi-drug-resistance-reverting agents: 2-arylazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">195</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200800329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1002%2Fcmdc.200800329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=19140144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXislWju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=188-195&author=N.+A.+Colabufoauthor=F.+Berardiauthor=M.+G.+Perroneauthor=M.+Cantoreauthor=M.+Continoauthor=C.+Ingleseauthor=M.+Nisoauthor=R.+Perrone&title=Multi-drug-resistance-reverting+agents%3A+2-arylazole+and+2-arylthiazole+derivatives+as+potent+BCRP+or+MRP1+inhibitors&doi=10.1002%2Fcmdc.200800329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors</span></div><div class="casAuthors">Colabufo, Nicola A.; Berardi, Francesco; Perrone, Maria Grazia; Cantore, Mariangela; Contino, Marialessandra; Inglese, Carmela; Niso, Mauro; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-195</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">2-Aryloxazole and 2-arylthiazole derivs. were evaluated for their inhibitory activity toward P-glycoprotein (P-gp) as well as their selectivity toward other ABC transporters involved in multidrug resistance such as BCRP and MRP1.  These derivs. have 6,7-dimethoxytetrahydroisoquinoline or cyclohexylpiperazine moieties, which are the same basic nuclei of the potent P-gp inhibitors MC70 (EC50 = 0.05 μM) and PB28 (EC50 = 0.55 μM), resp.  The results demonstrate that 2-aryloxazole and 2-arylthiazole derivs., planned as cycloisosteres of MC70, were found to be less potent than the ref. compd. in inhibiting P-gp.  These compds. were evaluated for their BCRP and MRP1 inhibitory activities.  In particular, 6,7-dimethoxytetrahydroisoquinoline derivs., unsubstituted, 3-Br, 3-Cl, and 3-OCH3 2-aryloxalzole derivs. showed the best BCRP inhibitory activity (EC50 range: 0.24-0.46 μM).  In contrast, all cyclohexylpiperazine derivs. except one (EC50 = 0.56 μM), showed decreased BCRP inhibitory activity.  All compds. tested were unable to inhibit the MRP1 pump, with the exception of the 2-OCH3 and 4-OCH3 derivs. of the 6,7-dimethoxytetrahydroisoquinoline series, which displayed high MRP1 inhibitory activity (EC50 = 0.84 and 0.90 μM, resp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprNAfet5qK9bVg90H21EOLACvtfcHk0li8Ay6M4Kd8Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXislWju7s%253D&md5=3a97e57563939e60a3e34485ea0a3d15</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200800329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200800329%26sid%3Dliteratum%253Aachs%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPerrone%26aufirst%3DM.%2BG.%26aulast%3DCantore%26aufirst%3DM.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DInglese%26aufirst%3DC.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DMulti-drug-resistance-reverting%2520agents%253A%25202-arylazole%2520and%25202-arylthiazole%2520derivatives%2520as%2520potent%2520BCRP%2520or%2520MRP1%2520inhibitors%26jtitle%3DChemMedChem%26date%3D2009%26volume%3D4%26spage%3D188%26epage%3D195%26doi%3D10.1002%2Fcmdc.200800329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L. W.</span></span> <span> </span><span class="NLM_article-title">Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">7981</span>– <span class="NLM_lpage">7991</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-0111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1158%2F0008-5472.CAN-10-0111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=20876799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1yqs7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=7981-7991&author=Y.+J.+Miauthor=Y.+J.+Liangauthor=H.+B.+Huangauthor=H.+Y.+Zhaoauthor=C.+P.+Wuauthor=F.+Wangauthor=L.+Y.+Taoauthor=C.+Z.+Zhangauthor=C.+L.+Daiauthor=A.+K.+Tiwariauthor=X.+X.+Maauthor=K.+K.+Toauthor=S.+V.+Ambudkarauthor=Z.+S.+Chenauthor=L.+W.+Fu&title=Apatinib+%28YN968D1%29+reverses+multidrug+resistance+by+inhibiting+the+efflux+function+of+multiple+ATP-binding+cassette+transporters&doi=10.1158%2F0008-5472.CAN-10-0111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters</span></div><div class="casAuthors">Mi, Yan-jun; Liang, Yong-ju; Huang, Hong-bing; Zhao, Hong-yun; Wu, Chung-Pu; Wang, Fang; Tao, Li-yang; Zhang, Chuan-zhao; Dai, Chun-Ling; Tiwari, Amit K.; Ma, Xiao-xu; To, Kenneth Kin Wah; Ambudkar, Suresh V.; Chen, Zhe-Sheng; Fu, Li-wu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7981-7991</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Apatinib, a small-mol. multitargeted tyrosine kinase inhibitor, is in phase III clin. trial for the treatment of patients with non-small-cell lung cancer and gastric cancer in China.  In this study, we detd. the effect of apatinib on the interaction of specific antineoplastic compds. with P-glycoprotein (ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), and breast cancer resistance protein (BCRP, ABCG2).  Our results showed that apatinib significantly enhanced the cytotoxicity of ABCB1 or ABCG2 substrate drugs in KBv200, MCF-7/adr, and HEK293/ABCB1 cells overexpressing ABCB1 and in S1-M1-80, MCF-7/FLV1000, and HEK293/ABCG2-R2 cells overexpressing ABCG2 (wild-type).  In contrast, apatinib did not alter the cytotoxicity of specific substrates in the parental cells and cells overexpressing ABCC1.  Apatinib significantly increased the intracellular accumulation of rhodamine 123 and doxorubicin in the multidrug resistance (MDR) cells.  Furthermore, apatinib significantly inhibited the photoaffinity labeling of both ABCB1 and ABCG2 with [125I]iodoarylazidoprazosin in a concn.-dependent manner.  The ATPase activity of both ABCB1 and ABCG2 was significantly increased by apatinib.  However, apatinib, at a concn. that produced a reversal of MDR, did not significantly alter the ABCB1 or ABCG2 protein or mRNA expression levels or the phosphorylation of AKT and extracellular signal-regulated kinase 1/2 (ERK1/2).  Importantly, apatinib significantly enhanced the effect of paclitaxel against the ABCB1-resistant KBv200 cancer cell xenografts in nude mice.  In conclusion, apatinib reverses ABCB1- and ABCG2-mediated MDR by inhibiting their transport function, but not by blocking the AKT or ERK1/2 pathway or downregulating ABCB1 or ABCG2 expression.  Apatinib may be useful in circumventing MDR to other conventional antineoplastic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7UdIyUL3T57Vg90H21EOLACvtfcHk0liQXwBwxz0qKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1yqs7nF&md5=ecf314e6eda8940a8a739398c959eb43</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-0111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-0111%26sid%3Dliteratum%253Aachs%26aulast%3DMi%26aufirst%3DY.%2BJ.%26aulast%3DLiang%26aufirst%3DY.%2BJ.%26aulast%3DHuang%26aufirst%3DH.%2BB.%26aulast%3DZhao%26aufirst%3DH.%2BY.%26aulast%3DWu%26aufirst%3DC.%2BP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DTao%26aufirst%3DL.%2BY.%26aulast%3DZhang%26aufirst%3DC.%2BZ.%26aulast%3DDai%26aufirst%3DC.%2BL.%26aulast%3DTiwari%26aufirst%3DA.%2BK.%26aulast%3DMa%26aufirst%3DX.%2BX.%26aulast%3DTo%26aufirst%3DK.%2BK.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DChen%26aufirst%3DZ.%2BS.%26aulast%3DFu%26aufirst%3DL.%2BW.%26atitle%3DApatinib%2520%2528YN968D1%2529%2520reverses%2520multidrug%2520resistance%2520by%2520inhibiting%2520the%2520efflux%2520function%2520of%2520multiple%2520ATP-binding%2520cassette%2520transporters%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D7981%26epage%3D7991%26doi%3D10.1158%2F0008-5472.CAN-10-0111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krauze, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grinberga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasnova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adlere, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domracheva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shestakova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andzans, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duburs, G.</span></span> <span> </span><span class="NLM_article-title">Thieno[3,2-b]pyridines–a new class of multidrug resistance (MDR) modulators</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5860</span>– <span class="NLM_lpage">5870</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.09.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bmc.2014.09.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=25311564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslCitLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5860-5870&author=A.+Krauzeauthor=S.+Grinbergaauthor=L.+Krasnovaauthor=I.+Adlereauthor=E.+Sokolovaauthor=I.+Domrachevaauthor=I.+Shestakovaauthor=Z.+Andzansauthor=G.+Duburs&title=Thieno%5B3%2C2-b%5Dpyridines%E2%80%93a+new+class+of+multidrug+resistance+%28MDR%29+modulators&doi=10.1016%2Fj.bmc.2014.09.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Thieno[2,3-b]pyridines-A new class of multidrug resistance (MDR) modulators</span></div><div class="casAuthors">Krauze, Aivars; Grinberga, Signe; Krasnova, Laura; Adlere, Ilze; Sokolova, Elina; Domracheva, Ilona; Shestakova, Irina; Andzans, Zigmars; Duburs, Gunars</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5860-5870</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">To identify new potent multidrug resistance modulators, we have synthesized a series of novel thieno[2,3-b]pyridines and furo[2,3-b]pyridines, and examd. their structure-activity relationships.  All synthesized compds. were tested to det. BCRP1, P-gp, and MRP1 inhibitor activity, and most potent MDR modulators were also screened for their toxicity, cytotoxicity and Ca2+ channel antagonist activity.  Among these compds., thieno[2,3-b]pyridine (6r) was found to exhibit a potent P-gp inhibitory action with EC50 = 0.3 ± 0.2 μM, MRP1 inhibitory action with EC50 = 1.1 ± 0.1 μM and BCRP1 inhibitory action with EC50 = 0.2 ± 0.05 μM and may represent suitable candidate for further pharmacol. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3HnHyKtS3y7Vg90H21EOLACvtfcHk0liQXwBwxz0qKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslCitLrE&md5=7f648cc8771774e04e6dab83b11fd4a8</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.09.023%26sid%3Dliteratum%253Aachs%26aulast%3DKrauze%26aufirst%3DA.%26aulast%3DGrinberga%26aufirst%3DS.%26aulast%3DKrasnova%26aufirst%3DL.%26aulast%3DAdlere%26aufirst%3DI.%26aulast%3DSokolova%26aufirst%3DE.%26aulast%3DDomracheva%26aufirst%3DI.%26aulast%3DShestakova%26aufirst%3DI.%26aulast%3DAndzans%26aufirst%3DZ.%26aulast%3DDuburs%26aufirst%3DG.%26atitle%3DThieno%255B3%252C2-b%255Dpyridines%25E2%2580%2593a%2520new%2520class%2520of%2520multidrug%2520resistance%2520%2528MDR%2529%2520modulators%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5860%26epage%3D5870%26doi%3D10.1016%2Fj.bmc.2014.09.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teodori, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riganti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manetti, i D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanelli, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trezza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Athanasios, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiga, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giampietro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dei, S.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">111655</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2019.111655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=31494468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslCgs73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2019&pages=111655&author=E.+Teodoriauthor=M.+Continoauthor=C.+Rigantiauthor=G.+Bartolucciauthor=L.+Braconiauthor=i+D.+Manettiauthor=M.+N.+Romanelliauthor=A.+Trezzaauthor=A.+Athanasiosauthor=O.+Spigaauthor=M.+G.+Perroneauthor=R.+Giampietroauthor=E.+Gazzanoauthor=M.+Salernoauthor=N.+A.+Colabufoauthor=S.+Dei&title=Design%2C+synthesis+and+biological+evaluation+of+stereo-+and+regioisomers+of+amino+aryl+esters+as+multidrug+resistance+%28MDR%29+reversers&doi=10.1016%2Fj.ejmech.2019.111655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers</span></div><div class="casAuthors">Teodori, Elisabetta; Contino, Marialessandra; Riganti, Chiara; Bartolucci, Gianluca; Braconi, Laura; Manetti, Dina; Romanelli, Maria Novella; Trezza, Alfonso; Athanasios, Asimidis; Spiga, Ottavia; Perrone, Maria Grazia; Giampietro, Roberta; Gazzano, Elena; Salerno, Milena; Colabufo, Nicola Antonio; Dei, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111655pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Stereo- and regioisomers of a series of N,N-bis(alkanol)amine aryl ester derivs. I [Ar = Ar1 = (E)3-(3,4,5-trimethoxyphenyl)acrylic acid, 3,4,5-trimethoxybenzoicacid, anthracene-9-carboxylic acid; n = 3, 5, 7] were prepd. and studied as multidrug resistance (MDR) modulators.  In the pirarubicin uptake assay on K562/DOX cell line these compds. I showed good activity and efficacy and in many cases enantioselectivity was obsd.  Docking studies confirmed the influence of the stereocenter on the interaction in the P-gp pocket.  The P-gp interaction mechanism and selectivity towards MRP1 and BCRP were also evaluated on MDCK transfected cells overexpressing the three transporters.  Almost all these compds. inhibited both P-gp and BCRP, but only derivs. with specific structural characteristics showed MRP1 activity.  Moreover, two compds., (S)-3 and (R)-7, showed the ability to induce collateral sensitivity (CS) against MDR cells.  Therefore, these two CS-promoting agents could be considered interesting leads for the development of selective cytotoxic agents for drug-resistant cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwUPLjN1vaDrVg90H21EOLACvtfcHk0ljwOHiMbkiZng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslCgs73K&md5=de524db6fbdcda6e3c2f2226ad5c53b4</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111655%26sid%3Dliteratum%253Aachs%26aulast%3DTeodori%26aufirst%3DE.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DRiganti%26aufirst%3DC.%26aulast%3DBartolucci%26aufirst%3DG.%26aulast%3DBraconi%26aufirst%3DL.%26aulast%3DManetti%26aufirst%3Di%2BD.%26aulast%3DRomanelli%26aufirst%3DM.%2BN.%26aulast%3DTrezza%26aufirst%3DA.%26aulast%3DAthanasios%26aufirst%3DA.%26aulast%3DSpiga%26aufirst%3DO.%26aulast%3DPerrone%26aufirst%3DM.%2BG.%26aulast%3DGiampietro%26aufirst%3DR.%26aulast%3DGazzano%26aufirst%3DE.%26aulast%3DSalerno%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DDei%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520stereo-%2520and%2520regioisomers%2520of%2520amino%2520aryl%2520esters%2520as%2520multidrug%2520resistance%2520%2528MDR%2529%2520reversers%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D182%26spage%3D111655%26doi%3D10.1016%2Fj.ejmech.2019.111655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manolaridis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">König, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, G.</span></span> <span> </span><span class="NLM_article-title">Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">112133</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2020.112133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=32105979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvVKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2020&pages=112133&author=F.+Antoniauthor=M.+Bauseauthor=M.+Schollerauthor=S.+Bauerauthor=S.+A.+Starkauthor=S.+M.+Jacksonauthor=I.+Manolaridisauthor=K.+P.+Locherauthor=B.+K%C3%B6nigauthor=A.+Buschauerauthor=G.+Bernhardt&title=Tariquidar-related+triazoles+as+potent%2C+selective+and+stable+inhibitors+of+ABCG2+%28BCRP%29&doi=10.1016%2Fj.ejmech.2020.112133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP)</span></div><div class="casAuthors">Antoni, Frauke; Bause, Manuel; Scholler, Matthias; Bauer, Stefanie; Stark, Simone A.; Jackson, Scott M.; Manolaridis, Ioannis; Locher, Kaspar P.; Koenig, Burkhard; Buschauer, Armin; Bernhardt, Guenther</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112133pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The current study comprises the synthesis and characterization of novel tariquidar-related inhibitors, obtained by bioisosteric replacement of the labile moieties in previous tariquidar analog UR-ME22-1.  CuAAC ("click" reaction) gave convenient access to a triazole core as a substitute for the labile amide group and the labile ester moiety was replaced by different acyl groups in a Sugasawa reaction.  A stability assay proved the enhancement of the stability in blood plasma.  Compds. UR-MB108 I (R1 = OMe) and UR-MB136 I (R1 = O(CH2CH2O)3Me) inhibited ABCG2 in a Hoechst 33342 transport assay with an IC50 value of about 80 nM and belong to the most potent ABCG2 inhibitors described so far.  Compd. I (R1 = OMe) was highly selective, whereas its PEGylated analog I (R1 = O(CH2CH2O)3Me) showed some potency at ABCB1.  Both compds. produced an ABCG2 ATPase-depressing effect which is in agreement with precedent cryo-EM study identifying I (R1 = O(CH2CH2O)3Me) as an ATPase inhibitor that exerts its effect via locking the inward-facing conformation.  Thermostabilization of ABCG2 by both compds. can be taken as a hint to comparable binding to ABCG2.  As ref. substances, both compds. allow addnl. mechanistic studies on ABCG2 inhibition.  The highly specific inhibitor (R1 = OMe) is suited for PET labeling, helping to further elucidate the (patho)physiol. role of ABCG2, e.g. at the BBB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSL6WpPUbeCrVg90H21EOLACvtfcHk0ljwOHiMbkiZng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvVKhu7s%253D&md5=1b7237b3d2a389ca0c1ee8f6c5928903</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112133%26sid%3Dliteratum%253Aachs%26aulast%3DAntoni%26aufirst%3DF.%26aulast%3DBause%26aufirst%3DM.%26aulast%3DScholler%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DStark%26aufirst%3DS.%2BA.%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DManolaridis%26aufirst%3DI.%26aulast%3DLocher%26aufirst%3DK.%2BP.%26aulast%3DK%25C3%25B6nig%26aufirst%3DB.%26aulast%3DBuschauer%26aufirst%3DA.%26aulast%3DBernhardt%26aufirst%3DG.%26atitle%3DTariquidar-related%2520triazoles%2520as%2520potent%252C%2520selective%2520and%2520stable%2520inhibitors%2520of%2520ABCG2%2520%2528BCRP%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D191%26spage%3D112133%26doi%3D10.1016%2Fj.ejmech.2020.112133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.-W.</span></span> <span> </span><span class="NLM_article-title">Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2009.01.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.canlet.2009.01.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=19232821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltlejt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2009&pages=74-83&author=C.-L.+Daiauthor=Y.-J.+Liangauthor=Y.-S.+Wangauthor=A.+K.+Tiwariauthor=Y.-Y.+Yanauthor=F.+Wangauthor=Z.-S.+Chenauthor=X.-Z.+Tongauthor=L.-W.+Fu&title=Sensitization+of+ABCG2-overexpressing+cells+to+conventional+chemotherapeutic+agent+by+sunitinib+was+associated+with+inhibiting+the+function+of+ABCG2&doi=10.1016%2Fj.canlet.2009.01.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2</span></div><div class="casAuthors">Dai, Chun-Ling; Liang, Yong-Ju; Wang, Yan-Sheng; Tiwari, Amit K.; Yan, Yan-Yan; Wang, Fang; Chen, Zhe-Sheng; Tong, Xiu-Zhen; Fu, Li-Wu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-83</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Sunitinib is an ATP-competitive multi-targeted tyrosine kinase inhibitor.  In this study, we evaluated the possible interaction of sunitinib with P-glycoprotein (P-gp, ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), breast cancer resistance protein (BCRP, ABCG2) and lung-resistance protein (LRP) in vitro.  Our results showed that sunitinib completely reverse drug resistance mediated by ABCG2 at a non-toxic concn. of 2.5 μM and has no significant reversal effect on ABCB1-, ABCC1- and LRP-mediated drug resistance, although a small synergetic effect was obsd. in combining sunitinib and conventional chemotherapeutic agents in ABCB1 overexpressing MCF-7/adr and parental sensitive MCF-7 cells, ABCC1 overexpressing C-A120 and parental sensitive KB-3-1 cells.  Sunitinib significantly increased intracellular accumulation of rhodamine 123 and doxorubicin and remarkably inhibited the efflux of rhodamine 123 and methotrexate by ABCG2 in ABCG2-overexpressing cells, and also profoundly inhibited the transport of [3H]-methotrexate by ABCG2.  However, sunitinib did not affect the expression of ABCG2 at mRNA or protein levels.  In addn., sunitinib did not block the phosphorylation of Akt and Erk1/2 in ABCG2-overexpressing or parental sensitive cells.  Overall, we conclude that sunitinib reverses ABCG2-mediated MDR through inhibiting the drug efflux function of ABCG2.  These findings may be useful for cancer combinational therapy with sunitinib in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri11_oxCDuL7Vg90H21EOLACvtfcHk0lgQY03SnCNH0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltlejt7w%253D&md5=3d448f3fd1ee17c338e8b7783a19ea82</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.01.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.01.027%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DC.-L.%26aulast%3DLiang%26aufirst%3DY.-J.%26aulast%3DWang%26aufirst%3DY.-S.%26aulast%3DTiwari%26aufirst%3DA.%2BK.%26aulast%3DYan%26aufirst%3DY.-Y.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DZ.-S.%26aulast%3DTong%26aufirst%3DX.-Z.%26aulast%3DFu%26aufirst%3DL.-W.%26atitle%3DSensitization%2520of%2520ABCG2-overexpressing%2520cells%2520to%2520conventional%2520chemotherapeutic%2520agent%2520by%2520sunitinib%2520was%2520associated%2520with%2520inhibiting%2520the%2520function%2520of%2520ABCG2%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D279%26spage%3D74%26epage%3D83%26doi%3D10.1016%2Fj.canlet.2009.01.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan Sheng, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumour cells</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">422</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.05.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2012.05.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=22743241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWntLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2012&pages=413-422&author=J.+Yuanauthor=I.+L.+Wongauthor=T.+Jiangauthor=S.+W.+Wangauthor=T.+Liuauthor=B.+J.+Wenauthor=L.+M.+Chowauthor=B.+Wan+Sheng&title=Synthesis+of+methylated+quercetin+derivatives+and+their+reversal+activities+on+P-gp-+and+BCRP-mediated+multidrug+resistance+tumour+cells&doi=10.1016%2Fj.ejmech.2012.05.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of methylated quercetin derivatives and their reversal activities on P-gp- and BCRP-mediated multidrug resistance tumor cells</span></div><div class="casAuthors">Yuan, Jian; Wong, Iris L. K.; Jiang, Tao; Wang, Si Wen; Liu, Tao; Bin, Jin Wen; Chow, Larry M. C.; Biao, Wan Sheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">413-422</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Three methylated quercetins and a series of O-3 substituted 5,7,3',4'-tetra-O-methylated quercetin derivs. have been synthesized and evaluated on the modulating activity of P-gp, BCRP and MRP1 in cancer cell lines.  Compd. I is the most potent P-gp modulator.  Three derivs. consistently exhibited promising BCRP-modulating activity.  Interestingly, I was found to be equipotent against both P-gp and BCRP.  Importantly, these synthetic quercetin derivs. did not exhibit any inherent cytotoxicity to cancer cell lines or normal mouse fibroblast cell lines.  These quercetin derivs. can be employed as safe and effective modulators of P-gp- or BCRP-mediated drug resistance in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfUvCzHF18QbVg90H21EOLACvtfcHk0lgQY03SnCNH0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWntLbM&md5=b2b5d4c5949f2af31840ec6ad3a71841</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.05.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.05.026%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DI.%2BL.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DS.%2BW.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DWen%26aufirst%3DB.%2BJ.%26aulast%3DChow%26aufirst%3DL.%2BM.%26aulast%3DWan%2BSheng%26aufirst%3DB.%26atitle%3DSynthesis%2520of%2520methylated%2520quercetin%2520derivatives%2520and%2520their%2520reversal%2520activities%2520on%2520P-gp-%2520and%2520BCRP-mediated%2520multidrug%2520resistance%2520tumour%2520cells%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D54%26spage%3D413%26epage%3D422%26doi%3D10.1016%2Fj.ejmech.2012.05.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flemming, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D. M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conseil, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tivnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polinsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudkov, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishvanath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, D. M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, S. P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, M. D.</span></span> <span> </span><span class="NLM_article-title">High-throughput screening identifies ceefourin 1 and ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2014.05.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bcp.2014.05.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=24973542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFOgtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2014&pages=97-108&author=L.+Cheungauthor=C.+L.+Flemmingauthor=F.+Wattauthor=N.+Masadaauthor=D.+M.+T.+Yuauthor=T.+Huynhauthor=G.+Conseilauthor=A.+Tivnanauthor=A.+Polinskyauthor=A.+V.+Gudkovauthor=M.+A.+Munozauthor=A.+Vishvanathauthor=D.+M.+F.+Cooperauthor=M.+J.+Hendersonauthor=S.+P.+C.+Coleauthor=J.+I.+Fletcherauthor=M.+Haberauthor=M.+D.+Norris&title=High-throughput+screening+identifies+ceefourin+1+and+ceefourin+2+as+highly+selective+inhibitors+of+multidrug+resistance+protein+4+%28MRP4%29&doi=10.1016%2Fj.bcp.2014.05.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4)</span></div><div class="casAuthors">Cheung, Leanna; Flemming, Claudia L.; Watt, Fujiko; Masada, Nanako; Yu, Denise M. T.; Huynh, Tony; Conseil, Gwenaelle; Tivnan, Amanda; Polinsky, Alexander; Gudkov, Andrei V.; Munoz, Marcia A.; Vishvanath, Anasuya; Cooper, Dermot M. F.; Henderson, Michelle J.; Cole, Susan P. C.; Fletcher, Jamie I.; Haber, Michelle; Norris, Murray D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">97-108</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multidrug resistance protein 4 (MRP4/ABCC4), a member of the ATP-binding cassette (ABC) transporter superfamily, is an org. anion transporter capable of effluxing a wide range of physiol. important signalling mols. and drugs.  MRP4 has been proposed to contribute to numerous functions in both health and disease; however, in most cases these links remain to be unequivocally established.  A major limitation to understanding the physiol. and pharmacol. roles of MRP4 has been the absence of specific small mol. inhibitors, with the majority of established inhibitors also targeting other ABC transporter family members, or inhibiting the prodn., function or degrdn. of important MRP4 substrates.  We therefore set out to identify more selective and well tolerated inhibitors of MRP4 that might be used to study the many proposed functions of this transporter.  Using high-throughput screening, we identified two chem. distinct small mols., Ceefourin 1 and Ceefourin 2, that inhibit transport of a broad range of MRP4 substrates, yet are highly selective for MRP4 over other ABC transporters, including P-glycoprotein (P-gp), ABCG2 (Breast Cancer Resistance Protein; BCRP) and MRP1 (multidrug resistance protein 1; ABCC1).  Both compds. are more potent MRP4 inhibitors in cellular assays than the most widely used inhibitor, MK-571, requiring lower concns. to effect a comparable level of inhibition.  Furthermore, Ceefourin 1 and Ceefourin 2 have low cellular toxicity, and high microsomal and acid stability.  These newly identified inhibitors should be of great value for efforts to better understand the biol. roles of MRP4, and may represent classes of compds. with therapeutic application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocSL--oUSDXbVg90H21EOLACvtfcHk0ligeN8GZKGOVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFOgtLrM&md5=11cf7f10449638e857c9f9379a77e778</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2014.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2014.05.023%26sid%3Dliteratum%253Aachs%26aulast%3DCheung%26aufirst%3DL.%26aulast%3DFlemming%26aufirst%3DC.%2BL.%26aulast%3DWatt%26aufirst%3DF.%26aulast%3DMasada%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DD.%2BM.%2BT.%26aulast%3DHuynh%26aufirst%3DT.%26aulast%3DConseil%26aufirst%3DG.%26aulast%3DTivnan%26aufirst%3DA.%26aulast%3DPolinsky%26aufirst%3DA.%26aulast%3DGudkov%26aufirst%3DA.%2BV.%26aulast%3DMunoz%26aufirst%3DM.%2BA.%26aulast%3DVishvanath%26aufirst%3DA.%26aulast%3DCooper%26aufirst%3DD.%2BM.%2BF.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DCole%26aufirst%3DS.%2BP.%2BC.%26aulast%3DFletcher%26aufirst%3DJ.%2BI.%26aulast%3DHaber%26aufirst%3DM.%26aulast%3DNorris%26aufirst%3DM.%2BD.%26atitle%3DHigh-throughput%2520screening%2520identifies%2520ceefourin%25201%2520and%2520ceefourin%25202%2520as%2520highly%2520selective%2520inhibitors%2520of%2520multidrug%2520resistance%2520protein%25204%2520%2528MRP4%2529%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2014%26volume%3D91%26spage%3D97%26epage%3D108%26doi%3D10.1016%2Fj.bcp.2014.05.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Voruciclib, a potent CDK4/6 inhibitor, antagonizes ABCB1 and ABCG2-mediated multi-drug resistance in cancer cells</span>. <i>Cell. Physiol. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1515</span>– <span class="NLM_lpage">1528</span>, <span class="refDoi"> DOI: 10.1159/000487578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1159%2F000487578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=29486476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlOgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=1515-1528&author=P.+Guptaauthor=Y.-K.+Zhangauthor=X.-Y.+Zhangauthor=Y.-J.+Wangauthor=K.+W.+Luauthor=T.+Hallauthor=R.+Pengauthor=D.-H.+Yangauthor=N.+Xieauthor=Z.-S.+Chen&title=Voruciclib%2C+a+potent+CDK4%2F6+inhibitor%2C+antagonizes+ABCB1+and+ABCG2-mediated+multi-drug+resistance+in+cancer+cells&doi=10.1159%2F000487578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells</span></div><div class="casAuthors">Gupta, Pranav; Zhang, Yun-Kai; Zhang, Xiao-Yu; Wang, Yi-Jun; Lu, Kimberly W.; Hall, Timothy; Peng, Richard; Yang, Dong-Hua; Xie, Ni; Chen, Zhe-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Physiology and Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1515-1528</span>CODEN:
                <span class="NLM_cas:coden">CEPBEW</span>;
        ISSN:<span class="NLM_cas:issn">1015-8987</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background/Aims: The overexpression of ATP-Binding Cassette (ABC) transporters has known to be one of the major obstacles impeding the success of chemotherapy in drug resistant cancers.  In this study, we evaluated voruciclib, a CDK 4/6 inhibitor, for its chemo-sensitizing activity in ABCB1- and ABCG2- overexpressing cells.  Methods: Cytotoxicity and reversal effect of voruciclib was detd. by MTT assay.  The intracellular accumulation and efflux of ABCB1 and ABCG2 substrates were measured by scintillation counter.  The effects on expression and intracellular localization of ABCB1 and ABCG2 proteins were detd. by Western blotting and immunofluorescence, resp.  Vanadate-sensitive ATPase assay was done to det. the effect of voruciclib on the ATPase activity of ABCB1 and ABCG2.  Flow cytometric anal. was done to det. the effect of voruciclib on apoptosis of ABCB1 and ABCG2-overexpressing cells and docking anal. was done to det. the interaction of voruciclib with ABCB1 and ACBG2 protein.  Results: Voruciclib significantly potentiated the effect of paclitaxel and doxorubicin in ABCB1-overexpressing cells, as well as mitoxantrone and SN-38 in ABCG2-overexpressing cells.  Voruciclib moderately sensitized ABCC10- overexpressing cells to paclitaxel, whereas it did not alter the cytotoxicity of substrates of ABCC1.  Furthermore, voruciclib increased the intracellular accumulation and decreased the efflux of substrate anti-cancer drugs from ABCB1- or ABCG2-overexpressing cells.  However, voruciclib did not alter the expression or the sub-cellular localization of ABCB1 or ABCG2.  Voruciclib stimulated the ATPase activity of both ABCB1 and ABCG2 in a concn.-dependent manner.  Lastly, voruciclib exhibited a drug-induced apoptotic effect in ABCB1- or ABCG2- overexpressing cells.  Conclusion: Voruciclib is currently a phase I clin. trial drug.  Our findings strongly support its potential use in combination with conventional anti-cancer drugs for cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoyadf1NgenrVg90H21EOLACvtfcHk0ligeN8GZKGOVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlOgtLo%253D&md5=03b4795bd5a136b1ea91f0403ee8fb5a</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1159%2F000487578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000487578%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.-K.%26aulast%3DZhang%26aufirst%3DX.-Y.%26aulast%3DWang%26aufirst%3DY.-J.%26aulast%3DLu%26aufirst%3DK.%2BW.%26aulast%3DHall%26aufirst%3DT.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DD.-H.%26aulast%3DXie%26aufirst%3DN.%26aulast%3DChen%26aufirst%3DZ.-S.%26atitle%3DVoruciclib%252C%2520a%2520potent%2520CDK4%252F6%2520inhibitor%252C%2520antagonizes%2520ABCB1%2520and%2520ABCG2-mediated%2520multi-drug%2520resistance%2520in%2520cancer%2520cells%26jtitle%3DCell.%2520Physiol.%2520Biochem.%26date%3D2018%26volume%3D45%26spage%3D1515%26epage%3D1528%26doi%3D10.1159%2F000487578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, I. L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Law, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. H.</span></span> <span> </span><span class="NLM_article-title">Triazole bridged flavonoid dimers as potent, nontoxic, and highly selective breast cancer resistance protein (BCRP/ABCG2) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8578</span>– <span class="NLM_lpage">8608</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00963</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00963" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs12jt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8578-8608&author=X.+Zhuauthor=I.+L.+K.+Wongauthor=K.+F.+Chanauthor=J.+Cuiauthor=M.+C.+Lawauthor=T.+C.+Chongauthor=X.+Huauthor=L.+M.+C.+Chowauthor=T.+H.+Chan&title=Triazole+bridged+flavonoid+dimers+as+potent%2C+nontoxic%2C+and+highly+selective+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29+inhibitors&doi=10.1021%2Facs.jmedchem.9b00963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors</span></div><div class="casAuthors">Zhu, Xuezhen; Wong, Iris L. K.; Chan, Kin-Fai; Cui, Jiahua; Law, Man Chun; Chong, Tsz Cheung; Hu, Xuesen; Chow, Larry M. C.; Chan, Tak Hang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8578-8608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The present work describes the syntheses of diverse triazole bridged flavonoid dimers and identifies potent, nontoxic, and highly selective BCRP inhibitors.  A homodimer, Ac22(Az8)2, with m-methoxycarbonylbenzyloxy substitution at C-3 of the flavone moieties and a bis-triazole-contg. linker (21 atoms between the two flavones) showed low toxicity (IC50 toward L929, 3T3, and HFF-1 > 100 μM), potent BCRP-inhibitory activity (EC50 = 1-2 nM), and high BCRP selectivity (BCRP selectivity over MRP1 and P-gp > 455-909).  Ac22(Az8)2 inhibits BCRP-ATPase activity, blocks the drug efflux activity of BCRP, elevates the intracellular drug accumulation, and finally restores the drug sensitivity of BCRP-overexpressing cells.  It does not down-regulate the surface BCRP protein expression to enhance the drug retention.  Therefore, Ac22(Az8)2 and similar flavonoid dimers appear to be promising candidates for further development into combination therapy to overcome MDR cancers with BCRP overexpression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT5xt1YU3qdLVg90H21EOLACvtfcHk0ligeN8GZKGOVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs12jt7zI&md5=3fe2b8583391b42b77d7205b1f32555a</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00963%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DI.%2BL.%2BK.%26aulast%3DChan%26aufirst%3DK.%2BF.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DLaw%26aufirst%3DM.%2BC.%26aulast%3DChong%26aufirst%3DT.%2BC.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DChow%26aufirst%3DL.%2BM.%2BC.%26aulast%3DChan%26aufirst%3DT.%2BH.%26atitle%3DTriazole%2520bridged%2520flavonoid%2520dimers%2520as%2520potent%252C%2520nontoxic%252C%2520and%2520highly%2520selective%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8578%26epage%3D8608%26doi%3D10.1021%2Facs.jmedchem.9b00963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casciano, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W. W.</span></span> <span> </span><span class="NLM_article-title">In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">522</span>– <span class="NLM_lpage">528</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10772630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3cXivVKgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2000&pages=522-528&author=E.-J.+Wangauthor=C.+N.+Cascianoauthor=R.+P.+Clementauthor=W.+W.+Johnson&title=In+vitro+flow+cytometry+method+to+quantitatively+assess+inhibitors+of+P-glycoprotein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein</span></div><div class="casAuthors">Wang, Er-Jia; Casciano, Christopher N.; Clement, Robert P.; Johnson, William W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">522-528</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P-glycoprotein (Pgp)-mediated drug efflux is a major factor contributing to the variance of absorption and distribution of many drugs (Hall et al., 1999).  A simple and reliable in vitro method to identify inhibitors of Pgp helps to prevent the potential of drug interactions.  Using daunorubicin as a fluorescent marker and vanadate as a pos. control compd., a functional flow cytometry method for assessing the ability of a drug to inhibit Pgp-mediated drug efflux from CR1R12 multidrug-resistant cells has been evaluated.  Quantitation of the relative fluorescence was used to compare potency of individual inhibitors.  Known Pgp inhibitors, such as cyclosporin A, nicardipine, verapamil, quinidine, terfenadine, tamoxifen, and vinblastine were demonstrated to inhibit the Pgp-mediated efflux of daunorubicin.  Cyclosporin A and terfenadine were the most potent inhibitors among the compds. tested.  Tetraphenylphosphonium and α-tocopherol had little inhibitory effect.  Progesterone produced significant inhibition at relatively high concns.  This study demonstrated that this in vitro flow cytometry method is a simple, sensitive, and quant. tool to assess the capacity of a drug to inhibit Pgp transporters, and is useful for screening or identifying inhibitors of Pgp as well as evaluation of potential for drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDfnK8-8FgsrVg90H21EOLACvtfcHk0lgqVlvzI_rbqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXivVKgurs%253D&md5=f13c2d00678cdf18ec816e52dbe0d0a4</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DE.-J.%26aulast%3DCasciano%26aufirst%3DC.%2BN.%26aulast%3DClement%26aufirst%3DR.%2BP.%26aulast%3DJohnson%26aufirst%3DW.%2BW.%26atitle%3DIn%2520vitro%2520flow%2520cytometry%2520method%2520to%2520quantitatively%2520assess%2520inhibitors%2520of%2520P-glycoprotein%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2000%26volume%3D28%26spage%3D522%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casciano, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clement, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, W. W.</span></span> <span> </span><span class="NLM_article-title">Cooperativity in the Inhibition of P-glycoprotein-mediated daunorubicin transport: evidence for half-of-the-sites reactivity</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1006/abbi.2000.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1006%2Fabbi.2000.2004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11097180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3cXot1KhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2000&pages=91-98&author=E.-J.+Wangauthor=C.+N.+Cascianoauthor=R.+P.+Clementauthor=W.+W.+Johnson&title=Cooperativity+in+the+Inhibition+of+P-glycoprotein-mediated+daunorubicin+transport%3A+evidence+for+half-of-the-sites+reactivity&doi=10.1006%2Fabbi.2000.2004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: Evidence for half-of-the-sites reactivity</span></div><div class="casAuthors">Wang, Er-jia; Casciano, Christopher N.; Clement, Robert P.; Johnson, William W.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-98</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">P-Glycoprotein (Pgp) is an important transport enzyme composed of two homologous domains and transports a wide range of structurally diverse xenobiotics from the cell.  Recent studies have indicated that allosteric interactions occur between the nucleotide binding domains and between the substrate binding domains of the two halves, but the extent of this interaction as well as the means by which the enzyme can transport such a wide variety of substrates has not been elucidated.  Herein, the Pgp-mediated transport of a marker substrate, daunorubicin (DNR), out of viable cells was examd. in the presence of a variety of other known substrates of Pgp.  For most of the typical Pgp substrates examd., the relation between inhibition of DNR efflux and competing substrate concn. with sigmoidal and therefore not a simple mutually exclusive competitive inhibition of transport.  The Hill coeff. ranged from about 3 to 5 for the inhibition of transport of DNR.  This neg. cooperativity in combination with recent evidence, including several examples of noncompetitive inhibition between the homologous halves of Pgp, indicates a "half-of-the-sites" reactivity.  Our data support the mechanistic proposal that substrate binding at one putative transport binding site precludes activity at another unequal site; many of the substrates examd. exert a neg. allosteric effect on the other transport site (and vice versa).  A half-of-the-sites reactivity model would account for many of these observations and may be crit. to the efficiency of Pgp substrate transport of a broad spectrum of compds.  (c) 2000 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiU9kmAbJogrVg90H21EOLACvtfcHk0lgqVlvzI_rbqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXot1KhsLw%253D&md5=19284896a9c39e96651719d43ebccd30</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1006%2Fabbi.2000.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabbi.2000.2004%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DE.-J.%26aulast%3DCasciano%26aufirst%3DC.%2BN.%26aulast%3DClement%26aufirst%3DR.%2BP.%26aulast%3DJohnson%26aufirst%3DW.%2BW.%26atitle%3DCooperativity%2520in%2520the%2520Inhibition%2520of%2520P-glycoprotein-mediated%2520daunorubicin%2520transport%253A%2520evidence%2520for%2520half-of-the-sites%2520reactivity%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2000%26volume%3D383%26spage%3D91%26epage%3D98%26doi%3D10.1006%2Fabbi.2000.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kühnle, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahringer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fricker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">König, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span> <span> </span><span class="NLM_article-title">Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the P-glycoprotein modulator tariquidar</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1190</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1021/jm8013822</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8013822" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Ohtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1190-1197&author=M.+K%C3%BChnleauthor=M.+Eggerauthor=C.+M%C3%BCllerauthor=A.+Mahringerauthor=G.+Bernhardtauthor=G.+Frickerauthor=B.+K%C3%B6nigauthor=A.+Buschauer&title=Potent+and+selective+inhibitors+of+breast+cancer+resistance+protein+%28ABCG2%29+derived+from+the+P-glycoprotein+modulator+tariquidar&doi=10.1021%2Fjm8013822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) Derived from the p-Glycoprotein (ABCB1) Modulator Tariquidar</span></div><div class="casAuthors">Kuehnle, Matthias; Egger, Michael; Mueller, Christine; Mahringer, Anne; Bernhardt, Gunther; Fricker, Gert; Koenig, Burkhard; Buschauer, Armin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1190-1197</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The efflux pumps ABCB1 (p-gp, MDR1) and ABCG2 (BCRP) are expressed to a high extent by endothelial cells at the blood-brain barrier (BBB) and other barrier tissues and are involved in drug resistance of tumor (stem) cells.  Whereas numerous ABCB1 inhibitors are known, only a few ABCG2 modulators with submicromolar activity have been published.  Starting from tariquidar (4) analogs as ABCB1 modulators, minimal structural modifications resulted in a drastic shift in favor of ABCG2 inhibition.  Highest potency was found when the 3,4-dimethoxy-2-(quinoline-3-carbonylamino)benzoyl moiety in 4 was replaced with a 4-methoxycarbonylbenzoyl moiety bearing a hetarylcarboxamido group in 3-position, e.g., quinoline-3-carboxamido (5, IC50: 119 nM) or quinoline-2-carboxamido (6, IC50: 60 nM, flow cytometric mitoxantrone efflux assay, topotecan-resistant MCF-7 breast cancer cells); the selectivity for ABCG2 over ABCB1 was about 100-500 fold and the compds. were inactive at ABCC2 (MRP2).  Chemosensitivity assays against MCF-7/Topo cells revealed that the nontoxic inhibitor 6 completely reverted ABCG2-mediated topotecan resistance at concns. >100 nM, whereas 5 showed ABCG2 independent cytotoxicity.  ABCG2 inhibitors might be useful for cancer treatment with respect to reversal of multidrug resistance, overcoming the BBB and targeting of tumor stem cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXaBXLV28GfbVg90H21EOLACvtfcHk0ljTho7g8ceimw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Ohtrg%253D&md5=7f6e62d7e127747c08e16db192392e12</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm8013822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8013822%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BChnle%26aufirst%3DM.%26aulast%3DEgger%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DMahringer%26aufirst%3DA.%26aulast%3DBernhardt%26aufirst%3DG.%26aulast%3DFricker%26aufirst%3DG.%26aulast%3DK%25C3%25B6nig%26aufirst%3DB.%26aulast%3DBuschauer%26aufirst%3DA.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%2520derived%2520from%2520the%2520P-glycoprotein%2520modulator%2520tariquidar%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1190%26epage%3D1197%26doi%3D10.1021%2Fjm8013822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Köhler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">HM30181 derivatives as novel potent and selective inhibitors of the breast cancer resistance protein (BCRP/ABCG2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3910</span>– <span class="NLM_lpage">3921</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00188</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00188" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjitlelsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3910-3921&author=S.+C.+K%C3%B6hlerauthor=M.+Wiese&title=HM30181+derivatives+as+novel+potent+and+selective+inhibitors+of+the+breast+cancer+resistance+protein+%28BCRP%2FABCG2%29&doi=10.1021%2Facs.jmedchem.5b00188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2)</span></div><div class="casAuthors">Kohler Sebastian C; Wiese Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3910-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The breast cancer resistance protein (BCRP, ABCG2) belongs to the superfamily of ATP binding-cassette (ABC) proteins.  In addition to other physiological functions, it transports potentially cell-damaging compounds out of the cell using the energy from ATP hydrolysis.  Certain tumors overexpressing BCRP were found to become resistant against various anticancer drugs.  In previous work, we found that tariquidar analogues lacking the tetrahydroisoquinoline moiety selectively inhibit BCRP.  In the present study, we synthesized 21 derivatives of the third-generation P-gp inhibitor HM30181, which is structurally related to tariquidar.  The compounds were tested for their inhibitory activities against BCRP and screened against P-glycoprotein (P-gp, ABCB1) and multidrug resistance protein 1 (MRP1, ABCC1) to confirm the selectivity toward BCRP.  The most potent compounds are selective toward BCRP and 2-fold more potent than the reference Ko143.  Qualitative structure-activity relationship (SAR) analysis revealed that the presence of a methoxy group in the ortho or para position of at least one phenyl ring is beneficial for inhibitory activity.  Furthermore, the cytotoxicity and multidrug resistance (MDR)-reversal ability of selected compounds were investigated.  It was shown that they have a low cytotoxicity and the ability to reverse the BCRP-mediated SN-38 resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_-1BYW7HmO9-cVm4E2RlLfW6udTcc2ebxOo6LbsXQ7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjitlelsg%253D%253D&md5=777b13f427105e8909ae751d11e8c7b4</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00188%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6hler%26aufirst%3DS.%2BC.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DHM30181%2520derivatives%2520as%2520novel%2520potent%2520and%2520selective%2520inhibitors%2520of%2520the%2520breast%2520cancer%2520resistance%2520protein%2520%2528BCRP%252FABCG2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3910%26epage%3D3921%26doi%3D10.1021%2Facs.jmedchem.5b00188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraege, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köhler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Acryloylphenylcarboxamides: a new class of breast cancer resistance protein (ABCG2) modulators</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2422</span>– <span class="NLM_lpage">2436</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1002%2Fcmdc.201600341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=27735138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2422-2436&author=S.+Kraegeauthor=S.+C.+K%C3%B6hlerauthor=M.+Wiese&title=Acryloylphenylcarboxamides%3A+a+new+class+of+breast+cancer+resistance+protein+%28ABCG2%29+modulators&doi=10.1002%2Fcmdc.201600341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Acryloylphenylcarboxamides: A New Class of Breast Cancer Resistance Protein (ABCG2) Modulators</span></div><div class="casAuthors">Kraege, Stefanie; Koehler, Sebastian C.; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2422-2435</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Chalcones are easily synthesized natural precursors of secondary plant metabolites, and their derivs. show various biol. activities including inhibition of ABC transporters.  Esp., their role as inhibitors of ABCG2, the most recently discovered ABC transporter involved in multidrug resistance, inspired the synthesis of new structurally diverse derivs.  Therefore, we combined the typical chalcone moiety with several acid chlorides by using an amide linker at position 2', 3', or 4' on ring A of the chalcone.  The resulting 35 compds. covered a wide spectrum of substitution patterns, which allowed development of structure-activity relationships and to find the optimal structural features for further investigations.  Synthesized acryloylphenylcarboxamides were investigated for their inhibitory activity against ABCG2 and their behavior toward ABCB1 and ABCC1.  Furthermore, for the most promising compds., their intrinsic cytotoxicity and their ability to reverse ABCG2-mediated multidrug resistance were detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0P-lyvFfxZbVg90H21EOLACvtfcHk0lhPIr-UBWrwFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbrF&md5=9ec4f956a6b65d38723bb2ee270c4196</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600341%26sid%3Dliteratum%253Aachs%26aulast%3DKraege%26aufirst%3DS.%26aulast%3DK%25C3%25B6hler%26aufirst%3DS.%2BC.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DAcryloylphenylcarboxamides%253A%2520a%2520new%2520class%2520of%2520breast%2520cancer%2520resistance%2520protein%2520%2528ABCG2%2529%2520modulators%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D2422%26epage%3D2436%26doi%3D10.1002%2Fcmdc.201600341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraege, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köhler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of acryloylphenylcarboxamides as inhibitors of ABCG2 and comparison with acryloylphenylcarboxylates</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2547</span>– <span class="NLM_lpage">2559</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600455</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1002%2Fcmdc.201600455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=27785905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslCrs7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2547-2559&author=S.+Kraegeauthor=K.+Stefanauthor=S.+C.+K%C3%B6hlerauthor=M.+Wiese&title=Optimization+of+acryloylphenylcarboxamides+as+inhibitors+of+ABCG2+and+comparison+with+acryloylphenylcarboxylates&doi=10.1002%2Fcmdc.201600455"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Acryloylphenylcarboxamides as Inhibitors of ABCG2 and Comparison with Acryloylphenylcarboxylates</span></div><div class="casAuthors">Kraege, Stefanie; Stefan, Katja; Koehler, Sebastian C.; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2547-2558</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">ABCG2 belongs to the superfamily of ATP binding cassette (ABC) proteins and is assocd. with the limited success of anticancer chemotherapy, given its responsibility for the cross-resistance of tumor cells, known as multidrug resistance (MDR).  Several classes of ABCG2 inhibitors were developed for increasing the efficacy of chemotherapy.  A series of chalcones coupled to an addnl. arom. residue was synthesized and investigated for their inhibition of ABC transporters.  In the authors' previous work the authors detd. the preferred position of the linker on the A-ring to be ortho, and found several substitution patterns at the addnl. ring that improved potency.  In this study the authors investigated whether a methoxy group that improved the inhibitory activity of chalcones would also be beneficial for the acryloylphenylcarboxamide scaffold.  Indeed, this modification led to highly potent ABCG2 inhibitors.  To support the hypothesis of a beneficial effect of the amide linker, six acryloylphenylcarboxylates were synthesized and investigated for their inhibitory activity.  Replacement of the amide linker with an ester group resulted in decreased inhibition.  Mol. modeling showed that the conformational preference of both series differs, thereby explaining the pos. effect of the amide linker.  Several compds. were characterized in detail by investigating their intrinsic cytotoxicity and capacity to reverse MDR in MTT assays and their effect on vanadate-sensitive ATPase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSSOhTSZbrG7Vg90H21EOLACvtfcHk0lhPIr-UBWrwFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslCrs7nL&md5=43572ddfbc073331704e4950b109bcf4</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600455%26sid%3Dliteratum%253Aachs%26aulast%3DKraege%26aufirst%3DS.%26aulast%3DStefan%26aufirst%3DK.%26aulast%3DK%25C3%25B6hler%26aufirst%3DS.%2BC.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520acryloylphenylcarboxamides%2520as%2520inhibitors%2520of%2520ABCG2%2520and%2520comparison%2520with%2520acryloylphenylcarboxylates%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D2547%26epage%3D2559%26doi%3D10.1002%2Fcmdc.201600455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnier-Suillerot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbeuf-Gueye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loetchutinat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokt, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowalczyk, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priebe, W.</span></span> <span> </span><span class="NLM_article-title">Analysis of drug transport kinetics in multidrug-resistant cells. Implications for drug action</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.2174/0929867013373967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.2174%2F0929867013373967" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=11172692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVSgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=51-64&author=A.+Garnier-Suillerotauthor=C.+Marbeuf-Gueyeauthor=M.+Salernoauthor=C.+Loetchutinatauthor=I.+Foktauthor=M.+Krawczykauthor=T.+Kowalczykauthor=W.+Priebe&title=Analysis+of+drug+transport+kinetics+in+multidrug-resistant+cells.+Implications+for+drug+action&doi=10.2174%2F0929867013373967"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of drug transport kinetics in multidrug-resistant cells: implications for drug action</span></div><div class="casAuthors">Garnier-Suillerot, Arlette; Marbeuf-Gueye, Carole; Salerno, Milena; Loetchutinat, Chatchanok; Fokt, Izabela; Krawczyk, Marta; Kowalczyk, Teresa; Priebe, Waldemar</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-64</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review with 80 refs.  Multidrug resistance (MDR) in model systems is known to be conferred by two different integral proteins--the 170-kDa P-glycoprotein (P-gp) and the 190-kDa multidrug resistance-assocd. protein (MRP1)--that pump drugs out of MDR cells.  The intracellular level of a drug, which influences the drug's cytotoxic effect, is a function of the amt. of drug transported inside the cell (influx) and the amt. of drug expelled from the cell (efflux).  One possible pharmacol. approach to overcoming drug resistance is the use of specific inhibitors that enhance the cytotoxicity of known antineoplastic agents.  Many compds. have been proven to be very efficient in inhibiting P-gp activity, but only some of them can inhibit MRP1.  However, the clin. results obtained so far by this approach have been rather disappointing.  The other likely approach is based on the design and synthesis of new non-cross-resistant drugs whose physicochem. properties favor the uptake of such drug by resistant cells.  Our recent studies have shown that whereas the P-gp- and MRP1-mediated efflux of different anthracycline-based drugs may not differ considerably, their kinetics of uptake do.  Thus, the high uptake of drug by cells may lead to concns. at the cellular target site high enough to achieve the needed cytotoxicity against MDR cells.  Therefore, increased drug lipophilicity might be one factor in improving drug cytotoxicity in MDR cells.  In vitro studies have shown that idarubicin, an analog of daunorub cin, is more effective than daunorubicin and doxorubicin against MDR tumor cell lines and that this increased effectiveness is related in part to the increased lipophilicity of idarubicin.  Other studies have also confirmed the strong impact of lipophilicity on the uptake and retention of anthracyclines in MDR cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouku4IcN0vOLVg90H21EOLACvtfcHk0lgxoTMYFbZC9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVSgsbY%253D&md5=312caa47b349690cdb759a21e9ccf323</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.2174%2F0929867013373967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867013373967%26sid%3Dliteratum%253Aachs%26aulast%3DGarnier-Suillerot%26aufirst%3DA.%26aulast%3DMarbeuf-Gueye%26aufirst%3DC.%26aulast%3DSalerno%26aufirst%3DM.%26aulast%3DLoetchutinat%26aufirst%3DC.%26aulast%3DFokt%26aufirst%3DI.%26aulast%3DKrawczyk%26aufirst%3DM.%26aulast%3DKowalczyk%26aufirst%3DT.%26aulast%3DPriebe%26aufirst%3DW.%26atitle%3DAnalysis%2520of%2520drug%2520transport%2520kinetics%2520in%2520multidrug-resistant%2520cells.%2520Implications%2520for%2520drug%2520action%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2001%26volume%3D8%26spage%3D51%26epage%3D64%26doi%3D10.2174%2F0929867013373967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Pyrrolopyrimidine derivatives and purine analogs as novel activators of multidrug resistance-associated protein 1 (MRP1, ABCC1)</span>. <i>Biochim. Biophys. Acta, Biomembr.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1859</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.bbamem.2016.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.bbamem.2016.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=27810353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKksbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1859&publication_year=2017&pages=69-79&author=S.+M.+Schmittauthor=K.+Stefanauthor=M.+Wiese&title=Pyrrolopyrimidine+derivatives+and+purine+analogs+as+novel+activators+of+multidrug+resistance-associated+protein+1+%28MRP1%2C+ABCC1%29&doi=10.1016%2Fj.bbamem.2016.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolopyrimidine derivatives and purine analogs as novel activators of Multidrug Resistance-associated Protein 1 (MRP1, ABCC1)</span></div><div class="casAuthors">Schmitt, Sven Marcel; Stefan, Katja; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Biomembranes</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1859</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-79</span>CODEN:
                <span class="NLM_cas:coden">BBBMBS</span>;
        ISSN:<span class="NLM_cas:issn">0005-2736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) is the main cause of diminished success in cancer chemotherapy.  ABC transport proteins are considered to be one important factor of MDR.  Besides P-glycoprotein (P-gp, ABCB1) and Breast Cancer Resistance Protein (BCRP, ABCG2), Multidrug Resistance-assocd. Protein 1 (MRP1, ABCC1) is assocd. with nonresponse to chemotherapy in different cancers.  While considerable effort was spent in overcoming MDR during the last two decades, almost nothing is known with respect to activators of transport proteins.  In this work the authors present certain pyrrolo[3,2-d]pyrimidine derivs. with variations at positions 4 and 5 and purine analogs with variations at position 6 as novel activators of MRP1-mediated transport of the MRP1 substrate calcein AM and the anticancer drug daunorubicin in low nanomolar concn. range.  Two different MRP1 overexpressing cell lines were used, the doxorubicin-selected human lung cancer cell line H69 AR and the transfected Madin-Darby Canine Kidney cell line MDCK II MRP1.  No effect was obsd. in the sensitive counterparts H69 and MDCK II wild type (wt.).  Derivs. with higher mol. wt. possessed also inhibitory properties at low micromolar concns., although most compds. were rather poor MRP1 inhibitors.  Purine analogs derived from potent MRP1 inhibitors of the pyrrolopyrimidine class showed equal activating, but no inhibiting effects at all.  All tested compds. were nontoxic and had only minor impact on P-gp or BCRP, showing no inhibition or activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiRhn6QKwRzbVg90H21EOLACvtfcHk0lgxoTMYFbZC9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKksbvO&md5=f471a639c01cedfac35c1bbbd9e1d2c1</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamem.2016.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamem.2016.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DS.%2BM.%26aulast%3DStefan%26aufirst%3DK.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DPyrrolopyrimidine%2520derivatives%2520and%2520purine%2520analogs%2520as%2520novel%2520activators%2520of%2520multidrug%2520resistance-associated%2520protein%25201%2520%2528MRP1%252C%2520ABCC1%2529%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Biomembr.%26date%3D2017%26volume%3D1859%26spage%3D69%26epage%3D79%26doi%3D10.1016%2Fj.bbamem.2016.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9800"><div class="reference"><strong class="refLabel"><a href="#ref9800" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit9800"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silbermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahu, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juvale, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharkar, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9800/cit9800&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2018.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9800/cit9800&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=30594677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9800/cit9800&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlt1Sh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=193-213&author=K.+Silbermannauthor=C.+P.+Shahauthor=N.+U.+Sahuauthor=K.+Juvaleauthor=S.+M.+Stefanauthor=P.+S.+Kharkarauthor=M.+Wiese&title=Novel+chalcone+and+flavone+derivatives+as+selective+and+dual+inhibitors+of+the+transport+proteins+ABCB1+and+ABCG2&doi=10.1016%2Fj.ejmech.2018.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9800R"><div class="casContent"><span class="casTitleNuber">9800</span><div class="casTitle"><span class="NLM_cas:atitle">Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2</span></div><div class="casAuthors">Silbermann, Katja; Shah, Chetan P.; Sahu, Niteshkumar U.; Juvale, Kapil; Stefan, Sven Marcel; Kharkar, Prashant S.; Wiese, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">193-213</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">During cancer chemotherapy, certain cancers may become cross-resistant to structurally diverse antineoplastic agents.  This so-called multidrug resistance (MDR) is highly assocd. with the overexpression of ATP-binding cassette (ABC) transport proteins.  These membrane-bound efflux pumps export a broad range of structurally diverse endo- and xenobiotics, including chem. unrelated anticancer agents.  This translocation of drugs from the inside to the outside of cancer cells is mediated at the expense of ATP.  In the last 40 years, three ABC transporters - ABCB1 (P-gp), ABCC1 (MRP1), and ABCG2 (BCRP) - have mainly been attributed to the occurrence of MDR in cancer cells.  One of the strategies to overcome MDR is to inhibit the efflux transporter function by small-mol. inhibitors.  In this work, we investigated new chalcone- and flavone-based compds. for selective as well as broad-spectrum inhibition of the stated transport proteins.  These include substituted chalcones with variations at rings A and B, and flavones with acetamido linker at position 3.  The synthesized mols. were evaluated for their inhibitory potential against ABCB1, ABCC1, and ABCG2 in calcein AM and pheophorbide A assays.  In further investigations with the most promising candidates from each class, we proved that ABCB1- and ABCG2-mediated MDR could be reversed by the compds.  Moreover, their intrinsic toxicity was found to be negligible in most cases.  Altogether, our findings contribute to the understanding of ABC transport proteins and reveal new compds. for ongoing evaluation in the field of ABC transporter-mediated MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm76_aHKScf7Vg90H21EOLACvtfcHk0lgxoTMYFbZC9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlt1Sh&md5=142434225d1c45fc9e8c66ee74606b15</span></div><a href="/servlet/linkout?suffix=cit9800&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DSilbermann%26aufirst%3DK.%26aulast%3DShah%26aufirst%3DC.%2BP.%26aulast%3DSahu%26aufirst%3DN.%2BU.%26aulast%3DJuvale%26aufirst%3DK.%26aulast%3DStefan%26aufirst%3DS.%2BM.%26aulast%3DKharkar%26aufirst%3DP.%2BS.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DNovel%2520chalcone%2520and%2520flavone%2520derivatives%2520as%2520selective%2520and%2520dual%2520inhibitors%2520of%2520the%2520transport%2520proteins%2520ABCB1%2520and%2520ABCG2%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D193%26epage%3D213%26doi%3D10.1016%2Fj.ejmech.2018.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kruijtzer, C. M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijnen, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">ten Bokkel Huinink, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schot, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jewell, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span> <span> </span><span class="NLM_article-title">Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2943</span>– <span class="NLM_lpage">2950</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.12.116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1200%2FJCO.2002.12.116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=12089223" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlslyrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=2943-2950&author=C.+M.+F.+Kruijtzerauthor=J.+H.+Beijnenauthor=H.+Rosingauthor=W.+W.+ten+Bokkel+Huininkauthor=M.+Schotauthor=R.+C.+Jewellauthor=E.+M.+Paulauthor=J.+H.+M.+Schellens&title=Increased+oral+bioavailability+of+topotecan+in+combination+with+the+breast+cancer+resistance+protein+and+P-glycoprotein+inhibitor+GF120918&doi=10.1200%2FJCO.2002.12.116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918</span></div><div class="casAuthors">Kruijtzer, C. M. F.; Beijnen, J. H.; Rosing, H.; ten Bokkel Huinink, W. W.; Schot, M.; Jewell, R. C.; Paul, E. M.; Schellens, J. H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2943-2950</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We discovered that breast cancer resistance protein (BCRP), a recently identified ATP-binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(-/-) P-glycoprotein (P-gp) knockout and wild-type mice.  GF120918 is a potent inhibitor of BCRP and P-gp.  The aim was to increase the bioavailability of topotecan by GF120918.  In cohort A, eight patients received 1.0 mg/m2 oral topotecan with or without coadministration of one single oral dose of 1,000 mg GF120918 (day 1 or day 8).  In cohort B, eight other patients received 1.0 mg/m2 i.v. topotecan with or without 1,000 mg oral GF120918 to study the effect of GF120918 on the systemic clearance of topotecan.  After oral topotecan, the mean area under the plasma concn.-time curve (AUC) of total topotecan increased significantly from 32.4±9.6 μg·h/L without GF120918 to 78.7±20.6 μg·h/L when GF120918 was coadministered (P =.008).  The mean max. plasma concn. of total topotecan increased from 4.1±1.5 μg/L without GF120918 to 11.5±2.4 μg/L with GF120918 (P =.008).  The apparent bioavailability in this cohort increased significantly from 40.0% (range, 32% to 47%) to 97.1 % (range, 91 to 120%) (P =.008).  Interpatient variability of the apparent bioavailability was 17% without and 11% with GF120918.  After i.v. administration of topotecan, coadministration of oral GF120918 had a small but statistically significant effect on the AUC and systemic clearance of total topotecan but no statistically significant effect on max. plasma concn. and terminal half-life of total topotecan.  Coadministration of the BCRP and P-gp inhibitor GF120918 resulted in a significant increase of the systemic exposure of oral topotecan.  The apparent oral bioavailability increased from 40.0% without to 97.1 % with GF120918.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRDASB6HJiOrVg90H21EOLACvtfcHk0ljEFGxViTn39g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlslyrt7w%253D&md5=c9d91c4360028e1d8ab13267d187d6ac</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.12.116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.12.116%26sid%3Dliteratum%253Aachs%26aulast%3DKruijtzer%26aufirst%3DC.%2BM.%2BF.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DRosing%26aufirst%3DH.%26aulast%3Dten%2BBokkel%2BHuinink%26aufirst%3DW.%2BW.%26aulast%3DSchot%26aufirst%3DM.%26aulast%3DJewell%26aufirst%3DR.%2BC.%26aulast%3DPaul%26aufirst%3DE.%2BM.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26atitle%3DIncreased%2520oral%2520bioavailability%2520of%2520topotecan%2520in%2520combination%2520with%2520the%2520breast%2520cancer%2520resistance%2520protein%2520and%2520P-glycoprotein%2520inhibitor%2520GF120918%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D2943%26epage%3D2950%26doi%3D10.1200%2FJCO.2002.12.116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, N. M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manolaridis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, K. P.</span></span> <span> </span><span class="NLM_article-title">Structure of the human multidrug transporter ABCG2</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">504</span>– <span class="NLM_lpage">509</span>, <span class="refDoi"> DOI: 10.1038/nature22345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fnature22345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=28554189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC2sXosFWntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2017&pages=504-509&author=N.+M.+I.+Taylorauthor=I.+Manolaridisauthor=S.+M.+Jacksonauthor=J.+Kowalauthor=H.+Stahlbergauthor=K.+P.+Locher&title=Structure+of+the+human+multidrug+transporter+ABCG2&doi=10.1038%2Fnature22345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the human multidrug transporter ABCG2</span></div><div class="casAuthors">Taylor, Nicholas M. I.; Manolaridis, Ioannis; Jackson, Scott M.; Kowal, Julia; Stahlberg, Henning; Locher, Kaspar P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue">7659</span>),
    <span class="NLM_cas:pages">504-509</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">ABCG2 is a constitutively expressed ATP-binding cassette (ABC) transporter that protects many tissues against xenobiotic mols.  Its activity affects the pharmacokinetics of commonly used drugs and limits the delivery of therapeutics into tumor cells, thus contributing to multidrug resistance.  Here we present the structure of human ABCG2 detd. by cryo-electron microscopy, providing the first high-resoln. insight into a human multidrug transporter.  We visualize ABCG2 in complex with two antigen-binding fragments of the human-specific, inhibitory antibody 5D3 that recognizes extracellular loops of the transporter.  We observe two cholesterol mols. bound in the multidrug-binding pocket that is located in a central, hydrophobic, inward-facing translocation pathway between the transmembrane domains.  Combined with functional in vitro analyses, our results suggest a multidrug recognition and transport mechanism of ABCG2, rationalize disease-causing single nucleotide polymorphisms (SNP) and the allosteric inhibition by the 5D3 antibody, and provide the structural basis of cholesterol recognition by other G-subfamily ABC transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYOlfrPNtVhrVg90H21EOLACvtfcHk0ljEFGxViTn39g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXosFWntbk%253D&md5=a3fd5157f639d2958e5abd996e2a6470</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fnature22345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature22345%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DN.%2BM.%2BI.%26aulast%3DManolaridis%26aufirst%3DI.%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DKowal%26aufirst%3DJ.%26aulast%3DStahlberg%26aufirst%3DH.%26aulast%3DLocher%26aufirst%3DK.%2BP.%26atitle%3DStructure%2520of%2520the%2520human%2520multidrug%2520transporter%2520ABCG2%26jtitle%3DNature%26date%3D2017%26volume%3D546%26spage%3D504%26epage%3D509%26doi%3D10.1038%2Fnature22345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manolaridis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zechner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, N. M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bause, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartholomaeus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koenig, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locher, K. P.</span></span> <span> </span><span class="NLM_article-title">Structural basis of small-molecule inhibition of human multidrug transporter ABCG2</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0049-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1038%2Fs41594-018-0049-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=29610494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOjsr7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=333-340&author=S.+M.+Jacksonauthor=I.+Manolaridisauthor=J.+Kowalauthor=M.+Zechnerauthor=N.+M.+I.+Taylorauthor=M.+Bauseauthor=S.+Bauerauthor=R.+Bartholomaeusauthor=G.+Bernhardtauthor=B.+Koenigauthor=A.+Buschauerauthor=H.+Stahlbergauthor=K.-H.+Altmannauthor=K.+P.+Locher&title=Structural+basis+of+small-molecule+inhibition+of+human+multidrug+transporter+ABCG2&doi=10.1038%2Fs41594-018-0049-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of small-molecule inhibition of human multidrug transporter ABCG2</span></div><div class="casAuthors">Jackson, Scott M.; Manolaridis, Ioannis; Kowal, Julia; Zechner, Melanie; Taylor, Nicholas M. I.; Bause, Manuel; Bauer, Stefanie; Bartholomaeus, Ruben; Bernhardt, Guenther; Koenig, Burkhard; Buschauer, Armin; Stahlberg, Henning; Altmann, Karl-Heinz; Locher, Kaspar P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">333-340</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">ABCG2 is an ATP-binding cassette (ABC) transporter that protects tissues against xenobiotics, affects the pharmacokinetics of drugs and contributes to multidrug resistance.  Although many inhibitors and modulators of ABCG2 have been developed, understanding their structure-activity relationship requires high-resoln. structural insight.  Here, we present cryo-EM structures of human ABCG2 bound to synthetic derivs. of the fumitremorgin C-related inhibitor Ko143 or the multidrug resistance modulator tariquidar.  Both compds. are bound to the central, inward-facing cavity of ABCG2, blocking access for substrates and preventing conformational changes required for ATP hydrolysis.  The high resolns. allowed for de novo building of the entire transporter and also revealed tightly bound phospholipids and cholesterol interacting with the lipid-exposed surface of the transmembrane domains (TMDs).  Extensive chem. modifications of the Ko143 scaffold combined with in vitro functional analyses revealed the details of ABCG2 interactions with this compd. family and provide a basis for the design of novel inhibitors and modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJBdcwrlGmAbVg90H21EOLACvtfcHk0ljEFGxViTn39g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOjsr7M&md5=b892ceb7a3ede9784a09c2cc98042d03</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0049-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0049-1%26sid%3Dliteratum%253Aachs%26aulast%3DJackson%26aufirst%3DS.%2BM.%26aulast%3DManolaridis%26aufirst%3DI.%26aulast%3DKowal%26aufirst%3DJ.%26aulast%3DZechner%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DN.%2BM.%2BI.%26aulast%3DBause%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DBartholomaeus%26aufirst%3DR.%26aulast%3DBernhardt%26aufirst%3DG.%26aulast%3DKoenig%26aufirst%3DB.%26aulast%3DBuschauer%26aufirst%3DA.%26aulast%3DStahlberg%26aufirst%3DH.%26aulast%3DAltmann%26aufirst%3DK.-H.%26aulast%3DLocher%26aufirst%3DK.%2BP.%26atitle%3DStructural%2520basis%2520of%2520small-molecule%2520inhibition%2520of%2520human%2520multidrug%2520transporter%2520ABCG2%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D333%26epage%3D340%26doi%3D10.1038%2Fs41594-018-0049-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pavek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagenaar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolscher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinkel, A. H.</span></span> <span> </span><span class="NLM_article-title">Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">144</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.073916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1124%2Fjpet.104.073916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=15365089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWmt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2005&pages=144-152&author=P.+Pavekauthor=G.+Merinoauthor=E.+Wagenaarauthor=E.+Bolscherauthor=M.+Novotnaauthor=J.+W.+Jonkerauthor=A.+H.+Schinkel&title=Human+breast+cancer+resistance+protein%3A+interactions+with+steroid+drugs%2C+hormones%2C+the+dietary+carcinogen+2-amino-1-methyl-6-phenylimidazo%284%2C5-b%29pyridine%2C+and+transport+of+cimetidine&doi=10.1124%2Fjpet.104.073916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Human breast cancer resistance protein: Interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine</span></div><div class="casAuthors">Pavek, Petr; Merino, Gracia; Wagenaar, Els; Bolscher, Ellen; Novotna, Martina; Jonker, Johan W.; Schinkel, Alfred H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">144-152</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The breast cancer resistance protein (BCRP/ABCG2) is an ATP-binding cassette drug efflux transporter that extrudes xenotoxins from cells, mediating drug resistance and affecting the pharmacol. behavior of many compds.  To study the interaction of human wild-type BCRP with steroid drugs, hormones, and the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP), we expressed human BCRP in the murine MEF3.8 fibroblast cell line, which lacks Mdr1a/1b P-glycoprotein and Mrp1, and in the polarized epithelial MDCKII cell line.  We show that PhIP was efficiently transported by human BCRP in MDCKII-BCRP cells, as was found previously for murine Bcrp1.  Furthermore, we show that six out of nine glucocorticoid drugs, corticosterone, and digoxin increased the accumulation of mitoxantrone in the MEF3.8-BCRP cell line, indicating inhibition of BCRP.  In contrast, aldosterone and ursodeoxycholic acid had no significant effect on BCRP.  The four most efficiently reversing glucocorticoid drugs (beclomethasone, 6α-methylprednisolone, dexamethasone, and triamcinolone) and 17β-estradiol showed a significantly reduced BCRP-mediated transepithelial transport of PhIP by MDCKII-BCRP cells, with the highest redn. of PhIP transport ratio for beclomethasone (from 25.0±1.1 to 2.7±0.0).  None of the tested endogenous steroids or synthetic glucocorticoids or digoxin, however, were transported substrates of BCRP.  We also identified the H2-receptor antagonist drug cimetidine as a novel efficiently transported substrate for human BCRP and mouse Bcrp1.  The generated BCRP-expressing cell lines thus provide valuable tools to study pharmacol. and toxicol. interactions mediated by BCRP and to identify new BCRP substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxbdxUda3-ErVg90H21EOLACvtfcHk0lgH_Zb4cwk1gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWmt7c%253D&md5=0f1615781de79b8fa8eaa1e7bc12d617</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.073916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.073916%26sid%3Dliteratum%253Aachs%26aulast%3DPavek%26aufirst%3DP.%26aulast%3DMerino%26aufirst%3DG.%26aulast%3DWagenaar%26aufirst%3DE.%26aulast%3DBolscher%26aufirst%3DE.%26aulast%3DNovotna%26aufirst%3DM.%26aulast%3DJonker%26aufirst%3DJ.%2BW.%26aulast%3DSchinkel%26aufirst%3DA.%2BH.%26atitle%3DHuman%2520breast%2520cancer%2520resistance%2520protein%253A%2520interactions%2520with%2520steroid%2520drugs%252C%2520hormones%252C%2520the%2520dietary%2520carcinogen%25202-amino-1-methyl-6-phenylimidazo%25284%252C5-b%2529pyridine%252C%2520and%2520transport%2520of%2520cimetidine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D312%26spage%3D144%26epage%3D152%26doi%3D10.1124%2Fjpet.104.073916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Köhler, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silbermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiese, M.</span></span> <span> </span><span class="NLM_article-title">Phenyltetrazolyl-phenylamides: substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1016%2Fj.ejmech.2016.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=27676469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A280%3ADC%252BC2svktFejtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=881-895&author=S.+C.+K%C3%B6hlerauthor=K.+Silbermannauthor=M.+Wiese&title=Phenyltetrazolyl-phenylamides%3A+substituent+impact+on+modulation+capability+and+selectivity+toward+the+efflux+protein+ABCG2+and+investigation+of+interaction+with+the+transporter&doi=10.1016%2Fj.ejmech.2016.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter</span></div><div class="casAuthors">Kohler Sebastian C; Silbermann Katja; Wiese Michael</div><div class="citationInfo"><span class="NLM_cas:title">European journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">881-895</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We recently presented a novel class of ABCG2 modulators based on the third-generation ABCB1 inhibitor tariquidar bearing a 2,5-linked tetrazole instead of an amid linker.  We investigated the modulating potential of the compound class by enlarging the substitution pattern on the outer phenyl rings of the scaffold.  To identify the structural conditions for achieving a high response, we decided to determine the individual influence of substituents on the scaffold using monosubstituted derivatives.  While electron withdrawing groups (with a few exceptions) and bulky moieties decreased the modulating potency, small electron donating groups ensured a high activity level.  Interestingly, the unsubstituted derivative 32 reached a similar inhibitory potential as the best derivatives in the previous study.  Enzyme kinetic assays indicated that our derivatives have the same binding site as reference inhibitor Ko143.  They were found to interact competitively and non-competitively with the substrates Hoechst 33342 and pheophorbide A, respectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTKMUV9LEUjjRwLZxei1HN8fW6udTcc2eZm1ELb0MhoDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svktFejtQ%253D%253D&md5=b13d7cae45b24d33faee9720a6ccd781</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25B6hler%26aufirst%3DS.%2BC.%26aulast%3DSilbermann%26aufirst%3DK.%26aulast%3DWiese%26aufirst%3DM.%26atitle%3DPhenyltetrazolyl-phenylamides%253A%2520substituent%2520impact%2520on%2520modulation%2520capability%2520and%2520selectivity%2520toward%2520the%2520efflux%2520protein%2520ABCG2%2520and%2520investigation%2520of%2520interaction%2520with%2520the%2520transporter%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D881%26epage%3D895%26doi%3D10.1016%2Fj.ejmech.2016.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit103"><span> <i>Molecular Operating
Environment (MOE)</i>, version <span class="NLM_edition">2018.01</span>; <span class="NLM_publisher-name">Chemical Computing Group ULC</span> (<span class="NLM_publisher-loc">1010
Sherbooke Street, West, Suite No. 910, Montreal,
QC, H3A 2R7, Canada</span>), <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Molecular+Operating%0AEnvironment+%28MOE%29%2C+version+2018.01%3B+Chemical+Computing+Group+ULC+%281010%0ASherbooke+Street%2C+West%2C+Suite+No.+910%2C+Montreal%2C%0AQC%2C+H3A+2R7%2C+Canada%29%2C+2018."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Operating%250AEnvironment%2520%2528MOE%2529%26pub%3DChemical%2520Computing%2520Group%2520ULC%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit104"><span> <i>LeadIT</i>, version <span class="NLM_edition">2.3.2</span>; <span class="NLM_publisher-name">BioSolveIT GmbH</span>: <span class="NLM_publisher-loc">Sankt Augustin,
Germany</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+LeadIT%2C+version+2.3.2%3B+BioSolveIT+GmbH%3A+Sankt+Augustin%2C%0AGermany%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DLeadIT%26pub%3DBioSolveIT%2520GmbH%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rarey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebe, G.</span></span> <span> </span><span class="NLM_article-title">A fast flexible docking method using an incremental construction algorithm</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">470</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1006/jmbi.1996.0477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=10.1006%2Fjmbi.1996.0477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=8780787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;key=1%3ACAS%3A528%3ADyaK28XltlKisLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1996&pages=470-489&author=M.+Rareyauthor=B.+Kramerauthor=T.+Lengauerauthor=G.+Klebe&title=A+fast+flexible+docking+method+using+an+incremental+construction+algorithm&doi=10.1006%2Fjmbi.1996.0477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">A fast flexible docking method using an incremental construction algorithm</span></div><div class="casAuthors">Rarey, Matthias; Kramer, Bernd; Lengauer, Thomas; Klebe, Gerhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">470-489</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">We present an automatic method for docking org. ligands into protein binding sites.  The method can be used in the design process of specific protein ligands.  It combines an appropriate model of the physico-chem. properties of the docked mols. with efficient methods for sampling the conformational space of the ligand.  If the ligand is flexible, it can adopt a large variety of different conformations.  Each such min. in conformational space presents a potential candidate for the conformation of the ligand in the complexed state.  Our docking method samples the conformation space of the ligand on the basis of a discrete model and uses a tree-search technique for placing the ligand incrementally into the active site.  For placing the first fragment of the ligand into the protein, we use hashing techniques adapted from computer vision.  The incremental construction algorithm is based on a greedy strategy combined with efficient methods for overlap detection and for the search of new interactions.  We present results on 19 complexes of which the binding geometry has been crystallog. detd.  All considered ligands are docked in at most three minutes on a current workstation.  The exptl. obsd. binding mode of the ligand is reproduced with 0.5 to 1.2 Å rms deviation.  It is almost always found among the highest-ranking conformations computed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx9N2sFXkOfLVg90H21EOLACvtfcHk0ljX7lpMzvpneQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XltlKisLo%253D&md5=8cd8f384906ed90e894d118399e4dc4a</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.1996.0477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.1996.0477%26sid%3Dliteratum%253Aachs%26aulast%3DRarey%26aufirst%3DM.%26aulast%3DKramer%26aufirst%3DB.%26aulast%3DLengauer%26aufirst%3DT.%26aulast%3DKlebe%26aufirst%3DG.%26atitle%3DA%2520fast%2520flexible%2520docking%2520method%2520using%2520an%2520incremental%2520construction%2520algorithm%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1996%26volume%3D261%26spage%3D470%26epage%3D489%26doi%3D10.1006%2Fjmbi.1996.0477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FFC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FFC','PDB','6FFC'); return false;">PDB: 6FFC</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i63"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00961">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_40601"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00961?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00961</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings and the biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00961/suppl_file/jm0c00961_si_001.xlsx">XLSX</a>)</p></li><li><p class="inline">LC–MS data of target compounds <b>18</b>–<b>40</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00961/suppl_file/jm0c00961_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Coordinates information for structure representation (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00961/suppl_file/jm0c00961_si_003.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00961/suppl_file/jm0c00961_si_001.xlsx">jm0c00961_si_001.xlsx (11.07 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00961/suppl_file/jm0c00961_si_002.pdf">jm0c00961_si_002.pdf (3.83 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00961/suppl_file/jm0c00961_si_003.pdb">jm0c00961_si_003.pdb (1.4 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB accession code for <b>19</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FFC">6FFC</a>. Authors will release the atomic coordinates upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00961&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-18%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00961%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00961" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a31cddd9c3c22","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
